

**IMMUNOSTIMULATORY BACTERIA ENGINEERED TO COLONIZE
TUMORS, TUMOR-RESIDENT IMMUNE CELLS, AND THE TUMOR
MICROENVIRONMENT**

RELATED APPLICATIONS

5 Benefit of priority is claimed to U.S. Provisional Application Serial No.
62/962,140, filed January 16, 2020, entitled “Immunostimulatory Bacteria Engineered
To Colonize Tumors, Tumor-Resident Immune Cells, And The Tumor
Microenvironment,” to Applicant Actym Therapeutics, Inc., and inventors
Christopher D. Thanos, Laura Hix Glickman, Justin Skoble, Alexandre Charles
10 Michel Iannello, and Haixing Kehoe.

 Benefit of priority also is claimed to U.S. Provisional Application Serial No.
62/934,478, filed November 12, 2019, entitled “Immunostimulatory Bacteria
Engineered To Colonize Tumors And The Tumor Microenvironment,” to Applicant
Actym Therapeutics, Inc., and inventors Christopher D. Thanos, Laura Hix Glickman,
15 Justin Skoble, and Alexandre Charles Michel Iannello.

 Benefit of priority also is claimed to U.S. Provisional Application Serial No.
62/828,990, filed April 03, 2019, entitled “Salmonella Strains Engineered To
Colonize Tumors And The Tumor Microenvironment,” to Applicant Actym
Therapeutics, Inc., and inventors Christopher D. Thanos, Laura Hix Glickman, Justin
20 Skoble, and Alexandre Charles Michel Iannello.

 Benefit of priority also is claimed to U.S. Provisional Application Serial No.
62/811,521, filed February 27, 2019, entitled, “Tumor-Targeting Microorganisms that
Promote Immuno-Stimulation of the Tumor Microenvironment,” to Applicant Actym
Therapeutics, Inc., and inventors Christopher D. Thanos, Laura Hix Glickman, Justin
25 Skoble, and Alexandre Charles Michel Iannello.

 Where permitted, the subject matter of each of these applications is
incorporated by reference in its entirety. The immunostimulatory bacteria provided in
each of these applications can be modified as described in this application, and such
bacteria are incorporated by reference herein.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED ELECTRONICALLY

An electronic version of the Sequence Listing is filed herewith, the contents of which are incorporated by reference in their entirety. The electronic file was created
5 on February 27, 2020, is 603 kilobytes in size, and is titled 1706SEQPC.txt.

BACKGROUND

Tumors have evolved a profoundly immunosuppressive environment. They initiate multiple mechanisms to evade immune surveillance, reprogram anti-tumor immune cells to suppress immunity, and continually mutate resistance to the latest
10 cancer therapies (see, *e.g.*, Mahoney *et al.* (2015) *Nat. Rev. Drug Discov.* 14(8):561-584). The field of cancer immunotherapy has made great strides, as evidenced by the clinical successes of anti-CTLA4, anti-PD-1 and anti-PD-L1 immune checkpoint antibodies (see, *e.g.*, Buchbinder *et al.* (2015) *J. Clin. Invest.* 125: 3377-3383; Hodi *et al.* (2015) *J. Clin. Invest.* 125:3392-4000; and Chen *et al.* (2015) *J. Clin. Invest.*
15 125:3384-3391). Designing immunotherapies that overcome immune tolerance and escape, while limiting the autoimmune-related toxicities of current immunotherapies, challenges the field of immuno-oncology. Hence, additional and innovative immunotherapies and other therapies are needed.

SUMMARY

20 Provided are bacteria modified to be immunostimulatory for anti-cancer therapy. Immunostimulatory bacteria, as provided herein, provide a multi-faceted approach to anti-tumor therapy. Bacteria provide a platform in which there are numerous avenues for eliciting anti-tumor immunostimulatory activity. As provided herein, bacteria, such as species of *Salmonella*, are fine-tuned to have potent anti-
25 tumor activity by increasing their ability to accumulate in or target tumors, tumor-resident-immune cells, and/or the tumor microenvironment (TME). This is achieved by modifications that, for example, alter the type of cells that they can infect (tropism), their toxicity, their ability to escape the immune system, such as escaping inactivation by complement, and/or the environments in which they can replicate. The
30 immunostimulatory bacteria also can encode, for example, products that enhance or invoke an immune response and other therapeutic/anti-cancer products. The immunostimulatory bacteria provided herein, by virtue of their improved colonization

of tumors/the tumor microenvironment/tumor-resident immune cells, and their resistance to complement and other anti-bacterial immune responses, can be administered systemically.

Bacteria by their nature stimulate the immune system; bacterial infection
5 induces immune and inflammatory pathways and responses, some of which are desirable for anti-tumor treatment, and others, are undesirable. Modification of the bacteria by deleting or modifying genes and products that result in undesirable inflammatory responses, and adding or modifying genes that induce desirable immunostimulatory anti-tumor responses, improves the anti-tumor activity of the
10 bacteria.

Bacteria accumulate in tumor cells and tissues, and by replicating therein can lyse cells. Bacteria migrate from the sites of administration and can accumulate in other (*e.g.*, distal/metastatic) tumors and tumor cells to provide an abscopal effect. The bacteria provided herein are modified so that they preferentially infect and
15 accumulate in tumor-resident immune cells, tumors, and the tumor microenvironment, and deliver their plasmids that encode the therapeutic anti-cancer proteins and products. Herein, these properties of that bacteria are exploited to produce demonstrably immunostimulatory bacteria with a plurality of anti-tumor activities and properties that can act individually and synergistically.

20 The genomes of the bacteria provided herein are modified to increase accumulation in tumors and in tumor-resident immune cells, and also in the tumor microenvironment. This is effected herein by deleting or disabling genes responsible for infection or invasion of non-tumor cells, such as epithelial cells, and/or decreasing the cytopathogenicity of the bacteria, particularly to immune cells and tumor-resident
25 immune cells.

Upon accumulation in the tumor-resident immune cells, proteins encoded on plasmids under control of eukaryotic regulatory signals, are expressed, and secreted into the TME. Immunostimulatory bacteria provided herein encode proteins that have anti-cancer activity, such as by modulating the anti-tumor immune response. Bacteria
30 provided herein encode proteins that lead to expression of type I interferon (IFN). Such proteins include STING (Stimulatory of Interferon Genes) and other immunostimulatory proteins that are part of a cytosolic DNA/RNA sensor pathway

leading to expression of type I IFN, and also variants of these proteins that increase expression of type I IFN or that result in constitutive expression of IFN. For example, the immunostimulatory proteins include constitutively active variants of cytosolic DNA/RNA sensors, such as those with gain-of-function mutations.

5 Provided are compositions, uses thereof and methods that modulate immune responses for the treatment of diseases, including for the treatment of cancer. The compositions contain immunostimulatory bacteria provided herein. Methods of treatment and uses of the bacteria for treatment also are provided. The subjects for treatment include humans and other primates, pets, such as dogs and cats, and other
10 animals, such as horses, cows and other farm and zoo animals.

 Provided are pharmaceutical compositions containing the immunostimulatory bacteria, and methods and uses thereof for treatment of diseases and disorders, particularly proliferative disorders, such as tumors, including solid tumors and hematologic malignancies.

15 Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria or pharmaceutical compositions or using the compositions for treatment. For example, provided are methods of administering or using a composition that contains, for a single dosage, an effective amount of an immunostimulatory bacterium, such as a *Salmonella* species,
20 to a subject, such as a human patient, having a solid tumor cancer.

 Provided are immunostimulatory bacteria that encode immunostimulatory proteins that are constitutively active proteins that stimulate or evoke expression of type I IFN. The immunostimulatory bacteria also can encode other anti-tumor therapeutics, such as RNAi, and cytokines and chemokines, and, other modifications
25 of the bacteria and the plasmids described herein, can be combined in any desired combination.

 Provided are immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by
30 deletion of genes encoding the flagella, and/or modification of the genes so that functional flagella are not produced, and/or deletion of *pagP* or modification of *pagP* to produce inactive PagP product. As a result, the immunostimulatory bacteria are

flagellin⁻ (*fliC*⁻/*fljB*⁻) and/or *pagP*⁻. Alternatively, or additionally, the immunostimulatory bacteria can be *pagP*⁻/*msbB*⁻.

The immunostimulatory bacteria can be aspartate-semialdehyde dehydrogenase⁻ (*asd*⁻), such as by virtue of disruption or deletion of all or a portion of the endogenous gene encoding aspartate-semialdehyde dehydrogenase (*asd*), whereby
5 the endogenous *asd* is not expressed. The immunostimulatory bacteria can be modified to encode aspartate-semialdehyde dehydrogenase (*asd*) on a plasmid under control of a bacterial promoter for growing the bacteria *in vitro*, so that bacteria will have limited replication *in vivo*.

10 The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of *asd*⁻, *purI*⁻ and *msbB*⁻. The immunostimulatory bacteria, such as *Salmonella* species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that
15 the bacteria preferentially infect immune cells in the tumor microenvironment or tumor-resident immune cells and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

Provided are methods of increasing tumor colonization of an
20 immunostimulatory bacterium, such as a *Salmonella* species, by modifying the genome of an immunostimulatory bacterium to be flagellin⁻ (*fliC*⁻/*fljB*⁻), whereby flagella are not produced, and/or to be *pagP*⁻. In particular, the bacteria are flagellin⁻ adenosine auxotrophs, and also are *asd*⁻. The bacteria that are flagellin⁻ are derived from bacterial species that express flagella.

25 The bacteria also contain plasmids that encode therapeutic products, such as anti-tumor agents, proteins that increase the immune response of a subject, proteins that lead to constitutive or increased expression of immune stimulating proteins, such as type I interferon (IFN), including interferon- β . This includes encoding proteins that stimulate the immune system as part of a pathway that results in type I IFN
30 expression, and, in particular, by rendering such proteins constitutively active. The plasmids also can encode immunostimulatory proteins, such as cytokines, that increase the anti-tumor immune response in the subject. The bacteria contain plasmids

that encode anti-cancer therapeutics, such as interfering RNA, including microRNA, shRNA, and siRNA, that are designed to suppress, inhibit, disrupt or otherwise silence immune checkpoint genes and products, and other targets that play a role in pathways that are immunosuppressive. The bacteria also can encode tumor antigens on the

5 plasmids to stimulate the immune response against the tumors. The encoded proteins are expressed under the control of promoters recognized by eukaryotic, such as mammalian and animal, or viral, promoters. The bacteria can express one, two, or more of the therapeutic proteins/products, including combinations of the gain-of-function immunostimulatory proteins, and/or cytokines. These heterologous proteins

10 are encoded on the plasmid under control of a promoter, such as an RNA polymerase II or III promoter, recognized by a eukaryotic host.

Provided are immunostimulatory bacteria containing a plasmid encoding a product under control of a eukaryotic promoter, where the genome of the immunostimulatory bacterium is modified whereby the bacterium is flagellin⁻ (*fliC*⁻

15 */fljB*⁻) and/or *pagP*⁺. The bacteria can be one or both of flagellin⁻ (*fliC*⁻/*fljB*⁻) and *pagP*⁺. These immunostimulatory bacteria exhibit increased tumor/tumor microenvironment and tumor-resident immune cell colonization, and have increased anti-tumor activity.

Also provided are immunostimulatory bacteria containing a plasmid encoding a therapeutic product under control of a eukaryotic promoter, where the genome of the

20 immunostimulatory bacterium is modified whereby the bacterium is *pagP*⁺/*msbB*⁻. These bacteria also have increased colonization of tumors, tumor-resident immune cells, and the tumor microenvironment. Because of the resulting change in bacterial membranes and structure, the host immune response, such as complement activity, is altered so that the bacteria are not eliminated upon systemic administration. These

25 bacteria also can be flagellin⁻ (*fliC*⁻/*fljB*⁻) and can comprise other modifications as described herein, including modifications that alter the cells that they can infect, resulting in accumulation in the tumor microenvironment, tumors and tumor-resident immune cells. Hence, the immunostimulatory bacteria provided herein can be

systemically administered and exhibit a high level of tumor/tumor microenvironment and/or tumor-resident immune cell colonization. The immunostimulatory bacteria can

30 be *purI*⁻ (*purM*⁻), and one or more of *asd*⁻, *purI*⁻, *msbB*⁻, and one or both of flagellin⁻ (*fliC*⁻/*fljB*⁻) and *pagP*⁺.

The immunostimulatory bacteria can be one or more of *purI*⁻ (*purM*⁻), *msbB*⁻, *purD*⁻, flagellin⁻ (*fliC*⁻/*fljB*⁻), *pagP*⁻, *adrA*⁻, *csgD*⁻, *qseC*⁻, *hilA*⁻, *lppA*⁻ and *lppB*⁻, and particularly flagellin⁻ (*fliC*⁻/*fljB*⁻) and/or *pagP*⁻, and/or *msbB*⁻/*pagP*⁻. For example, the immunostimulatory bacteria can include mutations in the genome, such as deletions or
5 disruptions that reduce toxicity or infectivity of non-immune cells in a host. For example, the immunostimulatory bacteria can be *pagP*⁻. As another example, the immunostimulatory bacteria can be flagellin⁻ (*fliC*⁻/*fljB*⁻), and can also be *pagP*⁻. The bacteria can be modified so that they accumulate and express the therapeutic product(s) in tumor-resident immune cells and in the tumor microenvironment (TME),
10 thereby delivering an immunotherapeutic anti-tumor product into the environment in which it has beneficial activity, and avoiding adverse or toxic side effects from expression in other cells/environments. The nucleic acids encoding the immunostimulatory protein(s)/therapeutic product(s) can be operatively linked for expression to nucleic acids encoding a secretory signal, whereby, upon expression, in
15 a host, the immunostimulatory protein/therapeutic product is secreted into the tumor microenvironment.

As discussed above, the genome of the immunostimulatory bacteria also is modified so that the bacteria preferentially infect immune cells, such as tumor-resident immune cells, and/or the genome is modified so that the bacteria induce less
20 cell death in tumor-resident immune cells (decreased pyroptosis) than the unmodified bacteria. As a result, the immunostimulatory bacteria accumulate, or accumulate to a greater extent than those without the modifications, in tumors or in the tumor microenvironment or in tumor-resident immune cells, to thereby deliver the immunostimulatory protein(s) and constitutively active variants thereof, and other
25 therapeutic products, to the cell to stimulate or induce expression of type I interferon. The bacteria can be one or more of flagellin⁻ (*fliC*⁻/*fljB*⁻), *pagP*⁻, and *msbB*⁻, and can include other such modifications as described herein.

The immunostimulatory bacteria can also be aspartate-semialdehyde dehydrogenase⁻ (*asd*⁻), such as by virtue of disruption or deletion of all or a portion of
30 the endogenous gene encoding aspartate-semialdehyde dehydrogenase (*asd*), whereby endogenous *asd* is not expressed. These immunostimulatory bacteria can be modified

to encode aspartate-semialdehyde dehydrogenase (*asd*) on the plasmid under control of a bacterial promoter so that the bacteria can be produced *in vitro*.

The immunostimulatory bacteria can be rendered auxotrophic for particular nutrients, that are rich or that accumulate in the tumor microenvironment, such as adenosine and adenine. Also, they can be modified to be auxotrophic for such nutrients to reduce or eliminate their ability to replicate. The inactivated/deleted bacterial genome genes can be complemented by providing them on a plasmid under the control of promoters recognized by the host.

Additionally, the genome of the immunostimulatory bacterium is modified so that it preferentially infects tumor-resident immune cells. This is achieved by deleting or disrupting bacterial genes that play a role in invasiveness or infectivity of the bacteria, and/or that play a role in inducing cell death. The bacteria are modified to preferentially infect tumor-resident immune cells, and/or to induce less cell death in such cells, than unmodified bacteria, or than in other cells that the bacteria can infect.

The immunostimulatory bacteria provided herein can include a modification of the bacterial genome, whereby the bacterium induces less cell death in tumor-resident immune cells; and/or a modification of the bacterial genome, whereby the bacterium accumulates more effectively in tumors, the TME, or tumor-resident immune cells. These immunostimulatory bacteria can be further modified so that the bacteria preferentially infect tumor-resident immune cells, and/or the genome of the immunostimulatory bacterium can be modified so that it induces less cell death in tumor-resident immune cells (decreases pyroptosis), whereby the immunostimulatory bacterium accumulates in tumors or in the tumor microenvironment or in tumor-resident immune cells, to thereby deliver a constitutively active immunostimulatory protein, or other therapeutic product(s), to the cell to stimulate or induce expression of type I IFN.

The immunostimulatory bacteria can include deletions or modifications of one or more genes or operons involved in SPI-1-dependent invasion (and/or SPI-2), whereby the immunostimulatory bacteria do not invade or infect epithelial cells. Exemplary of genes that can be deleted or inactivated are one or more of *avrA*, *hilA*, *hilD*, *invA*, *invB*, *invC*, *invE*, *invF*, *invG*, *invH*, *invI*, *invJ*, *iapP*, *iagB*, *spaO*, *spaP*, *spaQ*, *spaR*, *spaS*, *orgA*, *orgB*, *orgC*, *prgH*, *prgI*, *prgJ*, *prgK*, *sicA*, *sicP*, *sipA*, *sipB*,

sipC, *sipD*, *sirC*, *sopB*, *sopD*, *sopE*, *sopE2*, *sprB*, and *sptP*. Elimination of the ability to infect epithelial cells also can be achieved by engineering the immunostimulatory bacteria herein to contain knockouts or deletions of genes encoding proteins involved in SPI-1-independent invasion, such as one or more of the genes selected from among
5 *rck*, *pagN*, *hlyE*, *pefI*, *srgD*, *srgA*, *srgB*, and *srgC*. Similarly, the immunostimulatory bacteria can include deletions in genes and/or operons in SPI-2, for example, to engineer the bacteria to escape the *Salmonella*-containing vacuole (SCV). These genes include, for example, *sifA*, *sseJ*, *sseL*, *sopD2*, *pipB2*, *sseF*, *sseG*, *spvB*, and *steA*.

10 For example, the immunostimulatory bacteria can be modified to have reduced pathogenicity, whereby infection of epithelial and/or other non-immune cells is reduced, relative to the bacterium without the modification. These include modification of the type 3 secretion system (T3SS) or type 4 secretion system (T4SS), such as modification of the SPI-1 pathway or T3SS system of *Salmonella* as described
15 and exemplified herein. The bacteria further can be modified to induce less cell death, such as by deletion or disruption of nucleic acids encoding PagP (lipid A palmitoyltransferase), which reduces virulence of the bacterium.

The genome of the immunostimulatory bacteria provided herein can be modified to increase or promote infection of immune cells, particularly immune cells
20 in the tumor microenvironment, such as phagocytic cells. This includes reducing infection of non-immune cells, such as epithelial cells, or increasing infection of immune cells. The bacteria also can be modified to decrease pyroptosis in immune cells. Numerous modifications of the bacterial genome can do one or both of increasing infection of immune cells and decreasing pyroptosis. The
25 immunostimulatory bacteria provided herein include such modifications, for example, deletions and/or disruptions of genes involved in the SPI-1 T3SS pathway, such as disruption or deletion of *hilA*, and/or disruption/deletion of genes encoding flagellin, rod protein (PrgJ), needle protein (PrgI) and QseC.

The therapeutic products encoded on the plasmids for expression in a
30 eukaryotic, such as a human, host, are under control of eukaryotic regulatory sequences, including eukaryotic promoters, such as promoters recognized by RNA

polymerase II or III. These include viral and mammalian RNA polymerase II promoters.

Exemplary viral promoters, include, but are not limited to, a cytomegalovirus (CMV) promoter, an SV40 promoter, an Epstein Barr virus (EBV) promoter, a herpes virus promoter, a respiratory syncytial virus (RSV) promoter, and an adenovirus promoter. Other RNA polymerase II promoters include, but are not limited to, an elongation factor-1 (EF-1) alpha promoter, or a UbC promoter (lentivirus), or a PGK (3-phosphoglycerate kinase) promoter, a synthetic MND promoter, and a synthetic promoter such as a CAGG (or CAG) promoter. The synthetic CAG promoter contains the cytomegalovirus (CMV) early enhancer element (C); the promoter, the first exon and the first intron of chicken beta-actin gene (A); and the splice acceptor of the rabbit beta-globin gene (G). MND is a synthetic promoter that contains the U3 region of a modified MoMuLV LTR with myeloproliferative sarcoma virus enhancer (murine leukemia virus-derived MND promoter (myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted; see, *e.g.*, Li *et al.* (2010) *J. Neurosci. Methods* 189:56-64). Other strong regulatable or constitutive promoters can be used. Exemplary of the promoters are the EF-1alpha promoter, CMV, SV40, PGK, EIF4A1, CAG, and CD68 promoters. The regulatory sequences also include terminators, enhancers, secretory and other trafficking signals.

The plasmids included in the immunostimulatory bacteria can be present in low copy number or medium copy number, such as by selection of an origin of replication that results in medium-to-low copy number, such as a low copy number origin of replication. It is shown herein that the anti-tumor activity and other properties of the bacteria are improved when the plasmid is present in low to medium copy number, where medium copy number is less than 150 or less than about 150 and more than 20 or about 20 or is between 20 or 25 and 150, and low copy number is less than 25 or less than 20 or less than about 25 or less than about 20 copies.

The immunostimulatory bacteria provided herein include any of the strains and bacteria described in U.S. Application Serial No. 16/033,187, further modified to express an immunostimulatory protein and/or to preferentially infect and/or to be less toxic in immune cells in the tumor microenvironment, or in tumor-resident immune cells, as described and exemplified herein.

Encoded Therapeutic Proteins/Products

The immunostimulatory bacteria encode a therapeutic protein or product, on a plasmid in the bacterium, under control of a eukaryotic promoter, that, when expressed in a mammalian subject, confers or contributes to anti-tumor immunity in the tumor microenvironment.

Products encoded by the immunostimulatory bacteria include proteins that are part of a cytosolic DNA/RNA sensor pathway that leads to expression of type I interferon (IFN), and variants thereof. These include variant proteins with increased activity and variant proteins that result in constitutive expression of type I interferons.

These also include proteins that naturally, or by mutation, have decreased signaling activity in pathways that lead to undesirable immune responses, but that have type I interferon stimulating activity and/or interferon- β stimulating activity comparable to or greater than the native human proteins. In particular, the immunostimulatory bacteria encode gain-of-function (GOF) variants of an immunostimulatory protein that, in unmodified form, is part of a cytosolic DNA/RNA sensor pathway that leads to expression of type I interferon (IFN). Exemplary are gain-of function, constitutively active variants of an immunostimulatory protein that, in humans, promotes or causes interferonopathies, where the genome of the immunostimulatory bacterium is modified so that the bacterium preferentially infects tumor-resident immune cells, and/or the genome of the immunostimulatory bacterium is modified so that it induces less cell death in tumor-resident immune cells (decreases pyroptosis), whereby the immunostimulatory bacterium accumulates in tumors or in the tumor microenvironment or in tumor-resident immune cells, to thereby deliver the constitutively active immunostimulatory protein to the cell to stimulate or induce expression of type I IFN. The variant can include a mutation that eliminates a phosphorylation site in the immunostimulatory protein, to thereby reduce nuclear factor kappa-light-chain-enhancer of activated B cell (NF- κ B) signaling. These include, for example, STING, RIG-I, MDA-5, IRF-3, IRF-5, IRF-7, TRIM56, RIP1, Sec5, TRAF3, TRAF2, TRAF6, STAT1, LGP2, DDX3, DHX9, DDX1, DDX9, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200, and variants thereof, such as those expressed in interferonopathies and conservative variations thereof that have constitutive activity or increased activity. In some embodiments, these include

proteins that induce type I IFN, such as STING, RIG-I, IRF-3, IRF-7, or MDA5, and variants thereof that have increased activity or constitutive activity, where the immunostimulatory protein is STING, RIG-I, IRF-3, IRF-7, or MDA5.

Hence, provided herein are immunostimulatory bacteria comprising a plasmid
5 that contains heterologous nucleic acid encoding a gain-of-function variant of an immunostimulatory protein that, in unmodified form, is part of a cytosolic DNA/RNA sensor pathway that leads to expression of type I interferon (IFN). These gain-of-function proteins are encoded on a plasmid under control of eukaryotic regulatory signals, including promoters, and optionally other regulatory signals, such as
10 enhancers, polyA and transcription terminators. The nucleic acids encoding the proteins/products on the plasmid can be multiplexed, whereby a plurality of products are encoded. Strategies for multigene co-expression include use of multiple promoters in a single vector, fusion proteins, proteolytic cleavage sites between genes, internal ribosome entry sites (IRES), and “self-cleaving” (ribosome skipping) 2A peptides. 2A
15 peptides are 18–22 amino-acid (aa)-long viral oligopeptides that mediate “cleavage” of polypeptides during translation in eukaryotic cells. Thus, provided are plasmids that encode the therapeutic products on the plasmid under control of a single promoter by including 2A self-cleaving peptides between the coding portions, such as T2A, P2A, F2A, and E2A.

20 The unmodified forms of the immunostimulatory proteins are proteins in a signaling pathway that senses cytosolic DNA/RNA. They include those proteins that are modified with amino acid replacement(s) or deletions that increase activity and/or render the activity constitutive. Provided are immunostimulatory bacteria that contain a plasmid encoding a gain-of-function, constitutively active variant of an
25 immunostimulatory protein. These gain-of-function proteins, include proteins in the signaling pathway that leads to expression of type I interferon, including proteins that, in humans, promote or cause interferonopathies, and gain-of-function mutants that are modified, having been selected, to result in constitutive expression of type I interferon. The immunostimulatory protein in its unmodified form is one that senses
30 or interacts directly or indirectly as part of a signaling pathway with cytosolic nucleic acids, nucleotides, dinucleotides, or cyclic dinucleotides, to induce expression of type I interferon, and the variant protein induces expression of type I interferon in the

absence of the sensing or interacting with the cytosolic nucleic acids, nucleotides, dinucleotides, or cyclic dinucleotides (CDNs). Included are gain-of-function variants that do not require cytosolic nucleic acid, nucleotides, dinucleotides, or cyclic dinucleotides to result in expression of a type I interferon. Exemplary of such proteins

5 are STING, RIG-I, MDA-5, IRF-3, IRF-5, IRF-7, TRIM56, RIP1, Sec5, TRAF3, TRAF2, TRAF6, STAT1, LGP2, DDX3, DHX9, DDX1, DDX9, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200.

In these immunostimulatory bacteria, the encoded variant gain-of-function protein can be one that eliminates a phosphorylation site in the immunostimulatory

10 protein to thereby reduce nuclear factor kappa-light-chain-enhancer of activated B cell (NF- κ B) signaling. Alternatively, the bacteria can include one or more replacements of the amino acid serine (S) or threonine (T) at a phosphorylation site with aspartic acid (D), which is phosphomimetic, and results in increased or constitutive activity. Exemplary of the proteins in signaling pathways that result in type I interferon

15 expression are STING, RIG-I, IRF-3, IRF-7 and MDA5. Described herein are exemplary mutations that result in gain-of-function activity for each of these proteins. Mutations include those in which the encoded immunostimulatory protein is a variant STING, RIG-I, IRF-3, IRF-7 or MDA5, in which one or more serine (S) or threonine residue(s) that is/are phosphorylated as a consequence of viral infection, is/are

20 replaced with an aspartic acid (D), whereby the resulting variant is a phosphomimetic that constitutively induces type I interferon. For example, provided are immunostimulatory bacteria in which the immunostimulatory protein is IRF-3 that has one or more replacement(s) at residues at positions 385, 386, 396, 398, 402, 404 and 405, and the residues are replaced with aspartic acid residues; this includes IRF-3 that

25 has the replacement S396D with reference to SEQ ID NO:312, and IRF-3 that comprises the mutations S396D/S398D/S402D/T404D/S405D with reference to SEQ ID NO:312. Other examples are immunostimulatory bacteria wherein the immunostimulatory protein is selected from among STING, MDA5, IRF-7 and RIG-I, in which the mutations are selected as follows: a) in STING, with reference to human

30 STING of SEQ ID NOs: 305-309, one or more selected from among: S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A,

E296A, R197A/D205A, S272A/Q273A, R310A/E316A, E316A, E316N, E316Q, S272A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A, S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, R375A, and S324A/S326A; b) in MDA5, with reference to SEQ ID NO:310, one or more of: T331I, T331R, A489T, R822Q, G821S, A946T, R337G, D393V, G495R, R720Q, R779H, R779C, L372F, and A452T; c) in RIG-I, with reference to SEQ ID NO:311, one or both of E373A and C268F; and d) in IRF-7, with reference to SEQ ID NO:313, one or more of: S477D/S479D, S475D/S477D/S479D, S475D/S476D/S477D/S479D/S483D/S487D and Δ 247-467. Any of these replacements can be replaced with a conservative mutations in accord with the Table of Exemplary Conservative Amino Acid Substitutions below.

Also provided are delivery vehicles, such as exosomes, liposomes, oncolytic viruses, nanoparticles, the immunostimulatory bacteria, and other such vehicles, that contain nucleic acids encoding the gain-of-function proteins and other therapeutic products, as described above and elsewhere herein. For example, provided are delivery vehicles that contain nucleic acids, generally DNA encoding a gain-of-function immunostimulatory protein that is part of a signaling pathway that results in expression of type I interferon. The gain-of-function variants can render expression of type I interferon constitutive. For example, these variants include any discussed herein, such as a modified STING, where: the modifications in STING render its activity constitutive so that it does not require cGAMP (or other ligands/CDNs) for activity; modified STING is encoded by a modified *TMEM173* gene; the modifications comprise insertions, deletions or replacements of amino acid(s); and the modified STING has enhanced immunostimulatory activity compared to the unmodified STING. These amino acid replacement(s) in STING, with reference to human STING of SEQ ID NOs: 305-309, include one or more selected from among: S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A, E296A, R197A/D205A, S272A/Q273A, R310A/E316A, E316A, E316N, E316Q, S272A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A, S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, R375A, and S324A/S326A.

The immunostimulatory bacteria provided herein also can contain a sequence of nucleotides encoding an immunostimulatory protein that, when expressed in a mammalian subject, confers or contributes to anti-tumor immunity in the tumor microenvironment; the immunostimulatory protein is encoded on a plasmid in the
5 bacterium under control of a eukaryotic promoter. Exemplary promoters include, but are not limited to, an elongation factor-1 (EF1) alpha promoter, or a UbC promoter, or a PGK promoter, or a CAGG or CAG promoter.

The immunostimulatory bacterial also can encode an inhibitory RNA (RNAi) that, when expressed in a mammalian subject, confers or contributes to anti-tumor
10 immunity. The RNAi is encoded on a plasmid in the bacterium under control of a eukaryotic promoter. The genome of the immunostimulatory bacterium is modified so that it induces less cell death in tumor-resident immune cells and/or so that it accumulates in tumor-resident immune cells and in the tumor microenvironment/tumors.

15 The immunostimulatory bacteria provided herein also can encode other immunostimulatory proteins. The immunostimulatory protein can be a cytokine, such as a chemokine. Exemplary of immunostimulatory proteins are IL-2, IL-7, IL-12p70 (IL-12p40 + IL-12p35), IL-15, IL-15/IL-15R alpha chain complex, IL-36 gamma, IL-18, CXCL9, CXCL10, CXCL11, CCL3, CCL4, CCL5, proteins that are involved in
20 or that effect or potentiate the recruitment/persistence of T cells, CD40, CD40 Ligand (CD40L), OX40, OX40 Ligand (OX40L), 4-1BB, 4-1BB Ligand (4-1BBL), members of the B7-CD28 family, and members of the tumor necrosis factor receptor (TNFR) superfamily. In some embodiments, these include, for example, IL-2, IL-7, IL-12p70 (IL-12p40 + IL-12p35), IL-15, IL-23, IL-36 gamma, IL-2 that has attenuated binding
25 to IL-2Ra, IL-15/IL-15R alpha chain complex, IL-18, IL-2 modified so that it does not bind to IL-2Ra, CXCL9, CXCL10, CXCL11, interferon- α , interferon- β , CCL3, CCL4, CCL5, proteins that are involved in or that effect or potentiate recruitment/persistence of T cells, CD40, CD40 Ligand, OX40, OX40 Ligand, 4-1BB, 4-1BB Ligand, members of the B7-CD28 family, TGF-beta polypeptide antagonists,
30 and members of the tumor necrosis factor receptor (TNFR) superfamily.

The immunostimulatory bacteria can optionally include a sequence of nucleotides encoding inhibitory RNA (RNAi) that inhibits, suppresses or disrupts

expression of an immune checkpoint. The RNAi can be encoded on a plasmid in the bacterium. The nucleotides encoding the immunostimulatory protein, and optionally an RNAi, can be on a plasmid present in low to medium copy number.

The immunostimulatory bacteria also can encode therapeutic products, such as
5 RNAi or a CRISPR cassette that inhibits, suppresses or disrupts expression of an immune checkpoint or other target whose inhibition, suppression or disruption increases the anti-tumor immune response in a subject; the RNAi or CRISPR cassette is encoded on a plasmid in the bacterium. Other therapeutic products include, for example, antibodies that bind to immune checkpoints to inhibit their activities, such
10 as, for example, anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies.

RNAi includes all forms of double-stranded RNA that can be used to silence the expression of targeted nucleic acids. RNAi includes shRNA, siRNA and microRNA (miRNA). Any of these forms can be interchanged in the embodiments disclosed and described herein. In general, the RNAi is encoded on a plasmid in the
15 bacterium. The plasmids can include other heterologous nucleic acids that encode products of interest that modulate or add activities or products to the bacterium, or other such products that can modulate the immune system of a subject to be treated with the bacterium. Bacterial genes also can be added, deleted or disrupted. These genes can encode products for growth and replication of the bacteria, or products that
20 also modulate the immune response of the host to the bacteria.

Bacterial species include, but are not limited to, for example, strains of *Salmonella*, *Shigella*, *Listeria*, *E. coli*, and *Bifidobacteriae*. For example, species include *Shigella sonnei*, *Shigella flexneri*, *Shigella dysenteriae*, *Listeria monocytogenes*, *Salmonella typhi*, *Salmonella typhimurium*, *Salmonella gallinarum*,
25 and *Salmonella enteritidis*.

Species include, for example, strains of *Salmonella*, *Shigella*, *E. coli*, *Bifidobacteriae*, *Rickettsia*, *Vibrio*, *Listeria*, *Klebsiella*, *Bordetella*, *Neisseria*, *Aeromonas*, *Francisella*, *Cholera*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*, *Mycoplasma*, *Legionella*, *Rhodococcus*,
30 *Pseudomonas*, *Helicobacter*, *Bacillus*, and *Erysipelothrix*, or an attenuated strain thereof or a modified strain thereof of any of the preceding list of bacterial strains.

Other suitable bacterial species include *Rickettsia*, *Klebsiella*, *Bordetella*, *Neisseria*, *Aeromonas*, *Francisella*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*, *Mycoplasma*, *Legionella*, *Rhodococcus*, *Pseudomonas*, *Helicobacter*, *Vibrio*, *Bacillus*, and *Erysipelothrix*. For example,

5 *Rickettsia Rickettsiae*, *Rickettsia prowazekii*, *Rickettsia tsutsugamuchi*, *Rickettsia mooseri*, *Rickettsia sibirica*, *Bordetella bronchiseptica*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Aeromonas eucrenophila*, *Aeromonas salmonicida*, *Francisella tularensis*, *Corynebacterium pseudotuberculosis*, *Citrobacter freundii*, *Chlamydia pneumoniae*, *Haemophilus sornmus*, *Brucella abortus*, *Mycobacterium*

10 *intracellulare*, *Legionella pneumophila*, *Rhodococcus equi*, *Pseudomonas aeruginosa*, *Helicobacter mustelae*, *Vibrio cholerae*, *Bacillus subtilis*, *Erysipelothrix rhusiopathiae*, *Yersinia enterocolitica*, *Rochalimaea quintana*, and *Agrobacterium tumerfacium*.

Salmonella is exemplified herein, and particularly, *Salmonella typhimurium*

15 strains, such as the strain designated YS1646 (ATCC #202165) or VNP20009, and the wild-type strain deposited as ATCC #14028, or a strain having all of the identifying characteristics of ATCC #14028. Other strains include, for example, RE88, SL7207, χ 8429, χ 8431, and χ 8468. Exemplary *Salmonella* strains provided herein are immunostimulatory bacterium strains AST-104, AST-105, AST-106, AST-108, AST-

20 110, AST-112, AST-113, AST-115, AST-117, AST-118, AST-119, AST-120, AST-121, AST-122, and AST-123. These strains can be further modified to encode immunostimulatory proteins that are gain-of-function variants of proteins in signaling pathways that lead to expression of type I interferon or other immune modulatory proteins. The immunostimulatory bacteria also can encode immunostimulatory

25 proteins that increase the immune response in the tumor microenvironment, such as cytokines. The immunostimulatory bacteria also can be modified to preferentially infect immune cells in the tumor microenvironment or to infect tumor-resident immune cells, and/or to induce less cell death in such immune cells, as described herein. Sequences thereof and descriptions are provided in the detailed description,

30 examples and sequence listing. The immunostimulatory bacteria can be derived from attenuated strains of bacteria, or they become attenuated by virtue of the

modifications described herein, such as deletion of *asd*, whereby replication is limited *in vivo*.

It is understood that instances in which bacterial genes are modified and referenced herein, they are referenced with respect to their designation (name) in *Salmonella* species, which is exemplary of bacteria from which immunostimulatory bacteria can be produced. The skilled person recognizes that other species have corresponding proteins, but that their designation or name can be different from the name in *Salmonella*. The generic disclosure herein, however, can be applied to other bacterial species. For example, as shown herein, deletion or inactivation of flagellin (*fliC*/*fliB*) in *Salmonella* and/or *pagP* results in increased colonization of tumors. Similar genes for flagella or similar functions for infection can be modified in other bacterial species to achieve increased tumor colonization. Similarly, inactivation/deletion of bacterial products, such as the products of *pagP* and/or *msbB*, as described herein, can reduce complement activation and/or other inflammatory responses, thereby increasing targeting to tumors, tumor-resident immune cells and the tumor microenvironment. Corresponding genes in other species that are involved in activating the complement pathway or other inflammatory pathway, can be deleted, as exemplified herein for *Salmonella*.

The immunostimulatory bacteria provided herein encode inhibitors of various genes that contribute to reduced anti-tumor immune responses and/or express genes and/or gene products and/or products that stimulate the immune system, and thereby are immunostimulatory.

The immunostimulatory bacteria provided herein have properties that render them immunostimulatory. Adenosine auxotrophy also is immunostimulatory. They also they encode, on the plasmid, therapeutic payloads, such as gain-of-function/constitutively active STING mutants, and other immunostimulatory proteins. The effects of this combination are enhanced by the strains provided herein that are auxotrophic for adenosine, which provides preferential accumulation in, or recruitment into, adenosine-rich immunosuppressive tumor microenvironments (TMEs). Reducing adenosine in such TMEs further enhances the immunostimulatory effects. Such combinations of traits in any of the bacterial strains known, or that can

be engineered for therapeutic administration, provide similar immunostimulatory effects.

Engineered immunostimulatory bacteria, such as the *S. typhimurium* immunostimulatory bacteria provided herein, contain multiple synergistic modalities to induce immune re-activation of cold tumors to promote tumor antigen-specific immune responses, while inhibiting immune checkpoint pathways that the tumor utilizes to subvert and evade durable anti-tumor immunity. Included in embodiments is adenosine auxotrophy and enhanced vascular disruption. This improvement in tumor targeting through adenosine auxotrophy and enhanced vascular disruption increases potency, while localizing the inflammation to limit systemic cytokine exposure and the autoimmune toxicities observed with other immunotherapy modalities.

The heterologous proteins, such as the immunostimulatory proteins and gain-of-function immunostimulatory proteins, and RNAs are expressed on plasmids under the control of promoters that are recognized by the eukaryotic host cell transcription machinery, such as RNA polymerase II (RNAP II) and RNA polymerase III (RNAP III) promoters. RNAP III promoters generally are constitutively expressed in a eukaryotic host; RNAP II promoters can be regulated. The therapeutic products/immunostimulatory proteins are provided on plasmids stably expressed by the bacteria. Exemplary of such bacteria are *Salmonella* strains, generally attenuated strains, either attenuated by passage or other methods, or by virtue of modifications described herein, such as adenosine auxotrophy. Exemplary of *Salmonella* strains are modified *S. typhimurium* strains that have a defective *asd* gene. These bacteria can be modified to include carrying a functional *asd* gene on the introduced plasmid; this maintains selection for the plasmid so that an antibiotic-based plasmid maintenance/selection system is not needed. The *asd* defective strains that do not contain a functional *asd* gene on a plasmid are autolytic in the host.

The promoters can be selected for the environment of the tumor cell, such as a promoter expressed in a tumor microenvironment (TME), a promoter expressed in hypoxic conditions, or a promoter expressed in conditions where the pH is less than 7.

The plasmids in any of the bacteria described and enumerated above encode therapeutic products. Plasmids can be present in many copies or fewer. This can be

controlled by selection of elements, such as the origin of replication. Low and high and medium copy number plasmids and origins of replication are well known to those of skill in the art and can be selected. In embodiments of the immunostimulatory bacteria here, the plasmid can be present in low to medium copy number, such as
5 about 150 or 150 and fewer copies, to low copy number which is less than about 25 or about 20 or 25 copies. Exemplary origins of replication are those derived from pBR322, p15A, pSC101, pMB1, colE1, colE2, pPS10, R6K, R1, RK2, and pUC.

The plasmids encode therapeutic polypeptides, such as the polypeptides that induce type I interferons, such as those expressed in interferonopathies, and/or any
10 therapeutic proteins described herein, and/or known to those of skill in the art for use in cancer therapies. The plasmids also can include sequences of nucleic acids encoding listeriolysin O (LLO) protein lacking the signal sequence (cytoLLO), a CpG motif, a DNA nuclear targeting sequence (DTS), and a retinoic acid-inducible gene-I (RIG-I) binding element. The immunostimulatory bacterium that comprises nucleic
15 acids can include a CpG motif recognized by toll-like receptor 9 (TLR9). The CpG motif can be encoded on the plasmid. The CpG motif can be included in, or is part of, a bacterial gene that is encoded on the plasmid. For example, the gene that comprises CpGs can be *asd*, encoded on the plasmid. Immunostimulatory bacteria provided herein can include one or more of a CpG motif, an *asd* gene selectable marker for
20 plasmid maintenance and a DNA nuclear targeting sequence.

The immunostimulatory bacteria can be flagellin deficient, such as by deletion of or disruption in a gene(s) encoding the flagella. For example, provided are immunostimulatory bacteria that contain deletions in the genes encoding one or both of flagellin subunits *fljC* and *fljB*, whereby the bacterium is flagella deficient, and
25 wherein the wild-type bacterium expresses flagella. The immunostimulatory bacteria also can have a deletion or modification in the gene encoding endonuclease I (*endA*), whereby *endA* activity is inhibited or eliminated.

The immunostimulatory bacteria provided herein can be aspartate-semialdehyde dehydrogenase (*asd*⁻), which permits growth in DAP supplemented
30 medium, but limits replication *in vivo* when administered to subjects for treatment. Such bacteria will be self-limiting, which can be advantageous for treatment. The bacterium can be *asd*⁻ by virtue of disruption or deletion of all or a portion of the

endogenous gene encoding aspartate-semialdehyde dehydrogenase (*asd*), whereby the endogenous *asd* is not expressed. In other embodiments, the gene encoding aspartate-semialdehyde dehydrogenase can be included on the plasmid for expression *in vivo*.

Any of the immunostimulatory bacteria provided herein can include nucleic acid, generally on the plasmid, that includes a CpG motif or a CpG island, wherein the CpG motif is recognized by toll-like receptor 9 (TLR9). Nucleic acid encoding CpG motifs or islands are plentiful in prokaryotes, and, thus, the CpG motif can be included in, or can be a part of, a bacterial gene that is encoded on the plasmid. For example, the bacterial gene *asd* contains immunostimulatory CpGs.

The immunostimulatory bacteria provided herein can be auxotrophic for adenosine, or adenosine and adenine. Any of the bacteria herein can be rendered autotrophic for adenosine, which advantageously can increase the anti-tumor activity, since adenosine accumulates in many tumors, and is immunosuppressive.

The immunostimulatory bacteria provided herein can be flagellin deficient, where the wild-type bacterium comprises flagella. They can be rendered flagellin deficient by disrupting or deleting all or a part of the gene or genes that encode flagella. For example, provided are immunostimulatory bacteria that have deletions in the genes encoding one or both of flagellin subunits FliC and FljB, whereby the bacteria is flagella deficient.

The immunostimulatory bacteria provided herein can include a nucleic acid encoding cytoLLO, which is a listeriolysin O (LLO) protein lacking the periplasmic secretion signal sequence so that it accumulates in the cytoplasm. This mutation is advantageously combined with *asd* bacteria. LLO is a cholesterol-dependent pore forming hemolysin from *Listeria monocytogenes* that mediates phagosomal escape of bacteria. When the autolytic strain is introduced into tumor-bearing hosts, such as humans, the bacteria are taken up by phagocytic immune cells and enter the vacuole. In this environment, the lack of DAP prevents bacterial replication, and results in autolysis of the bacteria in the vacuole. Lysis then releases the plasmid and the accumulated LLO forms pores in the cholesterol-containing vacuole membrane and allows for delivery of the plasmid into the cytosol of the host cell. Here, the therapeutic products can be expressed using the host cell machinery, and released into the tumor microenvironment to effect anti-tumor therapy.

The immunostimulatory bacteria can include a DNA nuclear targeting sequence (DTS), such as an SV40 DTS, encoded on the plasmid.

The immunostimulatory bacteria can have a deletion or modification in the gene encoding endonuclease-1 (*endA*), whereby *endA* activity is inhibited or
 5 eliminated. Exemplary of these are immunostimulatory bacteria that contain one or more of a CpG motif, an *asd* gene selectable marker for plasmid maintenance and a DNA nuclear targeting sequence.

The immunostimulatory bacteria can contain nucleic acids on the plasmid encoding two or more different RNA molecules that inhibit, suppress or disrupt
 10 expression of an immune checkpoint or an RNA molecule that encodes an inhibitor of a metabolite that is immunosuppressive or is in an immunosuppressive pathway.

The nucleic acids encoding the RNAi, such as shRNA or miRNA or siRNA can include a transcriptional terminator following the RNA-encoding nucleic acid. In all embodiments, the RNAi encoded on the plasmid in the immunostimulatory
 15 bacteria can be short hairpin RNAs (shRNAs) or micro-RNAs (miRNAs).

The plasmids in any of the immunostimulatory bacteria also can encode a sequence of nucleotides that is an agonist of retinoic acid-inducible gene I (RIG-I) or a RIG-I binding element.

The immunostimulatory bacteria can include one or more of deletions in
 20 genes, such as one or more of *purI*⁻ (*purM*⁻), *msbB*⁻, *purD*⁻, *flagellin*⁻ (*fliC*⁻/*fliB*⁻), *pagP*⁻, *adrA*⁻, *csgD*⁻ and *hlyA*⁻. The immunostimulatory bacteria can be *msbB*⁻. For example, the immunostimulatory bacteria can contain one or more of a *purI* deletion, an *msbB* deletion, an *asd* deletion, and *adrA* deletion, and optionally a *csgD* deletion. Exemplary of bacterial gene deletions/modifications are any of the following:

25 one or more of a mutation in a gene that alters the biosynthesis of lipopolysaccharide selected from among one or more of *rfaL*, *rfaG*, *rfaH*, *rfaD*, *rfaP*, *rFb*, *rfa*, *msbB*, *htrB*, *firA*, *pagL*, *pagP*, *lpxR*, *arnT*, *eptA*, and *lpxT*; and/or

one or more of a mutation that introduces a suicide gene and is selected from one or more of *sacB*, *nuk*, *hok*, *gef*, *kil* or *phlA*; and/or

30 one or more of a mutation that introduces a bacterial lysis gene and is selected from one or both of *hly* and *cly*; and/or

a mutation in one or more virulence factor(s) selected from among *IsyA*, *pag*, *prg*, *iscA*, *virG*, *plc* and *act*; and/or

one or more mutations that modify the stress response selected from among *recA*, *htrA*, *htpR*, *hsp* and *groEL*; and/or

5 a mutation in *min* that disrupts the cell cycle; and/or

one or more mutations that disrupt or inactivate regulatory functions selected from among *cya*, *crp*, *phoP/phoQ*, and *ompR*.

The immunostimulatory bacterium can be a strain of *Salmonella*, *Shigella*, *E. coli*, *Bifidobacteriae*, *Rickettsia*, *Vibrio*, *Listeria*, *Klebsiella*, *Bordetella*, *Neisseria*,
10 *Aeromonas*, *Francisella*, *Cholera*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*, *Mycoplasma*, *Legionella*, *Rhodococcus*, *Pseudomonas*, *Helicobacter*, *Bacillus*, or *Erysipelothrix*, or an attenuated strain thereof or modified strain thereof of any of the preceding list of bacterial strains.

Exemplary of the immunostimulatory bacteria are those where the plasmid
15 contains one or more of a sequence of nucleic acids encoding a listeriolysin O (LLO) protein lacking the signal sequence (cytoLLO), a CpG motif, a DNA nuclear targeting sequence (DTS), and a retinoic acid-inducible gene-I (RIG-I) binding element.

Where the plasmid contains two or more therapeutic products under control of separate promoters each is separated by at least about 75 nucleotides, or at least 75
20 nucleotides, up to about or at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500 nucleotides (or base pairs), up to about 1600 or 1600 nucleotides (or base pairs), or between 75-1500 or 1600 nucleotides (or base pairs).

Other exemplary immunostimulatory bacteria include those that are
25 auxotrophic for adenosine, and comprise: one or more of a deletion in the gene(s) encoding the flagella; a deletion in *endA*; a plasmid that encodes CytoLLO; a nuclear localization sequence; and an *asd* plasmid complementation system; and encode a therapeutic product, including a gain-of-function variants of an immunostimulatory protein that, in unmodified form, is part of a cytosolic DNA/RNA sensor pathway that
30 leads to expression of type I interferon (IFN), such as any described herein.

Such immunostimulatory bacteria include strains of *Salmonella*, such as a wild type *Salmonella typhimurium* strain, such as the strain deposited under ATCC

accession no. 14028, or a strain having all of the identifying characteristics of the strain deposited under ATCC accession #14028. Other strains include, for example, an attenuated *Salmonella typhimurium* strain selected from among strains designated as AST-100, VNP20009, or strains YS1646 (ATCC #202165), RE88, SL7207, χ 8429, χ 8431, and χ 8468.

The immunostimulatory bacteria can contain one or more of a *purI* deletion, an *msbB* deletion, an *asd* deletion, and an *adrA* deletion, in addition to the modifications that increase accumulation in tumor cells and/or reduce cell death, and can encode an immunostimulatory protein as described herein. The

immunostimulatory bacteria also can include:

one or more of a mutation in a gene that alters the biosynthesis of lipopolysaccharide selected from among one or more of *rfaL*, *rfaG*, *rfaH*, *rfaD*, *rfaP*, *rFb*, *rfa*, *msbB*, *htrB*, *firA*, *pagL*, *pagP*, *lpxR*, *arnT*, *eptA*, and *lpxT*; and/or

one or more of a mutation that introduces a suicide gene and is selected from among one or more of *sacB*, *muk*, *hok*, *gef*, *kil* and *phlA*; and/or

one or more of a mutation that introduces a bacterial lysis gene and is selected from among one or both of *hly* and *cly*; and/or

a mutation in one or more virulence factor(s) selected from among *IsyA*, *pag*, *prg*, *iscA*, *virG*, *plc* and *act*; and/or

one or more mutations that modify the stress response selected from among *recA*, *htrA*, *htpR*, *hsp* and *groEL*; and/or

a mutation in *min* that disrupts the cell cycle; and/or

one or more mutations that disrupt or inactivate regulatory functions selected from among *cya*, *crp*, *phoP/phoQ* and *ompR*.

The strains can be one or more of *msbB*⁻, *asd*⁻, *hilA*⁻ and/or flagellin⁻ (*fliC*/*fljB*⁻), and/or *pagP*⁻. The therapeutic product, such as gain-of-function variants of an immunostimulatory protein that, in unmodified form, is part of a cytosolic DNA/RNA sensor pathway that leads to expression of type I interferon (IFN), RNAi, and immunostimulatory proteins, such as chemokines/cytokines, are expressed under control of a promoter recognized by the host, such as an RNAP III promoter or an RNAP II promoter, as described herein. The immunostimulatory bacterium can be a strain of *Salmonella*, *Shigella*, *E. coli*, *Bifidobacteriae*, *Rickettsia*, *Vibrio*, *Listeria*,

Klebsiella, Bordetella, Neisseria, Aeromonas, Francisella, Cholera, Corynebacterium, Citrobacter, Chlamydia, Haemophilus, Brucella, Mycobacterium, Mycoplasma, Legionella, Rhodococcus, Pseudomonas, Helicobacter, Bacillus, or Erysipelothrix, or an attenuated strain thereof or a modified strain thereof of any of the preceding list of bacterial strains. Generally, the strain is one that is attenuated in the host, either as an attenuated strain or by virtue of the modifications that alter its properties, including cells it can infect and ability to replication in certain cells or all cells. *Salmonella* strains, such as *S. typhimurium*, are exemplary of the bacteria. Exemplary strains include *Salmonella typhimurium* strains derived from strains designated as AST-100, VNP20009, or strains YS1646 (ATCC #202165), RE88, SL7207, χ 8429, χ 8431, χ 8468, and the wild-type strain ATCC #14028.

Compositions containing the immunostimulatory bacteria are provided. Such compositions contain the bacteria and a pharmaceutically acceptable excipient or vehicle. The immunostimulatory bacteria include any described herein or in patents/applications incorporated herein or known to those of skill in the art. Such bacteria are modified to encode a variant of an immunostimulatory protein that is part of a signaling pathway resulting in expression of a type I interferon. The protein, such as a STING protein, is modified so that it has increased activity and/or leads to constitutive expression of the type I interferon, such as interferon- α or interferon- β . The bacteria can also encode an immunostimulatory protein that increases anti-tumor activity in the tumor microenvironment or in the tumor, such as a cytokine. The genomes of the bacteria can be modified to have increased infectivity of immune cells, and or reduced infectivity of non-immune cells, and/or reduced ability to induce cell death of immune cells. Hence, the bacteria are modified as described herein to accumulate in tumors or the tumor microenvironment or tumor-resident immune cells, and/or to deliver immunostimulatory proteins that promote anti-tumor activity. The immunostimulatory bacteria can additionally contain a plasmid encoding RNAi, such as miRNA or shRNA, or a CRISPR cassette, that target an immune checkpoint, or otherwise enhance the anti-tumor activity of the bacteria.

A single dose is therapeutically effective for treating a disease or disorder in which immune stimulation effects treatment. Exemplary of such stimulation is an immune response, that includes, but is not limited to, one or both of a specific

immune response and non-specific immune response, specific and non-specific immune responses, an innate response, a primary immune response, adaptive immunity, a secondary immune response, a memory immune response, immune cell activation, immune cell proliferation, immune cell differentiation, and cytokine
5 expression.

Provided are immunostimulatory bacteria that are cGAS agonists. Exemplary of such bacteria are *Salmonella* species, such as *S. typhimurium*, that is one or both of a cGAS agonist and Stimulator of Interferon Genes (STING) agonist. These can be administered, for example, in uses and methods, such as radiotherapy and
10 chemotherapy, in which cytosolic DNA is produced or accumulates. STING activates innate immunity in response to sensing nucleic acids in the cytosol. Downstream signaling is activated through binding of cyclic dinucleotides (CDNs), which are synthesized by bacteria or by host enzyme cGAS in response to binding to cytosolic dsDNA. Bacterial and host-produced CDNs have distinct phosphate bridge structures,
15 which differentiates their capacity to activate STING. CDNs are synthesized by bacteria or by host enzyme cGAS in response to binding cytosolic dsDNA. IFN- β is the signature cytokine of activated STING.

Also provided are modified non-human STING proteins and STING protein chimeras, as well as delivery vehicles, including any described herein, including the
20 bacteria, liposomes, exosomes, minicells, nanoparticles, vectors, such as oncolytic virus, pharmaceutical compositions containing the proteins and/or the delivery vehicles, cells encoding or containing these STING proteins and/or containing the delivery vehicles, and uses thereof and methods of treatment of cancers. The modified non-human STING proteins and STING protein chimeras, as well as the delivery
25 vehicles, cells, immunostimulatory bacteria, uses, methods and pharmaceutical compositions, include, but are not limited to:

1. Modified non-human STING proteins, where the non-human STING protein is one that has lower NF- κ B activation than the human STING protein, and, optionally, higher type I interferon activation/signaling activity, compared to the wild
30 type (WT) human STING protein. These non-human STING proteins are modified to include a mutation or mutations so that they have increased activity or act constitutively, in the absence of cytosolic nucleic acid signaling. The mutations are

typically amino acid mutations that occur in interferonopathies in humans, such as those described above for human STING. The corresponding mutations are introduced into the non-human species STING proteins, where corresponding amino acid residues are identified by alignment (see, *e.g.*, figures 1-13). Also, in some
5 embodiments, the TRAF6 binding site in the C-terminal tail (CTT) of the STING protein is deleted, reducing NF- κ B signaling activity.

2. Modified STING proteins, particularly human STING proteins, that are chimeras, in which the CTT (C-terminal tail) region in the STING protein from one species, such as human, is replaced with the CTT from the STING protein of another,
10 non-human species that has lower NF- κ B signaling activity and/or higher type I IFN signaling activity than human STING. Also, the TRAF6 binding site is optionally deleted from the CTT in these chimeras.

3. The modified STING proteins of 2 that also include the mutations of 1.

4. Delivery vehicles, such as immunostimulatory bacteria, any provided
15 herein or known to those of skill in the art, including exosomes, minicells, liposomes, nanoparticles, oncolytic viruses, and other viral vectors, that encode the modified STING proteins of any of 1-3.

5. Delivery vehicles, such as immunostimulatory bacteria, any provided herein or known to those of skill in the art, including exosomes, minicells, liposomes,
20 nanoparticles, oncolytic viruses, and other viral vectors, that encode unmodified STING from non-human species whose STING protein has reduced NF- κ B signaling activity compared to that of human STING, and optionally increased type I interferon stimulating/signaling activity.

6. Cells (non-zygotes, if human), such as cells used for cell therapy, such as
25 T-cells and stem cells, and cells used to produce the proteins of any of 1-3.

7. Pharmaceutical compositions that contain the STING proteins of 1-3 or the delivery vehicles of 4 and 5, or the cells of 6.

8. Uses and methods of treatment of cancer by administering any of 1-7, as described herein for the immunostimulatory bacteria.

30 9. Also provided are immunostimulatory bacteria that encode non-human STING proteins, particularly any that have lower NF- κ B activity (signaling activity)

and similar or greater type I interferon stimulating activity or interferon- β stimulating activity compared to human STING.

Assays and methods to assess NF- κ B activity (signaling activity) and type I interferon stimulating activity or interferon- β stimulating activity of STING are described herein, and also are known to those of skill in the art. Methods include those described, for example, in de Oliveira Mann *et al.* (2019) *Cell Reports* 27:1165-1175, which describes, *inter alia*, the interferon- β and NF- κ B signaling activity of STING proteins from various species, including human, thereby identifying STING proteins from various species that have lower NF- κ B activity than human STING, and those that also have comparable or higher interferon- β activity than human STING. de Oliveira Mann *et al.* (2019) provides species alignments and identifies domains of STING in each species, including the CTT domain (see, also, the Supplemental Information for de Oliveira Mann *et al.* (2019)).

The non-human STING proteins can be, but are not limited to, STING proteins from the following species: Tasmanian devil (*Sarcophilus harrisii*; SEQ ID NO:331), marmoset (*Callithrix jacchus*; SEQ ID NO:341), cattle (*Bos taurus*; SEQ ID NO:342), cat (*Felis catus*; SEQ ID NO:338), ostrich (*Struthio camelus australis*; SEQ ID NO:343), crested ibis (*Nipponia nippon*; SEQ ID NO:344), coelacanth (*Latimeria chalumnae*; SEQ ID NOs:345-346), boar (*Sus scrofa*; SEQ ID NO:347), bat (*Rousettus aegyptiacus*; SEQ ID NO:348), manatee (*Trichechus manatus latirostris*; SEQ ID NO:349), ghost shark (*Callorhynchus milii*; SEQ ID NO:350), mouse (*Mus musculus*; SEQ ID NO:351), and zebrafish (*Danio rerio*; SEQ ID NO:330). These vertebrate STING proteins readily activate immune signaling in human cells, indicating that the molecular mechanism of STING signaling is shared in vertebrates (see, de Oliveira Mann *et al.* (2019) *Cell Reports* 27:1165-1175).

Pharmaceutical compositions containing any of the immunostimulatory bacteria and other delivery vehicles also are provided. As are uses thereof for treatment of cancers, and methods of treatment of cancer. Methods and uses include treating a subject who has cancer, comprising administering an immunostimulatory bacterium or the pharmaceutical composition to a subject, such as a human. A method of treating a subject who has cancer, comprising administering an immunostimulatory bacterium, is provided.

Methods and uses include combination therapy in which a second anti-cancer agent or treatment is administered. The second anti-cancer agent can be a chemotherapeutic agent that results in cytosolic DNA, or radiotherapy, or an immune checkpoint inhibitor, such as an anti-PD-1, or anti-PD-L1 or anti-CTLA-4 antibody, or CAR-T cells or other therapeutic cells, such as stem cells, TIL cells and modified cells for cancer therapy.

Administration can be by any suitable route, such as parenteral, and can include additional agents that can facilitate or enhance delivery. Administration can be oral or rectal or by aerosol into the lung, or intratumoral, intravenously, intramuscularly, or subcutaneously. Administration can be by any suitable route, including systemic or local or topical, such as parenteral, including, for example, oral or rectal or by aerosol into the lung, intratumoral, intravenously, intramuscularly, or subcutaneously.

Cancers include solid tumors and hematologic malignancies, such as, but not limited to, lymphoma, leukemia, gastric cancer, and cancer of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, colorectum, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, and liver.

The immunostimulatory bacteria can be formulated into compositions for administration, such as suspensions. They can be dried and stored as powders. Combinations of the immunostimulatory bacteria with other anti-cancer agents also are provided.

Combination therapies for treatment of cancers and malignancies are provided. The immunostimulatory bacteria can be administered before, after, intermittently with, or concurrently with, other cancer therapies, including radiotherapy, chemotherapies, particularly genotoxic chemotherapies that result in cytosolic DNA, and immunotherapies, such as checkpoint inhibitor antibodies, including anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA-4 antibodies, and other such immunotherapies.

Also provided are isolated cells that contain the immunostimulatory bacteria or that contain any of the other delivery vehicles, such as exosomes, liposomes and other such vehicles, that contain nucleic acids encoding the gain-of-function variant

proteins and other therapeutic products as described herein. Cells include, but are not limited to, immune cells, stem cells, tumor cells, primary cell lines, and other cells used in cell therapy. Exemplary cells include, for example, hematopoietic cells, such as T-cells, and hematopoietic stem cells. The hematopoietic cell can be a chimeric antigen myeloid cell, such as a macrophage. The delivery vehicles and immunostimulatory bacteria can be introduced into the cells *ex vivo*. Thus, for example, provided are isolated cells that contain immunostimulatory bacteria, where: the immunostimulatory bacterium is modified so that it preferentially infects tumor-resident immune cells, and/or the genome of the immunostimulatory bacterium is modified so that it induces less cell death in tumor-resident immune cells; and the cell is an immune cell, a stem cell, a cell from a primary cell line, or a tumor cell. The cells are used in methods of cell therapy, such as for the treatment of cancers. The cells can be allogeneic or autologous to the subject treated.

Also provided are methods for increasing tumor/tumor microenvironment colonization by an immunostimulatory bacterium. The methods include, for example, modifying the genome of a bacterium to render the bacterium flagellin⁻ (*fliC*⁻/*fljB*⁻) and/or *pagP*⁻.

The terms and expressions that are employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions to exclude any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are contemplated.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the alignment of wild-type human and Tasmanian devil STING proteins.

Figure 2 depicts the alignment of wild-type human and marmoset STING proteins.

Figure 3 depicts the alignment of wild-type human and cattle STING proteins.

Figure 4 depicts the alignment of wild-type human and cat STING proteins.

Figure 5 depicts the alignment of wild-type human and ostrich STING proteins.

Figure 6 depicts the alignment of wild-type human and crested ibis STING proteins.

Figure 7 depicts the alignment of wild-type human and coelacanth (SEQ ID NO:345) STING proteins.

Figure 8 depicts the alignment of wild-type human and zebrafish STING proteins.

5 **Figure 9** depicts the alignment of wild-type human and boar STING proteins.

Figure 10 depicts the alignment of wild-type human and bat STING proteins.

Figure 11 depicts the alignment of wild-type human and manatee STING proteins.

10 **Figure 12** depicts the alignment of wild-type human and ghost shark STING proteins.

Figure 13 depicts the alignment of wild-type human and mouse STING proteins.

DETAILED DESCRIPTION

OUTLINE

- 15 **A. DEFINITIONS**
- B. OVERVIEW OF THE IMMUNOSTIMULATORY BACTERIA**
- C. CANCER IMMUNOTHERAPEUTICS**
- 20 **1. Immunotherapies**
- 2. Adoptive Immunotherapies**
- 3. Cancer Vaccines and Oncolytic Viruses**
- D. BACTERIAL CANCER IMMUNOTHERAPY**
- 1. Bacterial Therapies**
- 2. Comparison of the Immune Responses to Bacteria and**
- Viruses**
- 25 **3. *Salmonella* Therapy**
- a. Tumor-tropic Bacteria**
- b. *Salmonella enterica* serovar *typhimurium***
- c. Bacterial Attenuation**
- 30 **i. *msbB* Mutants**
- ii. *purI* Mutants**
- iii. Combinations of Attenuating Mutations**

- iv. VNP20009 and Other Attenuated *S. typhimurium* strains
 - v. *S. typhimurium* Engineered To Deliver Macromolecules
 4. Enhancements of Immunostimulatory Bacteria to Increase Therapeutic Index and Expression in Tumor-Resident Immune Cells
 - a. *asd* Gene Deletion
 - b. Adenosine Auxotrophy
 - c. Flagellin Deficient Strains
 - d. Deletion of Genes in the LPS Biosynthetic Pathway
 - e. Deletions in Genes Required for Biofilm Formation
 - f. *Salmonella* Engineered to Escape the *Salmonella* Containing Vacuole (SCV)
 - g. Deletions of SPI-1 and SPI-2 Genes and/or Other Genes to Eliminate the Ability of the Bacteria to Infect Epithelial Cells, Including Deletion of Flagella
 - i. *Salmonella* Pathogenicity Island 1 (SPI-1)
 - SPI-1-Dependent Host Cell Invasion
 - SPI-1-Independent Host Cell Invasion
 - ii. *Salmonella* Pathogenicity Island 2 (SPI-2)
 - h. Endonuclease (*endA*) Mutations to Increase Plasmid Delivery
 - i. RIG-I Binding Sequences
 - j. DNase II Inhibition
 - k. RNase H2 Inhibition
 - l. Stabilin-1/CLEVER-1 Inhibition
 - m. CpG Motifs and CpG Islands
 5. Modifications that Increase Uptake of Gram-Negative Bacteria, such as *Salmonella*, by Immune Cells, and Reduce Immune Cell Death
 - a. Bacterial Uptake by Immune cells

-33-

- b. **Macrophage Pyroptosis**
 - i. **Flagellin**
 - ii. **SPI-1 Proteins**
 - Rod Protein (PrgJ)**
 - 5 **Needle protein (PrgI)**
 - iii. **QseC**
 - 6. **Bacterial Culture Conditions**
 - 7. **Increased Tumor Colonization**
- E. **NON-HUMAN STING PROTEINS AND GAIN-OF-FUNCTION**
 - 10 **MUTATIONS IN PROTEINS THAT STIMULATE THE**
 - IMMUNE RESPONSE IN THE TUMOR**
 - MICROENVIRONMENT**
 - 1. **Type I Interferons and Pathways**
 - 2. **Type I Interferonopathies and Gain-of-Function Mutants**
 - 15 3. **STING-Mediated Immune Activation**
 - 4. ***TMEM173* Alleles**
 - 5. **Constitutive STING Expression and Gain-of-Function**
 - Mutations**
 - 6. **Non-human STING Proteins, and Variants Thereof with**
 - 20 **Increased or Constitutive Activity, and STING Chimeras,**
 - and Variants Thereof with Increased or Constitutive**
 - Activity**
 - 7. **Other Gene Products that Act as Cytosolic DNA/RNA**
 - Sensors and Constitutive Variants**
 - 25 a. **Retinoic Acid-Inducible Gene I (RIG-I)-Like**
 - Receptors (RLRs)**
 - b. **MDA5/IFIH1**
 - c. **RIG-I**
 - d. **IRF-3 and IRF-7**
 - 30 8. **Other Type I IFN Regulatory Proteins**
 - 9. **Other Therapeutic Products**

- F. IMMUNOSTIMULATORY BACTERIA ENCODING THE PROTEINS AND CONSTRUCTION OF EXEMPLARY PLASMIDS AND DELIVERY VEHICLES**
1. Origin of Replication and Plasmid Copy Number
 2. Plasmid Maintenance/Selection Components
 3. RNA Polymerase Promoters
 4. DNA Nuclear Targeting Sequences
 5. CRISPR
- G. OTHER DELIVERY VEHICLES ENCODING THE NON-HUMAN STING PROTEINS AND GAIN-OF-FUNCTION MODIFIED PROTEINS THAT CONSTITUTIVELY INDUCE TYPE I INTERFERON AND OTHER THERAPEUTIC PRODUCTS**
1. Exosomes, Extracellular Vesicles, And Other Vesicular Delivery Vehicles
 2. Oncolytic Viruses
 - a. Adenovirus
 - b. Herpes Simplex Virus
 - c. Poxvirus
 - d. Measles Virus
 - e. Reovirus
 - f. Vesicular Stomatitis Virus (VSV)
 - g. Newcastle Disease Virus
 - h. Parvovirus
 - i. Coxsackie Virus
 - j. Seneca Valley Virus
- H. PHARMACEUTICAL PRODUCTION, COMPOSITIONS, AND FORMULATIONS**
1. Manufacturing
 - a. Cell Bank Manufacturing
 - b. Drug Substance Manufacturing
 - c. Drug Product Manufacturing

2. Compositions**3. Formulations****a. Liquids, Injectables, Emulsions****b. Dried Thermostable Formulations****5 4. Compositions for Other Routes of Administration****5. Dosages and Administration****6. Packaging and Articles of Manufacture****I. METHODS OF TREATMENT AND USES****1. Tumors****10 2. Administration****3. Monitoring****J. EXAMPLES****A. DEFINITIONS**

Unless defined otherwise, all technical and scientific terms used herein have
15 the same meaning as is commonly understood by one of skill in the art to which the
invention(s) belong. All patents, patent applications, published applications and
publications, GenBank sequences, databases, websites and other published materials
referred to throughout the entire disclosure herein, unless noted otherwise, are
incorporated by reference in their entirety. In the event that there are a plurality of
20 definitions for terms herein, those in this section prevail. Where reference is made to a
URL or other such identifier or address, it is understood that such identifiers can
change and particular information on the internet can come and go, but equivalent
information can be found by searching the internet. Reference thereto evidences the
availability and public dissemination of such information.

25 As used herein, therapeutic bacteria are bacteria that effect therapy, such as
cancer or anti-tumor therapy, when administered to a subject, such as a human.

As used herein, immunostimulatory bacteria are therapeutic bacteria that,
when introduced into a subject, accumulate in immunoprivileged tissues and cells,
such as tumors, and replicate and/or express products that are immunostimulatory or
30 that result in immunostimulation. For example, the immunostimulatory bacteria are
attenuated in the host by virtue of reduced toxicity or pathogenicity and/or by virtue
of encoded products that reduce toxicity or pathogenicity, as the immunostimulatory

bacteria cannot replicate and/or express products (or have reduced replication/product expression), except primarily in immunoprivileged environments. Immunostimulatory bacteria provided herein are modified to encode a product or products or exhibit a trait or property that renders them immunostimulatory. Such products, properties and traits
5 include, but are not limited to, for example, at least one of: an immunostimulatory protein, such as a cytokine or co-stimulatory molecule; a DNA/RNA sensor or gain-of-function variant thereof (*e.g.*, STING, MDA5, RIG-I); RNAi, such as siRNA (shRNA and microRNA), CRISPR, that targets, disrupts or inhibits a checkpoint gene such as TREX1 and/or PD-L1; or an inhibitor of an immune checkpoint such as an
10 anti-immune checkpoint antibody. Immunostimulatory bacteria also can include a modification that renders the bacterium auxotrophic for a metabolite that is immunosuppressive or that is in an immunosuppressive pathway, such as adenosine.

As used herein, the strain designations VNP20009 (see, *e.g.*, International PCT Application Publication No. WO 99/13053, see, also U.S. Patent No. 6,863,894)
15 and YS1646 and 41.2.9 are used interchangeably and each refer to the strain deposited with the American Type Culture Collection and assigned Accession No. 202165. VNP20009 is a modified attenuated strain of *Salmonella typhimurium*, which contains deletions in *msbB* and *purI*, and was generated from wild type strain ATCC 14028.

As used herein, the strain designations YS1456 and 8.7 are used
20 interchangeably and each refer to the strain deposited with the American Type Culture Collection and assigned Accession No. 202164 (see, U.S. Patent No. 6,863,894).

As used herein, an interferonopathy refers to a disorder associated with an upregulation of interferon by virtue of a mutation in a gene product involved in a pathway that regulates or induces expression of interferon. The activity of the
25 products normally is regulated by a mediator, such as cytosolic DNA or RNA or nucleotides; when mutated, the activity is constitutive. Type I interferonopathies include a spectrum of conditions, including the severe forms of Aicardi-Goutières Syndrome (AGS) and the milder Familial Chilblain Lupus (FCL). Nucleic acid molecules encoding mutated products with these properties can be produced *in vitro*,
30 such as by selecting for mutations that result in a gain-of-function in the product, compared to the product of an allele that has normal activity, or has further gain-of-

function compared to the disease-associated gain-of-function mutants described herein.

As used herein, a gain-of-function mutation is one that increases the activity of a protein compared to the same protein that does not have the mutation. For example,
5 if the protein is a receptor, it will have increased affinity for a ligand; if it is an enzyme, it will have increased activity, including constitutive activity.

As used herein, an origin of replication is a sequence of DNA at which replication is initiated on a chromosome, plasmid or virus. For small DNA, including bacterial plasmids and small viruses, a single origin is sufficient.

10 The origin of replication determines the vector copy number, which depends upon the selected origin of replication. For example, if the expression vector is derived from the low-copy-number plasmid pBR322, it is between about 25–50 copies/cell, and if derived from the high-copy-number plasmid pUC, it can be 150–200 copies/cell.

15 As used herein, medium copy number of a plasmid in cells is about or is 150 or less than 150, low copy number is 15-30, such as 20 or less than 20. Low to medium copy number is less than 150. High copy number is greater than 150 copies/cell.

As used herein, 2A peptides are 18–22 amino-acid (aa)-long viral
20 oligopeptides that mediate cleavage of polypeptides during translation in eukaryotic cells. The designation “2A” refers to a specific region of the viral genome and different viral 2As have generally been named after the virus they were derived from. Exemplary of these are F2A (foot-and-mouth disease virus 2A), E2A (equine rhinitis A virus), P2A (porcine teschovirus-1 2A), and T2A (Thosea asigna virus 2A). (See,
25 *e.g.*, Liu *et al.* (2017) *Scientific Reports* 7:2193, Fig. 1, for encoding sequences; see, also, SEQ ID NOs:367-370).

As used herein, a CpG motif is a pattern of bases that include an unmethylated central CpG ("p" refers to the phosphodiester link between consecutive C and G nucleotides) surrounded by at least one base flanking (on the 3' and the 5' side of) the
30 central CpG. A CpG oligodeoxynucleotide is an oligodeoxynucleotide that is at least about ten nucleotides in length and includes an unmethylated CpG. At least the C of the 5' CG 3' is unmethylated.

As used herein, a RIG-I binding sequence refers to a 5' triphosphate (5' ppp) structure directly, or that which is synthesized by RNA pol III from a poly(dA-dT) sequence, which by virtue of interaction with RIG-I can activate type I IFN via the RIG-I pathway. The RNA includes at least four A ribonucleotides (A-A-A-A); it can
5 contain 4, 5, 6, 7, 8, 9, 10 or more. The RIG-I binding sequence is introduced into a plasmid in the bacterium for transcription into the polyA.

As used herein, "cytokines" are a broad and loose category of small proteins (~5–20 kDa) that are important in cell signaling. Cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors. Cytokines are cell
10 signaling molecules that aid cell to cell communication in immune responses, and stimulate the movement of cells towards sites of inflammation, infection and trauma.

As used herein, "chemokines" refer to chemoattractant (chemotactic) cytokines that bind to chemokine receptors and include proteins isolated from natural sources as well as those made synthetically, as by recombinant means or by chemical
15 synthesis. Exemplary chemokines include, but are not limited to, IL-8, IL-10, GCP-2, GRO- α , GRO- β , GRO- γ , ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG (CXCL9), CXCL10, CXCL11, PF4, IP-10, SDF-1 α , SDF-1 β , SDF-2, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MIP-1 α (CCL3), MIP-1 β (CCL4), MIP-1 γ , MIP-2, MIP-2 α , MIP-3 α , MIP-3 β , MIP-4, MIP-5, MDC, HCC-1, ALP, lungkine, Tim-1, eotaxin-1, eotaxin-2, I-
20 309, SCYA17, TRAC, RANTES (CCL5), DC-CK-1, lymphotactin, and fractalkine, and others known to those of skill in the art. Chemokines are involved in the migration of immune cells to sites of inflammation, as well as in the maturation of immune cells and in the generation of adaptive immune responses.

As used herein, an "immunostimulatory protein" is a protein that exhibits or
25 promotes an anti-tumor immune response in the tumor microenvironment. Exemplary of such proteins are cytokines, chemokines, and co-stimulatory molecules, such as, but not limited to, GM-CSF, IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-23, IL-36 gamma, IFN α , IFN β , IL-12p70 (IL-12p40 + IL-12p35), IL-15/IL-15R alpha chain complex, CXCL9, CXCL10, CXCL11, CCL3, CCL4, CCL5, molecules involved in
30 the potential recruitment/persistence of T cells, CD40, CD40 ligand (CD40L), OX40, OX40 ligand (OX40L), 4-1BB, 4-1BB ligand (4-1BBL), members of the B7-CD28 family and members of the TNFR superfamily.

As used herein, a cytosolic DNA/RNA sensor pathway is one that is initiated by the presence of DNA, RNA, nucleotides, dinucleotides, cyclic nucleotides and/or cyclic dinucleotides or other nucleic acid molecules, that leads to production of type I interferon. The nucleic acid molecules in the cytosol occur from viral or bacterial or
5 radiation or other such exposure, leading to activation of an immune response in a host.

As used herein, an immunostimulatory protein that induces an innate immune response, such as induction of type I interferon, is a protein that is part of a cytosolic DNA/RNA sensor pathway that leads to expression of the immune response mediator,
10 such as type I interferon. For example, as described herein and known to those of skill in the art, cytosolic DNA is sensed by cGAS, leading to the production of cGAMP and subsequent STING (Stimulator of Interferon Genes)/TBK1 (TANK-binding kinase 1)/IRF3 (interferon regulatory factor) signaling, and type I IFN production. Bacterial cyclic dinucleotides (CDNs, such as bacterial cyclic di-AMP) also activate
15 STING. Hence, STING is an immunostimulatory protein that induces type I interferon. 5'- triphosphate RNA and double stranded RNA are sensed by RIG-I and either MDA-5 alone or MDA-5/LGP2. This leads to polymerization of mitochondrial MAVS (mitochondrial anti-signaling protein), and also activates TBK1 and IRF3. The proteins in such pathways are immunostimulatory proteins that lead to expression of
20 innate immune response mediators, such as type I interferon. The immunostimulatory proteins in the DNA/RNA sensor pathways can be modified so that they have increased activity or act constitutively, in the absence of cytosolic nucleic acid, to lead to the immune response, such as expression of type I interferon.

As used herein, the "carboxy-terminal tail" or "C-terminal tail" (CTT) of the
25 innate immune protein STING refers to the C-terminal portion of a STING protein that, in a wild-type STING protein, is tethered to the cGAMP-binding domain by a flexible linker region. The CTT includes an IRF3 binding site, a TBK1 binding site, and a TRAF6 binding site. STING promotes the induction of interferon beta (IFN- β) production via the phosphorylation of the STING protein C-terminal tail (CTT) by
30 TANK-binding kinase 1 (TBK1). The interaction between STING and TBK1 is mediated by an evolutionarily conserved stretch of eight amino-acid residues in the carboxy-terminal tail (CTT) of STING. TRAF6 catalyzes the formation of K63-linked

- ubiquitin chains on STING, leading to the activation of the transcription factor NF- κ B and the induction of an alternative STING-dependent gene expression program.
- Deletion of the TRAF6 binding site in the CTT can reduce activation of NF- κ B signaling. Substitution of the human CTT (or portions thereof) with the CTT (or
- 5 corresponding portion thereof) from STING of species with low NF- κ B activation can decrease NF- κ B activation by human STING. The STING CTT is an unstructured stretch of ~40 amino acids that contains sequence motifs required for STING phosphorylation and recruitment of IRF3 (see, de Oliveira Mann *et al.* (2019) *Cell Reports* 27:1165-1175). Human STING residue S366 has been identified as a primary
- 10 TBK1 phosphorylation site that is part of an LxIS motif shared among innate immune adaptor proteins that activate interferon signaling (see, de Oliveira Mann *et al.* (2019) *Cell Reports* 27:1165-1175). The human STING CTT contains a second PxPLR motif that includes the residue L374, which is required for TBK1 binding; the LxIS and PxPLR sequences are conserved among vertebrate STING alleles (see, de Oliveira
- 15 Mann *et al.* (2019) *Cell Reports* 27:1165-1175). Exemplary STING CTT sequences, and the IRF3, TBK1 and TRAF6 binding sites are set forth in the following table:

Species	C-terminal Tail (CTT) Sequence	SEQ ID NO.	IRF3 Binding Site	TBK1 Binding Site	TRAF6 Binding Site
Human	EKEEVTVGSLKTSAPVSTSTMS QEPELLISGMEKPLPLRTDFS	352	PELLIS	PLPLRT	DFS
Tasmanian devil	RQEEFAIGPKRAMTVTTSSTLS QEPQLLISGMEQPLSLRTDGF	353	PQLLIS	PLSLRT	DGF
Marmoset	EEEEVTVGSLKTSEVPSTSTMS QEPELLISGMEKPLPLRSDLF	354	PELLIS	PLPLRS	DLF
Cattle	EREVTMGSTETSVMPGSSVLS QEPELLISGLEKPLPLRSDVF	355	PELLIS	PLPLRS	DVF
Cat	EREVTVGSVGTSMVRNPSVLS QEPNLLISGMEQPLPLRTDVF	356	PNLLIS	PLPLRT	DVF
Ostrich	RQEEYTVCDGTLCSTDLSLQIS ESDLPQPLRSDCL	357	LSLQIS	PQPLRS	DCL
Boar	EREVTMGSAETSVVPTSSTLSQ EPELLISGMEQPLPLRSDIF	358	PELLIS	PLPLRS	DIF
Bat	EKEEVTVGTVGTYEAPGSSTL HQEPELLISGMDQPLPLRTDIF	359	PELLIS	PLPLRT	DIF
Manatee	EREVTVGSVGTSVVPSPSSPS TSSLSQEPKLLISGMEQPLPLRT DVF	360	PKLLIS	PLPLRT	DVF
Crested ibis	CHEEYTVYEGNQPHNPSTTLH STELNLQISEDLPQPLRSDCF	361	LNLQIS	PQPLRS	DCF
Coelacanth (variant 1)	QKEEYFMSEQTQPNSSSTSCLS TEPQLMISDTPHPTLKRQVC	362	PQLMIS	PHTLKR	QVC
Coelacanth (variant 2)	QKEEYFMSEQTQPNSSSTSCLS TEPQLMISDTPHPTLKS	363	PQLMIS	PHTLKS	GF

Zebrafish	DGEIFMDPTNEVHPVPEEGPV GNCNGALQATFHEEPMSDEPT LMFSRPQSLRSEPVETTDYFNP SSAMKQN	364	PTLMFS	PQSLRS	EPVETTDY
Ghost shark	LTEYPVAEPSNANETDCMSSE PHLMISDDPKPLRSYCP	365	PHLMIS	PKPLRS	YCP
Mouse	EKEEVTMNAPMTSVAPPPSVL SQEPRLISGMDQPLPLRTDLI	366	PRLIS	PLPLRT	DLI

As used herein, a bacterium that is modified so that it “induces less cell death in tumor-resident immune cells” is one that is less toxic than the bacterium without the modification, or one that has reduced virulence compared to the bacterium without the modification. Exemplary of such modifications are those that eliminate pyroptosis and that alter LPS profiles on the bacterium. These modifications include disruption of or deletion of flagellin genes, one or more components of the SPI-1 pathway, such as *hilA*, rod protein, needle protein, QseC and *pagP*.

As used herein, a bacterium that is “modified so that it preferentially infects tumor-resident immune cells” has a modification in its genome that reduces its ability to infect cells other than immune cells. Exemplary of such modifications are modifications that disrupt the type 3 secretion system or type 4 secretion system or other genes or systems that affect the ability of a bacterium to invade a non-immune cell. For example, disruption/deletion of an SPI-1 component, which is needed for infection of cells, such as epithelial cells, but does not affect infection of immune cells, such as phagocytic cells, by *Salmonella*.

As used herein, a “modification” is in reference to modification of a sequence of amino acids of a polypeptide or a sequence of nucleotides in a nucleic acid molecule and includes deletions, insertions, and replacements of amino acids or nucleotides, respectively. Methods of modifying a polypeptide are routine to those of skill in the art, such as by using recombinant DNA methodologies.

As used herein, a modification to a bacterial genome or to a plasmid or gene includes deletions, replacements and insertions of nucleic acid.

As used herein, RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules to inhibit translation and thereby expression of a targeted gene.

As used herein, RNA molecules that act via RNAi are referred to as inhibitory by virtue of their silencing of expression of a targeted gene. Silencing expression means that expression of the targeted gene is reduced or suppressed or inhibited.

As used herein, gene silencing via RNAi is said to inhibit, suppress, disrupt or
5 silence expression of a targeted gene. A targeted gene contains sequences of nucleotides that correspond to the sequences in the inhibitory RNA, whereby the inhibitory RNA silences expression of mRNA. Small interfering RNAs (siRNAs) are small pieces of double-stranded (ds) RNA, usually about 21 nucleotides long, with 3' overhangs (2 nucleotides) at each end that can be used to "interfere" with the
10 translation of proteins by binding to and promoting the degradation of messenger RNA (mRNA) at specific sequences. In doing so, siRNAs prevent the production of specific proteins based on the nucleotide sequences of their corresponding mRNAs. The process is called RNA interference (RNAi), and also is referred to as siRNA silencing or siRNA knockdown. A short-hairpin RNA or small-hairpin RNA
15 (shRNA) is an artificial RNA molecule with a tight hairpin turn that can be used to silence target gene expression via RNA interference (RNAi). Expression of shRNA in cells is typically accomplished by delivery of plasmids or through viral or bacterial vectors.

As used herein, inhibiting, suppressing, disrupting or silencing a targeted gene
20 refers to processes that alter expression, such as translation, of the targeted gene, whereby activity or expression of the product encoded by the targeted gene is reduced. Reduction, includes a complete knock-out or a partial knockout, whereby, with reference to the immunostimulatory bacteria provided herein and administration herein, treatment is effected.

As used herein, a tumor microenvironment (TME) is the cellular environment
25 in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules and the extracellular matrix (ECM). Conditions that exist include, but are not limited to, increased vascularization, hypoxia, low pH, increased lactate
30 concentration, increased pyruvate concentration, increased interstitial fluid pressure and altered metabolites or metabolism, such as higher levels of adenosine, indicative of a tumor.

As used herein, human type I interferons (IFNs) are a subgroup of interferon proteins that regulate the activity of the immune system. All type I IFNs bind to a specific cell surface receptor complex, such as the IFN- α receptor. Type I interferons include IFN- α and IFN- β , among others. IFN- β proteins are produced by fibroblasts, and have antiviral activity that is involved mainly in innate immune response. Two types of IFN- β are IFN- β 1 (IFNB1) and IFN- β 3 (IFNB3).

As used herein, recitation that a nucleic acid or encoded RNA targets a gene means that it inhibits or suppresses or silences expression of the gene by any mechanism. Generally, such nucleic acid includes at least a portion complementary to the targeted gene, where the portion is sufficient to form a hybrid with the complementary portion.

As used herein, "deletion," when referring to a nucleic acid or polypeptide sequence, refers to the deletion of one or more nucleotides or amino acids compared to a sequence, such as a target polynucleotide or polypeptide or a native or wild-type sequence.

As used herein, "insertion," when referring to a nucleic acid or amino acid sequence, describes the inclusion of one or more additional nucleotides or amino acids, within a target, native, wild-type or other related sequence. Thus, a nucleic acid molecule that contains one or more insertions compared to a wild-type sequence, contains one or more additional nucleotides within the linear length of the sequence.

As used herein, "additions" to nucleic acid and amino acid sequences describe addition of nucleotides or amino acids onto either termini compared to another sequence.

As used herein, "substitution" or "replacement" refers to the replacing of one or more nucleotides or amino acids in a native, target, wild-type or other nucleic acid or polypeptide sequence with an alternative nucleotide or amino acid, without changing the length (as described in numbers of residues) of the molecule. Thus, one or more substitutions in a molecule does not change the number of amino acid residues or nucleotides of the molecule. Amino acid replacements compared to a particular polypeptide can be expressed in terms of the number of the amino acid residue along the length of the polypeptide sequence.

As used herein, “at a position corresponding to,” or recitation that nucleotides or amino acid positions “correspond to” nucleotides or amino acid positions in a disclosed sequence, such as set forth in the Sequence Listing, refers to nucleotides or amino acid positions identified upon alignment with the disclosed sequence to maximize identity using a standard alignment algorithm, such as the GAP algorithm. By aligning the sequences, one skilled in the art can identify corresponding residues, for example, using conserved and identical amino acid residues as guides. In general, to identify corresponding positions, the sequences of amino acids are aligned so that the highest order match is obtained (see, *e.g.*, *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D. W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carrillo *et al.* (1988) *SIAM J Applied Math* 48:1073).

As used herein, alignment of a sequence refers to the use of homology to align two or more sequences of nucleotides or amino acids. Typically, two or more sequences that are related by 50% or more identity are aligned. An aligned set of sequences refers to 2 or more sequences that are aligned at corresponding positions and can include aligning sequences derived from RNAs, such as ESTs and other cDNAs, aligned with genomic DNA sequence. Related or variant polypeptides or nucleic acid molecules can be aligned by any method known to those of skill in the art. Such methods typically maximize matches, and include methods, such as using manual alignments and by using the numerous alignment programs available (*e.g.*, BLASTP) and others known to those of skill in the art. By aligning the sequences of polypeptides or nucleic acids, one skilled in the art can identify analogous portions or positions, using conserved and identical amino acid residues as guides. Further, one skilled in the art also can employ conserved amino acid or nucleotide residues as guides to find corresponding amino acid or nucleotide residues between and among human and non-human sequences. Corresponding positions also can be based on structural alignments, for example by using computer simulated alignments of protein

structure. In other instances, corresponding regions can be identified. One skilled in the art also can employ conserved amino acid residues as guides to find corresponding amino acid residues between and among human and non-human sequences.

As used herein, a “property” of a polypeptide, such as an antibody, refers to
5 any property exhibited by a polypeptide, including, but not limited to, binding specificity, structural configuration or conformation, protein stability, resistance to proteolysis, conformational stability, thermal tolerance, and tolerance to pH conditions. Changes in properties can alter an “activity” of the polypeptide. For example, a change in the binding specificity of the antibody polypeptide can alter the
10 ability to bind an antigen, and/or various binding activities, such as affinity or avidity, or *in vivo* activities of the polypeptide.

As used herein, an “activity” or a “functional activity” of a polypeptide, such as an antibody, refers to any activity exhibited by the polypeptide. Such activities can be empirically determined. Exemplary activities include, but are not limited to, ability
15 to interact with a biomolecule, for example, through antigen-binding, DNA binding, ligand binding, or dimerization, or enzymatic activity, for example, kinase activity or proteolytic activity. For an antibody (including antibody fragments), activities include, but are not limited to, the ability to specifically bind a particular antigen, affinity of antigen-binding (*e.g.*, high or low affinity), avidity of antigen-binding (*e.g.*, high or
20 low avidity), on-rate, off-rate, effector functions, such as the ability to promote antigen neutralization or clearance, virus neutralization, and *in vivo* activities, such as the ability to prevent infection or invasion of a pathogen, or to promote clearance, or to penetrate a particular tissue or fluid or cell in the body. Activity can be assessed *in vitro* or *in vivo* using recognized assays, such as ELISA, flow cytometry, surface
25 plasmon resonance or equivalent assays to measure on- or off-rate, immunohistochemistry and immunofluorescence histology and microscopy, cell-based assays, flow cytometry and binding assays (*e.g.*, panning assays).

As used herein, “bind,” “bound” or grammatical variations thereof refers to the participation of a molecule in any attractive interaction with another molecule,
30 resulting in a stable association in which the two molecules are in close proximity to one another. Binding includes, but is not limited to, non-covalent bonds, covalent bonds (such as reversible and irreversible covalent bonds), and includes interactions

between molecules such as, but not limited to, proteins, nucleic acids, carbohydrates, lipids, and small molecules, such as chemical compounds including drugs.

As used herein, “antibody” refers to immunoglobulins and immunoglobulin fragments, whether natural or partially or wholly synthetically, such as recombinantly produced, including any fragment thereof containing at least a portion of the variable heavy chain and light region of the immunoglobulin molecule that is sufficient to form an antigen binding site and, when assembled, to specifically bind an antigen. Hence, an antibody includes any protein having a binding domain that is homologous or substantially homologous to an immunoglobulin antigen-binding domain (antibody combining site). For example, an antibody refers to an antibody that contains two heavy chains (which can be denoted H and H’) and two light chains (which can be denoted L and L’), where each heavy chain can be a full-length immunoglobulin heavy chain or a portion thereof sufficient to form an antigen binding site (*e.g.*, heavy chains include, but are not limited to, VH chains, VH-CH1 chains and VH-CH1-CH2-CH3 chains), and each light chain can be a full-length light chain or a portion thereof sufficient to form an antigen binding site (*e.g.*, light chains include, but are not limited to, VL chains and VL-CL chains). Each heavy chain (H and H’) pairs with one light chain (L and L’, respectively). Typically, antibodies minimally include all or at least a portion of the variable heavy (VH) chain and/or the variable light (VL) chain. The antibody also can include all or a portion of the constant region.

For purposes herein, the term antibody includes full-length antibodies and portions thereof including antibody fragments, such as anti-EGFR antibody fragments. Antibody fragments, include, but are not limited to, Fab fragments, Fab’ fragments, F(ab’)₂ fragments, Fv fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fd’ fragments, single-chain Fvs (scFv), single-chain Fabs (scFab), diabodies, anti-idiotypic (anti-Id) antibodies, or antigen-binding fragments of any of the above. Antibody also includes synthetic antibodies, recombinantly produced antibodies, multispecific antibodies (*e.g.*, bispecific antibodies), human antibodies, non-human antibodies, humanized antibodies, chimeric antibodies, and intrabodies. Antibodies provided herein include members of any immunoglobulin class (*e.g.*, IgG, IgM, IgD, IgE, IgA and IgY), any subclass (*e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or sub-subclass (*e.g.*, IgG2a and IgG2b).

As used herein, "nucleic acid" refers to at least two linked nucleotides or nucleotide derivatives, including a deoxyribonucleic acid (DNA) and a ribonucleic acid (RNA), joined together, typically by phosphodiester linkages. Also included in the term "nucleic acid" are analogs of nucleic acids such as peptide nucleic acid (PNA), phosphorothioate DNA, and other such analogs and derivatives or combinations thereof. Nucleic acids also include DNA and RNA derivatives containing, for example, a nucleotide analog or a "backbone" bond other than a phosphodiester bond, for example, a phosphotriester bond, a phosphoramidate bond, a phosphorothioate bond, a thioester bond, or a peptide bond (peptide nucleic acid).

10 The term also includes, as equivalents, derivatives, variants and analogs of either RNA or DNA made from nucleotide analogs, single (sense or antisense) and double-stranded nucleic acids. Deoxyribonucleotides include deoxyadenosine, deoxycytidine, deoxyguanosine and deoxythymidine. For RNA, the uracil base is uridine.

As used herein, an isolated nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. An "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Exemplary isolated nucleic acid molecules provided herein include isolated nucleic acid molecules encoding an antibody or antigen-binding fragments provided.

15
20

As used herein, "operably linked" with reference to nucleic acid sequences, regions, elements or domains means that the nucleic acid regions are functionally related to each other. For example, a nucleic acid encoding a leader peptide can be operably linked to a nucleic acid encoding a polypeptide, whereby the nucleic acids can be transcribed and translated to express a functional fusion protein, wherein the leader peptide effects secretion of the fusion polypeptide. In some instances, the nucleic acid encoding a first polypeptide (*e.g.*, a leader peptide) is operably linked to a nucleic acid encoding a second polypeptide and the nucleic acids are transcribed as a single mRNA transcript, but translation of the mRNA transcript can result in one of two polypeptides being expressed. For example, an amber stop codon can be located between the nucleic acid encoding the first polypeptide and the nucleic acid encoding

25
30

the second polypeptide, such that, when introduced into a partial amber suppressor cell, the resulting single mRNA transcript can be translated to produce either a fusion protein containing the first and second polypeptides, or can be translated to produce only the first polypeptide. In another example, a promoter can be operably linked to
5 nucleic acid encoding a polypeptide, whereby the promoter regulates or mediates the transcription of the nucleic acid.

As used herein, “synthetic,” with reference to, for example, a synthetic nucleic acid molecule or a synthetic gene or a synthetic peptide refers to a nucleic acid molecule or polypeptide molecule that is produced by recombinant methods and/or by
10 chemical synthesis methods.

As used herein, the residues of naturally occurring α -amino acids are the residues of those 20 α -amino acids found in nature which are incorporated into protein by the specific recognition of the charged tRNA molecule with its cognate mRNA codon in humans.

15 As used herein, “polypeptide” refers to two or more amino acids covalently joined. The terms “polypeptide” and “protein” are used interchangeably herein.

As used herein, a “peptide” refers to a polypeptide that is from 2 to about or 40 amino acids in length.

As used herein, an “amino acid” is an organic compound containing an amino
20 group and a carboxylic acid group. A polypeptide contains two or more amino acids. For purposes herein, amino acids contained in the antibodies provided include the twenty naturally-occurring amino acids (see Table below), non-natural amino acids, and amino acid analogs (*e.g.*, amino acids wherein the α -carbon has a side chain). As used herein, the amino acids, which occur in the various amino acid sequences of
25 polypeptides appearing herein, are identified according to their well-known, three-letter or one-letter abbreviations (see Table below). The nucleotides, which occur in the various nucleic acid molecules and fragments, are designated with the standard single-letter designations used routinely in the art.

As used herein, “amino acid residue” refers to an amino acid formed upon
30 chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are generally in the “L” isomeric form. Residues in the “D” isomeric form can be substituted for any L-amino acid residue, as long as the

desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3557-59 (1968) and adopted at 37 C.F.R. §§ 1.821 - 1.822, abbreviations for amino acid residues are shown in the following Table:

Table of Correspondence

SYMBOL		
1-Letter	3-Letter	AMINO ACID
Y	Tyr	Tyrosine
G	Gly	Glycine
F	Phe	Phenylalanine
M	Met	Methionine
A	Ala	Alanine
S	Ser	Serine
I	Ile	Isoleucine
L	Leu	Leucine
T	Thr	Threonine
V	Val	Valine
P	Pro	Proline
K	Lys	Lysine
H	His	Histidine
Q	Gln	Glutamine
E	Glu	Glutamic acid
Z	Glx	Glutamic Acid and/or Glutamine
W	Trp	Tryptophan
R	Arg	Arginine
D	Asp	Aspartic acid
N	Asn	Asparagine
B	Asx	Aspartic Acid and/or Asparagine
C	Cys	Cysteine
X	Xaa	Unknown or other

All sequences of amino acid residues represented herein by a formula have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. The phrase "amino acid residue" is defined to include the amino acids listed in the above Table of Correspondence, modified, non-natural and unusual amino acids. A dash at the beginning or end of an amino acid residue sequence indicates a

peptide bond to a further sequence of one or more amino acid residues or to an amino-terminal group such as NH₂ or to a carboxyl-terminal group such as COOH.

In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in the art and generally can be made without altering a
 5 biological activity of a resulting molecule. Those of skill in the art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, *e.g.*, Watson *et al.*, *Molecular Biology of the Gene*, 4th Edition, 1987, The Benjamin/Cummings Pub. Co., p. 224).

Such substitutions, such as in the gain-of-function mutations described and
 10 provided herein, can be made in accordance with the exemplary substitutions set forth in the following Table:

Exemplary conservative amino acid substitutions

Original residue	Exemplary Conservative substitution(s)
Ala (A)	Gly; Ser
Arg (R)	Lys
Asn (N)	Gln; His
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
Gly (G)	Ala; Pro
His (H)	Asn; Gln
Ile (I)	Leu; Val
Leu (L)	Ile; Val
Lys (K)	Arg; Gln; Glu
Met (M)	Leu; Tyr; Ile
Phe (F)	Met; Leu; Tyr
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr
Tyr (Y)	Trp; Phe
Val (V)	Ile; Leu

Other substitutions also are permissible and can be determined empirically or in accord with other known conservative or non-conservative substitutions.

15 As used herein, "naturally occurring amino acids" refer to the 20 L-amino acids that occur in polypeptides.

As used herein, the term "non-natural amino acid" refers to an organic compound that has a structure similar to a natural amino acid but has been modified

structurally to mimic the structure and reactivity of a natural amino acid. Non-naturally occurring amino acids thus include, for example, amino acids or analogs of amino acids other than the 20 naturally occurring amino acids and include, but are not limited to, the D-stereoisomers of amino acids. Exemplary non-natural amino acids

5 are known to those of skill in the art, and include, but are not limited to, 2-Aminoadipic acid (Aad), 3-Aminoadipic acid (bAad), β -alanine/ β -Amino-propionic acid (Bala), 2-Aminobutyric acid (Abu), 4-Aminobutyric acid/piperidinic acid (4Abu), 6-Aminocaproic acid (Acp), 2-Aminoheptanoic acid (Ahe), 2-Aminoisobutyric acid (Aib), 3-Aminoisobutyric acid (Baib), 2-Aminopimelic acid

10 (Apm), 2,4-Diaminobutyric acid (Dbu), Desmosine (Des), 2,2'-Diaminopimelic acid (Dpm), 2,3-Diaminopropionic acid (Dpr), N-Ethylglycine (EtGly), N-Ethylasparagine (EtAsn), Hydroxylysine (Hyl), allo-Hydroxylysine (Ahyl), 3-Hydroxyproline (3Hyp), 4-Hydroxyproline (4Hyp), Isodesmosine (Ide), allo-Isoleucine (Aile), N-Methylglycine, sarcosine (MeGly), N-Methylisoleucine (MeIle), 6-N-Methyllysine

15 (MeLys), N-Methylvaline (MeVal), Norvaline (Nva), Norleucine (Nle), and Ornithine (Orn).

As used herein, a DNA construct is a single or double stranded, linear or circular DNA molecule that contains segments of DNA combined and juxtaposed in a manner not found in nature. DNA constructs exist as a result of human manipulation,

20 and include clones and other copies of manipulated molecules.

As used herein, a DNA segment is a portion of a larger DNA molecule having specified attributes. For example, a DNA segment encoding a specified polypeptide is a portion of a longer DNA molecule, such as a plasmid or plasmid fragment, which, when read from the 5' to 3' direction, encodes the sequence of amino acids of the

25 specified polypeptide.

As used herein, the term polynucleotide means a single- or double-stranded polymer of deoxyribonucleotides or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and can be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic

30 molecules. The length of a polynucleotide molecule is given herein in terms of nucleotides (abbreviated "nt") or base pairs (abbreviated "bp"). The term nucleotides is used for single- and double-stranded molecules where the context permits. When

the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term base pairs. It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide can differ slightly in length and that the ends thereof can be staggered; thus all nucleotides
5 within a double-stranded polynucleotide molecule cannot be paired. Such unpaired ends will, in general, not exceed 20 nucleotides in length.

As used herein, production by recombinant methods refers means the use of the well-known methods of molecular biology for expressing proteins encoded by cloned DNA.

10 As used herein, "heterologous nucleic acid" is nucleic acid that encodes products (*i.e.*, RNA and/or proteins) that are not normally produced *in vivo* by the cell in which it is expressed, or nucleic acid that is in a locus in which it does not normally occur, or that mediates or encodes mediators that alter expression of endogenous nucleic acid, such as DNA, by affecting transcription, translation, or other regulatable
15 biochemical processes. Heterologous nucleic acid, such as DNA, also is referred to as foreign nucleic acid. Any nucleic acid, such as DNA, that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which it is expressed, is herein encompassed by heterologous nucleic acid; heterologous nucleic acid includes exogenously added nucleic acid that is also expressed endogenously. Heterologous
20 nucleic acid is generally not endogenous to the cell into which it is introduced, but has been obtained from another cell or prepared synthetically or is introduced into a genomic locus in which it does not occur naturally, or its expression is under the control of regulatory sequences or a sequence that differs from the natural regulatory sequence or sequences.

25 Examples of heterologous nucleic acid herein include, but are not limited to, nucleic acid that encodes a protein in a DNA/RNA sensor pathway or a gain-of-function variant thereof, or an immunostimulatory protein, such as a cytokine, that confers or contributes to anti-tumor immunity in the tumor microenvironment. In the immunostimulatory bacteria, the heterologous nucleic acid generally is encoded on
30 the introduced plasmid, but it can be introduced into the genome of the bacterium, such as a promoter that alters expression of a bacterial product. Heterologous nucleic acid, such as DNA, includes nucleic acid that can, in some manner, mediate

expression of DNA that encodes a therapeutic product, or it can encode a product, such as a peptide or RNA, that in some manner mediates, directly or indirectly, expression of a therapeutic product.

As used herein, cell therapy involves the delivery of cells to a subject to treat
5 a disease or condition. The cells, which can be allogeneic or autologous, are modified *ex vivo*, such as by infection of cells with immunostimulatory bacteria provided herein, so that they deliver or express products when introduced to a subject.

As used herein, genetic therapy involves the transfer of heterologous nucleic acid, such as DNA, into certain cells, such as target cells, of a mammal, particularly a
10 human, with a disorder or condition for which such therapy is sought. The nucleic acid, such as DNA, is introduced into the selected target cells in a manner such that the heterologous nucleic acid, such as DNA, is expressed and a therapeutic product(s) encoded thereby is produced. Genetic therapy can also be used to deliver nucleic acid encoding a gene product that replaces a defective gene or supplements a gene product
15 produced by the mammal or the cell in which it is introduced. The introduced nucleic acid can encode a therapeutic compound, such as a growth factor or inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor thereof, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous nucleic acid,
20 such as DNA, encoding the therapeutic product, can be modified prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof. Genetic therapy can also involve delivery of an inhibitor or repressor or other modulator of gene expression.

As used herein, “expression” refers to the process by which polypeptides are
25 produced by transcription and translation of polynucleotides. The level of expression of a polypeptide can be assessed using any method known in art, including, for example, methods of determining the amount of the polypeptide produced from the host cell. Such methods can include, but are not limited to, quantitation of the polypeptide in the cell lysate by ELISA, Coomassie blue staining following gel
30 electrophoresis, Lowry protein assay and Bradford protein assay.

As used herein, a “host cell” is a cell that is used to receive, maintain, reproduce and/or amplify a vector. A host cell also can be used to express the

polypeptide encoded by the vector. The nucleic acid contained in the vector is replicated when the host cell divides, thereby amplifying the nucleic acids.

As used herein, a “vector” is a replicable nucleic acid from which one or more heterologous proteins, can be expressed when the vector is transformed into an appropriate host cell. Reference to a vector includes those vectors into which a nucleic acid encoding a polypeptide or fragment thereof can be introduced, typically by restriction digest and ligation. Reference to a vector also includes those vectors that contain nucleic acid encoding a polypeptide, such as a modified anti-EGFR antibody. The vector is used to introduce the nucleic acid encoding the polypeptide into the host cell for amplification of the nucleic acid or for expression/display of the polypeptide encoded by the nucleic acid. The vectors typically remain episomal, but can be designed to effect integration of a gene or portion thereof into a chromosome of the genome. Also contemplated are vectors that are artificial chromosomes, such as yeast artificial chromosomes and mammalian artificial chromosomes. Selection and use of such vehicles are well-known to those of skill in the art. A vector also includes “virus vectors” or “viral vectors.” Viral vectors are engineered viruses that are operatively linked to exogenous genes to transfer (as vehicles or shuttles) the exogenous genes into cells.

As used herein, an “expression vector” includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such additional segments can include promoter and terminator sequences, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well-known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

As used herein, “primary sequence” refers to the sequence of amino acid residues in a polypeptide or the sequence of nucleotides in a nucleic acid molecule.

As used herein, “sequence identity” refers to the number of identical or similar amino acids or nucleotide bases in a comparison between a test and a reference polypeptide or polynucleotide. Sequence identity can be determined by sequence alignment of nucleic acid or protein sequences to identify regions of similarity or identity. For purposes herein, sequence identity is generally determined by alignment to identify identical residues. The alignment can be local or global. Matches, mismatches and gaps can be identified between compared sequences. Gaps are null amino acids or nucleotides inserted between the residues of aligned sequences so that identical or similar characters are aligned. Generally, there can be internal and terminal gaps. When using gap penalties, sequence identity can be determined with no penalty for end gaps (*e.g.*, terminal gaps are not penalized). Alternatively, sequence identity can be determined without taking into account gaps as the number of identical positions/length of the total aligned sequence $\times 100$.

As used herein, a “global alignment” is an alignment that aligns two sequences from beginning to end, aligning each letter in each sequence only once. An alignment is produced, regardless of whether or not there is similarity or identity between the sequences. For example, 50% sequence identity based on “global alignment” means that in an alignment of the full sequence of two compared sequences each of 100 nucleotides in length, 50% of the residues are the same. It is understood that global alignment also can be used in determining sequence identity even when the length of the aligned sequences is not the same. The differences in the terminal ends of the sequences will be taken into account in determining sequence identity, unless the “no penalty for end gaps” is selected. Generally, a global alignment is used on sequences that share significant similarity over most of their length. Exemplary algorithms for performing global alignment include the Needleman-Wunsch algorithm (Needleman *et al.* (1970) *J. Mol. Biol.* 48: 443). Exemplary programs for performing global alignment are publicly available and include the Global Sequence Alignment Tool available at the National Center for Biotechnology Information (NCBI) website (ncbi.nlm.nih.gov/), and the program available at deepc2.psi.iastate.edu/aat/align/align.html.

As used herein, a "local alignment" is an alignment that aligns two sequences, but only aligns those portions of the sequences that share similarity or identity.

Hence, a local alignment determines if sub-segments of one sequence are present in another sequence. If there is no similarity, no alignment will be returned. Local

5 alignment algorithms include BLAST or Smith-Waterman algorithm (*Adv. Appl. Math.* 2: 482 (1981)). For example, 50% sequence identity based on "local alignment" means that in an alignment of the full sequence of two compared sequences of any length, a region of similarity or identity of 100 nucleotides in length has 50% of the residues that are the same in the region of similarity or identity.

10 For purposes herein, sequence identity can be determined by standard alignment algorithm programs used with default gap penalties established by each supplier. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov *et al.* (1986) *Nucl. Acids Res.* 14: 6745, 15 as described by Schwartz and Dayhoff, eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Whether any two nucleic acid molecules have nucleotide sequences or any two polypeptides have amino acid sequences that are at least 80%, 20 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical," or other similar variations reciting a percent identity, can be determined using known computer algorithms based on local or global alignment (*see e.g.*,

wikipedia.org/wiki/Sequence_alignment_software, providing links to dozens of known and publicly available alignment databases and programs). Generally, for 25 purposes herein sequence identity is determined using computer algorithms based on global alignment, such as the Needleman-Wunsch Global Sequence Alignment tool available from NCBI/BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&Page_TYPE=BlastHome); LAlign (William Pearson implementing the Huang and Miller algorithm (*Adv. Appl. Math.* 30 (1991) 12:337-357)); and program from Xiaoqui Huang available at deepc2.psi.iastate.edu/aat/align/align.html. Typically, the full-length sequence of each of the compared polypeptides or nucleotides is aligned across the full-length of each

sequence in a global alignment. Local alignment also can be used when the sequences being compared are substantially the same length.

Therefore, as used herein, the term "identity" represents a comparison or alignment between a test and a reference polypeptide or polynucleotide. In one non-limiting example, "at least 90% identical to" refers to percent identities from 90 to 100% relative to the reference polypeptide or polynucleotide. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polypeptide or polynucleotide length of 100 amino acids or nucleotides are compared, no more than 10% (*i.e.*, 10 out of 100) of amino acids or nucleotides in the test polypeptide or polynucleotide differ from those of the reference polypeptide. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they can be clustered in one or more locations of varying length up to the maximum allowable, *e.g.*, 10/100 amino acid difference (approximately 90% identity). Differences also can be due to deletions or truncations of amino acid residues. Differences are defined as nucleic acid or amino acid substitutions, insertions or deletions. Depending on the length of the compared sequences, at the level of homologies or identities above about 85-90%, the result can be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software.

As used herein, "disease or disorder" refers to a pathological condition in an organism resulting from cause or condition including, but not limited to, infections, acquired conditions, genetic conditions, and characterized by identifiable symptoms.

As used herein, "treating" a subject with a disease or condition means that the subject's symptoms are partially or totally alleviated, or remain static following treatment.

As used herein, treatment refers to any effects that ameliorate symptoms of a disease or disorder. Treatment encompasses prophylaxis, therapy and/or cure. Treatment also encompasses any pharmaceutical use of any immunostimulatory bacterium or composition provided herein.

As used herein, prophylaxis refers to prevention of a potential disease and/or a prevention of worsening of symptoms or progression of a disease.

As used herein, “prevention” or prophylaxis, and grammatically equivalent forms thereof, refers to methods in which the risk or probability of developing a disease or condition is reduced.

As used herein, a “pharmaceutically effective agent” includes any therapeutic
5 agent or bioactive agents, including, but not limited to, for example, anesthetics, vasoconstrictors, dispersing agents, and conventional therapeutic drugs, including small molecule drugs and therapeutic proteins.

As used herein, a “therapeutic effect” means an effect resulting from treatment of a subject that alters, typically improves or ameliorates, the symptoms of a disease
10 or condition or that cures a disease or condition.

As used herein, a “therapeutically effective amount” or a “therapeutically effective dose” refers to the quantity of an agent, compound, material, or composition containing a compound that is at least sufficient to produce a therapeutic effect following administration to a subject. Hence, it is the quantity necessary for
15 preventing, curing, ameliorating, arresting or partially arresting a symptom of a disease or disorder.

As used herein, “therapeutic efficacy” refers to the ability of an agent, compound, material, or composition containing a compound to produce a therapeutic effect in a subject to whom the agent, compound, material, or composition containing
20 a compound has been administered.

As used herein, a “prophylactically effective amount” or a “prophylactically effective dose” refers to the quantity of an agent, compound, material, or composition containing a compound that when administered to a subject, will have the intended prophylactic effect, *e.g.*, preventing or delaying the onset, or reoccurrence, of disease
25 or symptoms, reducing the likelihood of the onset, or reoccurrence, of disease or symptoms, or reducing the incidence of viral infection. The full prophylactic effect does not necessarily occur by administration of one dose, and can occur only after administration of a series of doses. Thus, a prophylactically effective amount can be administered in one or more administrations.

As used herein, amelioration of the symptoms of a particular disease or
30 disorder by a treatment, such as by administration of a pharmaceutical composition or other therapeutic, refers to any lessening, whether permanent or temporary, lasting or

transient, of the symptoms that can be attributed to or associated with administration of the composition or therapeutic.

As used herein, an “anti-cancer agent” refers to any agent that is destructive or toxic to malignant cells and tissues. For example, anti-cancer agents include agents
5 that kill cancer cells or otherwise inhibit or impair the growth of tumors or cancer cells. Exemplary anti-cancer agents are chemotherapeutic agents.

As used herein “therapeutic activity” refers to the *in vivo* activity of a therapeutic polypeptide. Generally, the therapeutic activity is the activity that is associated with treatment of a disease or condition.

10 As used herein, the term "subject" refers to an animal, including a mammal, such as a human being.

As used herein, a patient refers to a human subject.

As used herein, animal includes any animal, such as, but not limited to, primates including humans, gorillas and monkeys; rodents, such as mice and rats;
15 fowl, such as chickens; ruminants, such as goats, cows, deer, sheep; pigs and other animals. Non-human animals exclude humans as the contemplated animal. The polypeptides provided herein are from any source, animal, plant, prokaryotic and fungal. Most polypeptides are of animal origin, including mammalian origin.

As used herein, a “composition” refers to any mixture. It can be a solution,
20 suspension, liquid, powder, paste, aqueous, non-aqueous or any combination thereof.

As used herein, a “combination” refers to any association between or among two or more items. The combination can be two or more separate items, such as two compositions or two collections, a mixture thereof, such as a single mixture of the two or more items, or any variation thereof. The elements of a combination are generally
25 functionally associated or related.

As used herein, combination therapy refers to administration of two or more different therapeutics. The different therapeutic agents can be provided and administered separately, sequentially, intermittently, or can be provided in a single composition.

30 As used herein, a kit is a packaged combination that optionally includes other elements, such as additional reagents and instructions for use of the combination or

elements thereof, for a purpose including, but not limited to, activation, administration, diagnosis, and assessment of a biological activity or property.

As used herein, a “unit dose form” refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art.

5 As used herein, a “single dosage formulation” refers to a formulation for direct administration.

As used herein, a multi-dose formulation refers to a formulation that contains multiple doses of a therapeutic agent and that can be directly administered to provide several single doses of the therapeutic agent. The doses can be administered over the
10 course of minutes, hours, weeks, days or months. Multi-dose formulations can allow dose adjustment, dose-pooling and/or dose-splitting. Because multi-dose formulations are used over time, they generally contain one or more preservatives to prevent microbial growth.

As used herein, an “article of manufacture” is a product that is made and sold.
15 As used throughout this application, the term is intended to encompass any of the compositions provided herein contained in articles of packaging.

As used herein, a “fluid” refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.

20 As used herein, an isolated or purified polypeptide or protein (*e.g.*, an isolated antibody or antigen-binding fragment thereof) or biologically-active portion thereof (*e.g.*, an isolated antigen-binding fragment) is substantially free of cellular material or other contaminating proteins from the cell or tissue from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically
25 synthesized. Preparations can be determined to be substantially free if they appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification does not detectably alter the physical
30 and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure

compound, however, can be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound. As used herein, a “cellular extract” or “lysate” refers to a preparation or fraction which is made from a lysed or disrupted cell.

5 As used herein, a “control” refers to a sample that is substantially identical to the test sample, except that it is not treated with a test parameter, or, if it is a plasma sample, it can be from a normal volunteer not affected with the condition of interest. A control also can be an internal control.

 As used herein, the singular forms “a,” “an” and “the” include plural referents
10 unless the context clearly dictates otherwise. Thus, for example, reference to a polypeptide, comprising “an immunoglobulin domain” includes polypeptides with one or a plurality of immunoglobulin domains.

 As used herein, the term “or” is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive.

15 As used herein, ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. Hence “about 5 amino acids” means “about 5 amino acids” and also “5 amino acids.”

 As used herein, “optional” or “optionally” means that the subsequently described event or circumstance does or does not occur and that the description
20 includes instances where said event or circumstance occurs and instances where it does not. For example, an optionally variant portion means that the portion is variant or non-variant.

 As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage,
25 recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see, *Biochem.* (1972) 11(9):1726-1732).

 For clarity of disclosure, and not by way of limitation, the detailed description is divided into the subsections that follow.

B. OVERVIEW OF THE IMMUNOSTIMULATORY BACTERIA

30 Provided are modified bacteria, called immunostimulatory bacteria herein that accumulate and/or replicate in tumors and encode inhibitory RNAs, such as designed shRNAs and designed micro RNAs, that target genes whose inhibition, suppression or

silencing effects tumor therapy, upon expression of the RNAs in the treated subject. Strains of bacteria for modification are any suitable for therapeutic use. The modified immunostimulatory bacteria provided herein are for use and for methods for treating cancer. The bacteria are modified for such uses and methods.

- 5 The immunostimulatory bacteria provided herein are modified by deletion or modification of bacterial genes to attenuate their inflammatory responses, and are modified to enhance anti-tumor immune responses in hosts treated with the bacteria. For example, the plasmids encoding therapeutic, such as anti-tumor, products in the host are included in the bacteria, and the bacteria can be auxotrophic for adenosine.
- 10 Attenuation of the inflammatory response to the bacteria can be effected by deletion of the *msbB* gene, which decreases TNF- α in the host, and/or knocking out flagellin genes. The bacteria are modified to stimulate host anti-tumor activity, for example, by adding plasmids encoding immunostimulatory proteins, STING proteins, variant STING proteins, and proteins that target host immune checkpoints, and by
- 15 adding nucleic acid with CpGs.

- Bacterial strains can be attenuated strains or strains that are attenuated by standard methods or that by virtue of the modifications provided herein are attenuated in that their ability to colonize is limited primarily to immunoprivileged tissues and organs, particularly immune and tumor cells, including solid tumors. For purposes
- 20 herein, the bacteria are not necessarily attenuated per se, but rather, contain modification(s), such as genomic modifications, that limit or alter the cells that are infected by the bacteria. Bacteria include, but are not limited to, for example, strains of *Salmonella*, *Shigella*, *Listeria*, *E. coli*, and *Bifidobacteriae*. For example, species include *Shigella sonnei*, *Shigella flexneri*, *Shigella dysenteriae*, *Listeria*
- 25 *monocytogenes*, *Salmonella typhi*, *Salmonella typhimurium*, *Salmonella gallinarum*, and *Salmonella enteritidis*. Other suitable bacterial species include *Rickettsia*, *Klebsiella*, *Bordetella*, *Neisseria*, *Aeromonas*, *Francisella*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*, *Mycoplasma*, *Legionella*, *Rhodococcus*, *Pseudomonas*, *Helicobacter*, *Vibrio*, *Bacillus*, and
- 30 *Erysipelothrix*. For example, *Rickettsia Rickettsiae*, *Rickettsia prowazekii*, *Rickettsia tsutsugamuchi*, *Rickettsia mooseri*, *Rickettsia sibirica*, *Bordetella bronchiseptica*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Aeromonas eucrenophila*, *Aeromonas*

salmonicida, *Francisella tularensis*, *Corynebacterium pseudotuberculosis*,
Citrobacter freundii, *Chlamydia pneumoniae*, *Haemophilus sornmus*, *Brucella*
abortus, *Mycobacterium intracellulare*, *Legionella pneumophila*, *Rhodococcus equi*,
Pseudomonas aeruginosa, *Helicobacter mustelae*, *Vibrio cholerae*, *Bacillus subtilis*,
5 *Erysipelothrix rhusiopathiae*, *Yersinia enterocolitica*, *Rochalimaea quintana*, and
Agrobacterium tumerfacium.

The bacteria accumulate by virtue of one or more properties, including, diffusion, migration and chemotaxis to immunoprivileged tissues or organs or environments, environments that provide nutrients or other molecules for which they
10 are auxotrophic and/or environments that contain replicating cells that provide environments for entry and replication of bacteria. The immunostimulatory bacteria provided herein and species that effect such therapy include species of *Salmonella*, *Listeria*, and *E. coli*. The bacteria contain plasmids that encode a therapeutic product or products expressed under control of a eukaryotic promoter, such as an RNA
15 polymerase (RNAP) II or III promoter. Typically, RNAPIII (also referred to as POLIII) promoters are constitutive, and RNAPII (also referred to as POLII) can be regulated. Where a plurality of products are encoded, expression of each can be under control of different promoters.

Among the bacteria provided herein, are bacteria that are modified so that they
20 are auxotrophic for adenosine. This can be achieved by modification or deletion of genes involved in purine synthesis, metabolism, or transport. For example, disruption of the *tsx* gene in *Salmonella* species, such as *Salmonella typhi*, results in adenosine auxotrophy. Adenosine is immunosuppressive and accumulates to high concentrations in tumors; auxotrophy for adenosine improves the anti-tumor activity of the bacteria
25 because the bacteria selectively replicate in tissues rich in adenosine.

Also provided are bacteria that are modified so that they have a defective *asd* gene. These bacteria for use *in vivo* are modified to include carrying a functional *asd* gene on the introduced plasmid; this maintains selection for the plasmid so that an antibiotic-based plasmid maintenance/selection system is not needed. Also provided is
30 the use of *asd* defective strains that do not contain a functional *asd* gene on a plasmid and are thus engineered to be autolytic in the host.

Also provided are bacteria that are modified so that they are incapable of producing flagella. This can be achieved by modifying the bacteria by means of deleting the genes that encode the flagellin subunits. The modified bacteria lacking flagellin are less inflammatory and therefore better tolerated and induce a more potent anti-tumor response.

Also provided are bacteria that are modified to produce listeriolysin O, which improves plasmid delivery in phagocytic cells.

Also provided are bacteria modified to carry a low copy, CpG-containing plasmid. The plasmid further can include other modifications.

The bacteria also can be modified to grow in a manner such that the bacteria, if a *Salmonella* species, expresses less of the toxic SPI-1 (*Salmonella* pathogenicity island-1) genes. In *Salmonella*, genes responsible for virulence, invasion, survival, and extra intestinal spread are located in *Salmonella* pathogenicity islands (SPIs).

The bacteria can be further modified for other desirable traits, including for selection of plasmid maintenance, particularly for selection without antibiotics, for preparation of the strains. The immunostimulatory bacteria optionally can encode therapeutic polypeptides, including anti-tumor therapeutic polypeptides and agents.

Exemplary of the immunostimulatory bacteria provided herein are species of *Salmonella*. Exemplary of bacteria for modification as described herein are engineered strains of *Salmonella typhimurium*, such as strain YS1646 (ATCC Catalog # 202165; see, also, International PCT Application Publication No. WO 99/13053, also referred to as VNP20009) that is engineered with plasmids to complement an *asd* gene knockout and antibiotic-free plasmid maintenance.

Modified immunostimulatory bacterial strains that are rendered auxotrophic for adenosine are provided herein as are pharmaceutical compositions containing such strains formulated for administration to a subject, such as a human, for use in methods of treating tumors and cancers.

The engineered immunostimulatory bacteria provided herein contain multiple synergistic modalities to induce immune re-activation of cold tumors and to promote tumor antigen-specific immune responses, while inhibiting immune checkpoint pathways that the tumor utilizes to subvert and evade durable anti-tumor immunity. Improved tumor targeting through adenosine auxotrophy and enhanced vascular

disruption have improved potency, while localizing the inflammation to limit systemic cytokine exposure and the autoimmune toxicities observed with other immunotherapy modalities. Exemplary of the bacteria so-modified are *S. typhimurium* strains, including such modifications of the strain YS1646, particularly *asd⁻* strains, and of wild-type strains.

C. CANCER IMMUNOTHERAPEUTICS

The immunosuppressive milieu found within the tumor microenvironment (TME) is a driver of tumor initiation and progression. Cancers emerge after the immune system fails to control and contain tumors. Multiple tumor-specific mechanisms create tumor environments wherein the immune system is forced to tolerate tumors and their cells instead of eliminating them. The goal of cancer immunotherapy is to rescue the immune system's natural ability to eliminate tumors.

1. Immunotherapies

Several clinical cancer immunotherapies have sought to perturb the balance of immune suppression towards anti-tumor immunity. Strategies to stimulate immunity through directly administering cytokines such as IL-2 and IFN- α have seen modest clinical responses in a minority of patients, while inducing serious systemic inflammation-related toxicities (Sharma *et al.* (2011) *Nat. Rev. Cancer* 11:805-812). The immune system has evolved several checks and balances to limit autoimmunity, such as upregulation of programmed cell death protein 1 (PD-1) on T cells and its binding to its cognate ligand, programmed death-ligand 1 (PD-L1), which is expressed on both antigen presenting cells (APCs) and tumor cells. The binding of PD-L1 to PD-1 interferes with CD8⁺ T cell signaling pathways, impairing the proliferation and effector function of CD8⁺ T cells, and inducing T cell tolerance. PD-1 and PD-L1 are two examples of numerous inhibitory "immune checkpoints," which function by downregulating immune responses. Other inhibitory immune checkpoints include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), signal regulatory protein α (SIRP α), V-domain Ig suppressor of T cell activation (VISTA), programmed death-ligand 2 (PD-L2), indoleamine 2,3-dioxygenase (IDO) 1 and 2, lymphocyte-activation gene 3 (LAG3), Galectin-9, T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin-domain containing-3 (TIM-3, also known as hepatitis A virus cellular receptor 2 (HAVCR2)), herpesvirus

entry mediator (HVEM), CD39, CD73, B7-H3 (also known as CD276), B7-H4, CD47, CD48, CD80 (B7-1), CD86 (B7-2), CD155, CD160, CD244 (2B4), B- and T-lymphocyte attenuator (BTLA, or CD272) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1, or CD66a).

5 Antibodies designed to block immune checkpoints, such as anti-PD-1 (for example, pembrolizumab, nivolumab) and anti-PD-L1 (for example, atezolizumab, avelumab, durvalumab), have had durable success in preventing T cell anergy and breaking immune tolerance. Only a fraction of treated patients demonstrate clinical benefit, and those that do often present with autoimmune-related toxicities (see, *e.g.*,
10 Ribas (2015) *N. Engl. J. Med.* 373:1490-1492; Topalian *et al.* (2012) *N. Engl. J. Med.* 366:3443-3447). This is further evidence for the need for therapies, provided herein, that are more effective and less toxic.

 Another checkpoint blockade strategy inhibits the induction of CTLA-4 on T cells, which binds to and inhibits co-stimulatory receptors on APCs, such as CD80 or
15 CD86, out-competing the co-stimulatory cluster differentiation 28 (CD28), which binds the same receptors, but with a lower affinity. This blocks the stimulatory signal from CD28, while the inhibitory signal from CTLA-4 is transmitted, preventing T cell activation (see, Phan *et al.* (2003) *Proc. Natl. Acad. Sci. U.S.A.* 100:8372-8377). Anti-CTLA-4 therapy (for example, ipilimumab) has had clinical success and durability in
20 some patients, whilst exhibiting an even greater incidence of severe immune-related adverse events (see, *e.g.*, Hodi *et al.* (2010) *N. Engl. J. Med.* 363:711-723; Schadendorf *et al.* (2015) *J. Clin. Oncol.* 33:1889-1894). It also has been shown that tumors develop resistance to anti-immune checkpoint antibodies, highlighting the need for more durable anticancer therapies, such as those provided herein.

25 2. Adoptive Immunotherapies

 In seeking to reactivate a cold tumor to become more immunogenic, a class of immunotherapies known as adoptive cell therapy (ACT) encompasses a variety of strategies to harness immune cells and reprogram them to have anti-tumor activity (Hinrichs *et al.* (2011) *Immunol. Rev.* 240:40-51). Dendritic cell-based therapies
30 introduce genetically engineered dendritic cells (DCs) with more immune-stimulatory properties. These therapies have not been successful because they fail to break immune tolerance to cancer (see, *e.g.*, Rosenberg *et al.* (2004) *Nat. Med.* 12:1279). A

method using whole irradiated tumor cells containing endogenous tumor antigens and granulocyte macrophage colony-stimulating factor (GM-CSF) to stimulate DC recruitment, known as GVAX, similarly failed in the clinic due to the lack of ability to break tumor tolerance (Copier *et al.* (2010) *Curr. Opin. Mol. Ther.* 12:647-653). A
5 separate autologous cell-based therapy, Sipuleucel-T (Provenge), was FDA approved in 2010 for castration-resistant prostate cancer. It utilizes APCs retrieved from the patient and re-armed to express prostatic acid phosphatase (PAP) antigen to stimulate a T cell response, then re-introduced following lymphablation. Unfortunately, its broader adoption is limited by low observed objective response rates and high costs,
10 and its use is limited only to the early stages of prostate cancer (Anassi *et al.* (2011) *P T.* 36(4):197–202). Similarly, autologous T cell therapies (ATCs) harvest a patient's own T cells and reactivate them *ex vivo* to overcome tumor tolerance, then reintroduce them to the patient following lymphablation. ATCs have had limited clinical success, and only in melanoma, while generating serious safety and feasibility issues that limit
15 their utility (Yee *et al.* (2013) *Clin. Cancer Res.* 19:1-3).

Chimeric antigen receptor T cell (CAR-T) therapies are T cells harvested from patients that have been re-engineered to express a fusion protein between the T cell receptor and an antibody Ig variable extracellular domain. This confers upon
20 them the antigen-recognition properties of antibodies with the cytolytic properties of activated T cells (Sadelain (2015) *Clin. Invest.* 125:3392-400). Success has been limited to B cell and hematopoietic malignancies, at the cost of deadly immune-related adverse events (Jackson *et al.* (2016) *Nat. Rev. Clin. Oncol.* 13:370-383). Tumors can also mutate to escape recognition by a target antigen, including CD19 (Ruella *et al.*, (2016) *Comput Struct Biotechnol J.* 14: 357–362) and EGFRvIII
25 (O'Rourke *et al.* (2017) *Sci Transl Med.* Jul 19;9:399), thereby fostering immune escape. While CAR-T therapies are approved in the context of hematological malignancies, they face a significant hurdle for feasibility to treat solid tumors: overcoming the highly immunosuppressive nature of the solid tumor microenvironment. A number of additional modifications to existing CAR-T therapies
30 are needed to potentially provide feasibility against solid tumors (Kakarla, *et al.* (2014) *Cancer J.* Mar-Apr; 20(2):151–155).

3. Cancer Vaccines and Oncolytic Viruses

Cold tumors lack T cell and dendritic cell (DC) infiltration, and are non-T-cell-inflamed (Sharma *et al.* (2017) *Cell* 9;168(4):707-723). In seeking to reactivate a cold tumor to become more immunogenic, another class of immunotherapies harness microorganisms that can accumulate in tumors, either naturally or by virtue of engineering. These include viruses designed to stimulate the immune system to express tumor antigens, thereby activating and reprogramming the immune system to reject the tumor. Virally-based cancer vaccines have failed clinically for a number of factors, including pre-existing or acquired immunity to the viral vector itself, as well as a lack of sufficient immunogenicity to the expressed tumor antigens (Larocca *et al.* (2011) *Cancer J.* 17(5):359-371). Lack of proper adjuvant activation of APCs has also hampered other non-viral vector cancer vaccines, such as DNA vaccines. Oncolytic viruses preferentially replicate in dividing tumor cells over healthy tissue, whereupon subsequent tumor cell lysis leads to immunogenic tumor cell death and further viral dissemination. The oncolytic virus Talimogene laherparepvec (T-VEC), which uses a modified herpes simplex virus in combination with the DC-recruiting cytokine GM-CSF, is FDA approved for metastatic melanoma (Bastin *et al.* (2016) *Biomedicines* 4(3):21). While demonstrating clinical benefit in some melanoma patients, and with fewer immune toxicities than with other immunotherapies, its efficacy has been limited; there is a lack of distal tumor efficacy and broader application to other tumor types. Other oncolytic virus (OV)-based vaccines, such as those utilizing paramyxovirus, reovirus and picornavirus, among others, have met with similar limitations in inducing systemic anti-tumor immunity (Chiocca *et al.* (2014) *Cancer Immunol. Res.* 2(4):295-300). Systemic administration of oncolytic viruses presents unique challenges. Upon IV administration, the virus is rapidly diluted, thus requiring high titers that can lead to hepatotoxicity. If pre-existing immunity exists, the virus is rapidly neutralized in the blood, and acquired immunity then restricts repeat dosing (Maroun *et al.* (2017) *Future Virol.* 12(4):193-213).

Of the limitations of virally-based vaccine vectors and oncolytic viruses, the greatest limitations can be the virus itself. Viral antigens have strikingly higher affinities to human T cell receptors (TCR) compared to tumor antigens (Aleksic *et al.* (2012) *Eur J Immunol.* 42(12):3174-3179). Tumor antigens, presented alongside of

viral vector antigens by MHC-1 on the surface of even highly activated APCs, will be outcompeted for binding to TCRs, resulting in very poor antigen-specific anti-tumor immunity. A tumor-targeting immunostimulatory vector, as provided herein, that does not itself provide high affinity T cell epitopes can circumvent these limitations.

5 **D. BACTERIAL CANCER IMMUNOTHERAPY**

Provided herein are immunostimulatory bacteria that are modified so that they accumulate in tumor-resident immune cells, and do not infect epithelial or other cells. The immunostimulatory bacteria contain plasmids that encode and express, under control of a host-recognized promoter, and secrete, therapeutic products, such as
10 immunostimulatory proteins that are part of a cytosolic DNA/RNA sensor pathway, leading to the expression of type I IFN. Thus, the immunostimulatory bacteria are cancer therapeutics that, by virtue of modification of the bacterial genome, and the encoded therapeutic product(s), deliver an immunotherapy directly to the tumor microenvironment. The bacteria and methods and uses provided herein solve prior
15 problems encountered with other cancer immunotherapeutics. The immunostimulatory proteins that are part of a cytosolic DNA/RNA sensor pathway leading to the expression of type I IFN, in addition to expression in the immunostimulatory bacteria provided herein, can be encoded or provided in other delivery vehicles, such as exosomes, liposomes, oncolytic viruses, and gene therapy
20 vectors.

1. **Bacterial Therapies**

Acute inflammation associated with microbial infection has been observationally linked with the spontaneous elimination of tumors for centuries. The recognition that bacteria have anticancer activity goes back to the 1800s, when several
25 physicians observed regression of tumors in patients infected with *Streptococcus pyogenes*. William Coley began the first study using bacteria for the treatment of end stage cancers, and developed a vaccine composed of *S. pyogenes* and *Serratia marcescens*. This vaccine successfully was used to treat a variety of cancers, including sarcomas, carcinomas, lymphomas and melanomas. Since then, a number of
30 bacteria, including species of *Clostridium*, *Mycobacterium*, *Bifidobacterium*, *Listeria*, such as, *L. monocytogenes*, and *Escherichia* species, have been studied as sources of anti-cancer vaccines (see, *e.g.*, Published International PCT Application Nos. WO

1999/013053 and WO 2001/025399; Bermudes *et al.* (2002) *Curr. Opin. Drug Discov. Devel.* 5:194-199; Patyar *et al.* (2010) *Journal of Biomedical Science* 17:21; and Pawelek *et al.* (2003) *Lancet Oncol.* 4:548-556).

Bacteria can infect animal and human cells, and some possess the innate
5 ability to deliver DNA into the cytosol of cells. Bacteria also are suitable for therapy because they can be administered orally, they propagate readily *in vitro* and *in vivo*, and they can be stored and transported in a lyophilized state. Bacterial genetics readily are manipulated, and the complete genomes for many strains have been fully
10 characterized (Felgner *et al.* (2016) *mbio* 7(5):e01220-16). As a result, bacteria have been used to deliver and express a variety of genes, including those that encode cytokines, angiogenesis inhibitors, toxins and prodrug-converting enzymes. *Salmonella*, for example, has been used to express immune-stimulating molecules, such as IL-18 (Loeffler *et al.* (2008) *Cancer Gene Ther.* 15(12):787-794), LIGHT (Loeffler *et al.* (2007) *PNAS* 104(31):12879-12883), and Fas ligand (Loeffler *et al.*
15 (2008) *J. Natl. Cancer Inst.* 100:1113-1116), for treating tumors. Bacterial vectors also are cheaper and easier to produce than viral vectors, and bacterial delivery is favorable over viral delivery because it can be quickly eliminated by antibiotics if necessary, rendering it a safer alternative.

To be used, however, the strains must not be pathogenic, or not pathogenic
20 after modification, for use as a therapeutic. For example, in the treatment of cancer, the therapeutic bacterial strains must be attenuated or rendered sufficiently non-toxic so as to not cause systemic disease and/or septic shock, but still maintain some level of infectivity to effectively colonize tumors. Genetically modified bacteria have been described that are to be used as antitumor agents to elicit direct tumoricidal effects
25 and/or to deliver tumoricidal molecules (Clairmont, *et al.* (2000) *J. Infect. Dis.* 181:1996-2002; Bermudes, D. *et al.* (2002) *Curr. Opin. Drug Discov. Devel.* 5:194-199; Zhao, M. *et al.* (2005) *Proc. Natl. Acad. Sci. USA* 102:755-760; Zhao, M. *et al.* (2006) *Cancer Res.* 66:7647-7652). Among these are bioengineered strains of *Salmonella enterica* serovar Typhimurium (*S. typhimurium*). These bacteria
30 accumulate preferentially >1,000-fold greater in tumors than in normal tissues and disperse homogeneously in tumor tissues (Pawelek, J. *et al.* (1997) *Cancer Res.* 57:4537-4544; Low, K. B. *et al.* (1999) *Nat. Biotechnol.* 17:37-41). Preferential

replication allows the bacteria to produce and deliver a variety of anticancer therapeutic agents at high concentrations directly within the tumor, while minimizing toxicity to normal tissues. These attenuated bacteria are safe in mice, pigs, and monkeys when administered intravenously (Zhao, M. *et al.* (2005) *Proc Natl Acad Sci USA* 102:755-760; Zhao, M. *et al.* (2006) *Cancer Res* 66:7647-7652; Tjuvajev J. *et al.* (2001) *J. Control Release* 74:313-315; Zheng, L. *et al.* (2000) *Oncol. Res.* 12:127-135), and certain live attenuated *Salmonella* strains have been shown to be well tolerated after oral administration in human clinical trials (Chatfield, S. N. *et al.* (1992) *Biotechnology* 10:888-892; DiPetrillo, M. D. *et al.* (1999) *Vaccine* 18:449-459; Hohmann, E. L. *et al.* (1996) *J. Infect. Dis.* 173:1408-1414; Sirard, J. C. *et al.* (1999) *Immunol. Rev.* 171:5-26). The *S. typhimurium* *phoP/phoQ* operon is a typical bacterial two-component regulatory system composed of a membrane-associated sensor kinase (PhoQ) and a cytoplasmic transcriptional regulator (PhoP: Miller, S. I. *et al.* (1989) *Proc Natl Acad Sci USA* 86:5054-5058; Groisman, E. A. *et al.* (1989) *Proc Natl Acad Sci USA* 86: 7077-7081). PhoP/phoQ is required for virulence, and its deletion results in poor survival of this bacterium in macrophages and a marked attenuation in mice and humans (Miller, S. I. *et al.* (1989) *Proc Natl Acad Sci USA* 86:5054-5058; Groisman, E. A. *et al.* (1989) *Proc Natl Acad Sci USA* 86: 7077-7081; Galan, J. E. and Curtiss, R. III. (1989) *Microb Pathog* 6:433-443; Fields, P. I. *et al.* (1986) *Proc Natl Acad Sci USA* 83:189-193). PhoP/phoQ deletion strains have been employed as effective vaccine delivery vehicles (Galan, J. E. and Curtiss, R. III. (1989) *Microb Pathog* 6:433-443; Fields, P. I. *et al.* (1986) *Proc Natl Acad Sci USA* 83:189-193; Angelakopoulos, H. and Hohmann, E. L. (2000) *Infect Immun* 68:213-241). Attenuated *Salmonellae* have been used for targeted delivery of tumoricidal proteins (Bermudes, D. *et al.* (2002) *Curr Opin Drug Discov Devel* 5:194-199; Tjuvajev J. *et al.* (2001) *J Control Release* 74:313-315).

Bacterially-based cancer therapies have demonstrated limited clinical benefit. A variety of bacterial species, including *Clostridium novyi* (Dang *et al.* (2001) *Proc. Natl. Acad. Sci. U.S.A.* 98(26):15155-15160; U.S. Patent Publications Nos. 2017/0020931 and 2015/0147315; and U.S. Patent Nos. 7,344,710 and 3,936,354), *Mycobacterium bovis* (U.S. Patent Publications Nos. 2015/0224151 and 2015/0071873), *Bifidobacterium bifidum* (Kimura *et al.* (1980) *Cancer Res.* 40:2061-

2068), *Lactobacillus casei* (Yasutake *et al.* (1984) *Med Microbiol Immunol.* 173(3):113-125), *Listeria monocytogenes* (Le *et al.* (2012) *Clin. Cancer Res.* 18(3):858-868; Starks *et al.* (2004) *J. Immunol.* 173:420-427; U.S. Patent Publication No. 2006/0051380) and *Escherichia coli* (U.S. Patent No. 9,320,787), have been
5 studied as possible agents for anticancer therapy.

The Bacillus Calmette-Guerin (BCG) strain, for example, is approved for the treatment of bladder cancer in humans, and is more effective than intravesical chemotherapy, often being used as a first-line treatment (Gardlik *et al.* (2011) *Gene therapy* 18:425-431). Another approach utilizes *Listeria monocytogenes*, a live
10 attenuated intracellular bacterium capable of inducing potent CD8⁺ T cell priming to expressed tumor antigens in mice (Le *et al.* (2012) *Clin. Cancer Res.* 18(3):858-868). In a clinical trial of the *Listeria*-based vaccine incorporating the tumor antigen mesothelin, together with an allogeneic pancreatic cancer-based GVAX vaccine in a prime-boost approach, a median survival of 6.1 months was noted in patients with
15 advanced pancreatic cancer, versus a median survival of 3.9 months for patients treated with the GVAX vaccine alone (Le *et al.* (2015) *J. Clin. Oncol.* 33(12):1325-1333). These results were not replicated in a larger phase 2b study, possibly pointing to the difficulties in attempting to induce immunity to a low affinity self-antigen such as mesothelin.

20 Bacterial strains can be modified as described herein. The strains can be attenuated or their cellular targets modified by standard methods and/or by deletion or modification of genes, and by alteration or introduction of genes that render the bacteria able to grow *in vivo* primarily in immunoprivileged environments, such as the TME, in tumor cells, in tumor-resident immune cells, and solid tumors. Starting
25 strains for modification as described herein can be selected from among, for example, *Shigella*, *Listeria*, *E. coli*, *Bifidobacteriae* and *Salmonella*. For example, *Shigella sonnei*, *Shigella flexneri*, *Shigella dysenteriae*, *Listeria monocytogenes*, *Salmonella typhi*, *Salmonella typhimurium*, *Salmonella gallinarum*, and *Salmonella enteritidis*. Other suitable bacterial species include *Rickettsia*, *Klebsiella*, *Bordetella*, *Neisseria*,
30 *Aeromonas*, *Francisella*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*, *Mycoplasma*, *Legionella*, *Rhodococcus*, *Pseudomonas*, *Helicobacter*, *Vibrio*, *Bacillus*, and *Erysipelothrix*. For example, *Rickettsia Rickettsiae*,

Rickettsia prowazekii, *Rickettsia tsutsugamuchi*, *Rickettsia mooseri*, *Rickettsia sibirica*, *Bordetella bronchiseptica*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Aeromonas eucrenophila*, *Aeromonas salmonicida*, *Francisella tularensis*, *Corynebacterium pseudotuberculosis*, *Citrobacter freundii*, *Chlamydia pneumoniae*,
 5 *Haemophilus sordani*, *Brucella abortus*, *Mycobacterium intracellulare*, *Legionella pneumophila*, *Rhodococcus equi*, *Pseudomonas aeruginosa*, *Helicobacter mustelae*, *Vibrio cholerae*, *Bacillus subtilis*, *Erysipelothrix rhusiopathiae*, *Yersinia enterocolitica*, *Rochalimaea quintana*, and *Agrobacterium tumefaciens*. Any known therapeutic, including immunostimulatory, bacteria can be modified as described
 10 herein.

2. Comparison of the Immune Responses to Bacteria and Viruses

Bacteria, like viruses, have the advantage of being naturally immunostimulatory. Bacteria and viruses contain conserved structures known as Pathogen-Associated Molecular Patterns (PAMPs), which are sensed by host cell
 15 Pattern Recognition Receptors (PRRs). Recognition of PAMPs by PRRs triggers downstream signaling cascades that result in the induction of cytokines and chemokines, and the initiation of immune responses that lead to pathogen clearance (Iwasaki and Medzhitov (2010) *Science* 327(5963):291–295). The manner in which the innate immune system is engaged by PAMPs, and from what type of infectious
 20 agent, determines the appropriate adaptive immune response to combat the invading pathogen.

A class of PRRs known as Toll Like Receptors (TLRs) recognize PAMPs derived from bacterial and viral origins, and are located in various compartments within the cell. TLRs bind a range of ligands, including lipopolysaccharide (TLR4),
 25 lipoproteins (TLR2), flagellin (TLR5), unmethylated CpG motifs in DNA (TLR9), double-stranded RNA (TLR3), and single-stranded RNA (TLR7 and TLR8) (Akira *et al.* (2001) *Nat. Immunol.* 2(8):675-680; Kawai and Akira (2005) *Curr. Opin. Immunol.* 17(4):338-344). Host surveillance of *S. typhimurium* for example, is largely mediated through TLR2, TLR4 and TLR5 (Arpaia *et al.* (2011) *Cell* 144(5):675-688).
 30 These TLRs signal through MyD88 and TRIF adaptor molecules to mediate induction of NF- κ B dependent pro-inflammatory cytokines such as TNF- α , IL-6 and IFN- γ (Pandey *et al.* (2015) *Cold Spring Harb Perspect Biol* 7(1):a016246).

Another category of PRRs are the nod-like receptor (NLR) family. These receptors reside in the cytosol of host cells and recognize intracellular PAMPS. For example, *S. typhimurium* flagellin was shown to activate the NLRC4/NAIP5 inflammasome pathway, resulting in the cleavage of caspase-1 and induction of the pro-inflammatory cytokines IL-1 β and IL-18, leading to pyroptotic cell death of infected macrophages (Fink *et al.* (2007) *Cell Microbiol.* 9(11):2562–2570).

While engagement of TLR2, TLR4, TLR5 and the inflammasome induces pro-inflammatory cytokines that mediate bacterial clearance, they activate a predominantly NF- κ B-driven signaling cascade that leads to recruitment and activation of neutrophils, macrophages and CD4⁺ T cells, but not the DCs and CD8⁺ T cells that are required for anti-tumor immunity (Lui *et al.* (2017) *Signal Transduct Target Ther.* 2:17023). In order to activate CD8⁺ T cell-mediated anti-tumor immunity, IRF3/IRF7-dependent type I interferon signaling is critical for DC activation and cross-presentation of tumor antigens to promote CD8⁺ T cell priming (Diamond *et al.* (2011) *J. Exp. Med.* 208(10):1989–2003; Fuertes *et al.* (2011) *J. Exp. Med.* 208(10):2005–2016). Type I interferons (IFN- α , IFN- β) are the signature cytokines induced by two distinct TLR-dependent and TLR-independent signaling pathways. The TLR-dependent pathway for inducing IFN- β occurs following endocytosis of pathogens, whereby TLR3, 7, 8 and 9 detect pathogen-derived DNA and RNA elements within the endosomes. TLRs 7 and 8 recognize viral nucleosides and nucleotides, and synthetic agonists of these, such as resiquimod and imiquimod have been clinically validated (Chi *et al.* (2017) *Frontiers in Pharmacology* 8:304). Synthetic dsRNA, such as polyinosinic:polycytidylic acid (poly (I:C)) and poly ICLC, an analog that is formulated with poly L lysine to resist RNase digestion, is an agonist for TLR3 and MDA5 pathways and a powerful inducer of IFN- β (Caskey *et al.* (2011) *J. Exp. Med.* 208(12):2357-66). TLR9 detection of endosomal CpG motifs present in viral and bacterial DNA can also induce IFN- β via IRF3. Additionally, TLR4 has been shown to induce IFN- β via MyD88-independent TRIF activation of IRF3 (Owen *et al.* (2016) *mBio.* 7:1 e02051-15). It subsequently was shown that TLR4 activation of DCs was independent of type I IFN, so the ability of TLR4 to activate DCs via type I IFN is not likely biologically relevant (Hu *et al.* (2015) *Proc. Natl. Acad. Sci. U.S.A.*

112:45). Further, TLR4 signaling has not been shown to directly recruit or activate CD8⁺ T cells.

Of the TLR-independent type I IFN pathways, one is mediated by host recognition of single-stranded (ss) and double-stranded (ds) RNA in the cytosol.

- 5 These are sensed by RNA helicases, including retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA-5), and through the IFN- β promoter stimulator 1 (IPS-1; also known as mitochondrial antiviral-signaling protein or MAVS) adaptor protein-mediated phosphorylation of the IRF-3 transcription factor, leading to induction of IFN- β (Ireton and Gale (2011) *Viruses* 3(6):906-919).
- 10 Synthetic RIG-I-binding elements have also been discovered unintentionally in common lentiviral shRNA vectors, in the form of an AA dinucleotide sequence at the U6 promoter transcription start site. Its subsequent deletion in the plasmid prevented confounding off-target type I IFN activation (Pebernard *et al.* (2004) *Differentiation*. 72:103-111).

- 15 The second type of TLR-independent type I interferon induction pathway is mediated through Stimulator of Interferon Genes (STING), a cytosolic ER-resident adaptor protein that is now recognized as the central mediator for sensing cytosolic dsDNA from infectious pathogens or aberrant host cell damage (Barber (2011) *Immunol. Rev* 243(1):99-108). STING signaling activates the TANK binding kinase
- 20 (TBK1)/IRF3 axis and the NF- κ B signaling axis, resulting in the induction of IFN- β and other pro-inflammatory cytokines and chemokines that strongly activate innate and adaptive immunity (Burdette *et al.* (2011) *Nature* 478(7370):515-518). Sensing of cytosolic dsDNA through STING requires cyclic GMP-AMP synthase (cGAS), a host cell nucleotidyl transferase that directly binds dsDNA, and in response, synthesizes a
- 25 cyclic dinucleotide (CDN) second messenger, cyclic GMP-AMP (cGAMP), which binds and activates STING (Sun *et al.* (2013) *Science* 339(6121):786-791; Wu *et al.* (2013) *Science* 339(6121):826-830). CDNs derived from bacteria such as c-di-AMP produced from intracellular *Listeria monocytogenes* can also directly bind murine STING, but only 3 of the 5 human STING alleles. Unlike the CDNs produced by
- 30 bacteria, in which the two purine nucleosides are joined by a phosphate bridge with 3'-3' linkages, the internucleotide phosphate bridge in the cGAMP synthesized by mammalian cGAS is joined by a non-canonical 2'-3' linkage. These 2'-3' molecules

bind to STING with 300-fold better affinity than bacterial 3'-3' CDNs, and thus, are more potent physiological ligands of human STING (see, *e.g.*, Civril *et al.* (2013) *Nature* 498(7454):332-337; Diner *et al.* (2013) *Cell Rep.* 3(5):1355-1361; Gao *et al.* (2013) *Sci. Signal* 6(269):pl1; Ablasser *et al.* (2013) *Nature* 503(7477):530-534).

5 The cGAS/STING signaling pathway in humans has evolved to preferentially respond to viral pathogens over bacterial pathogens, and this can explain why previous bacterial vaccines harboring host tumor antigens have made for poor CD8⁺ T cell priming vectors in humans. TLR-independent activation of CD8⁺ T cells by STING-dependent type I IFN signaling from conventional DCs is the primary
10 mechanism by which viruses are detected, with TLR-dependent type I IFN production by plasmacytoid DCs operating only when the STING pathway has been virally-inactivated (Hervas-Stubbs *et al.* (2014) *J. Immunol.* 193:1151-1161). Further, for bacteria such as *S. typhimurium*, while capable of inducing IFN- β via TLR4, CD8⁺ T cells are neither induced nor required for clearance or protective immunity (Lee *et al.*
15 (2012) *Immunol Lett.* 148(2): 138–143). The lack of physiologically relevant CD8⁺ T epitopes for many strains of bacteria, including *S. typhimurium*, has impeded bacterial vaccine development and protective immunity to subsequent infections, even from the same genetic strains (Lo *et al.* (1999) *J. Immunol.* 162:5398-5406). Bacterially-based cancer immunotherapies are biologically limited in their ability to induce type I IFN
20 to recruit and activate CD8⁺ T cells, which is necessary to promote tumor antigen cross-presentation and durable anti-tumor immunity. The immunostimulatory bacteria provided herein, however, are engineered to solve this problem. The immunostimulatory bacteria provided herein induce viral-like TLR-independent type I IFN signaling, rather than TLR-dependent bacterial immune signaling, which
25 preferentially induces CD8⁺ T cell mediated anti-tumor immunity.

 STING activates innate immunity in response to sensing nucleic acids in the cytosol. Downstream signaling is activated through binding of CDNs, which are synthesized by bacteria or by the host enzyme cGAS in response to binding to cytosolic dsDNA. Bacterial and host-produced CDNs have distinct phosphate bridge
30 structures, which differentiates their capacity to activate STING. IFN- β is the signature cytokine of activated STING, and virally-induce type I IFN, rather than bacterially-induced IFN, is required for effective CD8⁺ T cell mediated anti-tumor

immunity. Immunostimulatory bacteria provided herein include those that are STING agonists and those that express STING.

3. *Salmonella* Therapy

Salmonella is exemplary of a bacterial genus that can be used as a cancer therapeutic. The *Salmonella* exemplified herein is an attenuated species or is one that, by virtue of the modifications described herein, for use as a cancer therapeutic, has reduced toxicity.

a. Tumor-tropic Bacteria

A number of bacterial species have demonstrated preferential replication within solid tumors when injected from a distal site. These include, but are not limited to, species of *Salmonella*, *Bifidobacterium*, *Clostridium*, and *Escherichia*. The natural tumor-homing properties of the bacteria combined with the host's innate immune response to the bacterial infection is thought to mediate the anti-tumor response. This tumor tissue tropism has been shown to reduce the size of tumors to varying degrees. One contributing factor to the tumor tropism of these bacterial species is the ability to replicate in anoxic or hypoxic environments. A number of these naturally tumor-tropic bacteria have been further engineered to increase the potency of the antitumor response (reviewed in Zu *et al.* (2014) *Crit Rev Microbiol.* 40(3):225–235; and Felgner *et al.* (2017) *Microbial Biotechnology* 10(5):1074–1078).

b. *Salmonella enterica* serovar Typhimurium

Salmonella enterica serovar Typhimurium (*S. typhimurium*) is exemplary of a bacterial species for use as an anti-cancer therapeutic. One approach to using bacteria to stimulate host immunity to cancer has been through the Gram-negative facultative anaerobe *S. typhimurium*, which preferentially accumulates in hypoxic and necrotic areas in the body, including tumor microenvironments. *S. typhimurium* accumulates in these environments due to the availability of nutrients from tissue necrosis, the leaky tumor vasculature, and their increased likelihood to survive in the immune system-evading tumor microenvironment (Baban *et al.* (2010) *Bioengineered Bugs* 1(6):385–294). *S. typhimurium* is able to grow under both aerobic and anaerobic conditions; therefore, it is able to colonize small tumors that are less hypoxic, and large tumors that are more hypoxic.

S. typhimurium is a Gram-negative, facultative pathogen that is transmitted via the fecal-oral route. It causes localized gastrointestinal infections, but also enters the bloodstream and lymphatic system after oral ingestion, infecting systemic tissues such as the liver, spleen and lungs. Systemic administration of wild-type *S. typhimurium* overstimulates TNF- α induction, leading to a cytokine cascade and septic shock, which, if left untreated, can be fatal. As a result, pathogenic bacterial strains, such as *S. typhimurium*, must be attenuated to prevent systemic infection, without completely suppressing their ability to effectively colonize tumor tissues. Attenuation is often achieved by mutating a cellular structure that can elicit an immune response, such as the bacterial outer membrane, or limiting its ability to replicate in the absence of supplemental nutrients.

S. typhimurium is an intracellular pathogen that is rapidly taken up by myeloid cells, such as macrophages, or it can induce its own uptake in non-phagocytic cells, such as epithelial cells. Once inside cells, it can replicate within a *Salmonella* containing vacuole (SCV) and can also escape into the cytosol of some epithelial cells. Many of the molecular determinants of *S. typhimurium* pathogenicity have been identified and the genes are clustered in *Salmonella* pathogenicity islands (SPIs). The two best characterized pathogenicity islands are SPI-1, which is responsible for mediating bacterial invasion of non-phagocytic cells, and SPI-2 which is required for replication within the SCV (Agbor and McCormick (2011) *Cell Microbiol.* 13(12):1858–1869). Both of these pathogenicity islands encode macromolecular structures called type three secretion systems (T3SS) that can translocate effector proteins across the host membrane (Galan and Wolf-Watz (2006) *Nature* 444:567-573).

25 c. Bacterial Attenuation

Therapeutic bacteria for administration as a cancer treatment should be modified so that they do not cause diseases. Various methods to achieve this are known in the art. Auxotrophic mutations, for example, render bacteria incapable of synthesizing an essential nutrient, and deletions/mutations in genes such as *aro*, *pur*, *gua*, *thy*, *nad* and *asd* (U.S. Patent Publication No. 2012/0009153) are widely used. Nutrients produced by the biosynthesis pathways involving these genes are often unavailable in host cells, and as such, bacterial survival is challenging. For example,

- attenuation of *Salmonella* and other species can be achieved by deletion of the *aroA* gene, which is part of the shikimate pathway, connecting glycolysis to aromatic amino acid biosynthesis (Felgner *et al.* (2016) *MBio* 7(5):e01220-16). Deletion of *aroA* therefore results in bacterial auxotrophy for aromatic amino acids and subsequent
- 5 attenuation (U.S. Patent Publication Nos. 2003/0170276, 2003/0175297, 2012/0009153 and 2016/0369282; International Application Publication Nos. WO 2015/032165 and WO 2016/025582). Similarly, other enzymes involved in the biosynthesis pathway for aromatic amino acids, including *aroC* and *aroD* have been deleted to achieve attenuation (U.S. Patent Publication No. 2016/0369282;
- 10 International Application Publication No. WO 2016/025582). For example, *S. typhimurium* strain SL7207 is an aromatic amino acid auxotroph (*aroA*⁻ mutant); strains A1 and A1-R are leucine-arginine auxotrophs. VNP20009 is a purine auxotroph (*purT*⁻ mutant). As shown herein, it is also auxotrophic for the immunosuppressive nucleoside adenosine.
- 15 Mutations that attenuate bacteria also include, but are not limited to, mutations in genes that alter the biosynthesis of lipopolysaccharide, such as *rfaL*, *rfaG*, *rfaH*, *rfaD*, *rfaP*, *rFb*, *rfa*, *msbB*, *htrB*, *firA*, *pagL*, *pagP*, *lpxR*, *arnT*, *eptA*, and *lpxT*; mutations that introduce a suicide gene, such as *sacB*, *muk*, *hok*, *gef*, *kil* or *phlA*; mutations that introduce a bacterial lysis gene, such as *hly* and *cly*; mutations in
- 20 virulence factors, such as *isyA*, *pag*, *prg*, *iscA*, *virG*, *plc* and *act*; mutations that modify the stress response, such as *recA*, *htrA*, *htpR*, *hsp* and *groEL*; mutations that disrupt the cell cycle, such as *min*; and mutations that disrupt or inactivate regulatory functions, such as *cya*, *crp*, *phoP/phoQ*, and *ompR* (U.S. Patent Publication Nos. 2012/0009153, 2003/0170276, 2007/0298012; U.S. Patent No. 6,190,657;
- 25 International Application Publication No. WO 2015/032165; Felgner *et al.* (2016) *Gut microbes* 7(2):171-177; Broadway *et al.* (2014) *J. Biotechnology* 192:177-178; Frahm *et al.* (2015) *mBio* 6(2):e00254-15; Kong *et al.* (2011) *Infection and Immunity* 79(12):5027-5038; Kong *et al.* (2012) *Proc. Natl. Acad. Sci. USA* 109(47):19414-19419). Ideally, the genetic attenuations comprise gene deletions rather than point
- 30 mutations to prevent spontaneous compensatory mutations that might result in reversion to a virulent phenotype.

i. *msbB* Mutants

The enzyme lipid A biosynthesis myristoyltransferase, encoded by the *msbB* gene in *S. typhimurium*, catalyzes the addition of a terminal myristyl group to the lipid A domain of lipopolysaccharide (LPS) (Low *et al.* (1999) *Nat. Biotechnol.* 17(1):37-41). Deletion of *msbB* thus alters the acyl composition of the lipid A domain of LPS, the major component of the outer membranes of Gram-negative bacteria. This modification significantly reduces the ability of the LPS to induce septic shock, attenuating the bacterial strain and reducing the potentially harmful production of TNF α , thus, lowering systemic toxicity. *S. typhimurium msbB* mutants maintain their ability to preferentially colonize tumors over other tissues in mice and retain anti-tumor activity, thus, increasing the therapeutic index of *Salmonella*-based immunotherapeutics (see, *e.g.*, U.S. Patent Publication Nos. 2003/0170276, 2003/0109026, 2004/0229338, 2005/0225088 and 2007/0298012).

For example, deletion of *msbB* in the *S. typhimurium* strain VNP20009 results in production of a predominantly penta-acylated LPS, which is less toxic than native hexa-acylated LPS, and allows for systemic delivery without the induction of toxic shock (Lee *et al.* (2000) *International Journal of Toxicology* 19:19–25). Other LPS mutations can be introduced into the bacterial strains provided herein, including the *Salmonella* strains, that dramatically reduce virulence, and thereby provide for lower toxicity, and permit administration of higher doses.

ii. *purI* Mutants

Immunostimulatory bacteria that can be attenuated by rendering them auxotrophic for one or more essential nutrients, such as purines (for example, adenine), nucleosides (for example, adenosine) or amino acids (for example, arginine and leucine), are employed. In particular, in embodiments of the immunostimulatory bacteria provided herein, such as *S. typhimurium*, the bacteria are rendered auxotrophic for adenosine, which preferentially accumulates in tumor microenvironments. Hence, strains of immunostimulatory bacteria described herein are attenuated because they require adenosine for growth, and they preferentially colonize TMEs, which, as discussed below, have an abundance of adenosine.

Phosphoribosylaminoimidazole synthetase, an enzyme encoded by the *purI* gene (synonymous with the *purM* gene), is involved in the biosynthesis pathway of

purines. Disruption of the *purI* gene thus renders the bacteria auxotrophic for purines. In addition to being attenuated, *purI* mutants are enriched in the tumor environment and have significant anti-tumor activity (Pawelek *et al.* (1997) *Cancer Research* 57:4537-4544). It was previously described that this colonization results from the high concentration of purines present in the interstitial fluid of tumors as a result of their rapid cellular turnover. Since the *purI* bacteria are unable to synthesize purines, they require an external source of adenine, and it was thought that this would lead to their restricted growth in the purine-enriched tumor microenvironment (Rosenberg *et al.* (2002) *J. Immunotherapy* 25(3):218-225). While the VNP20009 strain was initially reported to contain a deletion of the *purI* gene (Low *et al.* (2003) *Methods in Molecular Medicine* Vol. 90, *Suicide Gene Therapy*:47-59), subsequent analysis of the entire genome of VNP20009 demonstrated that the *purI* gene is not deleted, but is disrupted by a chromosomal inversion (Broadway *et al.* (2014) *Journal of Biotechnology* 192:177-178). The entire gene is contained within two parts of the VNP20009 chromosome that is flanked by insertion sequences (one of which has an active transposase).

It is shown herein, that, *purI* mutant *S. typhimurium* strains are auxotrophic for the nucleoside adenosine, which is highly enriched in tumor microenvironments. Hence, when using VNP20009, it is not necessary to introduce any further modification to achieve adenosine auxotrophy. For other strains and bacteria, the *purI* gene can be disrupted as it has been in VNP20009, or it can contain a deletion of all or a portion of the *purI* gene to prevent reversion to a wild-type gene.

iii. Combinations of Attenuating Mutations

A bacterium with multiple genetic attenuations by means of gene deletions on disparate regions of the chromosome is desirable for bacterial immunotherapies because the attenuation can be increased, while decreasing the possibility of reversion to a virulent phenotype by acquisition of genes by homologous recombination with a wild-type genetic material. Restoration of virulence by homologous recombination would require two separate recombination events to occur within the same organism. Ideally, the combination of attenuating mutations selected for use in an immunotherapeutic agent increases the tolerability without decreasing the potency, thereby increasing the therapeutic index.

For example, as discussed below, disruption of the *msbB* and *purI* genes in *S. typhimurium* strain VNP20009, has been used for tumor-targeting and growth suppression, and elicits low toxicity in animal models (Clairmont *et al.* (2000) *J. Infect. Dis.* 181:1996-2002; Bermudes *et al.* (2000) *Cancer Gene Therapy: Past Achievements and Future Challenges*, edited by Habib Kluwer Academic/Plenum Publishers, New York, pp. 57-63; Low *et al.* (2003) *Methods in Molecular Medicine*, Vol. 90, *Suicide Gene Therapy*:47-59; Lee *et al.* (2000) *International Journal of Toxicology* 19:19-25; Rosenberg *et al.* (2002) *J. Immunotherapy* 25(3):218-225; Broadway *et al.* (2014) *J. Biotechnology* 192:177-178; Loeffler *et al.* (2007) *Proc. Natl. Acad. Sci. U.S.A.* 104(31):12879-12883; Luo *et al.* (2002) *Oncology Research* 12:501-508). VNP20009, however, does not show the same tumor accumulation and anti-tumor activity in human trials. Higher doses, which are required to manifest any anti-tumor activity, thus, are not possible due to toxicity. The immunostimulatory bacteria provided herein, which contain combinations of genetic modifications that, for example, reduce virulence, increase tolerability, decrease or eliminate bacterial infection of epithelial (and other non-immune) cells, increase accumulation in tumor-resident immune cells, and reduce cell death of tumor-resident immune cells, among other desirable properties that improve the therapeutic index, address this problem.

iv. VNP20009 and Other Attenuated *S. typhimurium* Strains

Exemplary of a therapeutic bacterium that can be modified as described herein is the strain designated as VNP20009 (ATCC # 202165, YS1646). The clinical candidate, VNP20009 (ATCC # 202165, YS1646), was at least 50,000-fold attenuated for safety by deletion of both the *msbB* and *purI* genes (Clairmont *et al.* (2000) *J. Infect. Dis.* 181:1996-2002; Low *et al.* (2003) *Methods in Molecular Medicine*, Vol. 90, *Suicide Gene Therapy*:47-59; Lee *et al.* (2000) *International Journal of Toxicology* 19:19-25). Similar strains of *Salmonella* that are attenuated also are contemplated. As described above, deletion of *msbB* alters the composition of the lipid A domain of lipopolysaccharide, the major component of Gram-negative bacterial outer membranes (Low *et al.* (1999) *Nat. Biotechnol.* 17(1):37-41). This prevents lipopolysaccharide-induced septic shock, attenuating the bacterial strain and lowering systemic toxicity, while reducing the potentially harmful production of

TNF α (Dinarello, C.A. (1997) *Chest* 112(6 Suppl):321S-329S; Low *et al.* (1999) *Nat. Biotechnol.* 17(1):37-41). Deletion of the *purI* gene renders the bacteria auxotrophic for purines, which further attenuates the bacteria and enriches it in the tumor microenvironment (Pawelek *et al.* (1997) *Cancer Res.* 57:4537-4544; Broadway *et al.* (2014) *J. Biotechnology* 192:177-178).

The accumulation of VNP20009 in tumors results from a combination of factors including: the inherent invasiveness of the parental strain, ATCC #14028, its ability to replicate in hypoxic environments, and its requirement for high concentrations of purines that are present in the interstitial fluid of tumors. It also is shown herein that VNP20009 also is auxotrophic for the nucleoside adenosine, which can accumulate to pathologically high levels in the tumor microenvironment and contribute to an immunosuppressive tumor microenvironment (Peter Vaupel and Arnulf Mayer Oxygen Transport to Tissue XXXVII, *Advances in Experimental Medicine and Biology* 876 chapter 22, pp. 177-183). When VNP20009 was administered into mice bearing syngeneic or human xenograft tumors, the bacteria accumulated preferentially within the extracellular components of tumors at ratios exceeding 300-1000 to 1, reduced TNF α induction, and demonstrated tumor growth inhibition as well as prolonged survival compared to control mice (Clairmont *et al.* (2000) *J. Infect. Dis.* 181:1996-2002). Results from the Phase 1 clinical trial in humans, however, revealed that while VNP20009 was relatively safe and well tolerated, poor accumulation was observed in human melanoma tumors, and very little anti-tumor activity was demonstrated (Toso *et al.* (2002) *J. Clin. Oncol.* 20(1):142-152). Higher doses, which would be required to affect any anti-tumor activity, were not possible due to toxicity that correlated with high levels of pro-inflammatory cytokines.

Other strains of *S. typhimurium* can be used for tumor-targeted delivery and therapy, such as, for example, leucine-arginine auxotroph A-1 (Zhao *et al.* (2005) *Proc. Natl. Acad. Sci. USA* 102(3):755-760; Yu *et al.* (2012) *Scientific Reports* 2:436; U.S. Patent No. 8,822,194; U.S. Patent Publication No. 2014/0178341) and its derivative AR-1 (Yu *et al.* (2012) *Scientific Reports* 2:436; Kawagushi *et al.* (2017) *Oncotarget* 8(12):19065-19073; Zhao *et al.* (2006) *Cancer Res.* 66(15):7647-7652; Zhao *et al.* (2012) *Cell Cycle* 11(1):187-193; Tome *et al.* (2013) *Anticancer Research*

33:97-102; Murakami *et al.* (2017) *Oncotarget* 8(5):8035-8042; Liu *et al.* (2016) *Oncotarget* 7(16):22873-22882; Binder *et al.* (2013) *Cancer Immunol Res.* 1(2):123-133); *aroA*⁻ mutant *S. typhimurium* strain SL7207 (Guo *et al.* (2011) *Gene therapy* 18:95-105; U.S. Patent Publication Nos. 2012/0009153, 2016/0369282 and
 5 2016/0184456) and its obligate anaerobe derivative YB1 (International Application Publication No. WO 2015/032165; Yu *et al.* (2012) *Scientific Reports* 2:436; Leschner *et al.* (2009) *PLoS ONE* 4(8):e6692; Yu *et al.* (2012) *Scientific Reports* 2:436); *aroA*⁻/*aroD*⁻ mutant *S. typhimurium* strain BRD509, a derivative of the SL1344 (wild-type) strain (Yoon *et al.* (2017) *European J. of Cancer* 70:48-61); *asd*⁻
 10 */cydA/crp*⁻ mutant *S. typhimurium* strain χ 4550 (Sorenson *et al.* (2010) *Biology: Targets & Therapy* 4:61-73) and *phoP*⁻/*phoQ*⁻ *S. typhimurium* strain LH430 (International Application Publication No. WO 2008/091375).

The strain VNP20009 failed to show a clinical benefit in a study involving patients with advanced melanoma, but the treatment was safely administered to
 15 advanced cancer patients. A maximum tolerated dose (MTD) was established. Hence, this strain, as well as other similarly engineered bacterial strains, can be used as a starting material for tumor-targeting, therapeutic delivery vehicles. Modifications provided herein provide a strategy to increase efficacy, by increasing the anti-tumor efficiency and/or the safety and tolerability of the therapeutic agent.

20 v. *S. typhimurium* Engineered To Deliver Macromolecules

S. typhimurium also has been modified to deliver the tumor-associated antigen (TAA) survivin (SVN) to APCs to prime adaptive immunity (U.S. Patent Publication No. 2014/0186401; Xu *et al.* (2014) *Cancer Res.* 74(21):6260-6270). SVN is an
 25 inhibitor of apoptosis protein (IAP) which prolongs cell survival and provides cell cycle control, and is overexpressed in all solid tumors and poorly expressed in normal tissues. This technology employs the *Salmonella* Pathogenicity Island 2 (SPI-2) and its type III secretion system (T3SS) to deliver the TAAs into the cytosol of APCs, which then are activated to induce TAA-specific CD8⁺ T cells and anti-tumor
 30 immunity (Xu *et al.* (2014) *Cancer Res.* 74(21):6260-6270). Similar to the *Listeria*-based TAA vaccines, this approach has shown promise in mouse models, but has yet to demonstrate effective tumor antigen-specific T cell priming in humans.

In addition to gene delivery, *S. typhimurium* also has been used for the delivery of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) for cancer therapy. For example, attenuated *S. typhimurium* have been modified to express certain shRNAs, such as those that target STAT3 and IDO1 (International Application Publication No. WO 2008/091375; and U.S. Patent No. 9,453,227). VNP20009 transformed with an shRNA plasmid against the immunosuppressive gene indolamine deoxygenase (IDO), successfully silenced IDO expression in a murine melanoma model, resulting in tumor cell death and significant tumor infiltration by neutrophils (Blache *et al.* (2012) *Cancer Res.* 72(24):6447-6456). Combining this vector with the co-administration of PEGPH20 (an enzyme that depletes extracellular hyaluronan), showed positive results in the treatment of pancreatic ductal adenocarcinoma tumors (Manuel *et al.* (2015) *Cancer Immunol. Res.* 3(9):1096-1107; U.S. Patent Publication No. 2016/0184456). In another study, an *S. typhimurium* strain attenuated by a *phoP/phoQ* deletion and expressing a signal transducer and activator of transcription 3 (STAT3)-specific shRNA, was found to inhibit tumor growth and reduce the number of metastatic organs, extending the life of C57BL/6 mice (Zhang *et al.* (2007) *Cancer Res.* 67(12):5859-5864). In another example, *S. typhimurium* strain SL7207 has been used for the delivery of shRNA targeting CTNNB1, the gene that encodes β -catenin (Guo *et al.* (2011) *Gene therapy* 18:95-105; U.S. Patent Publication Nos. 2009/0123426, 2016/0369282), while *S. typhimurium* strain VNP20009 has been utilized in the delivery of shRNA targeting STAT3 (Manuel *et al.* (2011) *Cancer Res.* 71(12):4183-4191; U.S. Patent Publication Nos. 2009/0208534, 2014/0186401 and 2016/0184456; International Application Publication Nos. WO 2008/091375 and WO 2012/149364). siRNAs targeting the autophagy genes *Atg5* and *Beclin1* have been delivered to tumor cells using *S. typhimurium* strains A1-R and VNP20009 (Liu *et al.* (2016) *Oncotarget* 7(16):22873-22882). Improvement of such strains is needed so that they more effectively stimulate the immune response, and have other advantageous properties, such as the immunostimulatory bacteria provided herein. Further and alternative modifications of various bacteria have been described in published International PCT Application Publication No. WO 2019/014398 and U.S. Publication No. 2019/0017050 A1. The bacteria described in each of these publications, also described herein, can be

modified as described herein to further improve the immunostimulatory and tumor-targeting properties.

The bacteria can be modified as described herein to have reduced inflammatory effects, and thus, to be less toxic. As a result, for example, higher dosages can be administered. Any of these strains of *Salmonella*, as well as other species of bacteria, known to those of skill in the art and/or listed above and herein, can be modified as described herein, such as by introducing adenosine auxotrophy. Exemplary are the *S. typhimurium* species described herein.

The bacterial strains provided herein are engineered to deliver therapeutic molecules/products. The strains herein deliver immunostimulatory proteins, including modified gain-of-function variants of cytosolic DNA/RNA sensors that can constitutively evoke/induce type I IFN expression, and other immunostimulatory proteins, such as cytokines, that promote an anti-tumor immune response in the tumor microenvironment. The strains also can include genomic modifications that reduce pyroptosis of phagocytic cells, thereby providing for a more robust immune response, and/or reduce or eliminate the ability to infect/invade epithelial cells, but retain the ability to infect/invade phagocytic cells, so that they accumulate more effectively in tumors and in tumor-resident immune cells. The bacterial strains encode therapeutic products. Accumulation in tumor-resident immune cells allows the encoded therapeutic products to be expressed and secreted into the tumor microenvironment, increasing the therapeutic efficacy.

4. Enhancements of Immunostimulatory Bacteria to Increase Therapeutic Index and Expression in Tumor-Resident Immune Cells

Provided herein are enhancements to immunostimulatory bacteria that reduce toxicity and improve the anti-tumor activity. Exemplary of such enhancements are the following. They are described with respect to *Salmonella*, particularly *S. typhimurium*; it is understood that the skilled person can effect similar enhancements in other bacterial species and other *Salmonella* strains.

a. *asd* Gene Deletion

The *asd* gene in bacteria encodes an aspartate-semialdehyde dehydrogenase. *asd* mutants of *S. typhimurium* have an obligate requirement for diaminopimelic acid (DAP) which is required for cell wall synthesis and will undergo lysis in

environments deprived of DAP. This DAP auxotrophy can be used for plasmid selection and maintenance of plasmid stability *in vivo*, without the use of antibiotics, when the *asd* gene is complemented in trans on a plasmid. Non-antibiotic-based plasmid selection systems are advantageous and allow for: 1) the use of administered
5 antibiotics as a rapid clearance mechanism in the event of adverse symptoms, and 2) antibiotic-free scale up of production, where such use is commonly avoided. The *asd* gene complementation system provides for such selection (Galán *et al.* (1990) *Gene* 28:29-35). The use of the *asd* gene complementation system to maintain plasmids in the tumor microenvironment is expected to increase the potency of *S.*
10 *typhimurium* engineered to deliver plasmids encoding genes, and therapeutic products/proteins, such as the STING proteins, and other immunostimulatory proteins, as described herein.

An alternative use for an *asd* mutant of *S. typhimurium* is to exploit the DAP auxotrophy to produce an autolytic (or suicidal) strain for delivery of macromolecules
15 to infected cells without the ability to persistently colonize host tumors. Deletion of the *asd* gene makes the bacteria auxotrophic for DAP when grown *in vitro* or *in vivo*. An example described herein (see, *e.g.*, Example 3), provides an *asd* deletion strain that is auxotrophic for DAP and contains a plasmid that encodes a therapeutic product, and that does not contain an *asd* complementing gene, resulting in a strain
20 that is defective for replication *in vivo*. This strain is propagated *in vitro* in the presence of DAP and grows normally, and then is administered as an immunotherapeutic agent to a mammalian host, where DAP is not present. The suicidal strain is able to invade host cells but is not be able to replicate due to the absence of DAP in mammalian tissues, lysing automatically and delivering its
25 cytosolic contents (*e.g.*, plasmids or proteins).

In examples provided herein, an *asd* gene deleted strain of VNP20009 was further modified to express an LLO protein lacking its endogenous periplasmic secretion signal sequence (cytoLLO), causing it to accumulate in the cytoplasm of the *Salmonella*. LLO is a cholesterol-dependent pore forming hemolysin from *Listeria*
30 *monocytogenes* that mediates phagosomal escape of bacteria. When the autolytic strain is introduced into tumor bearing mice, the bacteria are taken up by phagocytic immune cells and enter the *Salmonella* containing vacuole (SCV). In this

environment, the lack of DAP will prevent bacterial replication, and result in autolysis of the bacteria in the SCV. Lysis of the suicidal strain will then allow for release of the plasmid and the accumulated LLO that will form pores in the cholesterol-containing SVC membrane, and allow for delivery of the plasmid into the cytosol of the host cell. Here, gene products encoded on the plasmid, that are under control of a eukaryotic promoter, can be expressed by the host cell machinery.

b. Adenosine Auxotrophy

Metabolites derived from the tryptophan and ATP/adenosine pathways are major drivers in forming an immunosuppressive environment within the tumor.

Adenosine, which exists in the free form inside and outside of cells, is an effector of immune function. Adenosine decreases T-cell receptor induced activation of NF- κ B, and inhibits IL-2, IL-4, and IFN- γ . Adenosine decreases T-cell cytotoxicity, increases T-cell anergy, and increases T-cell differentiation to Foxp3⁺ or Lag-3⁺ regulatory T-cells (T-regs). In NK cells, adenosine decreases IFN- γ production, and suppresses NK cell cytotoxicity. Adenosine blocks neutrophil adhesion and extravasation, decreases phagocytosis, and attenuates levels of superoxide and nitric oxide. Adenosine also decreases the expression of TNF- α , IL-12, and MIP-1 α (CCL3) on macrophages, attenuates MHC Class II expression, and increases levels of IL-10 and IL-6.

Adenosine immunomodulation activity occurs after its release into the extracellular space of the tumor and activation of adenosine receptors (ADRs) on the surfaces of target immune cells, cancer cells or endothelial cells. The high adenosine levels in the tumor microenvironment result in local immunosuppression, which limits the capacity of the immune system to eliminate cancer cells.

Extracellular adenosine is produced by the sequential activities of membrane associated ectoenzymes, CD39 and CD73, which are expressed on tumor stromal cells, together producing adenosine by phosphohydrolysis of ATP or ADP produced from dead or dying cells. CD39 converts extracellular ATP (or ADP) to 5'AMP, which is converted to adenosine by CD73. Expression of CD39 and CD73 on endothelial cells is increased under the hypoxic conditions of the tumor microenvironment, thereby increasing levels of adenosine. Tumor hypoxia can result from inadequate blood supply and disorganized tumor vasculature, impairing delivery of oxygen (Carroll and Ashcroft (2005) *Expert. Rev. Mol. Med.* 7(6):1-16). Hypoxia,

which occurs in the tumor microenvironment, also inhibits adenylylase kinase (AK), which converts adenosine to AMP, leading to very high extracellular adenosine concentrations. The extracellular concentration of adenosine in the hypoxic tumor microenvironment has been measured at 10-100 μ M, which is up to about 100-1000 fold higher than the typical extracellular adenosine concentration of approximately 0.1 μ M (Vaupel *et al.* (2016) *Adv Exp Med Biol.* 876:177-183; Antonioli *et al.* (2013) *Nat. Rev. Can.* 13:842-857). Since hypoxic regions in tumors are distal from microvessels, the local concentration of adenosine in some regions of the tumor can be higher than others.

10 To direct effects to inhibit the immune system, adenosine also can control cancer cell growth and dissemination by effects on cancer cell proliferation, apoptosis and angiogenesis. For example, adenosine can promote angiogenesis, primarily through the stimulation of A_{2A} and A_{2B} receptors. Stimulation of the receptors on endothelial cells can regulate the expression of intercellular adhesion molecule 1
15 (ICAM-1) and E-selectin on endothelial cells, maintain vascular integrity, and promote vessel growth (Antonioli *et al.* (2013) *Nat. Rev. Can.* 13:842-857). Activation of one or more of A_{2A}, A_{2B} or A₃ on various cells by adenosine can stimulate the production of the pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), or angiopoietin 2 (Antonioli *et al.* (2013)
20 *Nat. Rev. Can.* 13:842-857).

Adenosine also can directly regulate tumor cell proliferation, apoptosis and metastasis through interaction with receptors on cancer cells. For example, studies have shown that the activation of A₁ and A_{2A} receptors promote tumor cell proliferation in some breast cancer cell lines, and activation of A_{2B} receptors have
25 cancer growth-promoting properties in colon carcinoma cells (Antonioli *et al.* (2013) *Nat. Rev. Can.* 13:842-857). Adenosine also can trigger apoptosis of cancer cells, and various studies have correlated this activity to activation of the extrinsic apoptotic pathway through A₃ or the intrinsic apoptotic pathway through A_{2A} and A_{2B} (Antonioli *et al.* (2013)). Adenosine can promote tumor cell migration and metastasis, by
30 increasing cell motility, adhesion to the extracellular matrix, and expression of cell attachment proteins and receptors to promote cell movement and motility.

The extracellular release of adenosine triphosphate (ATP) occurs from stimulated immune cells and damaged, dying or stressed cells. The NLR family pyrin domain-containing 3 (NLRP3) inflammasome, when stimulated by this extracellular release of ATP, activates caspase-1 and results in the secretion of the cytokines IL-1 β and IL-18, which in turn activate innate and adaptive immune responses (Stagg and Smyth (2010) *Oncogene* 29:5346–5358). ATP is catabolized into adenosine by the enzymes CD39 and CD73. Activated adenosine acts as a highly immunosuppressive metabolite via a negative-feedback mechanism and has a pleiotropic effect against multiple immune cell types in the hypoxic tumor microenvironment (Stagg and Smyth (2010) *Oncogene* 29:5346–5358). Adenosine receptors A_{2A} and A_{2B} are expressed on a variety of immune cells and are stimulated by adenosine to promote cAMP-mediated signaling changes, resulting in immunosuppressive phenotypes of T-cells, B-cells, NK cells, dendritic cells, mast cells, macrophages, neutrophils, and NKT cells. As a result of this, adenosine levels can accumulate to over one hundred times their normal concentration in pathological tissues, such as solid tumors, which have been shown to overexpress ecto-nucleotidases, such as CD73. Adenosine has also been shown to promote tumor angiogenesis and development. An engineered bacterium that is auxotrophic for adenosine would thus exhibit enhanced tumor-targeting and colonization.

Immunostimulatory bacteria, such as *Salmonella typhi*, can be made auxotrophic for adenosine by deletion of the *tsx* gene (Bucarey *et al.* (2005) *Infection and Immunity* 73(10):6210–6219) or by deletion of *purD* (Husseiny (2005) *Infection and Immunity* 73(3):1598–1605). In the Gram negative bacteria *Xanthomonas oryzae*, a *purD* gene knockout strain was shown to be auxotrophic for adenosine (Park *et al.* (2007) *FEMS Microbiol Lett* 276:55–59). As exemplified herein, *S. typhimurium* strain VNP20009, is auxotrophic for adenosine due to its *purI* deletion, hence, further modification to render it auxotrophic for adenosine is not required. Hence, embodiments of the immunostimulatory bacterial strains, as provided herein, are auxotrophic for adenosine. Such auxotrophic bacteria selectively replicate in the tumor microenvironment, further increasing accumulation and replication of the administered bacteria in tumors, and decreasing the levels of adenosine in and around tumors, thereby reducing or eliminating the immunosuppression caused by

accumulation of adenosine. Exemplary of such bacteria, provided herein, is a modified strain of *S. typhimurium* containing *purI*⁻/*msbB*⁻ mutations to provide adenosine auxotrophy. Other genomic mutations also can be included to impart other advantageous properties to the bacteria, as discussed herein.

5 **c. Flagellin Deficient Strains**

Flagella are organelles on the surface of bacteria that are composed of a long filament attached via a hook to a rotary motor that can rotate in a clockwise or counterclockwise manner to provide a means for locomotion. Flagella in *S. typhimurium* are important for chemotaxis and for establishing an infection via the oral route, due to the ability to mediate motility across the mucous layer in the gastrointestinal tract. While flagella have been demonstrated to be required for chemotaxis to and colonization of tumor cylindroids *in vitro* (Kasinskas and Forbes (2007) *Cancer Res.* 67(7):3201-3209), and motility has been shown to be important for tumor penetration (Toley and Forbes (2012) *Integr Biol (Camb)*. 4(2):165-176),
10 flagella are not required for tumor colonization in animals when the bacteria are administered intravenously (Stritzker *et al.* (2010) *International Journal of Medical Microbiology* 300:449–456). Each flagellar filament is composed of tens of thousands of flagellin subunits. The *S. typhimurium* chromosome contains two genes, *fliC* and *fljB*, that encode antigenically distinct flagellin monomers. Mutants defective for both
15 *fliC* and *fljB* are nonmotile and avirulent when administered via the oral route of infection, but maintain virulence when administered parenterally.
20

Flagellin is a major pro-inflammatory determinant of *Salmonella* (Zeng *et al.* (2003) *J. Immunol.* 171:3668-3674), and is directly recognized by TLR5 on the surface of cells, and by NLRC4 in the cytosol (Lightfield *et al.* (2008) *Nat Immunol.* 9(10):1171–1178). Both pathways lead to pro-inflammatory responses resulting in the secretion of cytokines, including IL-1 β , IL-18, TNF- α and IL-6. Attempts have been made to make *Salmonella*-based cancer immunotherapy more potent by increasing the pro-inflammatory response to flagellin by engineering the bacteria to secrete *Vibrio vulnificus* flagellin B, which induces greater inflammation than flagellin encoded by
25 *fliC* and *fljB* (Zheng *et al.* (2017) *Sci. Transl. Med.* 9(376):eaak9537).
30

Provided are immunostimulatory bacteria, such as the *Salmonella* species *S. typhimurium*, engineered to lack both flagellin subunits *fliC* and *fljB*, to reduce pro-

inflammatory signaling. For example, as shown herein, a *Salmonella* strain lacking *msbB*, which results in reduced TNF- α induction, is combined with *fliC* and *fljB* knockouts. The resulting *Salmonella* strain has a combined reduction in TNF- α induction and reduction in TLR5 recognition. These modifications, *msbB*⁻, *fliC*⁻ and
5 *fljB*⁻, can be combined with a bacterial plasmid, optionally containing CpGs, and also a cDNA expression cassette to provide expression of a heterologous protein(s) under the control of a eukaryotic promoter, such as, for example, STING pathway gain-of-function protein variants, immunostimulatory cytokines, and/or also inhibitory RNAi molecule(s). The resulting bacteria have reduced proinflammatory signaling, and
10 robust anti-tumor activity.

Elimination of the flagella imparts additional advantageous properties that increase the therapeutic index of the bacteria. For example, as shown herein (see, e.g., Example 6), elimination of the flagella (i.e., in *Salmonella*, *fliC*⁻/*fljB*⁻), decreases pyroptosis in murine macrophages and in human monocytes, results in an inability to
15 infect epithelial cells, and restricts uptake of the bacteria to tumor-resident immune/myeloid cells.

As described below and elsewhere herein, deletion of the flagella can be combined with one or more other genomic modifications that impart advantageous properties that improve the therapeutic index of the bacteria, including, for example,
20 *asd*⁻, *msbB*⁻, *purI*⁻, *pagP*⁻, *csgD*⁻, *adrA*⁻, and/or other modifications as described herein. Such modified bacteria can be transformed with a plasmid encoding therapeutic products that increase the anti-tumor immune response in the subject, including, for example, cytosolic DNA/RNA sensors and gain-of-function mutants thereof, as well as immunostimulatory proteins, such as cytokines.

25 For example, as provided herein, a *fliC*⁻ and *fljB*⁻ double mutant was constructed in the *asd* deleted strain of *S. typhimurium* strain VNP20009. VNP20009, which is attenuated for virulence by disruption of *purI/purM*, also was engineered to contain an *msbB* deletion, that results in production of a lipid A subunit of LPS that is less toxigenic than wild-type lipid A. This results in reduced TNF- α production in a
30 mouse model after intravenous administration, compared to strains with wild-type lipid A. Also, a *fliC*⁻ and *fljB*⁻ double mutant was constructed on a wild-type strain of *S. typhimurium* containing the *asd*, *purI/purM* and *msbB* deletions. The resulting

strains are exemplary of strains that are attenuated for bacterial inflammation by modification of lipid A to reduce TLR2/4 signaling, and deletion of the flagellin subunits to reduce TLR5 recognition and inflammasome induction. Deletion of the flagellin subunits combined with modification of the LPS allows for greater tolerability in the host, and directs the immunostimulatory response towards production of immunostimulatory proteins and/or delivery of RNA interference against desired targets in the TME, which elicits an anti-tumor response and promotes an adaptive immune response to the tumor.

d. Deletion of Genes in the LPS Biosynthetic Pathway

The lipopolysaccharide (LPS) of Gram-negative bacteria is the major component of the outer leaflet of the bacterial membrane. It is composed of three major parts, lipid A, a nonrepeating core oligosaccharide, and the O antigen (or O polysaccharide). O antigen is the outermost portion on LPS and serves as a protective layer against bacterial permeability, however, the sugar composition of O antigen varies widely between strains. The lipid A and core oligosaccharide vary less, and are more typically conserved within strains of the same species. Lipid A is the portion of LPS that contains endotoxin activity. It is typically a disaccharide decorated with multiple fatty acids. These hydrophobic fatty acid chains anchor the LPS into the bacterial membrane, and the rest of the LPS projects from the cell surface.

The lipid A domain is responsible for much of the toxicity of Gram-negative bacteria. Typically, LPS in the blood is recognized as a significant pathogen associated molecular pattern (PAMP), and induces a profound pro-inflammatory response. LPS is the ligand for a membrane-bound receptor complex comprising CD14, MD2 and TLR4. TLR4 is a transmembrane protein that can signal through the MyD88 and TRIF pathways to stimulate the NF κ B pathway and result in the production of pro-inflammatory cytokines, such as TNF- α and IL-1 β , the result of which can be endotoxic shock, which can be fatal. LPS in the cytosol of mammalian cells can bind directly to the CARD domains of caspases 4, 5, and 11, leading to autoactivation and pyroptotic cell death (Hagar *et al.* (2015) *Cell Research* 25:149-150).

The composition of lipid A and the toxigenicity of lipid A variants is well documented. For example, a monophosphorylated lipid A is much less inflammatory

than lipid A with multiple phosphate groups. The number and length of the acyl chains on lipid A also can have a profound impact on the degree of toxicity.

Canonical lipid A from *E. coli* has six acyl chains, and this hexa-acylation is potentially toxic. *S. typhimurium* lipid A is similar to that of *E. coli*; it is a glucosamine

5 disaccharide that carries four primary and two secondary hydroxyacyl chains (Raetz and Whitfield (2002) *Annu. Rev. Biochem.* 71:635–700). As described above, *msbB*[−] mutants of *S. typhimurium* cannot undergo the terminal myristoylation of LPS, and produce predominantly penta-acylated lipid A that is significantly less toxic than hexa-acylated lipid A. The modification of lipid A with palmitate is catalyzed by
10 palmitoyl transferase (PagP). Transcription of the *pagP* gene is under control of the *phoP/phoQ* system, which is activated by low concentrations of magnesium, e.g., inside the SCV. Thus, the acyl content of *S. typhimurium* is variable, and with wild-type bacteria, it can be hexa- or penta-acylated. The ability of *S. typhimurium* to palmitate its lipid A increases resistance to antimicrobial peptides that are secreted
15 into phagolysosomes.

In wild-type *S. typhimurium*, expression of *pagP* results in a lipid A that is hepta-acylated. In an *msbB*[−] mutant (in which the terminal acyl chain of the lipid A cannot be added), the induction of *pagP* results in a hexa-acylated LPS (Kong *et al.* (2011) *Infection and Immunity* 79(12):5027–5038). Hexa-acylated LPS has been
20 shown to be the most pro-inflammatory. While other groups have sought to exploit this pro-inflammatory signal, for example, by deletion of *pagP* to allow only hexa-acylated LPS to be produced (Felgner *et al.* (2016) *Gut Microbes* 7(2):171–177; Felgner *et al.* (2018) *Oncoimmunology* 7(2): e1382791), this can lead to poor tolerability, due to the TNF- α -mediated pro-inflammatory nature of the LPS and
25 paradoxically less adaptive immunity (Kocijancic *et al.* (2017) *Oncotarget* 8(30):49988-50001).

LPS is a potent TLR4 agonist that induces TNF- α and IL-6. The dose-limiting toxicities in the I.V. VNP20009 clinical trial (Toso *et al.* (2002) *J. Clin. Oncol.* 20(1):142-152) at 1E9 CFU/m² were cytokine mediated (fever hypotension), with
30 TNF- α levels > 100,000 pg/ml and IL-6 levels > 10,000 pg/ml in serum at 2 hours. Despite the *msbB* deletion in VNP20009 and its reduced pyrogenicity, the LPS still can be toxic at high doses, possibly due to the presence of hexa-acylated LPS. Thus, a

pagP⁻/*msbB*⁻ strain is better tolerated at higher doses, as it cannot produce hexa-acylated LPS, and will allow for dosing in humans at or above 1E9 CFU/m². Higher dosing can lead to increased tumor colonization, enhancing the therapeutic efficacy of the immunostimulatory bacteria.

5 Herein, *Salmonella* bacteria, such as *S. typhimurium*, are engineered to lack both flagellin subunits *fliC* and *fljB*, to reduce pro-inflammatory signaling. For example, as shown herein, a *Salmonella* strain lacking *msbB*, which results in reduced TNF-alpha induction, is combined with *fliC* and *fljB* knockouts. This results in a *Salmonella* strain that has a combined reduction in TNF-alpha induction and
10 reduction in TLR5 recognition. These modifications can be combined with *pagP*⁻ and other genomic modifications discussed herein, and the resulting bacterial strain can be transformed with an immunostimulatory plasmid (encoding immunostimulatory protein(s)), optionally containing CpGs. The resulting bacteria have reduced pro-inflammatory signaling, but robust anti-tumor activity.

15 Exemplified herein, are live attenuated *Salmonella* strains, such as the exemplary strain of *S. typhimurium*, that only can produce penta-acylated LPS, that contain a deletion of the *msbB* gene (that prevents the terminal myristoylation of lipid A, as described above), and that further are modified by deletion of *pagP* (preventing palmitoylation). A strain modified to produce penta-acylated LPS will allow for lower
20 levels of pro-inflammatory cytokines, improved stability in the blood and resistance to complement fixation, increased sensitivity to antimicrobial peptides, enhanced tolerability, and increased anti-tumor immunity when further modified to express a therapeutic product(s), such as heterologous immune-stimulatory proteins and/or interfering RNAs against, for example, immune checkpoints.

25 As provided herein, for example, a *pagP*⁻ mutant also can be constructed on an *asd*, *msbB*, *purI/purM* and *fliC/fljB* deleted strain of *S. typhimurium* VNP20009, or other strains as described herein, or wild-type *S. typhimurium*. The resulting strains are exemplary of strains that are attenuated for bacterial inflammation by modification of lipid A to reduce TLR2/4 signaling, and deletion of the flagellin subunits to reduce
30 TLR5 recognition and inflammasome induction, and deletion of *pagP* to produce penta-acylated LPS. Deletion of the flagellin subunits combined with modification of the LPS allows for greater tolerability in the host, and greater stability in the blood

and resistance to complement fixation, providing for improved trafficking to the tumor site, in order to direct the immunostimulatory response towards production of any gene product, such as immunostimulatory proteins, and/or delivery of RNA interference against desired targets in the TME to elicit an anti-tumor response and
5 promote an adaptive immune response to the tumor.

e. Deletions in Genes Required for Biofilm Formation

Bacteria and fungi are capable of forming multicellular structures called biofilms. Bacterial biofilms are encased within a mixture of secreted and cell wall-associated polysaccharides, glycoproteins, and glycolipids, as well as extracellular
10 DNA, known collectively as extracellular polymeric substances. These extracellular polymeric substances protect the bacteria from multiple insults, such as cleaning agents, antibiotics, and antimicrobial peptides. Bacterial biofilms allow for colonization of surfaces, and are a cause of significant infection of prosthetics, such as injection ports and catheters. Biofilms also can form in tissues during the course of an
15 infection, which leads to increases in the duration of bacterial persistence and shedding, and limits the effectiveness of antibiotic therapies. Chronic persistence of bacteria in biofilms is associated with increased tumorigenesis, for example in *S. typhi* infection of the gall bladder (Di Domenico *et al.* (2017) *Int. J. Mol. Sci.* 18:1887).

S. typhimurium biofilm formation is regulated by CsgD. CsgD activates the
20 *csgBAC* operon, which results in increased production of the curli fimbrial subunits CsgA and CsgB (Zakikhani *et al.* (2010) *Molecular Microbiology* 77(3):771–786). CsgA is recognized as a PAMP by TLR2 and induces production of IL-8 from human macrophages (Tukel *et al.* (2005) *Molecular Microbiology* 58(1):289–304). Further, CsgD indirectly increases cellulose production by activating the *adrA* gene that
25 encodes for di-guanylate cyclase. The small molecule cyclic di-guanosine monophosphate (c-di-GMP) generated by AdrA is a ubiquitous secondary messenger found in almost all bacterial species. The AdrA-mediated increase in c-di-GMP enhances expression of the cellulose synthetase gene *bcsA*, which in turn increases cellulose production via stimulation of the *bcsABZC* and *bcsEFG* operons. Reduction
30 in the capability of immunostimulatory bacteria, such as *S. typhimurium*, to form biofilms can be achieved through deletion of genes involved in biofilm formation,

such as, for example, *csgD*, *csgA*, *csgB*, *adrA*, *bcsA*, *bcsB*, *bcsZ*, *bcsE*, *bcsF*, *bcsG*, *dsbA* or *dsbB* (Anwar *et al.* (2014) *PLoS One* 9(8):e106095).

S. typhimurium can form biofilms in solid tumors as protection against phagocytosis by host immune cells. *Salmonella* mutants that cannot form biofilms are
5 taken up more rapidly by host phagocytic cells and are cleared from infected tumors (Crull *et al.* (2011) *Cellular Microbiology* 13(8):1223-1233). This increase in intracellular localization within phagocytic cells can reduce the persistence of extracellular bacteria, and enhance the effectiveness of plasmid delivery, expression and release of encoded therapeutic products into the TME, as well as gene knockdown
10 by RNA interference, as described herein. Immunostimulatory bacteria engineered to reduce biofilm formation, will increase clearance rate from tumors/tissues and therefore increase the tolerability of the therapy, and will prevent colonization of prosthetics in patients, thereby increasing the therapeutic benefit of these strains. Adenosine mimetics can inhibit *S. typhimurium* biofilm formation, indicating that the
15 high adenosine concentration in the tumor microenvironment can contribute to tumor-associated biofilm formation (Koopman *et al.* (2015) *Antimicrob Agents Chemother* 59:76 -84). As provided herein, live attenuated strains of bacteria, such as *S. typhimurium*, that contain a *purI* disruption (and therefore, colonize adenosine-rich tumors), and are also prevented from forming biofilms by deletion of one or more
20 genes required for biofilm formation, are engineered to deliver plasmids encoding therapeutic products, such as cytosolic DNA/RNA sensors and gain-of-function variants thereof, and other immunostimulatory proteins, such as cytokines, and interfering RNA, to stimulate a robust anti-tumor immune response.

The *adrA* gene encodes a di-guanylate cyclase that produces c-di-GMP, which
25 is required for *S. typhimurium* biofilm formation. c-di-GMP binds to and is an agonist for the host cytosolic protein STING. Immunostimulatory bacteria that are reduced in c-di-GMP production via the deletion of *adrA* is counterintuitive, but bacterial mutants, such as *S. typhimurium* mutants, that are unable to form biofilms (including *adrA* mutants), have demonstrated reduced therapeutic potential in mouse tumor
30 models (Crull *et al.* (2011) *Cellular Microbiology* 13(8):1223–1233). Several human alleles of STING are refractory to binding bacterially-produced 3'3' CDNs (Corrales *et al.* (2015) *Cell Reports* 11:1022-1023).

As described herein, bacterial strains, such as *S. typhimurium* strains, that are engineered to be adenosine auxotrophic, and are reduced in their ability to induce pro-inflammatory cytokines by modification of the LPS and/or deletion of flagellin, and/or deletion of genes required for biofilm formation, are further modified to deliver interfering RNAs, and other therapeutic, anti-cancer products, such as immunostimulatory proteins, including cytosolic DNA/RNA sensors and gain-of-function variants thereof (e.g., STING and others) and cytokines, to promote robust anti-tumor immune responses.

f. *Salmonella* Engineered to Escape the *Salmonella* Containing Vacuole (SCV)

Salmonella, such as *S. typhimurium*, are intracellular pathogens that replicate primarily in a membrane bound compartment called a *Salmonella* containing vacuole (SCV). In some epithelial cell lines, and at a low frequency, *S. typhimurium* have been shown to escape into the cytosol where they can replicate. *Salmonella* engineered to escape the SCV with higher efficiency will be more efficient at delivering macromolecules, such as plasmids, to the host cell cytosol, as the lipid bilayer of the SCV is a potential barrier. Plasmid release into the host cytosol allows for the expression of therapeutic products encoded on the plasmid, that are under the control of host-recognized regulatory signals, such as eukaryotic promoters, increasing the efficiency of production and delivery of the therapeutic products to the TME, particularly when the bacteria are phagocytosed by tumor-resident immune cells, and improving the therapeutic index of the bacteria.

Provided herein are *Salmonella* strains and methods that have enhanced frequency of SCV escape. As discussed below and elsewhere herein, this is achieved by deletion of genes required for *Salmonella* induced filament (SIF) formation. These mutants have an increased frequency of SCV escape and can replicate in the cytosol of the host cell. For example, enhanced plasmid delivery using a *sifA* mutant of *S. typhimurium* has been demonstrated. The *sifA* gene encodes an SPI-2 T3SS-2 secreted effector protein that mimics or activates a RhoA family of host GTPases (Ohlson *et al.* (2008) *Cell Host & Microbe* 4:434–446). Other genes encoding secreted effectors involved in SIF formation can be targeted. These include, for example, *sseJ*, *sseL*, *sopD2*, *pipB2*, *sseF*, *sseG*, *spvB*, and *steA*. Enhancing the escape of *S. typhimurium* by

prevention of SIF formation releases live bacteria into the cytosol, where they can replicate.

Another method to enhance *S. typhimurium* escape from the SCV and increase the delivery of macromolecules such as plasmids to the cytosol, is the expression of a heterologous hemolysin that results in pore formation in, or rupture of, the SCV membrane. One such hemolysin is the Listeriolysin O protein (LLO) from *Listeria monocytogenes*, which is encoded by the *hlyA* gene. LLO is a cholesterol-dependent pore-forming cytolysin that is secreted from *L. monocytogenes* and is primarily responsible for phagosomal escape and entry into the cytosol of host cells. Secretion of LLO from *S. typhimurium* can result in bacterial escape and lead to replication in the cytosol. To prevent intact *S. typhimurium* from escaping the SCV and replicating in the cytosol, the nucleotides encoding the secretion signal sequence can be removed from the gene, producing cytoLLO. In this manner, the active LLO is contained within the cytoplasm of the *S. typhimurium* and LLO is only released when the bacteria undergo lysis (for example, due to the lack of intracellular DAP in an *asd^c* strain). Bacterial lysis in the SCV allows for the release of the plasmid and accumulated cytoLLO, which will form pores in the SCV, allowing for the delivery of the plasmid into the host cell cytosol, where the encoded therapeutic product(s) can be expressed.

As provided herein, *Salmonella* strains, such as the *S. typhimurium* strain VNP20009, engineered to express cytoLLO to enhance delivery of plasmids for expression of therapeutic products, such as STING proteins and variants thereof, and other immunostimulatory proteins, can increase the therapeutic potency of the immunostimulatory bacteria. This is advantageous, where the bacteria are engineered to accumulate in tumor-resident immune cells, as herein, whereby the expressed therapeutic products are released directly into the tumor microenvironment.

g. Deletions of SPI-1 and SPI-2 Genes and/or Other Genes to Eliminate the Ability of the Bacteria to Infect Epithelial Cells, Including Deletion of Flagella

As described above, pathogenesis, in certain bacterial species, including *Salmonella* species, such as *S. typhimurium*, involves a cluster of genes referred to as *Salmonella* pathogenicity islands (SPIs). *S. typhimurium* is an intracellular pathogen

that is rapidly taken up by myeloid cells, such as macrophages, or it can induce its own uptake in non-phagocytic cells, such as epithelial cells. Once inside cells, it can replicate within a *Salmonella* containing vacuole (SCV) and can also escape into the cytosol of some epithelial cells. The two best characterized pathogenicity islands are

5 SPI-1, which is responsible for mediating bacterial invasion of non-phagocytic cells, such as epithelial cells, and SPI-2, which is required for replication within the SCV (Agbor and McCormick (2011) *Cell Microbiol.* 13(12):1858–1869). SPI-1 and SPI-2 encode macromolecular structures called type three secretion systems (T3SS) that can translocate effector proteins across the host membrane (Galan and Wolf-Watz (2006)

10 *Nature* 444:567-573).

i. ***Salmonella* Pathogenicity Island 1 (SPI-1)**

SPI-1-Dependent Host Cell Invasion

The invasion-associated *Salmonella* pathogenicity island 1 (SPI-1), including the type 3 secretion system (T3SS), is responsible for the translocation of effector

15 proteins into the cytosol of host cells, causing actin rearrangements that lead to the uptake of *Salmonella*. *Salmonella* invades non-phagocytic intestinal epithelial cells using a type 3 secretion system (T3SS) encoded by SPI-1, which forms a needle-like structure that injects effector proteins directly into the cytosol of host cells. These effector proteins lead to rearrangement of the eukaryotic cell cytoskeleton to facilitate

20 invasion of the intestinal epithelium, and also induce proinflammatory cytokines. The SPI-1 locus includes 39 genes that encode components of this invasion system (see, e.g., Kimbrough *et al.* (2002) *Microbes Infect.* 4(1):75-82). SPI-1 genes comprise a number of operons, including: *sitABCD*, *sprB*, *avrA*, *hilC*, *orgABC*, *prgKJIH*, *hilD*, *hilA*, *iagB*, *sptP*, *sicC*, *iacP*, *sipADCB*, *sicA*, *spaOPQRS*, *invFGEABCIJ*, and *invH*.

25 The operons and genes and their functions are described and depicted, for example, in Kimbrough *et al.* ((2002) *Microbes Infect.* 4(1):75-82). SPI-1 genes include, but are not limited to: *avrA*, *hilA*, *hilD*, *invA*, *invB*, *invC*, *invE*, *invF*, *invG*, *invH*, *invI*, *invJ*, *iacP*, *iagB*, *spaO*, *spaP*, *spaQ*, *spaR*, *spaS*, *orgA*, *orgB*, *orgC*, *prgH*, *prgI*, *prgJ*, *prgK*, *sicA*, *sicP*, *sipA*, *sipB*, *sipC*, *sipD*, *sirC*, *sopB*, *sopD*, *sopE*, *sopE2*, *sprB*, and *sptP*.

30 T3SSs are complexes that play a large role in the infectivity of Gram-negative bacteria, by injecting bacterial protein effectors directly into host cells in an ATP-dependent manner. T3SS complexes cross the inner and outer bacterial membranes

and create a pore in eukaryotic cell membranes upon contact with a host cell. They consist of an exportation apparatus, a needle complex and a translocon at the tip of the needle (see, *e.g.*, Kimbrough *et al.* (2002) *Microbes Infect.* 4(1):75-82). The needle complex includes the needle protein PrgI, a basal body, which anchors the complex in the bacterial membranes and consists of the proteins PrgH, PrgK and InvG, and other proteins, including InvH, PrgJ (rod protein) and InvJ. The translocon, which forms the pore in the host cell, is a complex of the proteins SipB, SipC and SipD. The exportation apparatus, which allows for the translocation of the effector proteins, is comprised of the proteins SpaP, SpaQ, SpaR, SpaS, InvA, InvC and OrgB. A cytoplasmic sorting platform, which establishes the specific order of protein secretion, is composed of the proteins SpaO, OrgA and OrgB (see, *e.g.*, Manon *et al.* (2012), *Salmonella*, Chapter 17, eds. Annous and Gurtler, Rijeka, pp. 339-364).

The effectors translocated into the host cell by T3SS-1 (T3SS of SPI-1) include SipA, SipC, SopB, SopD, SopE, SopE2 and SptP, which are essential for cell invasion. For example, *S. typhimurium sipA* mutants exhibit 60-80% decreased invasion, *sipC* deletion results in a 95% decrease in invasion, and *sopB* deletion results in a 50% decrease in invasion (see, *e.g.*, Manon *et al.* (2012), *Salmonella*, Chapter 17, eds. Annous and Gurtler, Rijeka, pp. 339-364). Other effectors include AvrA, which controls *Salmonella*-induced inflammation. Chaperones, which bind secreted proteins and maintain them in a conformation that is competent for secretion, include SicA, InvB and SicP. Transcriptional regulators include HilA, HilD, InvF, SirC and SprB. Unclassified T3SS SPI-1 proteins, which have various functions in type III secretion, include OrgC, InvE, InvI, IacP and IagB (see, *e.g.*, Kimbrough *et al.* (2002) *Microbes Infect.* 4(1):75-82).

The SPI-1 T3SS is essential for crossing the gut epithelial layer, but is dispensable for infection when bacteria are injected parenterally. The injection of some proteins (*e.g.*, PrgI and PrgJ) and the needle complex itself also can induce inflammasome activation and pyroptosis of phagocytic cells. This pro-inflammatory cell death can limit the initiation of a robust adaptive immune response by directly inducing the death of antigen-presenting cells (APCs), as well as modifying the cytokine milieu to prevent the generation of memory T-cells. Thus, the inactivation of SPI-1-dependent invasion, through the inactivation or knockout of one or more genes

involved in SPI-1, eliminates the ability of the bacteria to infect epithelial cells, but does not affect their ability to infect or invade phagocytic cells, including phagocytic immune cells, such as tumor-associated myeloid cells. These SPI-1 genes include, but are not limited to, one more of: *avrA*, *hilA*, *hilD*, *invA*, *invB*, *invC*, *invE*, *invF*, *invG*,
 5 *invH*, *invI*, *invJ*, *iapP*, *iagB*, *spaO*, *spaP*, *spaQ*, *spaR*, *spaS*, *orgA*, *orgB*, *orgC*, *prgH*,
prgI, *prgJ*, *prgK*, *sicA*, *sicP*, *sipA*, *sipB*, *sipC*, *sipD*, *sirC*, *sopB*, *sopD*, *sopE*, *sopE2*,
sprB, and *sptP*.

SPI-1-Independent Host Cell Invasion

Salmonella mutants lacking the T3SS-1 have been shown to invade numerous
 10 cell lines/types, by a T3SS-1 independent invasion mechanism, involving several proteins, including the invasins Rck, PagN and HlyE. The *rck* operon contains 6 open reading frames: *pefI*, *srgD*, *srgA*, *srgB*, *rck* and *srgC*. *pefI* encodes a transcriptional regulator of the *pef* operon, which is involved in the biosynthesis of the Pef fimbriae. These fimbriae are involved in biofilm formation, adhesion to murine small intestine
 15 and fluid accumulation in the infant mouse. SrgA oxidizes the disulfide bond of PefA, the major structural subunit of the Pef fimbriae. *srgD* encodes a putative transcriptional regulator; SrgD together with PefI work to induce a synergistic negative regulation of flagellar gene expression. *srgB* encodes a putative outer membrane protein, and *srgC* encodes a putative transcriptional regulator (see, e.g.,
 20 Manon *et al.* (2012), *Salmonella*, Chapter 17, eds. Annous and Gurtler, Rijeka, pp. 339-364).

Rck is a 17 kDa outer membrane protein encoded by the large virulence plasmid of *S. Enteritidis* and *S. Typhimurium*, that induces adhesion to and invasion of epithelial cells, and confers a high level of resistance to neutralization by
 25 complement, by preventing the formation of the membrane attack complex. An *rck* mutant exhibited a 2-3 fold decrease in epithelial cell invasion compared to the wild-type strain, while Rck overexpression leads to increased invasion. Rck induces cell entry by a receptor-mediated process, promoting local actin remodeling and weak and closely adherent membrane extensions. Thus, *Salmonella* can enter cells by two
 30 distinct mechanisms: the Trigger mechanism mediated by the T3SS-1 complex, and a Zipper mechanism induced by Rck (see, e.g., Manon *et al.* (2012), *Salmonella*, Chapter 17, eds. Annous and Gurtler, Rijeka, pp. 339-364).

The invasin PagN is an outer membrane protein that has also been shown to play a role in *Salmonella* invasion. *pagN* expression is regulated by *phoP*. Specific stimuli, for example, acidified macrophage phagosome environments or low Mg^{2+} concentrations, are sensed by PhoQ, which then activates PhoP to regulate specific genes. It has been shown that the deletion of *pagN* in *S. typhimurium* results in a 3-fold decrease in the invasion of enterocytes, without altering cell adhesion. Although the PagN-mediated entry mechanism is not fully understood, it has been shown that actin polymerization is required for invasion. Studies have shown that PagN is required for *Salmonella* survival in BALB/c mice, and that a *pagN* mutant is less competitive for colonizing the spleen of mice than the parent strain. Because *pagN* is activated by PhoP, it is mostly expressed intracellularly, where the SPI-1 island encoding T3SS-1 is downregulated. It is thus possible that bacteria exiting epithelial cells or macrophages have an optimal level of PagN expression, but have low T3SS-1 expression, which can mediate subsequent interactions with other cells encountered following host cell destruction, indicating a role for PagN in *Salmonella* pathogenesis (see, e.g., Manon *et al.* (2012), *Salmonella*, Chapter 17, eds. Annous and Gurtler, Rijeka, pp. 339-364).

hlyE shares more than 90% sequence identity with the *E. coli* HlyE (ClyA) hemolysin. The HlyE protein lyses epithelial cells when exported from bacterial cells via outer membrane vesicle release, and is involved in epithelial cell invasion. HlyE also is involved in the establishment of systemic *Salmonella* infection (see, e.g., Manon *et al.* (2012), *Salmonella*, Chapter 17, eds. Annous and Gurtler, Rijeka, pp. 339-364).

As a result, elimination of the bacterium's ability to infect epithelial cells also can be achieved by engineering the immunostimulatory bacteria herein to contain knockouts or deletions/disruptions of genes encoding proteins involved in SPI-1-independent invasion, such as one or more of the genes *rck*, *pagN*, *hlyE*, *pefI*, *srgD*, *srgA*, *srgB*, and *srgC*.

The immunostimulatory bacteria provided herein include those with deletion or disruption of the *hilA* gene and/or other genes in the T3SS pathway. When these bacteria are administered, such as intravenously or intratumorally, infection is focused towards phagocytic cells, such as macrophages and dendritic cells, that do not require

the SPI-1 T3SS for uptake. This enhances the safety profile of the immunostimulatory bacteria provided herein. It prevents off-target cell invasion and prevents fecal-oral transmission. In addition to reducing the uptake of *Salmonella* by non-phagocytic cells, such as epithelial cells, deletion or disruption of genes in this pathway also
5 prolongs the longevity of the phagocytic cells, by preventing inflammasome activation and pyroptosis in macrophages, thus, inducing less cell death in human macrophages, compared to bacteria that do not contain a deletion in this pathway. For example, deletion of genes in the SPI-1 pathway (such as, for example, the needle and rod proteins) can prevent pyroptosis by preventing inflammasome activation, but
10 maintains TLR5 signaling. This, in turn, permits prolonged secretion of encoded proteins, such as the STING proteins or other therapeutic/anti-cancer products encoded by the immunostimulatory bacteria provided herein, and permits macrophage trafficking to tumors, thus improving the efficacy of the immunostimulatory bacteria.

As described herein, provided are immunostimulatory bacteria that are
15 modified so that they do not infect epithelial cells, but retain the ability to infect phagocytic cells, including tumor-resident immune cells, thereby effectively targeting the immunostimulatory bacteria, and the encoded therapeutic products, to the tumor microenvironment. This is achieved by deleting or knocking out any of the proteins in SPI-1, including, but not limited to, deletions of one more of: *avrA*, *hilA*, *hilD*, *invA*,
20 *invB*, *invC*, *invE*, *invF*, *invG*, *invH*, *invI*, *invJ*, *iacP*, *iagB*, *spaO*, *spaP*, *spaQ*, *spaR*, *spaS*, *orgA*, *orgB*, *orgC*, *prgH*, *prgI*, *prgJ*, *prgK*, *sicA*, *sicP*, *sipA*, *sipB*, *sipC*, *sipD*, *sirC*, *sopB*, *sopD*, *sopE*, *sopE2*, *sprB*, and *sptP*, as well as one or more of *rck*, *pagN*, *hlyE*, *pefI*, *srgD*, *srgA*, *srgB*, *rck* and *srgC*.

The immunostimulatory bacteria that do not infect epithelial cells can be
25 further modified as described herein, to encode therapeutic products that stimulate the immune system, including, for example, products that induce type I interferon (e.g., cytosolic DNA/RNA sensors and GOF variants thereof), and also to encode immunostimulatory proteins, such as cytokines. The bacteria generally have an *asd* deletion to render them unable to replicate in a mammalian host. For example,
30 provided are strains of *S. typhimurium* modified by deletion of one or more SPI-1 genes, and also modified by one or more of a *purI* deletion, an *msbB* deletion, and an *asd* deletion, and further modified by delivering plasmids encoding therapeutic

products, such as proteins that stimulate the immune system, such as cytosolic DNA/RNA sensors and gain-of-function mutants thereof, that induce type I interferon, and/or immunostimulatory cytokines.

For example, bacteria with deletions of a regulatory gene (*e.g.*, *hilA* or *invF*) required for expression of the SPI-1-associated type 3 secretion system (T3SS-1), a T3SS-1 structural gene (*e.g.*, *invG* or *prgH*), and/or a T3SS-1 effector gene (*e.g.*, *sipA* or *avrA*) are provided. As discussed above, this secretion system is responsible for injecting effector proteins into the cytosol of non-phagocytic host cells, such as epithelial cells, that cause the uptake of the bacteria; deletion of one or more of these genes eliminates infection/invasion of epithelial cells. Deletion of one or more of the genes, such as *hilA*, provides immunostimulatory bacteria that can be administered intravenously or intratumorally, resulting in infection of phagocytic cells, which do not require the SPI-1 T3SS for uptake, and also prolongs the longevity of these phagocytic cells. The *hilA* mutation also reduces the quantity of pro-inflammatory cytokines, increasing the tolerability of the therapy, as well as the quality of the adaptive immune response.

Additionally or alternatively, the immunostimulatory bacteria can contain knockouts or deletions in genes to inactivate products involved in SPI-1-independent infection/invasion, such as one or more of the genes *pagN*, *hlyE*, *pefI*, *srgD*, *srgA*, *srgB*, and *srgC*, reducing or eliminating the bacterium's ability to infect epithelial cells.

As described herein, genes involved in the SPI-1 pathway, and bacterial flagella, activate the inflammasome in phagocytic cells (immune cells), triggering pyroptosis. Knocking out or disrupting SPI-1 genes and genes that encode flagella, decreases or eliminates pyroptosis, and also, eliminates infection of epithelial cells, resulting in increased infection of phagocytic cells. Thus, the immunostimulatory bacteria can contain knockouts or deletions to inactivate products of genes that induce cell death of tumor-resident immune cells, such as genes that encode proteins that are directly recognized by the inflammasome; these include *fljB*, *fliC*, *prgI* and *prgJ*. As shown herein (see, *e.g.*, Example 6), elimination of the flagella (*i.e.*, in *Salmonella*, *fliC*⁻/*fljB*⁻), decreases pyroptosis in murine macrophages and in human monocytes,

results in an inability to infect epithelial cells, and restricts uptake of the bacteria to tumor-resident immune/myeloid cells.

Hence, provided are immunostimulatory bacteria that accumulate in phagocytic cells, particularly tumor-resident immune cells, in which they express products encoded on plasmids that are controlled by eukaryotic regulatory signals, such as RNA polymerase II. Products include those that evoke immune responses, such as through pathways that increase expression of type I interferons, which increase the host immune response in the tumor microenvironment. The immunostimulatory bacteria also can encode other products, including immunostimulatory proteins, such as IL-2, further enhancing the immune response in the tumor microenvironment.

ii. **Salmonella Pathogenicity Island 2 (SPI-2)**

Salmonella also have a *Salmonella* pathogenicity island 2 (SPI-2), encoding another T3SS that is activated following entry of the bacterium into the host cell, and interferes with phagosome maturation, resulting in the formation of a specialized *Salmonella*-containing vacuole (SCV), where the *Salmonella* resides during intracellular survival and replication. SPI-2 T3SS effectors include SseB, SseC, SseD and SpiC, which are responsible for assembly of the F-actin coat around intracellular bacteria; this actin coat promotes fusion of the SCV with actin-containing or actin-propelled vesicles, and prevents it from fusing with unfavorable compartments. SifA is responsible for the formation of *Salmonella*-induced filaments (SIFs), which are tubules that connect the individual SCVs in the infected cell. SifA is essential to maintaining the integrity of the SCV, and *sifA* mutants are released into the cytosol of host cells. SseF and SseG are components of the SPI-2 T3SS that are involved in SCV positioning and cellular trafficking processes that direct materials required for the bacterium's survival and replication, to the SCV. SseF and SseG also are involved in SIF formation. Other SPI-2 T3SS effectors include PipB2, SopD2, and SseJ, which are involved in SIF and SCV formation, and maintenance of vacuole integrity; SpvC, SseL, and SspH1, which are involved in host immune signaling; and SteC, SspH2, SrfH/SseI and SpvB, which are involved in the formation of the SCV F-actin meshwork, in the migration of infected phagocytes, in the inhibition of actin polymerization, and in P-body disassembly in infected cells (Coburn *et al.* (2007)

Clinical Microbiology Reviews 20(4):535-549; Figueira and Holden (2012) *Microbiology* 158:1147-1161).

The immunostimulatory bacteria herein can include deletions or modifications in any of the SPI-2 T3SS genes that affect the formation or integrity of the SCV and associated structures, such as SIFs. These mutants have an increased frequency of SCV escape and can replicate in the cytosol. For example, immunostimulatory bacteria, such as *Salmonella* species, engineered to escape the SCV are more efficient at delivering macromolecules, such as plasmids, to the host cell cytosol, as the lipid bilayer of the SCV is a potential barrier. Enhancing the escape of the bacteria from the SCV by prevention of SIF formation releases live bacteria into the cytosol, where they can replicate and express the encoded therapeutic products or proteins under control of the host cell machinery (*i.e.*, under the control of eukaryotic regulatory elements, such as eukaryotic promoters). This enhances the therapeutic efficacy of the bacteria, and is achieved by deletion or mutation of genes required for *Salmonella* induced filament (SIF) formation, including, for example, *sifA*, *sseJ*, *sseL*, *sopD2*, *pipB2*, *sseF*, *sseG*, *spvB*, and *steA*.

The immunostimulatory bacteria that can escape the SCV can be further modified as described herein to encode products that stimulate the immune system, including, for example, products that induce type I interferon, and also to encode cytokines. The bacteria generally have an *asd* deletion to render them unable to replicate in a mammalian host.

h. Endonuclease (*endA*) Mutations to Increase Plasmid Delivery

The *endA* gene (for example, SEQ ID NO:250) encodes an endonuclease (for example, SEQ ID NO:251) that mediates degradation of double stranded DNA (dsDNA) in the periplasm of Gram negative bacteria. Most common strains of laboratory *E. coli* are *endA*⁻, as a mutation in the *endA* gene allows for higher yields of plasmid DNA. This gene is conserved among species. To facilitate intact plasmid DNA delivery, the *endA* gene of the engineered immunostimulatory bacteria is deleted or mutated to prevent its endonuclease activity. Exemplary of such mutations is an E208K amino acid substitution (Durfee, *et al.* (2008) *J. Bacteriol.* 190(7):2597-2606) or a corresponding mutation in the species of interest. *endA*, including E208, is

conserved among bacterial species, including *Salmonella* (see, *e.g.*, SEQ ID NO:251). Thus, the E208K mutation can be used to eliminate endonuclease activity in other species, including *Salmonella* species. Those of skill in the art can introduce other mutations or deletions to eliminate *endA* activity. Effecting this mutation, or deleting
5 or disrupting the gene to eliminate activity of the *endA* in the immunostimulatory bacteria herein, such as in *Salmonella*, increases the efficiency of intact plasmid DNA delivery, thereby increasing expression of the encoded therapeutic product(s) and enhancing anti-tumor efficacy.

i. RIG-I Binding Sequences

10 As discussed above, type I interferons (IFN- α , IFN- β) are the signature cytokines induced by distinct TLR-dependent and TLR-independent signaling pathways. Of the TLR-independent type I IFN pathways, one is mediated by host recognition of single-stranded (ss) and double-stranded (ds) RNA in the cytosol. These are sensed by RNA helicases, including retinoic acid-inducible gene I (RIG-I),
15 melanoma differentiation-associated gene 5 (MDA-5), and through the IFN- β promoter stimulator 1 (IPS-1) adaptor protein-mediated phosphorylation of the IRF-3 transcription factor, leading to induction of type I IFN (Ireton and Gale (2011) *Viruses* 3(6):906-919). RIG-I recognizes dsRNA and ssRNA bearing 5'-triphosphates. This moiety can directly bind RIG-I, or be synthesized from a poly(dA-dT) template by the
20 poly DNA-dependent RNA polymerase III (Pol III) (Chiu, Y. H. *et al.* (2009) *Cell* 138(3):576-91). A poly(dA-dT) template containing two AA dinucleotide sequences occurs at the U6 promoter transcription start site in a common lentiviral shRNA cloning vector. Its subsequent deletion in the plasmid prevents type I IFN activation (Pebernard *et al.* (2004) *Differentiation*. 72:103-111). A RIG-I binding sequence can
25 be included in the plasmids provided herein; this inclusion can increase immunostimulation, by inducing type I IFN production, that increases anti-tumoral activity of the immunostimulatory bacteria herein.

j. DNase II Inhibition

Another nuclease responsible for degrading foreign and self DNA is DNase II,
30 an endonuclease, which resides in the endosomal compartment and degrades DNA following apoptosis. Lack of DNase II (*Dnase2a* in mice) results in the accumulation of endosomal DNA that escapes to the cytosol and activates cGAS/STING signaling

(Lan Y. Y. *et al.* (2014) *Cell Rep.* 9(1):180–192). DNase II-deficiency in humans presents with autoimmune type I interferonopathies. In cancer, dying tumor cells that are engulfed by tumor-resident macrophages prevent cGAS/STING activation, and potential autoimmunity, through DNase II digestion of DNA within the endosomal compartment (Ahn *et al.* (2018) *Cancer Cell* 33:862–873). Hence, embodiments of the immunostimulatory bacterial strains, as provided herein, which encode products that can inhibit DNase II in the tumor microenvironment, can provoke accumulation of endocytosed apoptotic tumor DNA in the cytosol, where it can act as a potent cGAS/STING agonist.

10 **k. RNase H2 Inhibition**

While TREX1 (three-prime repair exonuclease 1) and DNase II function to clear aberrant DNA accumulation, RNase H2 functions similarly to eliminate pathogenic accumulation of RNA:DNA hybrids in the cytosol. Deficiencies in RNase H2 also contribute to the autoimmune phenotype of Aicardi-Goutières syndrome (Rabe, B. (2013) *J. Mol. Med.* 91:1235–1240). Loss of RNase H2 and subsequent accumulation of RNA:DNA hybrids or genome-embedded ribonucleotide substrates has been shown to activate cGAS/STING signaling. (MacKenzie *et al.* (2016) *EMBO J.* Apr15;35(8):831-44). Hence, embodiments of the immunostimulatory bacterial strains that encode products that inhibit or reduce expression of RNase H2, thereby inhibiting RNase H2, result in tumor-derived RNA:DNA hybrids and derivatives thereof, which activate cGAS/STING signaling and enhance anti-tumor immunity.

l. Stabilin-1/CLEVER-1 Inhibition

Another molecule expressed primarily on monocytes, and involved in regulating immunity, is stabilin-1 (gene name *STAB1*, also known as *CLEVER-1*, *FEEL-1*). Stabilin-1 is a type I transmembrane protein that is upregulated on endothelial cells and macrophages following inflammation, and in particular, on tumor-associated macrophages (Kzhyshkowska *et al.* (2006) *J. Cell. Mol. Med.* 10(3):635-649). Upon inflammatory activation, stabilin-1 acts as a scavenger and aids in wound healing and apoptotic body clearance, and can prevent tissue injury, such as liver fibrosis (Rantakari *et al.* (2016) *Proc. Natl. Acad. Sci. USA* 113(33):9298–9303). Upregulation of stabilin-1 directly inhibits antigen-specific T-cell responses, and knockdown by siRNA in monocytes was shown to enhance their pro-inflammatory

function (Palani, S. *et al.* (2016) *J. Immunol.* 196:115-123). Hence, embodiments of the immunostimulatory bacterial strains that encode products that inhibit or reduce expression of Stabilin-1/CLEVER-1 in the tumor microenvironment, enhance the pro-inflammatory functions of tumor-resident macrophages.

5 **m. CpG Motifs and CpG Islands**

Unmethylated cytidine-phosphate-guanosine (CpG) motifs are prevalent in bacterial, but not vertebrate, genomic DNA. Pathogenic DNA and synthetic oligodeoxynucleotides (ODNs) containing CpG motifs activate host defense mechanisms, leading to innate and acquired immune responses. The unmethylated
10 CpG motifs contain a central unmethylated CG dinucleotide plus flanking regions. In humans, four distinct classes of CpG ODNs have been identified, based on differences in structure and the nature of the immune response they induce. K-type ODNs (also referred to as B-type) contain from 1 to 5 CpG motifs, typically on a phosphorothioate backbone. D-type ODNs (also referred to as A-type) have a mixed
15 phosphodiester/phosphorothioate backbone and have a single CpG motif, flanked by palindromic sequences that permits the formation of a stem-loop structure, as well as poly G motifs at the 3' and 5' ends. C-type ODNs have a phosphorothioate backbone and contain multiple palindromic CpG motifs that can form stem loop structures or dimers. P-Class CpG ODNs have a phosphorothioate backbone and contain multiple
20 CpG motifs with double palindromes that can form hairpins at their GC-rich 3' ends (Scheiermann and Klinman (2014) *Vaccine* 32(48):6377-6389). For purposes herein, the CpGs are encoded in the plasmid DNA; they can be introduced as a motif, or in a gene.

Toll-like receptors (TLRs) are key receptors for sensing pathogen-associated
25 molecular patterns (PAMPs) and activating innate immunity against pathogens (Akira *et al.* (2001) *Nat. Immunol.* 2(8):675-680). TLR9 recognizes hypomethylated CpG motifs in the DNA of prokaryotes that do not occur naturally in mammalian DNA (McKelvey *et al.* (2011) *J. Autoimmunity* 36:76-86). Recognition of CpG motifs upon phagocytosis of pathogens into endosomes in immune cell subsets induces IRF7-
30 dependent type I interferon signaling and activates innate and adaptive immunity.

Immunostimulatory bacteria, such as *Salmonella* species, such as *S. typhimurium* strains, carrying plasmids containing CpG islands/motifs, are provided

herein. These bacteria can activate TLR9 and induce type I IFN-mediated innate and adaptive immunity. As exemplified herein, bacterial plasmids that contain hypomethylated CpG islands can elicit innate and adaptive anti-tumor immune responses that, in combination with the encoded products, such as the gain-of-function variant STING proteins, can have synergistic or enhanced anti-tumor activity. For example, the *asd* gene (see, *e.g.*, SEQ ID NO:48) encodes a high frequency of hypomethylated CpG islands. CpG motifs can be included in combination with any of the therapeutic products, such as STING proteins and mutants thereof, described in or apparent from the description herein, in the immunostimulatory bacteria, and thereby enhance or improve the anti-tumor immune response, by modulating TLRs, such as TLR9.

Immunostimulatory CpGs can be included in the plasmids, by including a nucleic acid, typically from a bacterial gene (*e.g.*, *asd*), that encodes a gene product, and also by adding a nucleic acid that includes CpG motifs. The plasmids herein can include CpG motifs. Exemplary CpG motifs are known (see, *e.g.*, U.S. Patent Nos. 8,232,259, 8,426,375 and 8,241,844). These include, for example, synthetic immunostimulatory oligonucleotides, between 10 and 100, 10 and 20, 10 and 30, 10 and 40, 10 and 50, or 10 and 75 base pairs long, with the general formula:

$(\text{CpG})_n$, where *n* is the number of repeats.

Generally, at least one or two repeats are used; non-CG bases can be interspersed. Those of skill in the art are very familiar with the general use of CpG motifs for inducing an immune response by modulating TLRs, particularly TLR9.

5. Modifications That Increase Uptake of Gram-Negative Bacteria, such as *Salmonella*, by Immune Cells, and Reduce Immune Cell Death

The immunostimulatory bacteria provided herein, such as the exemplary strains of *S. typhimurium*, can be modified to increase uptake by immune cells, such as tumor-resident immune cells, and to decrease uptake by non-immune cells, such as epithelial cells. The bacteria also can be modified to decrease immune cell death, such as by decreasing macrophage pyroptosis. Numerous modifications of the bacterial genome can do one or both of increasing infection of immune cells and decreasing pyroptosis. The immunostimulatory bacteria provided herein include such modifications, for example, deletions and/or disruptions of genes involved in the SPI-

1 T3SS pathway, such as disruption or deletion of *hilA*, rod protein and/or needle protein, and/or disruption/deletion of other bacterial genes, encoding flagellin. These modifications allow the bacteria to accumulate in tumor-resident immune cells, where they can express the encoded therapeutic product(s) and release them directly into the
5 tumor microenvironment, enhancing the therapeutic efficacy. Additionally, prolonging the life of tumor-resident macrophages, *e.g.*, by decreasing pyroptosis, allows for the efficient production of the encoded therapeutic products, and activation of an immune response in the tumor microenvironment, further enhancing the anti-tumor therapeutic efficacy of the bacteria.

10 **a. Bacterial Uptake by Immune cells**

The genome of the immunostimulatory bacteria provided herein can be modified to increase or promote infection of immune cells, particularly immune cells in the tumor microenvironment, such as phagocytic cells. This includes reducing infection of non-immune cells, such as epithelial cells, or increasing infection of
15 immune cells. The invasive phenotype of Gram-negative bacteria, such as *Salmonella*, can result from the activity of genes encoded in pathways that promote the invasion of host cells. The invasion-associated *Salmonella* pathogenicity island 1 (SPI-1) of *Salmonella* is exemplary. SPI-1 includes the type 3 secretion system (T3SS), that is responsible for translocation of effector proteins into the cytosol of host cells. These
20 proteins can cause actin rearrangements that lead to the uptake of *Salmonella*. T3SS effectors mediate the uptake of *S. typhimurium* into non-phagocytic host cells, such as epithelial cells. The SPI-1 T3SS has been shown to be essential for crossing the gut epithelial layer, but is dispensable for infection when bacteria are injected parenterally, for example. SPI-1 mutants have defects in epithelial cell invasion,
25 dramatically reducing oral virulence, but are taken up normally by phagocytic cells, such as macrophages (Kong *et al.* (2012) *Proc. Natl. Acad. Sci. U.S.A.* 109(47):19414-19419).

The immunostimulatory bacteria, such as *S. typhimurium* strains, provided herein, can be engineered with mutations in SPI-1 T3SS genes, preventing their
30 uptake by epithelial cells, and focusing them to immune cells, such as macrophages, such as tumor-associated macrophages, enhancing the anti-tumor immune response. Additionally, as shown herein (see, *e.g.*, Example 6), elimination of the flagella,

results in an inability to infect epithelial cells, and restricts uptake of the bacteria to tumor-resident immune/myeloid cells. Thus, in embodiments herein, the immunostimulatory bacteria can be modified by deletion or disruption of genes in the SPI-1 T3SS and/or by deletion or disruption of genes encoding the flagella, to prevent or reduce infection of non-phagocytic cells (e.g., epithelial cells) and increase or restrict infection to tumor-resident myeloid cells. Such bacteria also can be modified with plasmids encoding therapeutic product(s), such as those that induce type I IFN, and immunostimulatory cytokines, further enhancing the anti-tumor immune response and the therapeutic efficacy by expressing the therapeutic products in tumor-resident immune cells.

b. Macrophage Pyroptosis

The macrophage NLRC4 inflammasome, which plays a role in the innate immune and antimicrobial responses, is a large multi-protein complex that recognizes cytosolic pathogens and provides for the autocatalytic activation of caspase-1. Activation of caspase-1 induces maturation and release of the pro-inflammatory cytokines IL-1 β and IL-18, and triggers pyroptosis, a rapid inflammatory form of macrophage cell death. This pro-inflammatory cell death can limit the initiation of a robust adaptive immune response by directly inducing the death of antigen-presenting cells (APCs), as well as modifying the cytokine milieu to prevent the generation of memory T-cells.

Infection by certain Gram-negative bacteria encoding type 3 or 4 secretion systems, such as *Salmonella typhimurium* and *Pseudomonas aeruginosa*, triggers the activation of the NLRC4 inflammasome upon recognition of bacterial ligands, such as needle protein, rod protein and flagellin, following translocation into the host cell cytosol by the *Salmonella* pathogenicity island-1 type III secretion system (SPI-1 T3SS). Pyroptosis is not limited to macrophages; caspase-1-dependent death has been observed in dendritic cells following infection with *Salmonella* (Li *et al.* (2016) *Scientific Reports* 6:37447; Chen *et al.* (2014) *Cell Reports* 8:570-582; (Fink and Cookson (2007) *Cellular Microbiology* 9(11):2562-2570)). As shown herein, the knock-out of genes in the *Salmonella* genome that are involved in the induction of pyroptosis enhances the anti-tumor immune response. This prevents the loss of immune cells, including macrophages, following bacterial infection. For example,

genes encoding HilA, rod protein (PrgJ), needle protein (PrgI), flagellin and/or QseC can be knocked out/disrupted in the immunostimulatory bacteria provided herein.

i. Flagellin

As discussed above, for some bacteria species, such as *Salmonella*, flagellin, in addition to SPI-1 T3SS, is necessary for triggering pyroptosis in macrophages, and can be detected by, and activate, the macrophage NLRC4 inflammasome. Flagellin, which is the major component of flagellum, is recognized by TLR5. *Salmonella* encodes two flagellin genes, *fliC* and *fliB*; elimination of flagellin subunits decreases pyroptosis in macrophages. For example, *S. typhimurium* with deletions in *fliC* and *fliB* resulted in significantly reduced IL-1 β secretion compared to the wild-type strain, whereas cellular uptake and intracellular replication of the bacterium remained unaffected. This demonstrates that flagellin plays a significant role in inflammasome activation. Additionally, *S. typhimurium* strains engineered to constitutively express FliC were found to induce macrophage pyroptosis (see, e.g., Li *et al.* (2016) *Scientific Reports* 6:37447; Fink and Cookson (2007) *Cellular Microbiology* 9(11):2562-2570; and Winter *et al.* (2015) *Infect. Immun.* 83(4):1546-1555).

The genome of the immunostimulatory bacteria herein can be modified to delete, disrupt or mutate the flagellin genes *fliC* and *fliB* in *S. typhimurium*, leading to decreased cell death of tumor-resident immune cells, such as macrophages, and enhancing the anti-tumor immune response of the immunostimulatory bacteria.

ii. SPI-1 Proteins

SPI-1 proteins also activate the NLRC4 inflammasome in macrophages, activating caspase-1 and leading to cell death via pyroptosis. These effectors include, but are not limited to, rod protein (PrgJ) and needle protein (PrgI), for example.

Rod protein (PrgJ)

The NLRC4 inflammasome also detects aflagellated *S. typhimurium*. The flagellin-independent response is due to the detection of PrgJ, which is the SPI-1 T3SS rod protein in *S. typhimurium*. Delivery of purified PrgJ protein to the macrophage cytosol results in rapid NLRC4-dependent caspase-1 activation, as well as secretion of IL-1 β , similar to the effects induced by flagellin (Miao *et al.* (2010) *Proc. Natl. Acad. Sci. U.S.A.* 107(7):3076-3080). Thus, the mutation or knockout of the gene encoding PrgJ in *S. typhimurium* can reduce macrophage pyroptosis, which

enhances the anti-tumor immune effect of the immunostimulatory bacteria, by preserving immune cells that are susceptible to being killed by the bacteria.

Needle protein (PrgI)

PrgI, which is the SPI-1 T3SS needle protein in *S. typhimurium*, also is
5 recognized by, and activates, the NLRC4 inflammasome. The delivery of *S. typhimurium* PrgI to the cytosol of human primary monocyte-derived macrophages results in IL-1 β secretion and subsequent cell death. A *Salmonella* mutant that expresses PrgI, but not flagellin, was shown to activate the inflammasome in primary monocyte-derived macrophages at later time points than strains expressing flagellin
10 (Kortmann *et al.* (2015) *J. Immunol.* 195:815-819). The immunostimulatory bacteria provided herein, thus, can be modified to mutate or delete the gene encoding the needle protein in *S. typhimurium*, preventing immune cell pyroptosis, and enhancing the anti-tumor immune effect.

iii. QseC

15 The sensor protein QseC is a highly conserved membrane histidine sensor kinase that is found in many Gram-negative bacteria, and that responds to the environment and regulates the expression of several virulence factors. These virulence factors include, for example, the *flhDC* gene that encodes the master regulator of flagellum biosynthesis in *S. typhimurium*; the *sopB* gene, which encodes a protein that
20 plays a role in the invasion of non-phagocytic cells, the early maturation and regulation of trafficking of the *Salmonella*-containing vacuole (SCV), and the inhibition of SCV-lysosome fusion; and the *sifA* gene, which is required for SCV maintenance and membrane integrity.

It has been shown that selective inhibition of QseC by LED209 inhibits
25 bacterial virulence without suppressing *S. typhimurium* growth, by inhibiting the QseC-mediated activation of virulence-related gene expression (*e.g.*, *flhDC*, *sifA* and *sopB*), and partially protects mice from death following infection with *S. typhimurium* or *Francisella tularensis*. QseC blockade was found to inhibit caspase-1 activation, IL-1 β release, and *S. typhimurium*-induced pyroptosis of macrophages, by inhibiting
30 excess inflammasome activation in the infected macrophages. Inhibition of QseC also suppresses flagellar gene expression and motility, and suppresses the invasion and replication capacities of *S. typhimurium* in epithelial cells (Li *et al.* (2016) *Scientific*

Reports 6:37447). Thus, modification of the immunostimulatory bacteria herein, to mutate or knockout the gene encoding QseC, can enhance the anti-tumor immune response by focusing *S. typhimurium* infection to non-epithelial cells, and by reducing cell death in immune cells, such as by preventing pyroptosis in macrophages.

5 6. Bacterial Culture Conditions

Culture conditions for bacteria can influence their gene expression. It has been documented that *S. typhimurium* can induce rapid pro-inflammatory caspase-dependent cell death of macrophages, but not epithelial cells, within 30 to 60 min of infection, by a mechanism involving the SPI-1 and its associated T3SS-1 (Lundberg
10 *et. al* (1999) *Journal of Bacteriology* 181(11):3433–3437). It is now known that this cell death is mediated by activation of the inflammasome that subsequently activates caspase-1, which promotes the maturation and release of IL-1 β and IL-18 and initiates a novel form of cell death called pyroptosis (Broz and Monack (2011) *Immunol. Rev.* 243(1):174–190). This pyroptotic activity can be induced by using log phase bacteria,
15 whereas stationary phase bacteria do not induce this rapid cell death in macrophages. The SPI-1 genes are induced during the log phase of bacterial growth. Thus, by harvesting *S. typhimurium*, to be used therapeutically, at the stationary phase, rapid pyroptosis of macrophages can be prevented. Macrophages are important mediators of the innate immune system and they can act to secrete cytokines that are critical for
20 establishing appropriate anti-tumor responses. In addition, limiting the secretion of pro-inflammatory cytokines, such as IL-1 β and IL-18, will improve the tolerability of administered *S. typhimurium* therapy. As provided herein, immunostimulatory *S. typhimurium*, harvested at stationary phase, will be used to induce anti-tumor responses.

25 7. Increased Tumor Colonization

VNP20009 is an attenuated *S. typhimurium*-based microbial cancer therapy that was developed for the treatment of cancer. VNP20009 is attenuated through deletion of the genes *msbB* and *purI* (*purM*). The *purI* deletion renders the microbe auxotrophic for purines or adenosine. Deletion of the *msbB* gene reduces the toxicity
30 associated with bacterial lipopolysaccharide (LPS), by preventing the addition of a terminal myristyl group to the lipid A domain, and producing a less toxic form of lipid A (Kahn *et al.* (1998) *Mol. Microbiol.* 29:571-579).

There is a difference between mouse and humans in the ability of VNP20009 to colonize tumors. Systemic administration of VNP20009 resulted in colonization of mouse tumors; whereas systemic administration of VNP20009 in human patients resulted in very little tumor colonization. It was shown that in mice, VNP20009 exhibited a high degree of tumor colonization after systemic administration (see, *e.g.*, Clairmont *et al.* (2000) *J. Infect. Dis.* 181:1996-2002; and Bermudes *et al.* (2001) *Biotechnol Genet Eng Rev.* 18:219-33). In a Phase 1 Study in advanced melanoma patients, however, very little VNP20009 was detected in human tumors after a 30-minute intravenous infusion (see, Toso *et al.* (2002) *J. Clin. Oncol.* 20:142-52). Patients that entered into a follow-up study evaluating a longer, four-hour infusion of VNP20009, also demonstrated a lack of detectable VNP20009 after tumor biopsy (Heimann *et al.* (2003) *J. Immunother.* 26:179-180). Following intratumoral administration, colonization of a derivative of VNP20009 was detected (Nemunaitis *et al.* (2003) *Cancer Gene Ther.* 10:737-44). Direct intratumoral administration of VNP20009 to human tumors resulted in tumor colonization, indicating that human tumors can be colonized at a high level, and that the difference in tumor colonization between mice and humans occurs only after systemic administration.

Strains, such as VNP20009, are inactivated by human complement, which leads to low tumor colonization. Strains that provide improved resistance to complement are provided herein. These strains contain modifications in the bacterial genome, and also can carry a plasmid, typically in low or medium copy number, to optionally encode genes to provide for replication (*asd* under the control of a eukaryotic promoter), and nucleic acid(s) encoding a therapeutic product(s), such as, but not limited to, cytokines, gain-of-function mutants of proteins that stimulate production of type I interferon, and other such therapeutic genes/products, as described elsewhere herein.

The table below summarizes the bacterial genotypes/modifications, their functional effects, and the effects/benefits.

Genotype/Modification	Functional effect	Effects/Benefits
$\Delta purI$	Purine/adenosine auxotrophy	Tumor-specific enrichment Limited replication in healthy tissue
$\Delta msbB$	LPS surface coat modification	Decreased TLR4 recognition Reduced immunosuppressive cytokine profile (TNF- α)

Genotype/Modification	Functional effect	Effects/Benefits
		Improved safety
Δ FLG	Flagella knockout	Removes major inflammatory and immune-suppressive element Decreased TLR5 recognition Reduced immunosuppressive cytokine profile Improved safety Reduces ability to invade non-phagocytic cells
Δ pagP	LPS surface coat modifications	Removes major inflammatory and immune-suppressive element Decreased TLR4 recognition Reduced IL-6 profile Improved safety
Δ asd (in genome)	Plasmid maintenance	Improved plasmid delivery Plasmid maintenance
plasmid	Express gene products under control of host-recognized promoter	Eukaryotic promoter limits expression to cells containing the plasmid Long term expression in the TME (<i>i.e.</i> , <i>asd</i> encoded on plasmid under control of host-recognized promoter) Expression of therapeutic product(s) CpGs to induce type I IFN-mediated innate and adaptive immunity

Strains provided herein are Δ FLG so that they have no flagella, and/or Δ pagP. Additionally, the strains are one or more of Δ purI (Δ purM), Δ msbB, and Δ asd (in the bacterial genome). The plasmid is modified to encode products under control of host-recognized promoters (*e.g.*, eukaryotic promoters, such as RNA polymerase II promoters, including those from eukaryotes, and animal viruses). The plasmids optionally can encode *asd* to permit replication *in vivo*, as well as nucleic acids with other beneficial functions (*e.g.*, CpGs) and gene products as described elsewhere herein.

The immunostimulatory bacteria are derived from suitable bacterial strains, including attenuated and wild-type or other non-attenuated strains. Bacterial strains can be attenuated strains, or strains that are attenuated by standard methods, or that, by virtue of the modifications provided herein, are attenuated in that their ability to colonize is limited primarily to immunoprivileged tissues and organs, particularly immune and tumor cells, including solid tumors. Bacteria include, but are not limited to, for example, strains of *Salmonella*, *Shigella*, *Listeria*, *E. coli*, and *Bifidobacteriae*. For example, species include *Shigella sonnei*, *Shigella flexneri*, *Shigella dysenteriae*,

Listeria monocytogenes, *Salmonella typhi*, *Salmonella typhimurium*, *Salmonella gallinarum*, and *Salmonella enteritidis*. Other suitable bacterial species include *Rickettsia*, *Klebsiella*, *Bordetella*, *Neisseria*, *Aeromonas*, *Francisella*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*,
5 *Mycoplasma*, *Legionella*, *Rhodococcus*, *Pseudomonas*, *Helicobacter*, *Vibrio*, *Bacillus*, and *Erysipelothrix*. For example, *Rickettsia Rickettsiae*, *Rickettsia prowazekii*, *Rickettsia tsutsugamuchi*, *Rickettsia mooseri*, *Rickettsia sibirica*, *Bordetella bronchiseptica*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Aeromonas eucrenophila*, *Aeromonas salmonicida*, *Francisella tularensis*, *Corynebacterium*
10 *pseudotuberculosis*, *Citrobacter freundii*, *Chlamydia pneumoniae*, *Haemophilus sornmus*, *Brucella abortus*, *Mycobacterium intracellulare*, *Legionella pneumophila*, *Rhodococcus equi*, *Pseudomonas aeruginosa*, *Helicobacter mustelae*, *Vibrio cholerae*, *Bacillus subtilis*, *Erysipelothrix rhusiopathiae*, *Yersinia enterocolitica*, *Rochalimaea quintana*, and *Agrobacterium tumefaciens*.

15 Exemplary of the immunostimulatory bacteria provided herein are species of *Salmonella*. Exemplary of bacteria for modification as described herein are wild-type strains of *Salmonella*, such as the strain that has all of the identifying characteristics of the strain deposited in the ATCC as accession #14028. Engineered strains of *Salmonella typhimurium*, such as strain YS1646 (ATCC Catalog # 202165; also
20 referred to as VNP20009, see, also International PCT Application Publication No. WO 99/13053) that is engineered with plasmids to complement an *asd* gene knockout and antibiotic-free plasmid maintenance, are provided. The strains then are modified to delete the flagellin genes and/or to delete *pagP*. The strains also are rendered auxotrophic for purines, particularly adenosine, and are *asd⁻* and *msbB⁻*. The *asd* gene
25 can be provided on a plasmid for replication in the eukaryotic host. These deletions and plasmids are described elsewhere herein. Any of the nucleic acids encoding therapeutic products and immunostimulatory proteins and other products, described elsewhere herein and/or known to those of skill in the art, can be included on the plasmid. The plasmid generally is present in low to medium copy number as
30 described elsewhere herein. Therapeutic products include gain-of-function mutants of cytosolic DNA/RNA sensors, that can constitutively evoke/induce type I IFN expression, and other immunostimulatory proteins, such as cytokines, that promote an

anti-tumor immune response in the tumor microenvironment, and other such products described herein.

E. NON-HUMAN STING PROTEINS AND GAIN-OF-FUNCTION MUTATIONS IN PROTEINS THAT STIMULATE THE IMMUNE RESPONSE IN THE TUMOR MICROENVIRONMENT

5 Provided are immunostimulatory bacteria that contain sequences of nucleotides that encode gene products that are therapeutic, particularly anti-cancer products, including products that promote or stimulate an anti-tumor or anti-viral immune response. Included among the therapeutic products are products, referred to
10 as cytosolic DNA/RNA sensors, that evoke immune responses when exposed to nucleic acids, such as RNA, DNA, nucleotides, dinucleotides, cyclic nucleotides, cyclic dinucleotides, and other such molecules, in the cytosol of cells. The immunostimulatory bacteria herein encode modified products that have increased activity or that constitutively evoke immune responses, and do not require the
15 presence of the DNA/RNA products in the cytosol. Exemplary are encoded proteins that include gain-of-function mutations that increase immune responses in the tumor microenvironment. Not only are immunostimulatory bacteria provided, but also, other delivery vehicles can be used to deliver nucleic acids encoding such immunostimulatory proteins, or to deliver the encoded proteins. These delivery
20 vehicles include exosomes, vectors, and viruses. For example, oncolytic viruses also can be modified to express the gain-of-function products, particularly oncolytic viruses, such as vaccinia virus, that are cytoplasmic viruses. The encoded gain-of-function products can be delivered in exosomes, liposomes, and other suitable vehicles, generally targeted to tumors.

25 The immunostimulatory bacteria that encode the gain-of-function products (and/or other therapeutic products) include immunostimulatory bacteria that preferentially infect tumors, including tumor-resident immune cells, and/or immunostimulatory bacteria in which the genome is modified so that the bacteria induces less cell death in tumor-resident immune cells, whereby the
30 immunostimulatory bacteria accumulate in tumor cells and tumor-resident immune cells, to thereby deliver the constitutively active proteins and/or other therapeutic products to the cells and the tumor microenvironment, to stimulate the immune response against the tumor. The immunostimulatory bacteria further can encode a

tumor antigen in the subject to enhance the response against the particular tumor. Any of the immunostimulatory bacteria provided herein and described above and below can be modified to encode such a gain-of-function product. The product is encoded on a plasmid under control of a promoter, and any other desired regulatory sequences
5 recognized in a eukaryotic, such as a human, or other animal, or mammalian, subject. Generally, the nucleic acid encoding the gain-of-function product is under the control of an RNA polymerase II promoter.

The therapeutic products, including the gain-of-function variants that include STING proteins and other proteins in the type I interferon signaling pathway as
10 described herein, and other anti-cancer products, are expressed under control of a eukaryotic promoter. Promoters include, for example, the EF-1 alpha promoter, CMV, SV40, PGK, EIF4A1, CAG, CD68 and synthetic MND promoters; viral promoters, such as O, MSCV and TLR promoters, and a respiratory syncytial virus (RSV) promoter; cellular promoters, such as EIF-1a; inducible chimeric promoters, such as
15 tet-CMV; and tissue-specific promoters (Chang *et al.* (2013) *Cold Spring Harb Protoc*; doi:10.1101/pdb.prot075853).

Additionally, any of the bacteria described herein for modification, such as any of the strains of *Salmonella*, *Shigella*, *E. coli*, *Bifidobacteriae*, *Rickettsia*, *Vibrio*,
20 *Listeria*, *Klebsiella*, *Bordetella*, *Neisseria*, *Aeromonas*, *Francisella*, *Cholera*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*, *Mycoplasma*, *Legionella*, *Rhodococcus*, *Pseudomonas*, *Helicobacter*, *Bacillus*, and *Erysipelothrix*, or attenuated strains thereof or modified strains thereof, exosomes, liposomes and oncolytic viruses, can be modified by introducing a plasmid containing, or encoding on a plasmid in the bacteria, nucleic acids encoding the gain-
25 of-function product(s) under control of an RNA polymerase promoter recognized by the host. The gain-of-function products are expressed in the infected subject's cells. The immunostimulatory bacteria include those that are modified, as described herein, to accumulate in, or to preferentially infect, tumors and tumor-resident immune cells. For example, immunostimulatory bacteria that encode gain-of-function products
30 leading to the expression of, or the constitutive expression of, type I interferon (IFN), such as IFN-beta, further are modified to have reduced ability or no ability to infect epithelial cells, but are able to infect phagocytic cells, including tumor-resident

immune cells, and/or the bacteria are modified so that they do not kill the infected phagocytic cells.

The immunostimulatory bacteria herein can encode products, referred to as cytosolic DNA/RNA sensors, that evoke immune responses when exposed to nucleic acids, such as RNA, DNA, nucleotides, dinucleotides, cyclic nucleotides, cyclic dinucleotides, and other such molecules, in the cytosol of cells. The immunostimulatory bacteria herein, encode modified products that constitutively evoke immune responses, and do not require the presence of the DNA/RNA and other nucleotides in the cytosol. Exemplary of such are components of pathways that induce type I interferon expression. The products contemplated herein include modified forms of these DNA/RNA sensors, that have constitutive activity or increased activity (gain-of-function products), such that type I interferon(s) is/are expressed or produced in the absence of nucleotides, dinucleotides, cyclic nucleotides, cyclic dinucleotides, and other such ligands, in the cytosol of cells. Expression of these modified products in cells, particularly in tumor cells and tumor-resident immune cells, leads to constitutive expression of type I interferons, including interferon- β , in the tumor microenvironment. Because the immunostimulatory bacteria, and also oncolytic viruses (and other delivery vehicles as described herein), that express these gain-of-function products accumulate in or preferentially infect tumor cells and tumor-resident immune cells, the products are expressed in the tumor microenvironment, resulting in increased immune responses in the tumor microenvironment, and enhanced therapeutic efficacy.

Exemplary gene products that can be encoded in the immunostimulatory bacteria and other vehicles, include, but are not limited to, proteins that sense or are involved in innate pathways that recognize cytosolic DNA/RNA and activate type I interferon production. Proteins involved in innate DNA/RNA recognition that activate type I interferon include, but are not limited to: STING, RIG-I, MDA-5, IRF-3, IRF-7, TRIM56, RIP1/RIPK1, Sec5/EXOC2, TRAF2, TRAF3, TRAF6, STAT1, LGP2/DHX58, DDX3/DDX3X, DHX9/DDX9, DDX1, DDX21, DHX15/DDX15, DHX33/DDX33, DHX36/DDX36, DDX60, and SNRNP200. Gain-of-function mutations in any of these proteins that result in constitutive type I interferon expression are known, or can be identified, and can be delivered by the

immunostimulatory bacteria, or other vectors, and delivery vehicles, such as exosomes or liposomes, to the tumor microenvironment, such as by infection of cells or targeting and binding to tumor cells. The gain-of-function mutations include those identified from individuals with disorders resulting from constitutive type I interferon
5 expression. Exemplary of gain-of-function products are those that occur in subjects with interferonopathies. As noted above, mutations can be identified by screening to generate gain-of-function products as well.

The immunostimulatory bacteria herein encode such proteins, such as STING, including non-human STING proteins that have lower NF- κ B signaling activity than
10 the NF- κ B signaling activity of human STING, and variants of the STING proteins and other DNA/RNA sensors that constitutively evoke immune responses, and do not require the presence of the DNA/RNA or other nucleotide ligands in the cytosol. Exemplary of such are components of pathways that induce type I interferon expression.

15 The nucleic acids encoding the identified gain-of-function mutant products can be further modified to improve properties for expression. Modifications include, for example, codon optimization to increase transcriptional efficiency in a mammalian, particularly human, subject, such as reduction of GC content or CpG dinucleotide content, removal of cryptic splicing sites, negative CpG islands,
20 replacement of the Shine-Dalgarno (SD) sequence, and replacement of TATA box and/or terminal signals to increase transcriptional efficiency. Also, codons can be optimized for increasing translation efficiency by altering codon usage bias, decreasing GC content, decreasing mRNA secondary structure, removing premature PolyA sites, removing RNA instability motifs (ARE), reducing stable free energy of
25 mRNA, modifying internal chi sites and ribosomal binding sites, and reducing RNA secondary structures.

1. Type I Interferons and Pathways

Type I interferon induction pathways, mediated by host recognition of nucleic acids, such as single-stranded and double-stranded RNA, and of cyclic di-nucleotides
30 and other such forms of nucleic acids, are known to induce type I IFN. There also are Toll-Like Receptor (TLR)-independent type I IFN pathways, mediated by host recognition of single-stranded (ss) and double-stranded (ds) RNA in the cytosol.

These nucleic acids are sensed by RNA helicases, including retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA-5), and through promoter stimulator 1 (IPS-1) adaptor protein-mediated phosphorylation of the IRF-3 transcription factor, leading to induction of IFN-beta (Ireton and Gale (2011) *Viruses* 3(6):906-919). As discussed herein, proteins in these pathways can be modified, or can exist as variants, that result in constitutive expression of type I interferons (also referred to as interferon type 1), which include IFN- α and IFN- β . Provided herein are immunostimulatory bacteria and other delivery vehicles, including exosomes, liposomes and oncolytic viruses, that encode the variant proteins. These delivery vehicles can be used to treat cancers by directly administering to subjects and/or by administering them to cells, allogeneic or autologous, for use in cell therapy protocols.

Type I interferons (IFNs; also referred to as interferon type 1), include IFN- α and IFN- β , and are pleiotropic cytokines with antiviral, antitumor and immunoregulatory activities. IFN- β is produced by most cell types; IFN- α primarily is produced by hematopoietic cells, particularly plasmacytoid dendritic cells. Type I IFNs are produced following the sensing of pathogen-associated molecular patterns (PAMPs), including microbial and virus nucleic acids and LPS (lipopolysaccharides), by pattern recognition receptors (PRRs) and by cytokines. They are involved in the innate immune response against pathogen, including viral, infection, and are potent immunomodulators that promote antigen presentation, mediate DC maturation, activate cytotoxic T lymphocytes (CTLs), natural killer (NK) cells and macrophages, and activate the adaptive immune system by promoting the development of high-affinity antigen-specific T and B cell responses and immunological memory.

Type I IFNs exhibit anti-proliferative and pro-apoptotic effects on tumors and have anti-angiogenic effects on tumor neovasculature. They induce the expression of MHC class I molecules on tumor cell surfaces, increase the immunogenicity of tumor cells, and activate cytotoxicity against them. Type I IFN has been used as a therapeutic for treatment of cancers and viral infections. For example, IFN- α (sold under the trademark Intron®/Roferon®-A) is approved for the treatment of hairy cell leukemia, malignant melanoma, AIDS-related Kaposi's sarcoma, and follicular non-Hodgkin's lymphoma; it also is used in the treatment of chronic myelogenous

leukemia (CML), renal cell carcinoma, neuroendocrine tumors, multiple myeloma, non-follicular non-Hodgkin's lymphoma, desmoid tumors and cutaneous T-cell lymphoma (Ivashkiv and Donlin (2014) *Nat. Rev. Immunol.* 14(1):36-49; Kalliolias and Ivashkiv (2010) *Arthritis Research & Therapy* 12(Suppl 1):S1; Lee, S. and Margolin, K. (2011) *Cancers* 3:3856-3893).

Expression of type I interferons in tumors and the tumor microenvironment is among the immune responses that the immunostimulatory bacteria and other delivery vehicles herein are designed to evoke. Inducing or evoking type I interferon provides anti-tumor immunity for the treatment of cancer.

10 2. Type I Interferonopathies and Gain-of-Function Mutants

The induction of type I interferons (IFNs), proinflammatory cytokines and chemokines is necessary for mounting an immune response that prevents or inhibits infection by pathogens. This response also can be effective as an anti-tumor agent. The immunostimulatory bacteria and other delivery vehicles provided herein encode
15 proteins that constitutively induce type I IFNs. Among these proteins are those that occur in individuals with various diseases or disorders that involve the over-production of immune response modulators. For example, over-production or excessive production, or defective negative regulation of type I IFNs and pro-inflammatory cytokines, can lead to undesirable effects, such as inflammatory and
20 autoimmune diseases. Disorders involving the overproduction, generally chronic, of type I IFNs and pro-inflammatory cytokines, are referred to as interferonopathies (see, e.g., Lu and MacDougall (2017) *Front. Genet.* 8:118; and Konno *et al.* (2018) *Cell Reports* 23:1112-1123). Disorders and clinical phenotypes associated with type I interferonopathies include Aicardi-Goutières syndrome (AGS), STING-associated
25 vasculopathy with onset in infancy (SAVI), Singleton-Merten syndrome (SMS), atypical SMS, familial chilblain lupus (FCL), systemic lupus erythematosus (SLE), bilateral striatal necrosis (BSN), cerebrovascular disease (CVD), dyschromatosis symmetrica hereditaria (DSH), spastic paraparesis (SP), X-linked reticulate pigmentary disorder (XLPDR), proteasome-associated auto-inflammatory syndrome
30 (PRAAS), intracranial calcification (ICC), Mendelian susceptibility to mycobacterial disease (MSMD), and spondyloenchondrodysplasia (SPENCD) (see, e.g., Rodero *et al.* (2016) *J. Exp. Med.* 213(12):2527-2538). These phenotypes are associated with

particular genotypes, involving mutations in genes that lead to constitutive activities of products involved in the induction of type I IFNs.

The sustained activation of interferon signaling can be due to: 1) loss-of-function mutations leading to increased cytosolic DNA (*e.g.*, mutations in *TREX1* and *SAMHD1*) or increased cytosolic RNA/DNA hybrids (*e.g.*, mutations in *RNASEH2A*, *RNASEH2B*, *RNASEH2C* and *POLAI*); 2) loss-of-function mutations resulting in a defect in RNA editing and abnormal sensing of self-nucleic acid RNA species in the cytosol (*e.g.*, mutations in *ADARI*); 3) gain-of-function mutations leading to constitutive activation of cytosolic IFN signaling pathways/increased sensitivity to cytosolic nucleic acid ligands (*e.g.*, mutations in *RIG-I*, *MDA5* and *STING*); 4) loss-of-function mutations leading to aberrant RNA signaling via MAVS caused by a disturbance of the unfolded protein response (*e.g.*, mutations in *SKIV2L*); 5) loss-of-function mutations in molecules responsible for limiting IFN receptor (IFNAR1/2) signaling, leading to uncontrolled IFN-stimulated gene (ISG) production (*e.g.*, mutations in *USP18* and *ISG15*); 6) proteasomal dysfunction, leading to increased IFN signaling through an unknown mechanism (*e.g.*, mutations in *PSMA3*, *PSMB4* and *PSMB8*); and 7) loss-of-function mutations in TRAP/ACP5 and C1q, where the mechanisms leading to type I IFN signaling remain unclear (Rodero *et al.* (2016) *J. Exp. Med.* 213(12):2527-2538).

Of interest herein are mutations that lead to gain-of-function. There are known mutations in *STING*, *MDA5* and *RIG-I*, associated with gain-of-function (GOF), resulting in the constitutive activation of the encoded proteins and/or enhanced sensitivity or increased affinity or binding to endogenous ligands. GOF mutations in *STING*, for example, are linked to SAVI and FCL; GOF mutations in *MDA5* are linked to AGS and SMS; and GOF mutations in *RIG-I* are linked to atypical SMS.

The immunostimulatory bacteria, and oncolytic viruses, provided herein that encode these proteins with gain-of-function mutations, exploit the constitutive activation of these proteins to increase production of type I IFNs and pro-inflammatory cytokines. Tumor-targeting immunostimulatory bacteria, as well as oncolytic viruses and other delivery vehicles, are provided herein that encode *STING*, *MDA5* and/or *RIG-I* with gain-of-function mutations. Such immunostimulatory bacteria and other delivery vehicles, increase the production of type I IFNs and pro-

inflammatory cytokines in the tumor microenvironment, potentiating the anti-tumor immune response and improving the therapeutic efficacy of the immunostimulatory bacteria. The gene encoding STING is referred to as *TMEM173*, the gene encoding MDA5 is *IFIH1*, and the gene encoding RIG-I is *DDX58*. There are numerous alleles for each gene, and known mutations that can occur in genes with any of the alleles, resulting in gain-of-function. The mutations listed below can occur singly or can be used in any combination. Other mutations that result in gain-of-function can be identified by routine screening/mutation protocols. The table below lists exemplary gain-of-function mutations in each of STING/TMEM173 (SEQ ID NOs: 305-309), MDA5/IFIH1 (SEQ ID NO: 310) and RIG-I/DDX58 (SEQ ID NO: 311). Other mutations, such as deletion of, or replacement of, a phosphorylation site or sites, such as 324-326 SLS → ALA in STING, and other replacements to eliminate a phosphorylation site to reduce nuclear factor-κB (NF-κB) signaling in STING, or other proteins that employ such signaling, also can be introduced.

The resulting proteins can be encoded in the immunostimulatory bacteria provided herein. The proteins are encoded on plasmids in the immunostimulatory bacteria or, can be encoded on the genome of an oncolytic virus, or delivered via a delivery vehicle, such as an exosome or liposome.

Table of Gain-Of-Function Mutants

Exemplary normal function proteins in which the mutations are introduced	Gain-of-function mutations
STING/TMEM173 (SEQ ID NOs: 305-309)	S102P
	V147L
	V147M
	N154S
	V155M
	G166E
	C206Y
	G207E
	S102P/F279L
	F279L
	R281Q
	R284G
	R284S
	R284M
	R284K
	R284T
	R197A
	D205A
	R310A
	R293A

Exemplary normal function proteins in which the mutations are introduced	Gain-of-function mutations
	T294A
	E296A
	R197A/D205A
	S272A/Q273A
	R310A/E316A
	E316A
	E316N
	E316Q
	S272A
	R293A/T294A/E296A
	D231A
	R232A
	K236A
	Q273A
	S358A/E360A/S366A
	D231A/R232A/K236A/R238A
	S358A
	E360A
	S366A
	R238A
	R375A
	S324A/S326A
MDA5/IFIH1 (SEQ ID NO: 310)	T331I
	T331R
	A489T
	R822Q
	G821S
	A946T
	R337G
	D393V
	G495R
	R720Q
	R779H
	R779C
	L372F
	A452T
RIG-I (SEQ ID NO: 311)	E373A
	C268F

Amino acid residues R197, D205, R310, R293, T294, E296, S272, Q273, R310, E316, D231, R232, K236, S358, E360, S366, and R238, with reference to the sequence of human STING, as set forth in SEQ ID NOs:305-309, correspond to amino acid residues R196, D204, R309, R292, T293, E295, S271, Q272, R309, E315, D230, R231, K235, S357, E359, S365 and

5 R237, respectively, with reference to the sequence of murine STING, as set forth in SEQ ID NO:351.

3. STING-Mediated Immune Activation

STING (stimulator of interferon genes), also known as transmembrane protein 173 (TMEM173), mediator of IRF3 activation (MITA), methionine-proline-tyrosine-

serine (MPYS), and ER IFN stimulator (ERIS), is a 379 amino acid protein that occurs in the endoplasmic reticulum, and that functions as a signaling adaptor protein, controlling the transcription of immune response genes, such as type I IFNs and pro-inflammatory cytokines. Stimulation of the STING pathway activates endothelial cells and induces the up-regulation of interferon-response genes, apoptosis pathway genes, and endothelial cell death in culture and tissue-factor expression, which is a potent initiator of the coagulation cascade (Liu *et al.* (2014) *N. Engl. J. Med.* 371:507-518).

Due to its role in promoting IFN production and inflammation, human STING is an immunotherapeutic target for cancers and infectious diseases. For example, studies have shown that direct activation of STING by its ligand cyclic dinucleotides (CDNs) can induce tumor death. As a result, tumors with increased STING expression can be killed directly by the activation of the STING-mediated cell death pathway. Activation of the STING pathway in dendritic cells (DCs) promotes DC maturation, which initiates CD8⁺ T cell-mediated cytotoxic responses and generates a memory response to prevent cancer relapse. STING also can enhance the therapeutic efficacy of radiotherapy and chemotherapy, due to the released DNA that results from these treatments. In mice, the efficacy of the Pneumovax23® vaccine depends on STING, as the vaccine is ineffective in a mouse model of the human *HAQ* loss-of-function allele. CDNs lose their adjuvant activity in the HAQ mice, demonstrating the role of STING in infection.

STING signaling boosts host immune recognition of tumor antigens and leads to potent antitumor responses. Studies have shown that STING expression and signaling are suppressed in many cancers, including colorectal carcinoma, and this loss of STING signaling hinders DNA damage responses and anti-tumor T cell priming. STING expression also is lost/deregulated in many primary and metastatic melanomas and in Burkett's lymphoma, breast cancer, leukemia, lymphoma, HPV⁺ cancers, HCV- or HBV-related hepatocellular carcinoma, and herpes virus associated cancer. Reconstitution of STING into cancer cells lines, such as 293T and MCF7, which are defective in intracellular DNA signaling, rescues the intracellular pathway, and can induce type I IFN and other signal transduction pathways (see, *e.g.*, U.S. Patent Application Publication No. 2018/0085432). As a result, STING agonists are being developed for cancer immunotherapy. U.S. Patent Application Publication No.

2018/0085432 describes the use of nucleic acid sequences encoding wild-type STING, for the modulation of the immune system to treat diseases, such as those caused by foreign agents, such as infections by bacteria, fungi, parasites and viruses, and also to induce an anti-tumor response. The STING can be administered to patients
5 for treatment of cancer as a polynucleotide, polypeptide, peptide, antisense oligonucleotide, vectors expressing STING, antibodies and the like. Vectors include viral vectors (adenoviruses, adeno-associated viruses, VSV and retroviruses), liposomes, other lipid-containing complexes, and other macromolecular complexes capable of mediating delivery of a polynucleotide to a host cell (U.S. Publication No.
10 2018/0085432). U.S. Publication No. 2018/0311343 describes administration of mRNA encoding a constitutively active human STING polypeptide with mRNA encoding an antigen of interest, such as a tumor, viral or bacterial antigen, in order to lead to an immune response against the antigen.

STING plays an important role in innate immunity as a cytosolic DNA/RNA
15 sensor. STING, by virtue of its interaction with a product from cytosolic dsDNA, “senses” cytosolic dsDNA from infectious pathogens or aberrant host cell damage. Sensing of cytosolic dsDNA through STING requires cyclic GMP-AMP synthase (cGAS), a host cell nucleotidyl transferase that directly binds to dsDNA, and in response, synthesizes a cyclic dinucleotide (CDN) second messenger, cyclic GMP-
20 AMP (cGAMP), which binds to and activates STING (see, *e.g.*, Barber (2011) *Immunol. Rev.* 243(1):99-108; Sun *et al.* (2013) *Science* 339(6121):786-791; and Wu *et al.* (2013) *Science* 339(6121):826-830). STING also is activated by CDNs synthesized by bacteria in the cytosol, including cyclic di-GMP and cyclic di-AMP. STING dimerizes after binding to CDNs and activates TANK binding kinase (TBK1),
25 which then phosphorylates IRF-3 and NF- κ B transcription factors. Activation of the IRF3-, IRF7- and NF- κ B-dependent signaling pathways induces the production of IFN- β and other pro-inflammatory cytokines, such as TNF- α , IL-12p40 and IFN- γ , that strongly activate innate and adaptive immunity (Burdette *et al.* (2011) *Nature* 478(7370):515-518). Aberrant or variant STING, which acts constitutively without
30 binding to CDNs, occurs in subjects with interferonopathies. It thereby can constitutively induce production of type I IFNs. STING is encoded by *TMEM173*.

4. *TMEM173* Alleles

Stimulator of interferon genes (STING) is encoded by the transmembrane protein 173 (*TMEM173*) gene, which is a ~7 kb-long gene. The human *TMEM173* gene is characterized by significant heterogeneity and population stratification of alleles. The most common human *TMEM173* allele is referred to as *R232* (referencing the amino acid present at residue 232; see SEQ ID NOs: 305-309, setting forth the sequences of various human *TMEM173* alleles). More than half the American population is not *R232/R232*. The second most common allele is *R71H-G230A-R293Q* (*HAQ*). Other common alleles include *AQ* (*G230A-R293Q*), *Q293* and *H232*. *HAQ/HAQ* cells were found to express STING protein to an extremely low degree, and had decreased levels of *TMEM173* transcripts in comparison to *R232/R232* cells. *R232/R232* is the most common genotype in Europeans, while *HAQ/R232* is the most common genotype in East Asians. Africans have no *HAQ/HAQ* genotypes, but have the *Q293* allele, and ~4% of Africans are *AQ/AQ*, which is absent in other ethnic populations. *HAQ* and *H232* are likely loss-of-function alleles, and ~30% of East Asians and ~10% of Europeans are *HAQ/HAQ*, *HAQ/H232*, or *H232/H232* (Patel and Jin (2018) *Genes & Immunity*, doi:10.1038/s41435-018-0029-9).

5. Constitutive STING Expression and Gain-of-Function Mutations

Several activating or gain-of-function (GOF) mutations in *TMEM173*, inherited and *de novo*, have been linked to a rare auto-inflammatory disease known as SAVI (STING-associated vasculopathy with onset in infancy). SAVI is an autosomal dominant disease and is characterized by systemic inflammation, interstitial lung disease, cutaneous vasculitis, and recurrent bacterial infection. SAVI with *de novo* *TMEM173* mutations typically is characterized by an early-onset (< 8 weeks) and severe phenotype, while familial mutations result in late-onset (teens to adults) and milder clinical symptoms. Inherited *TMEM173* activating mutations include G166E and V155M, whereas *de novo* mutations include N154S, V155M, V147M, V147L, C206Y, R284G, R281Q and S102P/F279L (Patel and Jin (2018) *Genes & Immunity*, doi:10.1038/s41435-018-0029-9). Other activating *TMEM173* mutations that have been identified include R284M, R284K, R284T and R375A (U.S. Pat. Publication No. 2018/0311343). Another gain-of-function mutation in *TMEM173* is R284S, which results in a highly constitutively active STING and was found to trigger innate

immune signaling in the absence of activating CDNs, leading to chronic production of pro-inflammatory cytokines (Konno *et al.* (2018) *Cell Reports* 23:1112-1123).

TMEM173 mutations, such as N154S, V155M and V147L, and/or any of the mutations listed in the table above, singly or in any combination, result in a gain-of-
5 function STING that is constitutively active and hypersensitive to ligand stimulation, leading to chronic activation of the STING-interferon pathway. This has been demonstrated (Liu *et al.* (2014) *N. Engl. J. Med.* 371:507-518). Constructs of mutated *TMEM173* (with each of the replacements V147L, N154S, V155M and loss-of-
10 function mutant V155R) and non-mutated *TMEM173* were transfected into STING-negative HEK293T cells, and stimulated with the STING ligand, cGAMP. Cells transfected with the N154S, V155M and V147L mutants exhibited highly elevated *IFNB1* (the gene encoding IFN- β) reporter activity, which was not significantly boosted by stimulation with the STING ligand cGAMP. Cells that were transfected with the loss-of-function mutant (V155R), non-mutated *TMEM173*, or control
15 plasmid, had no significant baseline activation. Stimulation with cGAMP resulted in a response in a dose-dependent manner in cells with non-mutated *TMEM173*, and resulted in a minimal response only at the highest cGAMP concentration, in cells expressing the loss-of-function mutant (Liu *et al.* (2014) *N. Engl. J. Med.* 371:507-518). These results show that the activating *TMEM173* mutations result in constitutive
20 activation of STING, even in the absence of stimulation by cGAMP.

G207E is another gain-of-function STING mutation that causes alopecia, photosensitivity, thyroid dysfunction, and SAVI-features. The G207E mutation causes constitutive activation of inflammation-related pathways in HEK cells, as well as aberrant interferon signature and inflammasome activation in patient peripheral blood
25 mononuclear cells (PBMCs). Using STING variants with the R232 or H232 allele and the GOF mutation G207E, it was shown that after stimulation with CDN, the R232 + G207E variant resulted in slight increases of activity in the IFN- β and STAT1/2 pathways, while with the H232 + G207E variant, IFN- β levels remained constant, and STAT1/2 showed diminished activity. Both variants showed similar STAT3 and NF- κ B pathway activation following stimulation. These results show that R at position
30 232 is important for cGAMP binding and IFN induction, and show that G207E mutants result in constitutive activation of STING signaling pathways and ligand-

dependent hyperactivation of the NF- κ B pathway. Patients with the R232 allele and G207E had more severe disease; this polymorphism strengthens the constitutive activation of the mutant STING, leading to the overexpression of downstream targets such as IFN, IL1- β and IL-18 (see, *e.g.*, Keskitalo *et al.* (2018) available from:

5 doi.org/10.1101/394353).

67 amino acids in murine STING (see, *e.g.*, SEQ ID NO:351) were mutated (Burdette *et al.* (2011) *Nature* 478(7370):515-518) either individually or in groups, to identify amino acids involved in cyclic di-GMP (c-di-GMP) binding and/or IFN induction. Among the mutants identified were hyperactive mutants R196A/D204A,
10 S271A/Q272A, R309A/E315A, E315A, E315N, E315Q and S271A (corresponding to R197A/D205A, S272A/Q273A, R310A/E316A, E316A, E316N, E316Q and S272A, respectively, with reference to the sequence of human STING as set forth in SEQ ID NOs:305-309), that spontaneously induced IFN at low levels of transfection and did not respond to c-di-GMP, and the mutants R374A, R292A/T293A/E295A/E299A,
15 D230A, R231A, K235A, Q272A, S357A/E359A/S365A, D230A/R231A/K235A/R237A and R237A (corresponding to R375A, R293A/T294A/E296A (there is no equivalent to E299A in human STING), D231A, R232A, K236A, Q273A, S258A/E360A/S366A, D231A/R232A/K236A/R238A and R238A, respectively, with reference to human STING, as set forth in SEQ ID
20 NOs:305-309), that induced IFN when overexpressed but did not respond to c-di-GMP.

Administering nucleic acids encoding wild-type STING can induce an immune response; the administration of gain-of-function STING mutants, with constitutive activity as provided herein, in tumor-targeted delivery vehicles, leads to a
25 more potent immune response and more effective anti-cancer therapeutic. The enhanced immune response by the tumor-targeted administration of constitutively active STING or other such modified DNA/RNA sensors, such as gain-of-function mutants of MDA5 or RIG-I, as provided herein, provides a therapeutically more effective anti-cancer treatment. For example, as described herein, modifying the
30 immunostimulatory bacteria so that they do not infect epithelial cells, but retain the ability to infect phagocytic cells, including tumor-resident immune cells, effectively targets the immunostimulatory bacteria to the tumor microenvironment, improving

therapeutic efficiency and preventing undesirable systemic immune responses. These tumor-targeted bacteria are engineered to encode gain-of-function STING, MDA5 or RIG-I mutants, which are constitutively active, for example, even in the absence of ligand stimulation, providing a potent type I IFN response to improve the anti-cancer immune response in the tumor microenvironment.

Thus, for example, the administration of constitutively activated STING can provide an alternative means to boost STING signaling for the immunotherapeutic treatment of cancer. In certain embodiments, the tumor-targeting immunostimulatory bacteria provided herein, and also oncolytic viruses, can be modified to encode STING/TMEM731 (SEQ ID NOs: 305-309) with gain-of-function mutations selected from S102P, V147L, V147M, N154S, V155M, G166E, R197A, D205A, R197A/D205A, C206Y, G207E, D231A, R232A, K236A, R238A, D231A/R232A/K236A/R238A, S272A, Q273A, S272A/Q273A, F279L, S102P/F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R293A, T294A, E296A, R293A/T294A/E296A, R310A, E316A, E316N, E316Q, R310A/E316A, S324A/S326A, S358A, E360A, S366A, S358A/E360A/S366A, and R375A.

6. Non-human STING Proteins, and Variants Thereof with Increased or Constitutive Activity, and STING Chimeras, and Variants Thereof with Increased or Constitutive activity

As discussed above, cytosolic double-stranded DNA (dsDNA) stimulates the production of type I interferon (IFN) through the endoplasmic reticulum (ER)-resident adaptor protein STING (stimulator of IFN genes), which activates the transcription factor interferon regulatory factor 3 (IRF3). The TANK binding kinase (TBK1)/IRF3 axis results in the induction of type I IFNs, and the activation of dendritic cells (DCs) and cross-presentation of tumor antigens to activate CD8⁺ T cell-mediated anti-tumor immunity. STING signaling also activates the nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) signaling axis, resulting in a pro-inflammatory response, but not in the activation of the DCs and CD8⁺ T cells that are required for anti-tumor immunity.

Upon recognition of 2'3' cGAMP, STING translocates from the endoplasmic reticulum through the Golgi apparatus, allowing the recruitment of TANK-binding kinase 1 (TBK1) and activation of the transcription factors IRF3 and NF-κB. The carboxyl-terminal tail (C-terminal tail or CTT) region of STING is necessary and

sufficient to activate TBK1 and stimulate the phosphorylation of IRF3; it also is involved in NF- κ B signaling. The CTT is an unstructured stretch of approximately 40 amino acids that contains sequence motifs required for STING phosphorylation and recruitment of IRF3. IRF3 and NF- κ B downstream signaling is attributed to the
5 specific sequence motifs within the C-terminal tail (CTT) of STING that are conserved among vertebrate species. Modular motifs in the CTT, which include IRF3, TBK1 and TRAF6 binding modules, control the strength and specificity of cell signaling and immune responses.

Depending on the species and the respective characteristics of their STING
10 CTT discrete elements, the IRF-3 and NF- κ B downstream responses can be affected and sometimes opposite. The STING CTT elements dictate and finely tune the balance between the two signaling pathways, resulting in different biological responses. In human and mouse immune cells, for example, STING-dependent IRF-3 activation results predominantly in a type I interferon response. STING signaling in
15 human cells also drives a pro-inflammatory response through canonical and possibly non-canonical NF- κ B pathways via TRAF6 recruitment. Human STING residue S366 (see, *e.g.*, SEQ ID NOs:305-309) is a primary TBK1 phosphorylation site that is part of an LxIS motif in the CTT, which is required for IRF3 binding, while a second PxPLR motif, including residue L374, is required for TBK1 binding. The LxIS and
20 PxPLR motifs are highly conserved in all vertebrate STING alleles. In other species, STING signaling results predominantly in the activation of the NF- κ B signaling axis. For example, the zebrafish CTT, which is responsible for hyperactivation of NF- κ B signaling, contains an extension with a highly conserved PxExxD motif at the extreme C-terminus that is not present in human and mammalian STING alleles; this motif
25 shares similarity with tumor necrosis factor receptor-associated factor 6 (TRAF6) binding sites. While the role of TRAF6 in human STING signaling is non-essential, TRAF6 recruitment is essential for zebrafish STING-induced NF- κ B activation. A human-zebrafish STING chimera, in which human STING was engineered to contain the zebrafish STING CTT module DPVETTDY, induced more than 100-fold
30 activation of NF- κ B activation, indicating that this region is necessary and sufficient to direct enhanced NF- κ B signal activation. The addition of the zebrafish CTT also

resulted in an increased STING interferon response (see, de Oliveira Mann *et al.* (2019) *Cell Reports* 27:1165-1175).

The differences among species in the balance between IRF3 and NF- κ B signaling is exploited herein to produce modified STING proteins that have reduced
5 NF- κ B signaling, and/or optionally, increased IRF3 signaling, so that when the STING protein is delivered to and expressed in the TME, the resulting response is an increased anti-tumor/anti-viral response, compared to the unmodified STING protein.

In some embodiments, STING proteins from species that have low or no NF- κ B signaling activity are provided in delivery vehicles, including any of the
10 immunostimulatory bacteria described herein or known to those of skill in the art, as well as in other delivery vehicles, such as viral vectors, including oncolytic vectors, minicells, exosomes, liposomes, and in cells, such as T-cells used in cell therapy and used to deliver vehicles, such as bacteria and oncolytic vectors.

The non-human STING proteins can be, but are not limited to, STING
15 proteins from the following species: Tasmanian devil (*Sarcophilus harrisi*; SEQ ID NO:331), marmoset (*Callithrix jacchus*; SEQ ID NO:341), cattle (*Bos taurus*; SEQ ID NO:342), cat (*Felis catus*; SEQ ID NO:338), ostrich (*Struthio camelus australis*; SEQ ID NO:343), crested ibis (*Nipponia nippon*; SEQ ID NO:344), coelacanth (*Latimeria chalumnae*; SEQ ID NOs:345-346), boar (*Sus scrofa*; SEQ ID NO:347), bat
20 (*Rousettus aegyptiacus*; SEQ ID NO:348), manatee (*Trichechus manatus latirostris*; SEQ ID NO:349), ghost shark (*Callorhynchus milii*; SEQ ID NO:350), and mouse (*Mus musculus*; SEQ ID NO:351). These vertebrate STING proteins readily activate immune signaling in human cells, indicating that the molecular mechanism of STING signaling is shared amongst vertebrates (see, de Oliveira Mann *et al.* (2019) *Cell*
25 *Reports* 27:1165-1175).

In other embodiments, the non-human STING proteins contain any of the constitutive STING expression and gain-of-function mutations in corresponding loci in the non-human STING (see, Figures 1-13, which provide exemplary alignments, and Example 28, which provides corresponding mutations in various species) to those
30 in human STING, described in section 5 above.

In other embodiments, chimeras of STING proteins are provided. In the chimeras, the CTT region, or portion thereof that confers or participates in NF- κ B

signaling/activity, of a first species STING protein is replaced with the corresponding CTT or portion(s) thereof from a second species, whose STING protein has lower or very little, less than human, NF- κ B signaling activity. The CTT from the second species also, or alternatively, has increased type I IFN signaling. Generally, the first
5 species is human, and the CTT or portion(s) thereof is from the STING of a species such as Tasmanian devil, marmoset, cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, and ghost shark, which have much lower NF- κ B activity. This thereby results in a STING protein that induces type I interferon, which is important for anti-tumor activity, and that has limited or no NF- κ B activity, which is not
10 desirable in an anti-tumor therapy. The chimeras can further include the constitutive STING expression and gain-of-function mutations in corresponding loci to increase or render type I interferon activity constitutive. In all embodiments, the TRAF6 binding motif can be deleted to further decrease or eliminate activity that is not desirable in an anti-tumor therapeutic.

15 These non-human STING proteins, chimeras, and mutants are provided in delivery vehicles, such as any described herein or known to those of skill in the art, including oncolytic viral vectors, cells, such as stem cells and T-cells used in cell therapies, exosomes, minicells, liposomes, and the immunostimulatory bacteria provided herein, which accumulate in tumor-resident immune cells, and deliver
20 encoded proteins to the tumor microenvironment and tumors. The non-human STING proteins, modified STING proteins and chimeras are for use as therapeutics for the treatment of tumors as described herein or in other methods known to those of skill in the art. Pharmaceutical compositions containing the STING proteins, delivery vehicles, and encoding nucleic acids also are provided.

25 **7. Other Gene Products that Act as Cytosolic DNA/RNA Sensors and Constitutive Variants**

a. Retinoic Acid-Inducible Gene I (RIG-I)-Like Receptors (RLRs)

Other gene products that sense or interact with cytosolic nucleic acids are the
30 retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), which include RIG-I and MDA5 (melanoma differentiation-associated protein 5). RLRs are cytoplasmic sensors of viral dsRNA and nucleic acids secreted by bacteria, and include RIG-I,

MDA5 and LGP2 (laboratory of genetics and physiology 2). Upon the binding of a ligand, such as a viral dsRNA, RIG-I and MDA5 activate the mitochondrial antiviral-signaling adaptor protein, or MAVS, which recruits tumor necrosis factor (TNF) receptor-associated factors (TRAFs), to assemble a signaling complex at the outer
5 membranes of the mitochondria. Downstream signaling components further are recruited by TRAFs, resulting in the phosphorylation and activation of IRF-3 (interferon regulatory factor 3), IRF-7, NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells), and AP-1 (activator protein 1). As a result, the expression of IFNs, proinflammatory cytokines and other genes involved in pathogen
10 clearance, is induced (see, *e.g.*, Lu and MacDougall (2017) *Front. Genet.* 8:118).

Like STING, the constitutive activation of MDA5 and RIG-I due to gain-of-function mutations leads to the induction of type I IFNs, which can be leveraged to enhance the anti-tumor immune response in immunostimulatory bacteria and oncolytic viruses.

15 **b. MDA5/IFIH1**

Another interferonopathy gene is the IFN-induced with helicase C domain-containing protein 1 (IFIH1), also known as melanoma differentiation-associated protein 5 (MDA5), which is a member of the RIG-I-like family of cytoplasmic DExD/H box RNA receptors. MDA5, encoded by *IFIH1*, is a 1025 amino acid
20 cytoplasmic pattern-recognition receptor that senses viral double-stranded RNA (dsRNA) and secreted bacterial nucleic acids in the cytoplasm, and activates type I IFN signaling through an adaptor molecule, MAVS (mitochondrial antiviral signaling protein). MAVS recruits tumor necrosis factor (TNF) receptor-associated factors (TRAFs), which in turn recruit downstream signaling components, resulting in the
25 phosphorylation and activation of IRF-3 (interferon regulatory factor 3), IRF-7, NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells), and AP-1 (activator protein 1). This results in the expression of IFNs, proinflammatory cytokines and other genes involved in pathogen clearance (Rutsch *et al.* (2015) *Am. J. Hum. Genet.* 96:275-282; Rice *et al.* (2014) *Nat. Genet.* 46(5):503-509; Lu and
30 MacDougall (2017) *Front. Genet.* 8:118).

Gain-of-function (GOF) *IFIH1* variants occur in subjects with autoimmune disorders, including Aicardi-Goutières syndrome (AGS) and Singleton-Merten

syndrome (SMS), which are characterized by prominent vascular inflammation. AGS is an inflammatory disease particularly affecting the brain and skin, and is characterized by an upregulation of interferon-induced transcripts. AGS typically occurs due to mutations in any of the genes encoding DNA exonuclease TREX1, the
5 three non-allelic components of the RNase H2 endonuclease complex, the deoxynucleoside triphosphate triphosphohydrolase SAMHD1, and the double-stranded RNA editing enzyme ADAR1. Some patients with AGS do not have mutations in any of these six genes, but have GOF mutations in *IFIH1*, indicating that this gene also is implicated in AGS. Singleton-Merten syndrome (SMS) is an
10 autosomal-dominant disorder characterized by abnormalities in the blood vessels (*e.g.*, calcification), teeth (*e.g.*, early-onset periodontitis, root resorption) and bones (*e.g.*, osteopenia, acro-osteolysis, osteoporosis). Interferon signature genes are upregulated in SMS patients, which was linked to GOF mutations in *IFIH1* (Rice *et al.* (2014) *Nat. Genet.* 46(5):503-509; Rutsch *et al.* (2015) *Am. J. Hum. Genet.* 96:275-282).

The IFN- β reporter stimulatory activity of wild-type *IFIH1* and six *IFIH1* GOF mutants identified in AGS patients (R720Q, R779H, R337G, R779C, G495R, D393V) was compared in HEK293T cells, which express low levels of endogenous viral RNA receptors. Wild-type *IFIH1* was induced upon binding of the long (> 1 kb)
20 dsRNA analog polyinosinic-polycytidylic acid (polyI:C), but not by a short 162 bp dsRNA, and had minimal activity in the absence of exogenous RNA. The *IFIH1* mutants displayed a significant induction of IFN signaling in response to the short 162 bp dsRNA, in addition to robust signaling in response to polyI:C. The mutants also displayed a 4-10 fold higher level of baseline signaling activity in the absence of
25 exogenous ligand (Rice *et al.* (2014) *Nat. Genet.* 46(5):503-509).

Another gain-of-function *IFIH1* mutation, R822Q, was identified as causing SMS by triggering type I IFN production, and leading to early arterial calcification, as well as dental inflammation and resorption. HEK293T cells (which have the lowest endogenous *IFIH1* expression levels) were used to overexpress wild-type and R822Q
30 MDA5. Wild-type *IFIH1* expression led to an increase in the expression of *IFNB1* (interferon, beta 1, fibroblast) in a dose-dependent manner, whereas the mutated *IFIH1* led to approximately 20-fold more *IFNB1* expression. Following stimulation

with the dsRNA analog poly(I:C), R822Q *IFIH1* resulted in higher levels of *IFNB1* expression than wild-type *IFIH1*, indicating that R822Q *IFIH1* is hyperactive to non-self dsRNA. There was also higher expression of interferon signature genes, such as *IFI27*, *IFI44L*, *IFIT1*, *ISG15*, *RSG15*, *RSAD2* and *SIGLEC1* in whole-blood samples
5 from SMS patients, which was in agreement with the higher expression level of *IFNB1* by R822Q *IFIH1* (Rutsch *et al.* (2015) *Am. J. Hum. Genet.* 96:275-282).

The interferon signature observed in patients with another *IFIH1* GOF mutation, A489T, is indicative of a type I interferonopathy; *IFIH1* A489T is associated with increased interferon production and phenotypes resembling chilblain
10 lupus, AGS and SMS (Bursztejn *et al.* (2015) *Br. J. Dermatol.* 173(6):1505-1513). The A489T variant not only resulted in IFN induction following stimulation with the long dsRNA analog poly(I:C), but also with short dsRNA. Two additional gain-of-function mutations in *IFIH1*, T331I and T331R, were identified in patients with SMS phenotypes, who presented with a significant upregulation of IFN-induced transcripts.
15 The T331I and T331R variants resulted in increased expression of IFN- β , even in the absence of exogenous dsRNA ligand, consistent with the observed constitutive activation of MDA5 (Lu and MacDougall (2017) *Front. Genet.* 8:118).

A946T is another *IFIH1* GOF mutation that leads to the increased production of type I IFN, promoting inflammation and increasing the risk of autoimmunity. The
20 A946T mutation in *IFIH1* results in additive effects when combined with the *TMEM173* R232 allele and G207E GOF mutation, leading to a severe early-onset phenotype with features similar to SAVI (Keskitalo *et al.* (2018) preprint, available from doi.org/10.1101/394353). G821S is a GOF mutation in *IFIH1* which has been shown to lead to spontaneously developed lupus-like autoimmune symptoms in a
25 mouse model (Rutsch *et al.* (2015) *Am. J. Hum. Genet.* 96:275-282), while the *IFIH1* missense mutations A452T, R779H and L372F, identified in individuals with AGS, were shown to cause type I interferon overproduction (Oda *et al.* (2014) *Am. J. Hum. Genet.* 95:121-125).

The tumor-targeting immunostimulatory bacteria provided herein, and also
30 oncolytic viruses, can be modified to encode MDA5/IFIH1 (SEQ ID NO: 310) with gain-of-function mutations selected from T331I, T331R, R337G, L372F, D393V,

A452T, A489T, G495R, R720Q, R779H, R779C, G821S, R822Q and A946T, singly or in any combination.

c. RIG-I

Retinoic acid-inducible gene I (RIG-I), also known as DDX58 (DEXD/H-box
5 helicase 58) is another protein whose constitutive activation has been linked to the
development interferonopathies, such as atypical SMS. RIG-I, like MDA5/IFIH1, is a
member of the RIG-I-like receptor (RLR) family, and is a 925-residue cytosolic
pattern recognition receptor that functions in the detection of viral dsRNA. RIG-I
initiates an innate immune response to viral RNA through independent pathways that
10 promote the expression of type I and type III IFNs and proinflammatory cytokines
(Jang *et al.* (2015) *Am. J. Hum. Genet.* 96:266-274; Lu and MacDougall (2017) *Front.*
Genet. 8:118).

Atypical SMS, without hallmark dental anomalies, but with variable
phenotypes, including glaucoma, aortic calcification and skeletal abnormalities, has
15 been found to be caused by mutations in the DEXD/H-box helicase 58 gene (*DDX58*),
which encodes retinoic acid-inducible gene I (RIG-I). In particular, the mutations
E373A and C268F in *DDX58* were identified as causing gain-of-function in RIG-I.
Elevated amounts of mutated DDX58 were associated with a significant increase in
the basal levels of NF- κ B reporter gene activity, and this activity was further
20 increased by stimulation with the dsRNA analog poly(I:C). The RIG-I mutations also
induced IRF-3 phosphorylation and dimerization at the basal level, and led to
increased expression of *IFNB1*, *interferon-stimulated gene 15 (ISG15)*, and
chemokine (C-C motif) ligand 5 (CCL5) in both basal, and poly(I:C) transfected
HEK293FT cells. These results indicate that the mutated DDX58/RIG-I results in
25 constitutive activation, leading to increased IFN activity and IFN-stimulated gene
expression (Jang *et al.* (2015) *Am. J. Hum. Genet.* 96:266-274; Lu and MacDougall
(2017) *Front. Genet.* 8:118).

Tumor-targeting immunostimulatory bacteria, and oncolytic viruses, provided
herein can be modified to encode RIG-I/DDX58 (SEQ ID NO: 311) with gain-of-
30 function mutations such as, but not limited to, E373A and C268F, singly or in
combination.

d. IRF-3 and IRF-7

Pathogen-associated molecular patterns (PAMPs) are recognized by host pattern recognition receptors (PRRs), such as the RIG-I-like receptors, RIG-I and MDA5, resulting in downstream signaling through the transcription factors IRF-3, IRF-7 and NF- κ B, which leads to the production of type I IFNs.

5 IRF-3 (interferon regulatory factor 3) and IRF-7 are key activators of type I IFN genes. Following virus-induced C-terminal phosphorylation (by TBK1), activated IRF-3 and IRF-7 form homodimers, translocate from the cytoplasm to the nucleus, and bind to IFN-stimulated response elements (ISREs) to induce type I IFN responses. IRF-3 is expressed constitutively in unstimulated cells, and exists as an
10 inactive cytoplasmic form, while IRF-7 is not constitutively expressed in cells, and is induced by IFN, lipopolysaccharide and virus infection. Overexpression of IRF-3 significantly increases the virus-mediated expression of type I IFN genes, resulting in the induction of an antiviral state. IRF-3 activation also has been shown to up-regulate the transcription of the CC-chemokine RANTES (CCL5) following viral infection
15 (Lin *et al.* (1999) *Mol. Cell Biol.* 19(4):2465-2474).

Residues S385, S386, S396, S398, S402, T404 and S405 in the C-terminal domain of IRF-3 are phosphorylated after virus infection, inducing a conformational change that results in the activation of IRF-3. IRF-3 activation is induced, not only by viral infection, but also by lipopolysaccharide (LPS) and poly(I:C). Of the seven resi-
20 dues that can be phosphorylated in the C-terminal cluster of IRF-3, a single point mutation, S396D, is sufficient for the generation of a constitutively active form of IRF-3. IRF-3(S396D) enhances the transactivation of IFN α 1, IFN- β and RANTES promoters by 13-, 14- and 11-fold, respectively, compared to wild-type IRF-3. Another mutant, IRF-3(S396D/S398D) enhances the transactivation of IFN α 1, IFN- β and RANTES
25 promoters by 13-, 12- and 12-fold, respectively, over wild-type IRF-3. Another constitutively active mutant of IRF3 is IRF-3(5D), in which the serine or threonine residues at positions 396, 398, 402, 404 and 405 are replaced by phosphomimetic aspartic acid residues (IRF-3(S396D/S398D/S402D/T404D/S405D)). Similar gain-of-function mutations, leading to constitutive activity of immune response mediators, such as
30 induction of type I interferon, can be achieved by mutating serine residues to phosphomimetic aspartic acid in other proteins, such as RIG-I, MDA5 and STING, that are in immune response signaling pathways.

IRF-3(5D) displays constitutive DNA binding and transactivation activities, dimer formation, association with the transcription coactivators p300 (also called EP300 or E1A binding protein p300)/ CBP (also known as CREB-binding protein or CREBBP), and nuclear localization. Its transactivation activity is not induced further
5 by virus infection. IRF-3(5D) is a very strong activator of IFN- β and ISG-15 gene expression; IRF-3(5D) alone stimulates IFN- β expression as strongly as virus infection, and enhances transactivation of IFN α 1, IFN- β and RANTES promoters by 9-fold, 5.5-fold and 8-fold, respectively, over wild-type IRF-3 (see, *e.g.*, Lin *et al.* (2000) *J. Biol. Chem.* 275(44):34320-34327; Lin *et al.* (1998) *Mol. Cell Biol.* 18(5):2986-2996; Servant *et al.* (2003) *J. Biol. Chem.* 278(11):9441-9447). Any of positions S385, S386, S396, S398, S402, T404 and S405 can be mutated, alone or in combination, to produce constitutively active IRF-3 mutants in the immunostimulatory bacteria, oncolytic viruses and other delivery agents, such as exosomes, provided herein.

15 Constitutively active forms of IRF-7 include mutants in which different C-terminal serines are substituted by phosphomimetic Asp, including IRF-7(S477D/S479D), IRF-7(S475D/S477D/S479D), and IRF-7(S475D/S476D/S477D/S479D/S483D/S487D). IRF-7(S477D/S479D) is a strong transactivator for IFNA and RANTES gene expression, and stimulates gene
20 expression, even in the absence of virus infection. IRF-7(S475D/S477D/S479D), and IRF-7(S475D/S476D/S477D/S479D/S483D/S487D) do not further augment the transactivation activity of IRF-7(S477D/S479D), but the transactivation activity of all 3 mutants is stimulated further by virus infection. The mutant IRF-7(Δ 247-467), which localizes to the nucleus in uninfected cells, is a very strong constitutive form of
25 IRF-7; it activates transcription more than 1500-fold higher than wild-type IRF-7 in unstimulated and virus infected cells (Lin *et al.* (2000) *J. Biol. Chem.* 275(44):34320-34327). The immunostimulatory bacteria, viruses and other delivery agents, such as exosomes, provided herein, can encode and express constitutively active IRF-7 mutants, including those with replacements at residues 475-477, 479, 483 and 487,
30 and those with amino acid deletions. The immunostimulatory bacteria encode these proteins on plasmids under the control of promoters and, any other desired regulatory signals, recognized by mammalian hosts, including humans.

8. Other Type I IFN Regulatory Proteins

Other proteins involved in the recognition of DNA/RNA that activate type I IFN responses can be mutated to generate constitutive type I IFN expression. The unmodified and/or modified proteins can be encoded in the immunostimulatory

- 5 bacteria, oncolytic viruses, and other delivery vehicles, such as exosomes and liposomes, provided herein, to be used to deliver the protein to the tumor microenvironment, such as to tumor-resident immune cells, to increase expression of type I IFN.

These proteins include, but are not limited to, proteins designated as TRIM56,
 10 RIP1, Sec5, TRAF2, TRAF3, TRAF6, STAT1, LGP2, DDX3, DHX9, DDX1, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200.

Gene	Encoded Protein	Activity/Function
TRIM56	Tripartite motif-containing protein 56/ E3 ubiquitin-protein ligase TRIM56	Promotes dimerization of STING in response to dsDNA stimulation, resulting in production of IFN- β ; potentiates extracellular dsRNA-induced expression of IFNB1 and IFN-stimulated genes ISG15, IFIT1/ISG56, CXCL10, OASL and CCL5; positive regulator of TL3 signaling
RIP1/RIPK1	Receptor-interacting serine/threonine protein (kinase) 1	Transduces inflammatory and cell-death signals (programmed necrosis) following death receptor ligation, activation of pathogen recognition receptors and DNA damage; indirectly activates NF- κ B; directs LPS-induced IFN- β synthesis in mice
Sec5 (EXOC2)	Exocyst complex component 2	Component of exocyst complex, involved in docking of exocytic vesicles with fusion sites on plasma membrane; co-localizes with STING and TBK1 after intracellular DNA stimulation, inducing type I IFN production
TRAF2	TNF receptor-associated factor 2	Regulates activation of NF- κ B and JNK/MAPK8; mediates type I IFN induction
TRAF3	TNF receptor-associated factor 3	Regulates activation of NF- κ B and MAP kinases; mediates activation of IRF-3; mediates type I IFN induction; mediates cytokine production
TRAF6	TNF receptor-associated factor 6	Activates NF- κ B, JUN and AP-1; induces type I IFN production in response to viral infection and intracellular dsRNA; induces production of proinflammatory cytokines
STAT1	Signal transducer and activator of transcription 1	Forms part of ISGF3 transcription factor, which binds IFN stimulated response elements (ISREs) to activate transcription of IFN-stimulated genes (ISGs)
LGP2 (DHX58)	Laboratory of genetics and physiology 2 / Probable ATP-dependent RNA helicase DHX58	Regulates RIG-I/DDX58 and IFIH1/MDA5 mediated antiviral signaling
DDX3 (DDX3X)	ATP-dependent RNA helicase DDX3X	Promotes production of type I IFN; acts as viral RNA sensor; involved in TBK1 and IKK ϵ -dependent IRF-3 activation, leading to induction of IFNB; associates with IFNB promoters; associates with MAVS and RIG-

Gene	Encoded Protein	Activity/Function
		I to induce signaling in early stages of infection; binds MDA5 to enhance its recognition of dsRNA
DHX9/DDX9	DExH/H-box helicase 9 / ATP-dependent RNA helicase A	Senses viral nucleic acids; triggers host responses to non-self DNA in MyD88-dependent manner; interacts with MAVS to stimulate NF- κ B-mediated innate immunity against virus infection and activate IRF-3 and MAPK pathways; potentiates virus-triggered induction of IL-6 and IFN- β
DDX1	ATP-dependent RNA helicase DDX1	Component of a multi-helicase-TRIF complex that senses viral double-stranded RNA (dsRNA), activates the NF- κ B signaling pathway, and induces production of type I IFN and proinflammatory cytokines
DDX21	Nucleolar RNA helicase 2	Component of a multi-helicase-TRIF complex that senses viral double-stranded RNA (dsRNA), activates the NF- κ B signaling pathway, and induces production of type I IFN and proinflammatory cytokines
DHX15 (DDX15)	Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15	Viral RNA sensor that interacts with MAVS to induce type I IFN and proinflammatory cytokine production; activates IRF-3, NF- κ B and MAPK signaling
DHX33 (DDX33)	ATP-dependent RNA helicase DHX33	Viral dsRNA sensor that interacts with MAVS and triggers type I IFN response; activates NF- κ B, IRF-3 and MAPK signaling pathways; activates NLRP3 inflammasome, resulting in secretion of proinflammatory cytokines
DHX36 (DDX36)	ATP-dependent DNA/RNA helicase DHX36	Component of a multi-helicase-TRIF complex that senses viral double-stranded RNA (dsRNA), activates the NF- κ B signaling pathway, and induces production of type I IFN and proinflammatory cytokines
DDX60	Probable ATP-dependent RNA helicase DDX60	Senses viral RNA and DNA; forms complex with RIG-I like receptors to promote antiviral activity; positively regulates RIG-I and MDA5-dependent type I IFN and IFN-inducible gene expression in response to viral infection; binds ssRNA, dsRNA and dsDNA; promotes binding of RIG-I to dsRNA
SNRNP200	U5 small nuclear ribonucleoprotein 200 kDa helicase	Senses/binds viral RNA and interacts with TBK1 to promote IRF-3 activation and type I IFN production

Site-directed mutagenesis can be performed *in vitro* to identify mutations with enhanced activity, that lead to higher level and/or constitutive type I IFN expression. Intact genomic DNA can be obtained from non-related patients experiencing autoimmune and auto-inflammatory symptoms, and from healthy individuals, to screen for and identify other products whose expression leads to increased or constitutive type I IFN expression. Whole exome sequencing can be performed, and introns and exons can be analyzed, such that proteins with mutations in the pathways associated with the increased or constitutive expression of type I interferon are identified. After identification of mutations, cDNA molecules encoding the full-length gene, with and without the identified mutation(s), are transfected into a reporter cell line that

measures expression of type I interferon. For example, a reporter cell line can be generated where the expression of luciferase is placed under the promoter for IFN- β . A gain-of-function mutant that is constitutively active will promote the expression of IFN- β , whereas the unstimulated wild-type protein will not. Stimulation can be by virus infection, bacterial infection, bacterial nucleic acids, LPS, dsRNA, poly(I:C), or by increasing exogenous levels of the protein's ligand (*e.g.*, CDNs). Identified proteins also include those that enhance an immune response to an antigen(s) of interest in a subject. The immune response comprises a cellular or humoral immune response characterized by one or more of: (i) stimulating type I interferon pathway signaling; (ii) stimulating NF- κ B pathway signaling; (iii) stimulating an inflammatory response; (iv) stimulating cytokine production; (v) stimulating dendritic cell development, activity or mobilization; (vi) any other responses indicative of a product whose expression enhances an immune response; and (vii) a combination of any of (i)-(vi).

9. Other Therapeutic Products

Immunostimulatory Proteins

The immunostimulatory bacteria also can encode immunostimulatory proteins, such as cytokines, including chemokines, that enhance or stimulate or evoke an anti-tumor immune response, particularly when expressed in tumors, in the tumor microenvironment and/or in tumor-resident immune cells. The immunostimulatory bacteria herein can be modified to encode an immunostimulatory protein that promotes or induces or enhances an anti-tumor response. The immunostimulatory protein can be encoded on a plasmid in the bacterium, under the control of a eukaryotic promoter, such as a promoter recognized by RNA polymerase II, for expression in a eukaryotic subject, particularly the subject for whom the immunostimulatory bacterium is to be administered, such as a human. The nucleic acid encoding the immunostimulatory protein can include, in addition to the eukaryotic promoter, other regulatory signals for expression or trafficking in the cells, such as for secretion or expression on the surface of a cell.

The immunostimulatory bacteria herein can be modified to encode an immunostimulatory protein that promotes or induces or enhances an anti-tumor response. The immunostimulatory protein can be encoded on a plasmid in the

bacterium, under the control of a eukaryotic promoter, such as a promoter recognized by RNA polymerase II, for expression in a eukaryotic subject, particularly the subject for whom the immunostimulatory bacterium is to be administered, such as a human. The nucleic acid encoding the immunostimulatory protein can include, in addition to
5 the eukaryotic promoter, other regulatory signals for expression or trafficking in the cells, such as for secretion or expression on the surface of a cell.

Immunostimulatory proteins are those that, in the appropriate environment, such as a tumor microenvironment (TME), can promote or participate in or enhance an anti-tumor response by the subject to whom the immunostimulatory bacterium is
10 administered. Immunostimulatory proteins include, but are not limited to, cytokines, chemokines and co-stimulatory molecules. These include cytokines, such as, but not limited to, IL-2, IL-7, IL-12, IL-15, and IL-18; chemokines, such as, but not limited to, CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11; and/or co-stimulatory molecules, such as, but not limited to, CD40, CD40L, OX40, OX40L, 4-1BB, 4-
15 1BBL, members of the TNF/TNFR superfamily and members of the B7-CD28 family. Other such immunostimulatory proteins that are used for treatment of tumors or that can promote, enhance or otherwise increase or evoke an anti-tumor response, known to those of skill in the art, are contemplated for encoding in the immunostimulatory bacteria provided herein.

20 In some embodiments, the immunostimulatory bacteria herein are engineered to express cytokines to stimulate the immune system, including, but not limited to, IL-2, IL-7, IL-12 (IL-12p70 (IL12p40 + IL-12p35)), IL-15 (and the IL-15:IL-15R alpha chain complex), and IL-18. Cytokines stimulate immune effector cells and stromal cells at the tumor site, and enhance tumor cell recognition by cytotoxic cells. In some
25 embodiments, the immunostimulatory bacteria can be engineered to express chemokines, such as, for example, CCL3, CCL4, CCL5, CXCL9, CXCL10 and CXCL11. These modifications and bacteria encoding them are discussed above, and exemplified below.

Immunostimulatory Bacteria Encoding Cytokines and

30 Chemokines

In some embodiments, the immunostimulatory bacteria herein are engineered to express cytokines to stimulate the immune system, including, but not limited to, IL-

2, IL-7, IL-12 (IL-12p70 (IL12p40 + IL-12p35)), IL-15 (and the IL-15:IL-15R alpha chain complex), and IL-18. Cytokines stimulate immune effector cells and stromal cells at the tumor site, and enhance tumor cell recognition by cytotoxic cells. In some embodiments, the immunostimulatory bacteria can be engineered to express
5 chemokines, such as, for example, CCL3, CCL4, CCL5, CXCL9, CXCL10 and CXCL11.

Immunostimulatory proteins are those that, in the appropriate environment, such as a tumor microenvironment (TME), can promote or participate in or enhance an anti-tumor response by the subject to whom the immunostimulatory bacterium is
10 administered. Immunostimulatory proteins include, but are not limited to, cytokines, chemokines and co-stimulatory molecules. These include cytokines, such as, but not limited to, IL-2, IL-7, IL-12, IL-15, and IL-18; chemokines, such as, but not limited to, CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11; and/or co-stimulatory molecules, such as, but not limited to, CD40, CD40L, OX40, OX40L, 4-1BB, 4-
15 1BBL, members of the TNF/TNFR superfamily and members of the B7-CD28 family. Other such immunostimulatory proteins that are used for treatment of tumors or that can promote, enhance or otherwise increase or evoke an anti-tumor response, known to those of skill in the art, are contemplated for encoding in the immunostimulatory bacteria provided herein.

20 The genome of the immunostimulatory bacteria provided herein also can be modified to increase or promote infection of immune cells, particularly immune cells in the tumor microenvironment, such as phagocytic cells. The bacteria also can be modified to decrease pyroptosis in immune cells. The immunostimulatory bacteria include those, for example, that have modifications that disrupt/inhibit the SPI-1
25 pathway, such as disruption or deletion of *hilA*, and/or disruption/deletion of flagellin genes, rod protein, needle protein, and/or *pagP*, as detailed and exemplified elsewhere herein.

IL-2

Interleukin-2 (IL-2), which was the first cytokine approved for the treatment
30 of cancer, is implicated in the activation of the immune system by several mechanisms, including the activation and promotion of CTL growth, the generation of lymphokine-activated killer (LAK) cells, the promotion of Treg cell growth and

proliferation, the stimulation of TILs, and the promotion of T cell, B cell and NK cell proliferation and differentiation. Recombinant IL-2 (rIL-2) is FDA-approved for the treatment of metastatic renal cell carcinoma (RCC) and metastatic melanoma (Sheikhi *et al.* (2016) *Iran J. Immunol.* 13(3):148-166).

5

IL-7

IL-7, which is a member of the IL-2 superfamily, is implicated in the survival, proliferation and homeostasis of T cells. Mutations in the IL-7 receptor have been shown to result in the loss of T cells, and the development of severe combined immunodeficiency (SCID), highlighting the critical role that IL-7 plays in T cell development. IL-7 is a homeostatic cytokine that provides continuous signals to resting naïve and memory T cells, and which accumulates during conditions of lymphopenia, leading to an increase in both T cell proliferation and T cell repertoire diversity. In comparison to IL-2, IL-7 is selective for expanding CD8⁺ T cells over CD4⁺FOXP3⁺ regulatory T cells. Recombinant IL-7 has been shown to augment antigen-specific T cell responses following vaccination and adoptive cell therapy in mice. IL-7 also can play a role in promoting T-cell recovery following chemotherapy of hematopoietic stem cell transplantation. Early phase clinical trials on patients with advanced malignancy have shown that recombinant IL-7 is well-tolerated and has limited toxicity at biologically active doses (*i.e.*, in which the numbers of circulating CD4⁺ and CD8⁺ T cells increased by 3-4 fold) (Lee, S. and Margolin, K. (2011) *Cancers* 3:3856-3893). IL-7 has been shown to possess antitumor effects in tumors such as gliomas, melanomas, lymphomas, leukemia, prostate cancer and glioblastoma, and the *in vivo* administration of IL-7 in murine models resulted in decreased cancer cell growth. IL-7 also has been shown to enhance the antitumor effects of IFN- γ in rat glioma tumors, and to induce the production of IL-1 α , IL-1 β and TNF- α by monocytes, which results in the inhibition of melanoma growth. Additionally, administration of recombinant IL-7 following the treatment of pediatric sarcomas resulted in the promotion of immune recovery (Lin *et al.* (2017) *Anticancer Research* 37:963-968).

30

IL-12 (IL-12p70 (IL-12p40 + IL-12p35))

Bioactive IL-12 (IL-12p70), which promotes cell-mediated immunity, is a heterodimer, composed of p35 and p40 subunits, whereas IL-12p40 monomers and

homodimers act as IL-12 antagonists. IL-12, which is secreted by antigen-presenting cells, promotes the secretion of IFN- γ from NK and T cells, inhibits tumor angiogenesis, results in the activation and proliferation of NK cells, CD8⁺ T cells and CD4⁺ T cells, enhances the differentiation of CD4⁺ Th0 cells into Th1 cells, and promotes antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells. IL-12 has been shown to exhibit antitumor effects in murine models of melanoma, colon carcinoma, mammary carcinoma and sarcoma (Kalinski *et al.* (2001) *Blood* 97:3466-3469; Sheikhi *et al.* (2016) *Iran J. Immunol.* 13(3):148-166; Lee, S. and Margolin, K. (2011) *Cancers* 3:3856-3893).

10 **IL-15 and IL-15:IL-15R α**

IL-15 is structurally similar to IL-2, and while both IL-2 and IL-15 provide early stimulation for the proliferation and activation of T cells, IL-15 blocks IL-2 induced apoptosis, which is a process that leads to the elimination of stimulated T cells and induction of T-cell tolerance, limiting memory T cell responses and potentially limiting the therapeutic efficacy of IL-2 alone. IL-15 also supports the persistence of memory CD8⁺ T cells for maintaining long-term antitumor immunity, and has demonstrated significant antitumor activity in pre-clinical murine models via the direct activation of CD8⁺ effector T cells in an antigen-independent manner. In addition to CD8⁺ T cells, IL-15 is responsible for the development, proliferation and activation of effector natural killer (NK) cells (Lee, S. and Margolin, K. (2011) *Cancers* 3:3856-3893; Han *et al.* (2011) *Cytokine* 56(3):804-810).

IL-15 and IL-15 receptor alpha (IL-15R α) are coordinately expressed by antigen-presenting cells such as monocytes and dendritic cells, and IL-15 is presented *in trans* by IL-15R α to the IL-15R $\beta\gamma_C$ receptor complex expressed on the surfaces of CD8⁺ T cells and NK cells. Soluble IL-15:IL-15R α complexes have been shown to modulate immune responses via the IL-15R $\beta\gamma_C$ complex, and the biological activity of IL-15 has been shown to be increased 50-fold by administering it in a preformed complex of IL-15 and soluble IL-15R α , which has an increased half-life compared to IL-15 alone. This significant increase in the therapeutic efficacy of IL-15 by pre-association with IL-15R α has been demonstrated in murine tumor models (Han *et al.* (2011) *Cytokine* 56(3):804-810).

30 **IL-18**

IL-18 induces the secretion of IFN- γ by NK and CD8⁺ T cells, enhancing their toxicity. IL-18 also activates macrophages and stimulates the development of Th1 helper CD4⁺ T cells. IL-18 has shown promising anti-tumor activity in several preclinical mouse models. For example, administration of recombinant IL-18 (rIL-18) resulted in the regression of melanoma or sarcoma in syngeneic mice through the activation of CD4⁺ T cells and/or NK cell-mediated responses. Other studies showed that IL-18 anti-tumor effects were mediated by IFN- γ and involved antiangiogenic mechanisms. The combination of IL-18 with other cytokines, such as IL-12, or with co-stimulatory molecules, such as CD80, enhances the IL-18-mediated anti-tumor effects. Phase I clinical trials in patients with advanced solid tumors and lymphomas showed that IL-18 administration was safe, and that it resulted in immune modulatory activity and in the increase of serum IFN- γ and GM-CSF levels in patients and modest clinical responses. Clinical trials showed that IL-18 can be combined with other anticancer therapeutic agents, such as monoclonal antibodies, cytotoxic drugs or vaccines (Fabbi *et al.* (2015) *J. Leukoc. Biol.* 97:665-675; Lee, S. and Margolin, K. (2011) *Cancers* 3:3856-3893).

It was found that an attenuated strain of *Salmonella typhimurium*, engineered to express IL-18, inhibited the growth of s.c. tumors or pulmonary metastases in syngeneic mice without any toxic effects following systemic administration. Treatment with this engineered bacterium induced the accumulation of T cells, NK cells and granulocytes in tumors, and resulted in the intratumoral production of cytokines (Fabbi *et al.* (2015) *J. Leukoc. Biol.* 97:665-675).

Chemokines

Chemokines are a family of small cytokines that mediate leukocyte migration to areas of injury or inflammation and are involved in mediating immune and inflammatory responses. Chemokines are classified into four subfamilies, based on the position of cysteine residues in their sequences, namely XC-, CC-, CXC- and CX3C-chemokine ligands, or XCL, CCL, CXCL and CX3CL. The chemokine ligands bind to their cognate receptors and regulate the circulation, homing and retention of immune cells, with each chemokine ligand-receptor pair selectively regulating a certain type of immune cell. Different chemokines attract different leukocyte

populations, and form a concentration gradient *in vivo*, with attracted immune cells moving through the gradient towards the higher concentration of chemokine (Argyle D. and Kitamura, T. (2018) *Front. Immunol.* 9:2629; Dubinett *et al.* (2010) *Cancer J.* 16(4):325-335). Chemokines can improve the antitumor immune response by
5 increasing the infiltration of immune cells into the tumor, and facilitating the movement of antigen-presenting cells (APCs) to tumor-draining lymph nodes, which primes naïve T cells and B cells (Lechner *et al.* (2011) *Immunotherapy* 3(11):1317-1340). The immunostimulatory bacteria herein can be engineered to encode chemokines, including, but not limited to, CCL3, CCL4, CCL5, CXCL9, CXCL10
10 and CXCL11.

CCL3, CCL4, CCL5

CCL3, CCL4 and CCL5 share a high degree of homology, and bind to CCR5 (CCL3, CCL4 and CCL5) and CCR1 (CCL3 and CCL5) on several cell types, including immature DCs and T cells, in both humans and mice. Therapeutic T cells
15 have been shown to induce chemotaxis of innate immune cells to tumor sites, via the tumor-specific secretion of CCL3, CCL4 and CCL5 (Dubinett *et al.* (2010) *Cancer J.* 16(4):325-335).

The induction of the T helper cell type 1 (Th1) response releases CCL3. *In vivo* and *in vitro* studies of mice have indicated that CCL3 is chemotactic for both
20 neutrophils and monocytes; specifically, CCL3 can mediate myeloid precursor cell (MPC) mobilization from the bone marrow, and has MPC regulatory and stimulatory effects. Human ovarian carcinoma cells transfected with CCL3 showed enhanced T cell infiltration and macrophages within the tumor, leading to an improved antitumor response, and indicated that CCL3-mediated chemotaxis of neutrophils suppressed
25 tumor growth. DCs transfected with the tumor antigen human melanoma-associated gene (MAGE)-1 that were recruited by CCL3 exhibited superior anti-tumor effects, including increased lymphocyte proliferation, cytolytic capacity, survival, and decreased tumor growth in a mouse model of melanoma. A combinatorial use of CCL3 with an antigen-specific platform for MAGE-1 has also been used in the
30 treatment of gastric cancer. CCL3 production by CT26, a highly immunogenic murine colon tumor, slowed *in vivo* tumor growth; this process was indicated to be driven by the CCL3-dependent accumulation of natural killer (NK) cells, and thus, IFN γ ,

resulting in the production of CXCL9 and CXCL10 (Allen *et al.* (2017) *Oncoimmunology* 7(3):e1393598; Schaller *et al.* (2017) *Expert Rev. Clin. Immunol.* 13(11):1049-1060).

CCL3 has been used as an adjuvant for the treatment of cancer.

- 5 Administration of a CCL3 active variant, ECI301, after radiofrequency ablation in mouse hepatocellular carcinoma increased tumor-specific responses, and this mechanism was further shown to be dependent on the expression of CCR1. CCL3 has also shown success as an adjuvant in systemic cancers, whereby mice vaccinated with CCL3 and IL-2 or granulocyte-macrophage colony-stimulating factor (GM-CSF) in a
10 model of leukemia/lymphoma exhibited increased survival (Schaller *et al.* (2017) *Expert Rev. Clin. Immunol.* 13(11):1049-1060).

- CCL3 and CCL4 play a role in directing CD8⁺ T cell infiltration into primary tumor sites in melanoma and colon cancers. Tumor production of CCL4 leads to the accumulation of CD103⁺ DCs; suppression of CCL4 through a WNT/ β -catenin-
15 dependent pathway prevented CD103⁺ DC infiltration of melanoma tumors (Spranger *et al.* (2015) *Nature* 523(7559):231-235). CCL3 was also shown to enhance CD4⁺ and CD8⁺ T cell infiltration to the primary tumor site in a mouse model of colon cancer (Allen *et al.* (2017) *Oncoimmunology* 7(3):e1393598).

- The binding of CCL3 or CCL5 to their receptors (CCR1 and CCR5,
20 respectively), moves immature DCs, monocytes and memory and T effector cells from the circulation into sites of inflammation or infection. For example, CCL5 expression in colorectal tumors contributes to T lymphocyte chemoattraction and survival. CCL3 and CCL5 have been used alone or in combination therapy to induce tumor regression and immunity in several preclinical models. For example, studies
25 have shown that the subcutaneous injection of Chinese hamster ovary cells genetically modified to express CCL3 resulted in tumor inhibition and neutrophilic infiltration. In another study, a recombinant oncolytic adenovirus expression *CCL5* (Ad-RANTES-E1A) resulted in primary tumor regression and blocked metastasis in a mammary carcinoma murine model (Lechner *et al.* (2011) *Immunotherapy* 3(11):1317-1340).

- 30 In a translational study of colorectal cancer, CCL5 induced an “antiviral response pattern” in macrophages. As a result of CXCR3 mediated migration of lymphocytes at the invasive margin of liver metastases in colorectal cancer, CCL5 is

produced. Blockade of CCR5, the CCL5 receptor, results in tumor death, driven by macrophages producing IFN and reactive oxygen species. While macrophages are present in the tumor microenvironment, CCR5 inhibition induces a phenotypic shift from an M2 to an M1 phenotype. CCR5 blockade also leads to clinical responses in colorectal cancer patients (Halama *et al.* (2016) *Cancer Cell* 29(4):587-601).

CCL3, CCL4 and CCL5 can be used treating conditions including lymphatic tumors, bladder cancer, colorectal cancer, lung cancer, melanoma, pancreatic cancer, ovarian cancer, cervical cancer or liver cancer (U.S. Patent Publication No. US 2015/0232880; International Patent Publication Nos. WO 2015/059303, WO 2017/043815, WO 2017/156349 and WO 2018/191654).

CXCL9, CXCL10, CXCL11

CXCL9 (MIG), CXCL10 (IP10) and CXCL11 (ITAC) are induced by the production of IFN- γ . These chemokines bind CXCR3, preferentially expressed on activated T cells, and function both angiostatically and in the recruitment and activation of leukocytes. Prognosis in colorectal cancer is strongly correlated to tumor-infiltrating T cells, particularly Th1 and CD8⁺ effector T cells; high intratumoral expression of CXCL9, CXCL10 and CXCL11 is indicative of good prognosis. For example, in a sample of 163 patients with colon cancer, those with high levels of CXCL9 or CXCL11 showed increased post-operative survival, and patients with high CXC expression had significantly higher numbers of CD3⁺ T-cells, CD4⁺ T-helper cells, and CD8⁺ cytotoxic T-cells. In liver metastases of colorectal cancer patients, CXCL9 and CXCL10 levels were increased at the invasive margin and correlated with effector T cell density. The stimulation of lymphocyte migration via the action of CXCL9 and CXCL10 on CXCR3 leads to the production of CCL5 at the invasive margin (Halama *et al.* (2016) *Cancer Cell* 29(4):587-601; Kistner *et al.* (2017) *Oncotarget* 8(52):89998-90012).

In vivo, CXCL9 functions as a chemoattractant for tumor-infiltrating lymphocytes, activated peripheral blood lymphocytes, natural killer (NK) cells and Th1 lymphocytes. CXCL9 also is critical for T cell-mediated suppression of cutaneous tumors. For example, when combined with systemic IL-2, CXCL9 has been shown to inhibit tumor growth via the increased intratumoral infiltration of CXCR3⁺ mononuclear cells. In a murine model of colon carcinoma, a combination of the

huKS1/4-IL-2 fusion protein with CXCL9 gene therapy achieved a superior anti-tumor effect and prolonged lifespan through the chemoattraction and activation of CD8⁺ and CD4⁺ T lymphocytes (Dubinett *et al.* (2010) *Cancer J.* 16(4):325-335; Ruelmann *et al.* (2001) *Cancer Res.* 61(23):8498-8503).

5 CXCL10, produced by activated monocytes, fibroblasts, endothelial cells and keratinocytes, is chemotactic for activated T cells and can act as an inhibitor of angiogenesis *in vivo*. Expression of CXCL10 in colorectal tumors has been shown to contribute to cytotoxic T lymphocyte chemoattraction and longer survival. The administration of immunostimulatory cytokines, such as IL-12, has been shown to
10 enhance the antitumor effects generated by CXCL10. A DC vaccine primed with a tumor cell lysate and transfected with CXCL10 had increased immunological protection and effectiveness in mice; the animals showed a resistance to a tumor challenge, a slowing of tumor growth and longer survival time. *In vivo* and *in vitro* studies in mice using the CXCL10-mucin-GPI fusion protein resulted in tumors with
15 higher levels of recruited NK cells compared to tumors not treated with the fusion protein. Interferons (which can be produced by plasmacytoid dendritic cells; these cells are associated with primary melanoma lesions and can be recruited to a tumor site by CCL20) can act on tumor DC subsets, for example, CD103⁺ DCs, which have been shown to produce CXCL9/10 in a mouse melanoma model and were associated
20 with CXCL9/10 in human disease. CXCL10 also has shown higher expression in human metastatic melanoma samples relative to primary melanoma samples. Therapeutically, adjuvant IFN- α melanoma therapy upregulates CXCL10 production, whereas the chemotherapy agent cisplatin induces CXCL9 and CXCL10 (Dubinett *et al.* (2010) *Cancer J.* 16(4):325-335; Kuo *et al.* (2018) *Front. Med. (Lausanne)* 5:271;
25 Li *et al.* (2007) *Scand. J. Immunol.* 65(1):8-13; Muenchmeier *et al.* (2013) *PLoS One* 8(8):e72749).

CXCL10/11 and CXCR3 expression has been established in human keratinocytes derived from basal cell carcinomas (BCCs). CXCL11 also is capable of promoting immunosuppressive indoleamine 2,3-dioxygenase (IDO) expression in
30 human basal cell carcinoma as well as enhancing keratinocyte proliferation, which could reduce the anti-tumor activity of any infiltrating CXCR3⁺ effector T cells (Kuo *et al.* (2018) *Front. Med. (Lausanne)* 5:271).

CXCL9, CXCL10 and CXCL11 can be encoded in oncolytic viruses for treating cancer (U.S. Patent Publication No. US 2015/0232880; International Patent Publication No. WO 2015/059303). Pseudotyped oncolytic viruses or a genetically engineered bacterium encoding the gene for CXCL10 also can be used to treat cancer
5 (International Application Publication Nos. WO 2018/006005 and WO 2018/129404).

Co-stimulatory Molecules

Co-stimulatory molecules enhance the immune response against tumor cells, and co-stimulatory pathways are inhibited by tumor cells to promote tumorigenesis. The immunostimulatory bacteria herein can be engineered to express co-stimulatory
10 molecules, such as, for example, CD40, CD40L, 4-1BB, 4-1BBL, OX40 (CD134), OX40L (CD252), other members of the TNFR superfamily (*e.g.*, CD27, GITR, CD30, Fas receptor, TRAIL-R, TNF-R, HVEM, RANK), B7 and CD28. The immunostimulatory bacteria herein also can be engineered to express agonistic antibodies against co-stimulatory molecules to enhance the anti-tumor immune
15 response.

TNF Receptor Superfamily

The TNF superfamily of ligands (TNFSF) and their receptors (TNFRSF) are involved in the proliferation, differentiation, activation and survival of tumor and immune effector cells. Members of this family include CD30, Fas-L, TRAIL-R and
20 TNF-R, which induce apoptosis, and CD27, OX40L, CD40L, GITR-L and 4-1BBL, which regulate B and T cell immune responses. Other members include herpesvirus entry mediator (HVEM) and CD27. The expression of TNFSF and TNFRSF by the immunostimulatory bacteria herein can enhance the antitumor immune response. It has been shown, for example, that the expression of 4-1BBL in murine tumors
25 enhances immunogenicity, and intratumoral injection of dendritic cells (DCs) with increased expression of OX40L can result in tumor rejection in murine models. Studies have also shown that injection of an adenovirus expressing recombinant GITR into B16 melanoma cells promotes T cell infiltration and reduces tumor volume. Stimulatory antibodies against molecules such as 4-1BB, OX40 and GITR also can be
30 encoded by the immunostimulatory bacteria to stimulate the immune system. For example, agonistic anti-4-1BB monoclonal antibodies have been shown to enhance anti-tumor CTL responses, and agonistic anti-OX40 antibodies have been shown to

increase anti-tumor activity in transplantable tumor models. Additionally, agonistic anti-GITR antibodies have been shown to enhance anti-tumor responses and immunity (Lechner *et al.* (2011) *Immunotherapy* 3(11):1317-1340; Peggs *et al.* (2009) *Clinical and Experimental Immunology* 157:9-19).

5 **CD40 and CD40L**

CD40, which is a member of the TNF receptor superfamily, is expressed by APCs and B cells, while its ligand, CD40L (CD154), is expressed by activated T cells. Interaction between CD40 and CD40L stimulates B cells to produce cytokines, resulting in T cell activation and tumor cell death. Studies have shown that antitumor
10 immune responses are impaired with reduced expression of CD40L on T cells or CD40 on dendritic cells. CD40 is expressed on the surface of several B-cell tumors, such as follicular lymphoma, Burkitt lymphoma, lymphoblastic leukemia, and chronic lymphocytic leukemia, and its interaction with CD40L has been shown to increase the expression of B7.1/CD80, B7.2/CD86 and HLA class II molecules in the CD40⁺
15 tumor cells, as well as enhance their antigen-presenting abilities. Transgenic expression of CD40L in a murine model of multiple myeloma resulted in the induction of CD4⁺ and CD8⁺ T cells, local and systemic antitumor immune responses and reduced tumor growth. Anti-CD40 agonistic antibodies also induced anti-tumor T cell responses (Marin-Acevedo *et al.* (2018) *Journal of Hematology & Oncology*
20 11:39; Dotti *et al.* (2002) *Blood* 100(1):200-207; Murugaiyan *et al.* (2007) *J. Immunol.* 178:2047-2055).

4-1BB and 4-1BBL

4-1BB (CD137) is an inducible co-stimulatory receptor that is expressed by T cells, NK cells and APCs, including DCs, B cells and monocytes, which binds its
25 ligand, 4-1BBL to trigger immune cell proliferation and activation. 4-1BB results in longer and more wide spread responses of activated T cells. Anti-4-1BB agonists and 4-1BBL fusion proteins have been shown to increase immune-mediated antitumor activity, for example, against sarcoma and mastocytoma tumors, mediated by CD4⁺ and CD8⁺ T cells and tumor-specific CTL activity (Lechner *et al.* (2011)
30 *Immunotherapy* 3(11):1317-1340; Marin-Acevedo *et al.* (2018) *Journal of Hematology & Oncology* 11:39).

OX40 and OX40L

OX40 (CD134) is a member of the TNF receptor superfamily that is expressed on activated effector T cells, while its ligand, OX40L is expressed on APCs, including DCs, B cells and macrophages, following activation by TLR agonists and CD40-CD40L signaling. OX40-OX40L signaling results in the activation, potentiation, proliferation and survival of T cells, as well as the modulation of NK cell function and inhibition of the suppressive activity of Tregs. Signaling through OX40 also results in the secretion of cytokines (IL-2, IL-4, IL-5 and IFN- γ), boosting Th1 and Th2 cell responses. The recognition of tumor antigens by TILs results in increased expression of OX40 by the TILs, which has been correlated with improved prognosis. Studies have demonstrated that treatment with anti-OX40 agonist antibodies or Fc-OX40L fusion proteins results in enhanced tumor-specific CD4⁺ T cell responses and increased survival in murine models of melanoma, sarcoma, colon carcinoma and breast cancer, while Fc-OX40L incorporated into tumor cell vaccines protected mice from subsequent challenge with breast carcinoma cells (Lechner *et al.* (2011) *Immunotherapy* 3(11):1317-1340; Marin-Acevedo *et al.* (2018) *Journal of Hematology & Oncology* 11:39).

B7-CD28 Family

CD28 is a costimulatory molecule expressed on the surface of T cells that acts as a receptor for B7-1 (CD80) and B7-2 (CD86), which are co-stimulatory molecules expressed on antigen-presenting cells. CD28-B7 signaling is required for T cell activation and survival, and prevention of T cell anergy, and results in the production of interleukins such as IL-6.

Optimal T-cell priming requires two signals: (1) T-cell receptor (TCR) recognition of MHC-presented antigens and (2) co-stimulatory signals resulting from the ligation of T-cell CD28 with B7-1 (CD80) or B7-2 (CD86) expressed on APCs. Following T cell activation, CTLA-4 receptors are induced, which then outcompete CD28 for binding to B7-1 and B7-2 ligands. Antigen presentation by tumor cells is poor due to their lack of expression of costimulatory molecules such as B7-1/CD80 and B7-2/CD86, resulting in a failure to activate the T-cell receptor complex. As a result, upregulation of these molecules on the surfaces of tumor cells can enhance their immunogenicity. Immunotherapy of solid tumors and hematologic malignancies has been successfully induced by B7, for example, via tumor cell expression of B7, or

soluble B7-immunoglobulin fusion proteins. The viral-mediated tumor expression of B7, in combination with other co-stimulatory ligands such as ICAM-3 and LFA-3, has been successful in preclinical and clinical trials for the treatment of chronic lymphocytic leukemia and metastatic melanoma. Additionally, soluble B7 fusion proteins have demonstrated promising results in the immunotherapy of solid tumors as single agent immunotherapies (Lechner *et al.* (2011) *Immunotherapy* 3(11):1317-1340; Dotti *et al.* (2002) *Blood* 100(1):200-207).

F. IMMUNOSTIMULATORY BACTERIA ENCODING THE PROTEINS AND CONSTRUCTION OF EXEMPLARY PLASMIDS AND DELIVERY VEHICLES

The therapeutic products, including those described above, are encoded in the immunostimulatory bacteria provided herein on a plasmid and generally under the control of host-recognized regulatory signals. The immunostimulatory bacteria provided herein are modified to increase accumulation in tumor-resident immune cells and the tumor microenvironment. They include modifications to the bacterial genome, bacterial expression and host cell invasion, discussed above, such as to improve or increase targeting to or accumulation in tumors, tumor-resident immune cells, and the tumor microenvironment, and also, to include plasmids that encode products that are expressed in the bacteria by including a bacterial promoter, or in the host by including an appropriate eukaryotic promoter and other regulatory regions as appropriate. The immunostimulatory bacteria are modified as described above, such as by deletion of flagella, and other modifications, so that the bacteria are one or more of *asd⁻*, *msbB⁻*, and *pagP⁻*, and are adenosine auxotrophs.

To introduce the plasmids, the bacteria are transformed using standard methods, such as electroporation with purified DNA plasmids constructed with routine molecular biology tools and methods (DNA synthesis, PCR amplification, DNA restriction enzyme digestion and ligation of compatible cohesive end fragments with ligase). As discussed below and elsewhere herein, the plasmids encode proteins, such as immunostimulatory proteins, such as interleukins, and/or modified gain-of-function proteins, under the control of host-recognized promoters. These encoded proteins stimulate the immune system, particularly in the tumor microenvironment.

The bacteria can encode other products on the plasmids, generally expressed under control of a eukaryotic promoter, such as an RNA polymerase (RNAP) II or III

promoter. Typically, RNAPIII (also referred to as POLIII) promoters are constitutive, and RNAPII (also referred to as POLII) can be regulated. As provided herein, bacterial strains, such as strains of *Salmonella*, including *S. typhimurium*, are modified or identified to be auxotrophic for adenosine in the tumor

5 microenvironment, and to carry plasmids encoding therapeutic proteins, such as the STING and other immunostimulatory proteins that are part of a cytosolic DNA/RNA sensor pathway leading to expression of type I IFN, and also variants of these proteins that increase expression of type I IFN or that result in constitutive expression of type I IFN.

10 Encoded therapeutic products, for example, on plasmids in the immunostimulatory bacteria provided herein, include cytosolic DNA/RNA sensors that induce type I IFNs, as well as constitutively active variants thereof. These include, for example STING, RIG-I, MDA5, IRF-3 and IRF-7, as well as GOF variants thereof, that constitutively induce type I IFN, and/or are activated and induce
15 type I IFN in the absence of stimulation by ligands, such as cytosolic nucleic acid, including CDNs. Encoded STING proteins include wild-type and GOF variants of human STING (including allelic variants), as well as wild-type or modified STING (e.g., GOF variants) from other species, such as Tasmanian devil, marmoset, cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, mouse and ghost shark, which
20 can exhibit lower NF- κ B activity, and optionally, increased IRF3/type I IFN signaling. Other therapeutic products include immunostimulatory proteins such as cytokines, chemokines, and co-stimulatory molecules.

Bacteria, such as *S. typhimurium*, can infect multiple cell types, including tumor cells and macrophages. For cells infected with the immunostimulatory bacteria,
25 such as *S. typhimurium*, the plasmid is released and encoded proteins are transcribed by host RNA polymerases and are secreted into the tumor microenvironment and tumors.

1. Origin of Replication and Plasmid Copy Number

Plasmids are autonomously-replicating extra-chromosomal circular double
30 stranded DNA molecules that are maintained within bacteria by means of a replication origin. Copy number influences the plasmid stability. High copy number generally results in greater stability of the plasmid when the random partitioning occurs at cell

division. A high number of plasmids generally decreases the growth rate, thus possibly allowing for cells with few plasmids to dominate the culture, since they grow faster. The origin of replication also determines the plasmid's compatibility: its ability to replicate in conjunction with another plasmid within the same bacterial cell.

- 5 Plasmids that utilize the same replication system cannot co-exist in the same bacterial cell. They are said to belong to the same compatibility group. The introduction of a new origin, in the form of a second plasmid from the same compatibility group, mimics the result of replication of the resident plasmid. Thus, any further replication is prevented until after the two plasmids have been segregated to different cells to
- 10 create the correct pre-replication copy number.

Origin of Replication	Copy Number	SEQ ID NO.
pMB1	15-20	254
p15A	10-12	255
pSC101	~5	256
pBR322	15-20	243
ColE1	15-20	257
pPS10	15-20	258
RK2	~5	259
R6K (alpha origin)	15-20	260
R6K (beta origin)	15-20	261
R6K (gamma origin)	15-20	262
P1 (oriR)	Low	263
R1	Low	264
pWSK	Low	265
ColE2	10-15	266
pUC (pMB1)	500-700	267
F1	300-500	268

- Numerous bacterial origins of replication are known to those of skill in the art, including those listed in the table above. The origin can be selected to achieve a desired copy number. Origins of replication contain sequences that are recognized as initiation sites of plasmid replication via DNA dependent DNA polymerases (Solar *et al.* (1998) *Microbiology And Molecular Biology Reviews* 62(2):434-464). Different
- 15 origins of replication provide for varying plasmid copy levels within each cell and can range from one to hundreds of copies per cell. Commonly used bacterial plasmid origins of replication include, but are not limited to, pMB1 derived origins, which have very high copy derivatives, ColE1 origins, p15A, pSC101, pBR322, and others,
- 20 which have low copy numbers. Such origins are well known to those of skill in the

art. The pUC19 origin results in copy number of 500-700 copies per cell. The pBR322 origin has a known copy number of 15-20. These origins only vary by a single base pair. The ColE1 origin copy number is 15-20, and derivatives such as pBluescript have copy numbers ranging from 300-500. The p15A origin that is in pACYC184, for example, results in a copy number of approximately 10. The pSC101 origins confer a copy number of approximately 5. Other low copy number vectors from which origins can be obtained, include, for example, pWSK29, pWKS30, pWKS129 and pWKS130 (see, Wang *et al.* (1991) *Gene* 100:195-199). Medium to low copy number is less than 150, or less than 100. Low copy number is less than 20, 25, or 30. Those of skill in the art can identify plasmids with low or high copy number. For example, to determine experimentally if the copy number is high or low is to perform a miniprep. A high-copy plasmid should yield between 3-5 µg DNA per 1 ml LB culture; a low-copy plasmid will yield between 0.2-1 µg DNA per ml of LB culture.

Sequences of bacterial plasmids, including identification of and sequence of the origin of replication, are well known (see, *e.g.*, snapgene.com/resources/plasmid_files/basic_cloning_vectors/pBR322/). High copy plasmids are selected for heterologous expression of proteins *in vitro* because the gene dosage is increased relative to chromosomal genes and higher specific yields of protein, and for therapeutic bacteria, higher therapeutic dosages of encoded therapeutics. It is shown, herein, however, that for delivery of plasmids encoding therapeutic products by the immunostimulatory bacteria provided herein, a lower copy number is more effective.

The requirement for bacteria to maintain the high copy plasmids can be a problem if the expressed molecule is toxic to the organism. The metabolic requirements for maintaining these plasmids can come at a cost of replicative fitness *in vivo*. Optimal plasmid copy number for delivery of plasmids encoding therapeutic products can depend on the mechanism of attenuation of the strain engineered to deliver the plasmid. If needed, the skilled person, in view of the disclosure herein, can select an appropriate copy number for a particular immunostimulatory species and strain of bacteria. It is shown herein, that low copy number can be advantageous.

2. Plasmid Maintenance/Selection Components

The maintenance of plasmids in laboratory settings is usually ensured by inclusion of an antibiotic resistance gene on the plasmid and use of antibiotics in growth media. As described above, the use of an *asd* deletion mutant complemented with a functional *asd* gene on the plasmid allows for plasmid selection *in vitro* without the use of antibiotics, and allows for plasmid selection *in vivo*. The *asd* gene complementation system provides for such selection (Galán *et al.* (1990) *Gene* 28:29-35). The use of the *asd* gene complementation system to maintain plasmids in the tumor microenvironment increases the potency of *S. typhimurium* engineered to deliver plasmids encoding therapeutic proteins or interfering RNAs.

3. RNA Polymerase Promoters

In eukaryotic cells, DNA is transcribed by three types of RNA polymerases; RNA Pol I, II and III. RNA Pol I transcribes only ribosomal RNA (rRNA) genes, RNA Pol II transcribes DNA into mRNA and small nuclear RNAs (snRNAs), and RNA Pol III transcribes DNA into ribosomal 5S rRNA (type I), transfer RNA (tRNA) (type II) and other small RNAs such as U6 snRNAs (type III). Prokaryotic promoters, including T7, pBAD and pepT promoters can be utilized when transcription occurs in a bacterial cell (Guo *et al.* (2011) *Gene therapy* 18:95-105; U.S. Patent Publication Nos. 2012/0009153, 2016/0369282; International Application Publication Nos. WO 2015/032165, WO 2016/025582). Because the bacteria provided herein are designed to deliver the plasmid into tumor-resident immune cells for expression by host cell transcription/translation machinery, the nucleic acids encoding the therapeutic proteins/products, are operatively linked to eukaryotic promoters, such as RNAPII and RNAPIII promoters.

RNA pol III promoters generally are used for constitutive expression. For inducible expression, RNA pol II promoters are used. Examples include the pBAD promoter, which is inducible by L-arabinose; tetracycline-inducible promoters such as TRE-tight, IPT, TRE-CMV, Tet-ON and Tet-OFF; retroviral LTR; IPTG-inducible promoters such as LacI, Lac-O responsive promoters; LoxP-stop-LoxP system promoters (U.S. Patent No. 8,426,675; International Application Publication No. WO 2016/025582); and pepT, which is a hypoxia-induced promoter. (Yu *et al.* (2012)

Scientific Reports 2:436). These promoters are well known. Exemplary of these promoters are human U6 (SEQ ID NO:73) and human H1 (SEQ ID NO:74).

SEQ ID NO.	Name	Sequence
73	human U6 RNA pol III promoter	aa ggtcgggcag gaagagggcc 721 tatttcccat gattccttca tattgcata tacgatacaa ggctgttaga gagataatta 781 gaattaattt gactgtaaac acaagatat tagtacaaaa tacgtgacgt agaaagtaat 841 aatttctgg gtagttgca gttttaaata tatgttttaa aatggactat catatgctta 901 ccgtaacttg aaagtatttc gatttcttgg ctttatatat ctgtgggaaa ggacgaaact 961 ag
74	human H1 RNA pol III promoter	atatttgc tctcgtatg 721 tgttctggga aatcaccata aacgtgaaat gtctttggat ttgggaatct tataagtctt 781 gtatgagacc actccctagg

Tissue specific promoters include TRP2 promoter for melanoma cells and melanocytes; MMTV promoter or WAP promoter for breast and breast cancer cells, Villin promoter or FABP promoter for intestinal cells, RIP promoter for pancreatic beta cells, Keratin promoter for keratinocytes, Probasin promoter for prostatic epithelium, Nestin promoter or GFAP promoter for CNS cells/cancers, Tyrosine Hydroxylase S100 promoter or neurofilament promoter for neurons, Clara cell secretory protein promoter for lung cancer, and Alpha myosin promoter in cardiac cells (U.S. Patent No. 8,426,675). Other promoters for controlling expression of the encoded therapeutic products, such as the gain-of-function variants of proteins that induce type I interferons by increasing expression or rendering it constitutive, include, for example, the EF-1alpha promoter, CMV, SV40, PGK, EIF4A1, CAG, and CD68 promoters.

4. DNA Nuclear Targeting Sequences

DNA nuclear targeting sequences (DTS)s, such as the SV40 DTS, mediate the translocation of DNA sequences through the nuclear pore complex. The mechanism of this transport is reported to be dependent on the binding of DNA binding proteins that contain nuclear localization sequences. The inclusion of a DTS on a plasmid to increase nuclear transport and expression has been demonstrated (see, *e.g.*, Dean, D.A. *et al.* (1999) *Exp. Cell Res.* 253(2):713-722), and has been used to increase gene expression from plasmids delivered by *S. typhimurium* (see, *e.g.*, Kong *et al.* (2012) *Proc. Natl. Acad. Sci. U.S.A.* 109(47):19414-19419).

Rho-independent or class I transcriptional terminators such as the T1 terminator of the *rrnB* gene of *E. coli* contain sequences of DNA that form secondary structures that cause dissociation of the transcription elongation complex.

Transcriptional terminators can be included in the plasmid in order to prevent
5 expression of the encoded therapeutic products by the *S. typhimurium* transcriptional machinery. This ensures that expression of the encoded products is confined to the host cell transcriptional machinery.

Plasmids used for transformation of *Salmonella*, such as *S. typhimurium*, as a cancer therapy described herein, contain all or some of the following attributes: 1) a
10 CpG island, 2) a bacterial origin of replication, 3) an *asd* gene selectable marker for plasmid maintenance, 4) one or more expression cassettes, 5) DNA nuclear targeting sequence(s), and 6) transcriptional terminators.

5. CRISPR

An immunostimulatory bacterium, encoding a CRISPR cassette, can be used
15 to infect human immune, myeloid, or hematopoietic cells in order to site-specifically knockout a target gene of interest. The strain used can be *asd⁻* and can contain a plasmid that lacks the complementary *asd* cassette and contains a kan cassette. In order to grow the strain *in vitro* in liquid media, DAP is added to complement the *asd⁻* genetic deficiency. After infection of human cells, the strain can no longer replicate,
20 and the CRISPR cassette-encoded plasmid is delivered. The strain can also be *hila⁻* or lack one or more parts of the SPI-1, or lack flagellin, or any combination thereof, which reduces or prevents pyroptosis (inflammatory-mediated cell death) of phagocytic cells.

25 G. OTHER DELIVERY VEHICLES ENCODING THE NON-HUMAN STING PROTEINS AND GAIN-OF-FUNCTION MODIFIED PROTEINS THAT CONSTITUTIVELY INDUCE TYPE I INTERFERON AND OTHER THERAPEUTIC PRODUCTS

As described herein, provided are immunostimulatory bacteria, oncolytic viruses and other delivery vehicles, such as exosomes, liposomes and nanoparticles,
30 that contain nucleic acids encoding therapeutic products, such as proteins that induce, directly or indirectly via pathways, type I interferons (IFNs), including interferon- β and interferon- α . Such proteins include human and non-human STING, and others, such as RIG-1 and MDA5 proteins, and GOF mutants thereof that contain mutations

that render their activity constitutive, so that type I interferon is constitutively expressed. Other therapeutic products, such as cytokines and other immunostimulatory proteins, also can be encoded in and/or delivered by these delivery vehicles. The vehicles accumulate in tumor cells or in the tumor microenvironment, such as in tumor-resident immune cells.

1. Exosomes, Extracellular Vesicles, And Other Vesicular Delivery Vehicles

Numerous methods for preparing and using and targeting exosomes and nanoparticles are known to those of skill in the art (see, *e.g.*, Published U.S. Application Nos. 2013/0337066, 2014/0093557, 2018/0104187, 2018/0193266 and 2018/0236104). Exosomes are small, 30–100 nm vesicles secreted by various cell types. They have been adapted as vehicles for the delivery of nucleic acids. They can be targeted to tumors. For example, they can be engineered to express tumor-targeting ligands on their surfaces.

Exosomes are small membrane vesicles of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane. The size of exosomes ranges between 30 and 100 nm in diameter. Their surface consists of a lipid bilayer from the donor cell's cell membrane, and they contain cytosol from the cell that produced the exosome, and exhibit membrane proteins from the parental cell on the surface.

Exosomes are nanoparticles that are secreted endogenously by many types of cell *in vitro* and *in vivo*, and commonly can be isolated from body fluids, such as blood, urine and malignant ascites. Exosomes are cup-like multivesicular bodies (MVBs) that can be formed by inward budding and scission of vesicles from the limiting membranes into the endosomal lumen. During the formation of MVBs, transmembrane and peripheral membrane proteins are absorbed into the vesicle membrane, and at the same time, cytosolic components are also embedded in the vesicles. As this process progresses, the MVBs ultimately fuse with the cellular membrane, triggering the release of the exosomes from the cells.

Exosomes exhibit different compositions and functions depending on the cell type from which they are derived. Exosomes are produced by many cells, including epithelial cells, B and T lymphocytes, mast cells (MCs), and dendritic cells (DCs). In

humans, exosomes occur in blood plasma, urine, bronchoalveolar lavage fluid, intestinal epithelial cells and tumor tissues. Exosomes have been used to transfer nucleic acids into cells, and can be targeted to any cell in the body, including cells in the immune system. Exosomes can be isolated from cells of different origins, including from cells growing *in vitro*, and from the human body. They can be produced so that they lack genetic material of their own. Methods for producing exosomes devoid of genetic material are known to those of skill in the art. They include UV-exposure, mutation of proteins that carry RNA into exosomes, electroporation and chemical treatments to open pores in the exosomal membranes. The methods include mutation/deletion of any protein that can modify loading of any nucleic acid into exosomes. Genetic constructs of RNA or DNA can be introduced into exosomes by using conventional molecular biology techniques, such as *in vitro* transformation, transfection, and microinjection.

Provided herein are exosomes and other extracellular vesicles and other such vehicles containing nucleic acid, DNA or RNA, that encode a gain-of-function modified protein, or that contain the encoded protein, in a cell that leads to constitutive activation of cytosolic IFN signaling pathways/increased sensitivity to cytosolic nucleic acid ligands (*e.g.*, gain-of-function mutations in RIG-I, MDA5 and STING, as described herein). These vehicles can encode additional proteins, such as immunostimulatory proteins that enhance the immune response, including cytokines, for example. The exosomes and other vehicles can be designed to target or accumulate in cells in the tumor microenvironment, including tumor-resident immune cells and tumor cells.

2. Oncolytic Viruses

Oncolytic viruses accumulate and replicate in tumors, which can lead to tumor cell lysis, and immune responses to released tumor antigens and to viral products, resulting in tumor regression. Oncolytic viruses effect treatment by colonizing or accumulating in tumor cells, including metastatic tumor cells, such as circulating tumor cells. Oncolytic viruses can be engineered to encode therapeutic products that are expressed in tumor cells.

Oncolytic viruses include naturally-occurring and engineered recombinant viruses such as, but not limited to, poxvirus, such as vaccinia virus, herpes simplex

virus, adenovirus, adeno-associated virus, measles virus, reovirus, vesicular stomatitis virus (VSV), coxsackie virus, Semliki Forest Virus, Seneca Valley Virus, Newcastle Disease Virus, Sendai Virus, Dengue Virus, picornavirus, poliovirus, parvovirus, retrovirus, lentivirus, alphavirus, flavivirus, rhabdovirus, papillomavirus, influenza virus, mumps virus, gibbon ape leukemia virus, and Sindbis virus, among others. In many cases, tumor selectivity is an inherent property of the virus, such as vaccinia viruses and other oncolytic viruses. Oncolytic viruses include, but are not limited to, those known to one of skill in the art and include, for example, vesicular stomatitis virus (see, *e.g.*, U.S. Patent Nos. 7,731,974, 7,153,510, and 6,653,103; U.S. Patent Publication Nos. 2010/0178684, 2010/0172877, 2010/0113567, 2007/0098743, 2005/0260601, and 2005/0220818; and EP Patent Nos. 1385466, 1606411 and 1520175); herpes simplex virus (see, *e.g.*, U.S. Patent Nos. 7,897,146, 7,731,952, 7,550,296, 7,537,924, 6,723,316, and 6,428,968; and U.S. Pat. Pub. Nos. 2011/0177032, 2011/0158948, 2010/0092515, 2009/0274728, 2009/0285860, 2009/0215147, 2009/0010889, 2007/0110720, 2006/0039894 and 2004/0009604); retroviruses (see, *e.g.*, U.S. Patent Nos. 6,689,871, 6,635,472, 6,639,139, 5,851,529, 5,716,826, and 5,716,613; and U.S. Patent Publication No. 2011/0212530); and adeno-associated viruses (see, *e.g.*, U.S. Patent Nos. 8,007,780, 7,968,340, 7,943,374, 7,906,111, 7,927,585, 7,811,814, 7,662,627, 7,241,447, 7,238,526, 7,172,893, 7,033,826, 7,001,765, 6,897,045, and 6,632,670). Those of skill in the art know how to grow, select, and modify oncolytic viruses for therapy.

The oncolytic viruses provided herein are modified to encode products that induce expression of type I interferons, such as polypeptides that activate type I interferon pathway signaling and/or NF- κ B signaling. These proteins include human and non-human STING, and gain-of-function mutants of STING, and other such proteins, including RIG-I and MDA5, and their gain-of-function mutants, including those described herein. The oncolytic viruses also can encode immunostimulatory proteins, such as cytokines, including interleukin 2 (IL-2). These proteins are under control of a viral promoter or can be under control of other RNA polymerase II promoters. The oncolytic viruses also can encode other therapeutic products, such as RNAi, such as an shRNA or a microRNA that targets a receptor or other target that suppresses immune responses, such as TREX1. The viruses are administered by any

suitable methods, including, but not limited to, parenteral administration, such as intravenous, intratumoral and intraperitoneal administration. The viruses can be any known to those of skill in the art, and can encode additional therapeutic products. The viruses can be combined with other therapies suitable for the tumors, such as cisplatin
5 for ovarian tumors, or gemcitabine for pancreatic tumors. Exemplary oncolytic viruses are those discussed below.

a. Adenovirus

Adenoviruses (Ads) are non-enveloped ds-DNA viruses with a linear genome. Human Ads are classified into 57 serotypes (Ad1-Ad57), based on cross-
10 susceptibility, and 7 subgroups (A-G), based on virulence and tissue tropism. Adenovirus serotype 5 (Ad5) is the most commonly used adenovirus for oncolytic virotherapy. Infections in humans are mild and result in cold-like symptoms (Yokoda *et al.* (2018) *Biomedicines* 6, 33) and systemic administration results in liver tropism and can lead to hepatotoxicity (Yamamoto *et al.* (2017) *Cancer Sci.* 108:831-837), but
15 Ads are considered safe for therapeutic purposes. Ads enter cells by attaching to the coxsackievirus and adenovirus receptor (CAR), followed by interaction between the $\alpha v\beta 3$ and $\alpha v\beta 5$ integrins on the cell surface and the Arg-Gly-Asp tripeptide motif (RGD) at the adenoviral penton base (Jiang *et al.* (2015) *Curr. Opin. Virol.* 13:33-39). CAR is expressed on the surfaces of most normal cells, but expression is highly
20 variable across cancer cell types. On the other hand, RGD-related integrins are highly expressed by cancer cells, but are expressed at much lower levels in normal cells (Jiang *et al.* (2015)). As a result, adenoviruses can be targeted to cancer cells via the RGD motif.

Ads are attractive as oncolytic viruses due to their high transduction efficiency
25 in transformed cells, their lack of integration into the host genome/lack of insertional mutagenesis, their genomic stability, the ability to insert large therapeutic genes into their genomes, and their capacity for tumor selectivity via genetic manipulation, such as the substitution of viral promoters with cancer tissue-selective promoters (Yokoda *et al.* (2018) *Biomedicines* 6, 33; Choi *et al.* (2015) *J. Control. Release* 10(219):181-
30 191).

Examples of oncolytic Ads with tumor-specific promoters include CV706 for prostate cancer treatment, with the adenovirus early region 1A (E1A) gene under

control of the prostate specific antigen promoter, and OBP-301, which utilizes the telomerase reverse transcriptase (TERT) promoter for regulation of E1A gene expression (Yamamoto *et al.* (2017) *Cancer Sci.* 108:831-837). Another method for inducing tumor selectivity is the introduction of mutations in the E1 region of the Ad genome, where the missing genes are functionally complemented by genetic mutations commonly found in tumor cells, such as abnormalities in the retinoblastoma (Rb) pathway or p53 mutations (Yamamoto *et al.* (2017) *Cancer Sci.* 108:831-837). For example, the oncolytic Ads ONYX-015 and H101 have deletions in the E1B55K gene, which inactivates p53. These mutants cannot block the normal apoptotic defense pathway, resulting in tumor selectivity via the infection of neoplastic cells with defective p53 tumor suppressor pathways (Yamamoto *et al.* (2017) *Cancer Sci.* 108:831-837; Uusi-Kerttula *et al.* (2015) *Viruses* 7:6009-6042). E1A Δ 24 is an oncolytic Ad that contains a 24-bp mutation in the E1A gene, disrupting the Rb-binding domain and promoting viral replication in cancer cells with Rb pathway mutations. ICOVIR-5 is an oncolytic Ad that combines E1A transcriptional control by the E2F promoter, the Δ 24 mutation of E1A and an RGD-4C insertion into the adenoviral fiber (Yamamoto *et al.* (2017) *Cancer Sci.* 108:831-837; Uusi-Kerttula *et al.* (2015)). Delta-24-RGD, or DNX-2401, is an oncolytic Ad in which the Δ 24 backbone is modified by insertion of the RGD motif, that demonstrated enhanced oncolytic effects *in vitro* and *in vivo* (Jiang *et al.* (2015)).

An alternative strategy for improving tumor selectivity involves overcoming the physical barrier in solid tumors by targeting the extracellular matrix (ECM). For example, an oncolytic Ad that expresses hyaluronidase, such as VCN-01, can be used to facilitate delivery of encoded products and virus throughout the tumor. Ads also have been engineered to express relaxin to disrupt the ECM (Yamamoto *et al.* (2017) *Cancer Sci.* 108:831-837; Shaw and Suzuki (2015) *Curr. Opin. Virol.* 21:9-15). Ads expressing suicide genes, such as cytosine deaminase (CD) and HSV-1 thymidine kinase (TK) have shown enhanced antitumor efficacy *in vivo*, as have Ads expressing immunostimulatory cytokines, such as ONCOS-102, which expresses GM-CSF (Yamamoto *et al.* (2017) *Cancer Sci.* 108:831-837; Shaw and Suzuki (2015) *Curr. Opin. Virol.* 21:9-15). A Δ 24-based oncolytic Ad expressing an anti-CTLA4 antibody has shown promise in preclinical studies (Jiang *et al.* (2015)).

The adenovirus H101 (available under the trademark Oncorine®) was the first oncolytic Ad approved for clinical use in China in combination with chemotherapy, for treating patients with advanced nasopharyngeal cancer in 2005. Clinical trials have demonstrated the use of oncolytic adenoviruses for the treatment of a wide variety of cancers. For example, there have been and are clinical trials of: an oncolytic Ad5 encoding IL-12 in patients with metastatic pancreatic cancer (NCT03281382); an immunostimulatory Ad5 (LOAd703) expressing TMX-CD40L and 41BBL in patients with pancreatic adenocarcinoma, ovarian cancer, biliary carcinoma and colorectal cancer (NCT03225989); LOAd703 in combination with gemcitabine and nab-paclitaxel in patients with pancreatic cancer (NCT02705196); an oncolytic adenovirus encoding human PH20 hyaluronidase (VCN-01) in combination with gemcitabine and Abraxane® in patients with advanced solid tumors, including pancreatic adenocarcinoma (NCT02045602; NCT02045589); Telomelysin® (OBP-301), an oncolytic Ad with tumor selectivity, containing the human telomerase reverse transcriptase (hTERT) promoter, in patients with hepatocellular carcinoma (NCT02293850); an E1B gene deleted Ad5 in combination with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (NCT01869088); CG0070, an oncolytic Ad that expresses GM-CSF and contains the cancer-specific E2F-1 promoter to drive expression of E1A, in patients with bladder cancer (NCT02365818; NCT01438112); Enadenotucirev (Colo-Ad1), an Ad11p/Ad3 chimeric Group B oncolytic virus, in patients with colon cancer, non-small cell lung cancer, bladder cancer and renal cell carcinoma (NCT02053220); and DNX-2401 (Ad5 E1AΔ24RGD) in combination with Temozolomide (NCT01956734), or in combination with IFN γ (NCT02197169) in patients with glioblastoma.

25 **b. Herpes Simplex Virus**

Herpes simplex virus (HSV) belongs to the family Herpesviridae and has a large linear double-stranded DNA genome, including many genes that are nonessential for viral replication, making it an ideal candidate for genetic manipulation. Other advantages include its ability to infect a broad range of cell types, its sensitivity to antivirals such as acyclovir and ganciclovir, and its lack of insertional mutagenesis (Sokolowski *et al.* (2015) *Oncolytic Virotherapy* 4:207-219; Yin *et al.* (2017) *Front. Oncol.* 7:136). There are two types of HSV, HSV type I (HSV-1) and

type II (HSV-2), with the majority of oncolytic HSVs being derived from HSV-1. In humans, HSV-1 causes fever blister disease and infects epithelial cells, neurons, and immune cells by binding to nectins, glycoproteins, and the herpesvirus entry mediator (HVEM) on the cell surface (Kohlhapp and Kaufman (2016) *Clin. Cancer Res.*

5 22(5):1048-1054).

Many different oncolytic HSV-1 viruses have been generated to date. Any can be further modified to encode the modified DNA/RNA gain-of-function proteins, as described herein, so that upon accumulation in tumors and the tumor microenvironment, the HSVs that are so-modified, express the encoded protein to

10 constitutively express immune response mediators, such as a type I interferon. For example, HSV-1 has been engineered to express the anti-HER-2 antibody trastuzumab, targeting tumors that overexpress HER-2, such as breast and ovarian cancers, gastric carcinomas and glioblastomas. The gene encoding trastuzumab was inserted into two regions within the HSV-1 gD glycoprotein gene, generating two

15 oncolytic HSVs, R-LM113 and R-LM249. R-LM113 and R-LM249 demonstrated preclinical activity against human breast and ovarian cancers, and against a murine model of HER2+ glioblastoma. Another oncolytic HSV-1, dlsptk HSV-1, contains a deletion in the unique long 23 (UL23) gene, which encodes the viral homologue of thymidine kinase (TK), while the hrR3 HSV-1 mutant contains a LacZ insertion

20 mutation of the large subunit of ribonucleotide reductase (RR), also known as ICP6, encoded by the gene UL39. As a result, dlsptk and hrR3 HSV-1 mutants can only replicate in cancer cells that overexpress TK and RR, respectively (Sokolowski *et al.* (2015) *Oncolytic Virotherapy* 4:207-219).

HF10 is a spontaneously mutated oncolytic HSV-1 that lacks the genes

25 encoding UL43, UL49.5, UL55, UL56 and latency-associated transcripts, and overexpresses UL53 and UL54. HF10 has shown promising results in preclinical studies and demonstrated high tumor selectivity, high viral replication, potent antitumor activity and a favorable safety profile (Eissa *et al.* (2017) *Front. Oncol.* 7:149). Clinical trials investigating HF10 include: a phase I study in patients with

30 refractory head and neck cancer, squamous cell carcinoma of the skin, carcinoma of the breast and malignant melanoma (NCT01017185), and a Phase I study of HF10 in combination with chemotherapy (gemcitabine, Nab-paclitaxel, TS-1) in patients with

unresectable pancreatic cancer (NCT03252808). HF10 also has been combined with the anti-CTLA-4 antibody ipilimumab, resulting in improved therapeutic efficacy in patients with stage IIIb, IIIc or IV unresectable or metastatic melanoma (NCT03153085). A phase II clinical study is investigating the combination of HF10 with the anti-PD-1 antibody Nivolumab in patients with resectable stage IIIb, IIIc and IV melanoma (NCT03259425) and in combination with ipilimumab in patients with unresectable or metastatic melanoma (NCT02272855). Paclitaxel and HF10 combination therapy resulted in superior survival rates in peritoneal colorectal cancer models compared with either treatment alone, while combination treatment with HF10 and erlotinib resulted in improved activity against pancreatic xenografts *in vitro* and *in vivo* over either HF10 or erlotinib alone (Eissa *et al.* (2017) *Front. Oncol.* 7:149).

Talimogene laherparepvec (Imlygic®, T-VEC), previously known as OncoVEXGM-CSF, is an FDA-approved oncolytic herpes simplex virus for the treatment of advanced melanoma, that was generated from the JS1 strain of HSV-1 and genetically engineered to express granulocyte macrophage stimulating factor (GM-CSF; Aref *et al.* (2016) *Viruses* 8:294). In T-VEC, GM-CSF expression enhances the antitumor cytotoxic immune response, while deletion of both copies of the infected cell protein 34.5 (ICP34.5) gene suppresses replication in normal tissues, and deletion of the ICP47 gene increases expression of MHC class I molecules, allowing for antigen presentation on infected cells (Eissa *et al.* (2017)). T-VEC exhibits tumor selectivity by binding to nectins on the surface of cancer cells and preferentially replicates in tumor cells by exploiting disrupted oncogenic and antiviral signaling pathways, particularly the protein kinase R (PKR) and type I IFN pathways. In normal cells, PKR is activated by viral infection, which then phosphorylates the eukaryotic initiation factor-2A protein (eIF-2A), inactivating it and in turn, inhibiting cellular protein synthesis, blocking cell proliferation and preventing viral replication. Wild-type HSV escapes the antiviral response due to expression of the ICP34.5 protein, which activates a phosphatase that dephosphorylates eIF-2A, restoring protein synthesis in the infected cells. Thus, deletion of ICP34.5 precludes viral replication of T-VEC in normal cells. The PKR-eIF-2A pathway in cancer cells, however, is disrupted, permitting continuous cell growth and uninhibited viral

replication (Kohlhapp and Kaufman (2016) *Clin. Cancer Res.* 22(5):1048-1054; Yin *et al.* (2017) *Front. Oncol.* 7:136). The expression of GM-CSF improves the immunogenicity of T-VEC by causing dendritic cell accumulation, promoting antigen-presentation and priming T-cell responses (Kohlhapp and Kaufman (2016) *Clin. Cancer Res.* 22(5):1048-1054).

T-VEC has shown preferential replication in a variety of different cancer cell lines, including breast cancer, colorectal adenocarcinoma, melanoma, prostate cancer, and glioblastoma. Clinical trials include, for example, those investigating T-VEC in pancreatic cancer (NCT03086642, NCT00402025), recurrent breast cancer (NCT02658812), advanced non-CNS tumors in children (NCT02756845), non-melanoma skin cancer (NCT03458117), non-muscle invasive bladder transitional cell carcinoma (NCT03430687), and malignant melanoma (NCT03064763), as well as T-VEC in combination with atezolizumab in patients with metastatic triple negative breast cancer and metastatic colorectal cancer with liver metastases (NCT03256344), in combination with paclitaxel in patients with triple negative breast cancer (NCT02779855), in combination with nivolumab in patients with refractory lymphomas or advanced/refractory non-melanoma skin cancers (NCT02978625), in combination with cisplatin and radiotherapy in patients with advanced head and neck cancer (NCT01161498), and in combination with pembrolizumab in patients with liver tumors (NCT02509507), carcinoma of the head and neck (NCT02626000), sarcoma (NCT03069378) and melanoma (NCT02965716, NCT02263508).

In addition to GM-CSF, numerous other immune stimulating genes have been inserted into oncolytic HSVs, including those encoding IL-12, IL-15, IL-18, TNF α , IFN α/β and fms-like tyrosine kinase 3 ligand, resulting in increased therapeutic efficacy (Sokolowski *et al.* (2015); Yin *et al.* (2017)).

Another oncolytic HSV-1, R3616 contains deletions in both copies of the RL1 (also known as γ 134.5) gene, which encodes ICP34.5, targeting cancer cells with disrupted PKR pathways. NV1020 (or R7020) is an HSV-1 mutant that contains deletions in the UL55, UL56, ICP4, RL1 and RL2 genes, resulting in reduced neurovirulence and cancer selectivity. NV1020 displayed promising results in murine models of head and neck squamous cell carcinoma, epidermoid carcinoma and prostate adenocarcinoma (Sokolowski *et al.* (2015)). Additionally, clinical trials have

investigated the safety and efficacy of NV1020 in colorectal cancer metastatic to the liver (NCT00149396 and NCT00012155).

G207 (or MGH-1) is another HSV-1 mutant with an RL1 (γ 134.5) deletion and a LacZ inactivating insertion in the UL39 neurovirulence gene. Clinical studies
5 utilizing G207 include the investigation of G207 administration alone or with a single radiation dose in children with progressive or recurrent supratentorial brain tumors (NCT02457845), the investigation of the safety and efficacy of G207 in patients with recurrent brain cancer (glioma, astrocytoma, glioblastoma) (NCT00028158), and the investigation of the effects of G207 administration followed by radiation therapy in
10 patients with malignant glioma (NCT00157703).

G207 was used to generate G47 Δ , which contains a further deletion in the gene encoding ICP47. Other HSV-1 derived oncolytic viruses include HSV1716, which contains deletions in RL1, but has an intact UL39 gene and replicates selectively in actively dividing cells, and the KM100 mutant, which has insertions in
15 the UL48 and RL2 genes, resulting in a loss of expression of immediate early viral genes and cancer cell selectivity (Sokolowski *et al.* (2015); Yin *et al.* (2017) *Front. Oncol.* 7:136).

Oncolytic viruses also have been derived from HSV-2. For example, FusOn-H2 is an HSV-2 oncolytic virus with a deletion of the N-terminal region of the ICP10
20 gene that encodes a serine/threonine protein kinase (PK) domain. This PK is responsible for phosphorylating GTPase-activating protein Ras-FAP, which activates the Ras/MEK/MAPK mitogenic pathway and induces and stabilizes c-Fos, which is required for efficient HSV-2 replication. Normal cells usually have an inactivated Ras signaling pathway. Thus, FusOn-H2 exhibits tumor selectivity by replicating only in
25 tumor cells with activated Ras signaling pathways (Fu *et al.* (2006) *Clin. Cancer Res.* 12(10):3152-3157). FusOn-H2 has demonstrated activity against pancreatic cancer xenografts (Fu *et al.* (2006) *Clin. Cancer Res.* 12(10):3152-3157), against Lewis lung carcinoma xenografts in combination with cyclophosphamide, and against syngeneic murine mammary tumors and neuroblastoma (Li *et al.* (2007) *Cancer Res.* 67:7850-
30 7855).

c. Poxvirus

Vaccinia viruses are exemplary of poxviruses. Vaccinia is a cytoplasmic virus, thus, it does not insert its genome into the host genome during its life cycle. Vaccinia virus has a linear, double-stranded DNA genome of approximately 180,000 base pairs in length that is made up of a single continuous polynucleotide chain (Baroudy *et al.* (1982) *Cell* 28:315-324). The structure is due to the presence of 10,000 base pair inverted terminal repeats (ITRs). The ITRs are involved in genome replication. Genome replication involves self-priming, leading to the formation of high molecular weight concatemers (isolated from infected cells), which subsequently are cleaved and repaired to make virus genomes (see, *e.g.*, Traktman, P., Chapter 27, Poxvirus DNA Replication, pp. 775-798, in DNA Replication in Eukaryotic Cells, Cold Spring Harbor Laboratory Press (1996)). The genome contains approximately 250 genes. In general, the non-segmented, non-infectious genome is arranged such that centrally located genes are essential for virus replication (and are thus conserved), while genes near the two termini effect more peripheral functions such as host range and virulence. Vaccinia viruses practice differential gene expression by utilizing open reading frames (ORFs) arranged in sets that, as a general principle, do not overlap.

Vaccinia virus possesses a variety of features for use in cancer gene therapy and vaccination, including broad host and cell type range, and low toxicity. For example, while most oncolytic viruses are natural pathogens, vaccinia virus has a unique history in its widespread application as a smallpox vaccine that has resulted in an established track record of safety in humans. Toxicities related to vaccinia administration occur in less than 0.1% of cases, and can be effectively addressed with immunoglobulin administration. In addition, vaccinia virus possesses a large carrying capacity for foreign genes (up to 25 kb of exogenous DNA fragments, approximately 12% of the vaccinia genome size, can be inserted into the vaccinia genome) and high sequence homology among different strains for designing and generating modified viruses in other strains. Techniques for production of modified vaccinia strains by genetic engineering are well established (Moss (1993) *Curr. Opin. Genet. Dev.* 3: 86-90; Broder and Earl (1999) *Mol. Biotechnol.* 13: 223-245; Timiryasova *et al.* (2001) *Biotechniques* 31: 534-540). Vaccinia virus strains have been shown to specifically colonize solid tumors, while not infecting other organs (see, *e.g.*, Zhang *et al.* (2007) *Cancer Res.* 67:10038-10046; Yu *et al.* (2004) *Nat. Biotech.* 22:313-320; Heo *et al.*

(2011) *Mol. Ther.* 19:1170-1179; Liu *et al.* (2008) *Mol. Ther.* 16:1637-1642; Park *et al.* (2008) *Lancet Oncol.* 9:533-542).

Examples of vaccinia viruses include, but are not limited to, Lister (also known as Elstree), New York City Board of Health (NYCBH), Dairen, Ikeda,
5 LC16M8, Western Reserve (WR), Copenhagen (Cop), Tashkent, Tian Tan, Wyeth, Dryvax, IHD-J, IHD-W, Brighton, Ankara, Modified Vaccinia Ankara (MVA), Dairen I, LIPV, LC16M0, LIPV, WR 65-16, EM63, Bern, Paris, CVA382, NYVAC, ACAM2000 and Connaught strains. Vaccinia viruses are oncolytic viruses that possess a variety of features that make them particularly suitable for use in wound and
10 cancer gene therapy. For example, vaccinia is a cytoplasmic virus, thus, it does not insert its genome into the host genome during its life cycle. Unlike many other viruses that require the host's transcription machinery, vaccinia virus can support its own gene expression in the host cell cytoplasm using enzymes encoded in the viral genome. Vaccinia viruses also have a broad host and cell type range. In particular,
15 vaccinia viruses can accumulate in immunoprivileged cells or immunoprivileged tissues, including tumors and/or metastases, and also including wounded tissues and cells. Yet, unlike other oncolytic viruses, vaccinia virus can typically be cleared from the subject to whom the viruses are administered by activity of the subject's immune system, and hence are less toxic than other viruses such as adenoviruses. Thus, while
20 the viruses can typically be cleared from the subject to whom the viruses are administered by activity of the subject's immune system, viruses can nevertheless accumulate, survive and proliferate in immunoprivileged cells and tissues such as tumors, because such immunoprivileged areas are isolated from the host's immune system.

25 Vaccinia viruses also can be easily modified by insertion of heterologous genes. This can result in the attenuation of the virus and/or permit delivery of therapeutic proteins. For example, the vaccinia virus genome has a large carrying capacity for foreign genes, where up to 25 kb of exogenous DNA fragments (approximately 12% of the vaccinia genome size) can be inserted. The genomes of
30 several of the vaccinia strains have been completely sequenced, and many essential and nonessential genes identified. Due to high sequence homology among different strains, genomic information from one vaccinia strain can be used for designing and

generating modified viruses in other strains. Finally, the techniques for production of modified vaccinia strains by genetic engineering are well established (Moss (1993) *Curr. Opin. Genet. Dev.* 3:86-90; Broder and Earl (1999) *Mol. Biotechnol.* 13:223-245; Timiryasova *et al.* (2001) *Biotechniques* 31:534-540).

5 Various vaccinia viruses have been demonstrated to exhibit antitumor activities. In one study, for example, nude mice bearing non-metastatic colon adenocarcinoma cells were systemically injected with a WR strain of vaccinia virus modified by having a vaccinia growth factor deletion and an enhanced green fluorescent protein inserted into the thymidine kinase locus. The virus was observed
10 to have antitumor effects, including one complete response, despite a lack of exogenous therapeutic genes in the modified virus (McCart *et al.* (2001) *Cancer Res.* 1:8751-8757). In another study, vaccinia melanoma oncolysate (VMO) was injected into sites near melanoma positive lymph nodes in a Phase III clinical trial of melanoma patients. As a control, a New York City Board of Health strain vaccinia
15 virus (VV) was administered to melanoma patients. The melanoma patients treated with VMO had a survival rate better than that for untreated patients, but similar to patients treated with the VV control (Kim *et al.* (2001) *Surgical Oncol.* 10:53-59).

LIVP strains of vaccinia virus also have been used for the diagnosis and therapy of tumors, and for the treatment of wounded and inflamed tissues and cells
20 (see, *e.g.*, Zhang *et al.* (2007) *Surgery* 142:976-983; Lin *et al.* (2008) *J. Clin. Endocrinol. Metab.* 93:4403-7; Kelly *et al.* (2008) *Hum. Gene Ther.* 19:774-782; Yu *et al.* (2009) *Mol. Cancer Ther.* 8:141-151; Yu *et al.* (2009) *Mol. Cancer* 8:45; U.S. Patent No. 7,588,767; U.S. Patent No. 8,052,968; and U.S. Publication No. 2004/0234455). For example, when intravenously administered, LIVP strains have
25 been demonstrated to accumulate in internal tumors at various loci *in vivo*, and have been demonstrated to effectively treat human tumors of various tissue origin, including, but not limited to, breast tumors, thyroid tumors, pancreatic tumors, metastatic tumors of pleural mesothelioma, squamous cell carcinoma, lung carcinoma and ovarian tumors. LIVP strains of vaccinia, including attenuated forms thereof,
30 exhibit less toxicity than WR strains of vaccinia virus, and result in increased and longer survival of treated tumor-bearing animal models (see, *e.g.*, U.S. Publication No. 2011/0293527).

d. Measles Virus

Measles virus (MV) is an enveloped, single-stranded RNA virus with a negative-sense genome that belongs to the family of Paramyxoviruses. Its non-segmented genome is stable, with a low risk of mutating and reverting to its pathogenic form, and due to its replication in the cytoplasm, poses no risk of insertional DNA mutagenesis in infected cells. MV was first isolated from a patient called Edmonston in 1954, and developed into a live vaccine with an excellent safety profile, that has successfully protected over a billion individuals worldwide for 50 years, by attenuation following multiple *in vitro* passages (Aref *et al.* (2016) *Viruses* 8:294; Hutzen *et al.* (2015) *Oncolytic Virotherapy* 4:109-118). Derivatives of this strain, denoted as MV-Edm, are the most commonly utilized MV strains in oncolytic therapy studies. The Schwarz/Moraten measles vaccine strain is more attenuated and immunogenic than Edm derivatives, which makes it safer and more immunomodulatory (Veinalde *et al.* (2017) *Oncimmunology* 6(4):e1285992). The oncolytic effects of wildtype MV were documented in the 1970s, with reports of improvements in patients with acute lymphoblastic leukemia, Burkitt's lymphoma and Hodgkin's lymphoma (Aref *et al.* (2016)).

MV uses three main receptors for entry into target cells: CD46, nectin-4 and signaling lymphocyte activation molecule (SLAM) (Aref *et al.* (2016); Hutzen *et al.* (2015)). Whereas SLAM, which is expressed on activated B and T cells, immature thymocytes, monocytes and dendritic cells, is the main receptor for wildtype strains, attenuated and tumor-selective MV-Edm strains primarily target the CD46 receptor, a regulator of complement activation that is overexpressed in many tumor cells (Aref *et al.* (2016); Hutzen *et al.* (2015); Jacobson *et al.* (2017) *Oncotarget* 8(38):63096-63109; Msaouel *et al.* (2013) *Expert Opin. Biol. Ther.* 13(4)). Nectin-4, which is predominantly expressed in the respiratory epithelium, is utilized by both wild-type and attenuated MV strains (Aref *et al.* (2016); Msaouel *et al.* (2013) *Expert Opin. Biol. Ther.* 13(4)). As with other oncolytic viruses, defects in the IFN antiviral response of tumor cells also facilitates the tumor-selectivity of MV (Aref *et al.* (2016); Jacobson *et al.* (2017) *Oncotarget* 8(38):63096-63109). Clinical trials investigating MV in the treatment of several cancers, including multiple myeloma (NCT02192775, NCT00450814), head and neck cancer (NCT01846091),

mesothelioma (NCT01503177), and ovarian cancer (NCT00408590, NCT02364713) have been conducted.

MV has been genetically engineered to express immune-stimulating and immunomodulatory genes, including those encoding IL-13, IFN-beta, GM-CSF and
5 Helicobacter pylori neutrophil-activating protein (NAP), for example (Aref *et al.* (2016), Hutzen *et al.* (2015); Msaouel *et al.* (2013) *Expert Opin. Biol. Ther.* 13(4)). Combination therapies utilizing oncolytic MV with anti-CTLA-4 and anti-PD-L1 antibodies have been effective in melanoma mouse models (Aref *et al.* (2016); Hutzen *et al.* (2015)).
10 MV-CEA, which is genetically engineered to express the tumor marker carcinoembryonic antigen (CEA), results in the release of CEA into the blood stream of patients following infection of cancer cells, allowing the detection of CEA levels and thus, the tracking of *in vivo* viral infection (Aref *et al.* (2016); Hutzen *et al.* (2015)). The therapeutic use of MV-CEA has been demonstrated pre-clinically, and is
15 in Phase I clinical trials for the treatment of ovarian cancer (NCT00408590).

e. Reovirus

Respiratory Enteric Orphan virus, commonly known as Reovirus, is a non-enveloped double-stranded RNA virus of the Reoviridae family that is nonpathogenic to humans. Wild-type reovirus is ubiquitous throughout the environment, resulting in
20 a 70-100% seropositivity in the general population (Gong *et al.* (2016) *World J. Methodol.* 6(1):25-42). There are three serotypes of reovirus, which include type 1 Lang, type 2 Jones, type 3 Abney and type 3 Dearing (T3D). T3D is the most commonly used naturally occurring oncolytic reovirus serotype in pre-clinical and clinical studies.

25 Oncolytic reovirus is tumor-selective due to activated Ras signaling that is characteristic of cancer cells (Gong *et al.* (2016)); Zhao *et al.* (2016) *Mol. Cancer Ther.* 15(5):767-773). Activation of the Ras signaling pathway disrupts the cell's anti-viral responses, by inhibiting the phosphorylation of dsRNA-dependent protein kinase (PKR), a protein that is normally responsible for preventing viral protein synthesis
30 (Zhao *et al.* (2016)). Ras activation also enhances viral un-coating and disassembly, results in enhanced viral progeny generation and infectivity, and accelerates the release of progeny through enhanced apoptosis (Zhao *et al.* (2016)). It is estimated

that approximately 30% of all human tumors display aberrant Ras signaling (Zhao *et al.* (2016)). For example, the majority of malignant gliomas possess activated Ras signaling pathways, with reovirus demonstrating antitumor activity in 83% of malignant glioma cells *in vitro*, as well as *in vivo* in human malignant glioma models, and in 100% of glioma specimens *ex vivo* (Gong *et al.* (2016) *World J. Methodol.* 6(1):25-42). Additionally, pancreatic adenocarcinomas display a very high incidence of Ras mutations (approximately 90%), and reovirus has shown potent cytotoxicity in 100% of pancreatic cell lines tested *in vitro*, and induced regression in 100% of subcutaneous tumor mouse models *in vivo*. (Gong *et al.* (2016)).

Reovirus has demonstrated broad anticancer activity pre-clinically across a spectrum of malignancies including colon, breast, ovarian, lung, skin (melanoma), neurological, hematological, prostate, bladder, and head and neck cancers (Gong *et al.* (2016)). Reovirus therapy has been tested in combination with radiotherapy, chemotherapy, immunotherapy, and surgery. The combination of reovirus and radiation therapy has proven beneficial in the treatment of head and neck, colorectal and breast cancer cell lines *in vitro*, as well as colorectal cancer and melanoma models *in vivo* (Gong *et al.* (2016)). The combination of reovirus and gemcitabine, as well as reovirus, paclitaxel and cisplatin, have proven successful in mouse tumor models (Zhao *et al.* (2016)). Preclinical studies in B16 melanoma mouse models have shown that the combination of oncolytic reovirus and anti-PD-1 therapy demonstrated improved anticancer efficacy in comparison to reovirus alone (Gong *et al.* (2016); Zhao *et al.* (2016); Kemp *et al.* (2015) *Viruses* 8, 4).

The promising pre-clinical results demonstrated by reovirus have led to many clinical trials. Reolysin® reovirus, developed by the Canadian company Oncolytics Biotech Inc., is the only therapeutic wild-type reovirus in clinical development, and has demonstrated anticancer activity in many malignancies alone, and in combination with other therapeutics. For example, a phase I clinical study of the Reolysin® reovirus in the treatment of recurrent malignant gliomas (NCT00528684) found that the reovirus was well tolerated, while a phase I/II trial found that Reolysin® reovirus kills tumor cells without damaging normal cells in patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that did not respond to platinum chemotherapy (NCT00602277). A phase II clinical trial of Reolysin®

reovirus demonstrated safety and efficacy in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung (NCT00503295). A phase I clinical trial of Reolysin® reovirus in combination with FOLFIRI and bevacizumab in patients with metastatic colorectal cancer (NCT01274624) has been conducted. A phase II clinical trial of Reolysin® reovirus in combination with the chemotherapeutic gemcitabine was carried out in patients with advanced pancreatic adenocarcinoma (NCT00998322), a phase II clinical study investigated the therapeutic potential of Reolysin® in combination with docetaxel in metastatic castration resistant prostate cancer (NCT01619813), and a phase II clinical trial investigated the combination of Reolysin® reovirus with paclitaxel in patients with advanced/metastatic breast cancer (NCT01656538). A phase III clinical trial investigated the efficacy of Reolysin® in combination with paclitaxel and carboplatin in platinum-refractory head and neck cancers (NCT01166542), while phase II clinical studies employing this combination therapy were carried out in patients with non-small cell lung cancer (NCT00861627) and metastatic melanoma (NCT00984464). A phase I clinical trial of Reolysin® in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma is ongoing (NCT02101944).

f. Vesicular Stomatitis Virus (VSV)

Vesicular stomatitis virus (VSV) is a member of the Vesiculovirus genus within the Rhabdoviridae family. Its genome, which consists of a single-stranded RNA with negative-sense polarity, consists of 11,161 nucleotides and encodes for five genes: nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and large polymerase protein (Bishnoi *et al.* (2018) *Viruses* 10(2), 90). VSV is transmitted by insect vectors and disease is limited to its natural hosts, including horses, cattle, and pigs, with mild and asymptomatic infection in humans (Bishnoi *et al.* (2018) *Viruses* 10(2), 90). VSV is a potent and rapid inducer of apoptosis in infected cells, and has been shown to sensitize chemotherapy-resistant tumor cells. VSV has been shown to infect tumor vasculature, resulting in a loss of blood flow to the tumor, blood-coagulation, and lysis of neovasculature. This virus also is capable of replication and induction of cytopathic effects and cell lysis in hypoxic tissues. In addition, WT VSV grows to high titers in a variety of tissue culture cells lines, facilitating large-scale virus production, it has a small and easy to manipulate genome,

and it replicates in the cytoplasm without risk of host cell transformation (Bishnoi *et al.* (2018); Felt and Grdzelishvili (2017). *Journal of General Virology* 98:2895-2911). These factors, together with the fact that it is not pathogenic to humans and there is generally no pre-existing human immunity to VSV, make it a good candidate for viral oncotherapy.

Although VSV can attach to ubiquitously expressed cell-surface molecules, making it "pantropic," WT VSV is sensitive to type I IFN responses and thus displays oncoselectivity based on the defective or inhibited type I IFN signaling of tumors (Felt and Grdzelishvili (2017)). Due to its infectivity of normal cells, VSV can cause neuropathogenicity, but can be attenuated by modifying its matrix protein and/or glycoprotein. For example, the matrix protein can be deleted or the methionine residue at position 51 of the matrix protein can be deleted or substituted with arginine (Bishnoi *et al.* (2018); Felt and Grdzelishvili (2017)). Another approach replaces the glycoprotein of VSV with that of lymphocytic choriomeningitis virus (LCMV) (rVSV-GP) (Bishnoi *et al.* (2018); Felt and Grdzelishvili (2017)). VSV also can be genetically modified to include suicide genes, such as herpes virus thymidine kinase (TK), or to express immune-stimulatory cytokines such as IL-4, IL-12, and IFN β , or co-stimulatory agents such as granulocyte-macrophage-colony-stimulating factor 1 (GM-CSF1), to enhance oncolytic activity (Bishnoi *et al.* (2018)). VSV-IFN β -sodium iodide symporter (VSV-IFN β -NIS), which encodes NIS and IFN β , is being tested in the USA in several phase I clinical trials (see details at ClinicalTrials.gov for trials NCT02923466, NCT03120624 and NCT03017820).

Vesicular stomatitis virus (VSV) is an effective oncolytic therapeutic when administered intravenously (IV) in a variety of murine cancer models. In one study, VSV-GP was successful in the intratumoral treatment of subcutaneously engrafted G62 human glioblastoma cells, as well as the intravenous treatment of orthotopic U87 human glioma cells, in immune-deficient mouse models. Intratumoral injection of VSV-GP also was effective against intracranial CT2A murine glioma cells (Muik *et al.* (2014) *Cancer Res.* 74(13):3567-3578). It was found that VSV-GP did not elicit a detectable neutralizing antibody response, and that this genetically modified oncolytic virus was insensitive to human complement, remaining stable over the length of the experiment (Muik *et al.* (2014)). In another example, intratumoral administration of

VSV-GP was found to effectively infect and kill human A375 malignant melanoma cells transplanted in a mouse model, as well as the murine B16 melanoma cell line (Kimpel *et al.* (2018) *Viruses* 10, 108). Intravenous injection of the oncolytic virus was not successful, and even in the intratumorally-administered groups, the tumors all eventually grew, due to type I IFN responses (Kimpel *et al.* (2018)). In another study, a subcutaneous xenograft mouse model with A2780 human ovarian cancer cells was treated with intratumoral injection of VSV-GP, and although tumor remission was initially observed with no neurotoxicity, remission was temporary and the tumors recurred. This was found to be due to type I IFN responses, with an observed reversal of the antiviral state by combining VSV-GP with the JAK1/2 inhibitor ruxolitinib. (Dold *et al.* (2016) *Molecular Therapy - Oncolytics* 3, 16021).

g. Newcastle Disease Virus

Newcastle Disease Virus (NDV) is an avian paramyxovirus with a single-stranded RNA genome of negative polarity that infects poultry and is generally non-pathogenic to humans, but can cause flu-like symptoms (Tayeb *et al.* (2015) *Oncolytic Virotherapy* 4:49-62; Cheng *et al.* (2016) *J. Virol.* 90:5343-5352). Due to its cytoplasmic replication, lack of host genome integration and recombination, and high genomic stability, NDV and other paramyxoviruses provide safer and more attractive alternatives to other oncolytic viruses, such as retroviruses or some DNA viruses (Matveeva *et al.* (2015) *Molecular Therapy - Oncolytics* 2, 150017). NDV has been shown to demonstrate tumor selectivity, with 10,000 times greater replication in tumor cells than normal cells, resulting in oncolysis due to direct cytopathic effects and induction of immune responses (Tayeb *et al.* (2015); Lam *et al.* (2011) *Journal of Biomedicine and Biotechnology*, Article ID: 718710). Though the mechanism of NDV's tumor selectivity is not entirely clear, defective interferon production and responses to IFN signaling in tumor cells allow the virus to replicate and spread (Cheng *et al.* (2016); Ginting *et al.* (2017) *Oncolytic Virotherapy* 6:21-30). The high affinity of paramyxoviruses towards cancer cells can also be due to overexpression of viral receptors on cancer cell surfaces, including sialic acid (Cheng *et al.* (2016); Matveeva *et al.* (2015); Tayeb *et al.* (2015)).

Non-engineered NDV strains are classified as lentogenic (avirulent), mesogenic (intermediate), or velogenic (virulent), based on their pathogenicity in

chickens, with velogenic and mesogenic strains being capable of replication in (and lysis of) multiple human cancer cell lines, but not lentogenic strains (Cheng *et al.* (2016); Matveeva *et al.* (2015)). NDV strains also are categorized as lytic or non-lytic, with only the lytic strains being able to produce viable and infectious progeny (Ginting *et al.* (2017); Matveeva *et al.* (2015)). On the other hand, the oncolytic effects of non-lytic strains stems mainly from their ability to stimulate immune responses that result in antitumor activity (Ginting *et al.* (2017) *Oncolytic Virotherapy* 6:21-30). Mesogenic lytic strains commonly utilized in oncotherapy include PV701 (MK107), MTH-68/H and 73-T, and lentogenic non-lytic strains commonly utilized include HUI, Ulster and Hitchner-B1 (Tayeb *et al.* (2015); Lam *et al.* (2011); Freeman *et al.* (2006) *Mol. Ther.* 13(1):221-228).

The NDV strain PV701 displayed activity against colorectal cancer in a phase 1 trial (Laurie *et al.* (2006) *Clin. Cancer Res.* 12(8):2555-2562), and NDV strain 73-T demonstrated *in vitro* oncolytic activity against various human cancer cell lines, including fibrosarcoma, osteosarcoma, neuroblastoma and cervical carcinoma, as well as *in vivo* therapeutic effects in mice bearing human neuroblastomas, fibrosarcoma xenografts and several carcinoma xenografts, including colon, lung, breast and prostate cancer xenografts (Lam *et al.* (2011)). NDV strain MTH-68/H resulted in significant regression of tumor cell lines, including PC12, MCF7, HCT116, DU-145, HT-29, A431, HELA, and PC3 cells, and demonstrated favorable responses in patients with advanced cancers when administered by inhalation (Lam *et al.* (2011)). The non-lytic strain Ulster demonstrated cytotoxic effects against colon carcinoma, while the lytic strain Italien effectively killed human melanomas (Lam *et al.* (2011)). Lentogenic NDV strain HUI demonstrated oncolytic activity against recurrent glioblastoma multiforme when administered intravenously to patients, while lentogenic strain LaSota prolonged survival in colorectal cancer patients (Lam *et al.* (2011); Freeman *et al.* (2006) *Mol. Ther.* 13(1):221-228) and was capable of infecting and killing non-small cell lung carcinoma (A549), glioblastoma (U87MG and T98G), mammary gland adenocarcinoma (MCF7 and MDA-MB-453) and hepatocellular carcinoma (Huh7) cell lines (Ginting *et al.* (2017) *Oncolytic Virotherapy* 6:21-30).

Genetically engineered NDV strains also have been evaluated for oncolytic therapy. For example, the influenza NS1 gene, an IFN antagonist, was introduced into

the genome of NDV strain Hitchner-B1, resulting in an enhanced oncolytic effect in a variety of human tumor cell lines and a mouse model of B16 melanoma (Tayeb *et al.* (2015)). The antitumor/immunostimulatory effects of NDV have been augmented by introduction of IL-2 or GM-CSF genes into the viral genome (Lam *et al.* (2011)).

- 5 Combination therapy, utilizing intratumoral NDV injection with systemic CTLA-4 antibody administration resulted in the efficient rejection of pre-established distant tumors (Matveeva *et al.* (2015)).

h. Parvovirus

- H-1 parvovirus (H-1PV) is a small, non-enveloped single-stranded DNA virus
10 belonging to the family Parvoviridae, whose natural host is the rat (Angelova *et al.* (2017) *Front. Oncol.* 7:93; Angelova *et al.* (2015) *Frontiers in Bioengineering and Biotechnology* 3:55). H-1PV is nonpathogenic to humans, and is attractive as an oncolytic virus due to its favorable safety profile, the absence of preexisting H-1PV immunity in humans, and their lack of host cell genome integration (Angelova *et al.*
15 (2015)). H-1PV has demonstrated broad oncosuppressive activity against solid tumors, including preclinical models of breast, gastric, cervical, brain, pancreatic and colorectal cancer, as well as hematological malignancies, including lymphoma and leukemia (Angelova *et al.* (2017)). H-1PV stimulates anti-tumor responses via the increased presentation of tumor-associated antigens, maturation of dendritic cells, and
20 the release of pro-inflammatory cytokines (Moehler *et al.* (2014) *Frontiers in Oncology* 4:92). H-1PV also displays tumor selectivity, which is thought to be due to the availability of cellular replication and transcription factors, the overexpression of cellular proteins that interact with the NS1 parvoviral protein, and the activation of metabolic pathways involved in the functional regulation of NS1 in tumor cells, but
25 not normal cells. Due to the innocuous nature of H-1PV, the wild type strain is often utilized, negating the need for attenuation by genetic engineering (Angelova *et al.* (2015)).

- Studies have shown that oncolytic H-1PV infection of human glioma cells results in efficient cell killing, and high-grade glioma stem cell models were also
30 permissive to lytic H-1PV infection. Enhanced killing of glioma cells has been observed when the virus was applied shortly after tumor cell irradiation, indicating that this protocol can be useful in non-resectable recurrent glioblastoma (Angelova *et*

al. (2017)). Intracerebral or systemic H-1PV injection led to regression of gliomas without toxic side effects in immunocompetent rats with orthotopic RG-2 tumors, as well as in immunodeficient animals implanted with human U87 gliomas (Angelova *et al.* (2015)). Del H-1PV, a fitness variant with higher infectivity and spreading in

5 human transformed cell lines, demonstrated oncolytic effects *in vivo* in pancreatic cancer and cervix carcinoma xenograft models (Geiss *et al.* (2017) *Viruses* 9, 301). H-1PV also demonstrated oncolytic activity against a panel of five human osteosarcoma cell lines (CAL 72, H-OS, MG-63, SaOS-2, U-2OS) (Geiss *et al.* (2017) *Viruses* 9, 301) and against human melanoma cells (SK29-Mel-1, SK29-Mel-1.22) (Moehler *et al.* (2014) *Frontiers in Oncology* 4:92). In another study, nude rats bearing cervical carcinoma xenografts demonstrated dose-dependent tumor growth arrest and regression following treatment with H-1PV (Angelova *et al.* (2015)). The intratumoral and intravenous administration of H-1PV also demonstrated significant growth suppression in human mammary carcinoma xenografts in immunocompromised mice

15 (Angelova *et al.* (2015)). Intratumoral H-1PV injection in human gastric carcinoma or human Burkitt lymphoma-bearing mice resulted in tumor regression and growth suppression (Angelova *et al.* (2015)).

A phase I/IIa clinical trial of an oncolytic H-1PV (ParvOryx01) in recurrent glioblastoma multiforme patients (clinical trial NCT01301430), demonstrated

20 progression-free survival, clinical safety and patient tolerability with intratumoral or intravenous injection (Angelova *et al.* (2017); Geiss *et al.* (2017) *Viruses* 9, 301; Geletneky *et al.* (2017) *Mol. Ther.* 25(12):2620-2634). This trial demonstrated the ability of H-1PV to cross the blood-brain barrier in a dose-dependent manner and to establish an immunogenic anti-tumor response, characterized by leukocytic

25 infiltration, predominantly by CD8⁺ and CD4⁺ T lymphocytes, and the detection in locally treated tumors of several markers of immune cell activation, including perforin, granzyme B, IFN γ , IL-2, CD25 and CD40L (Geletneky *et al.* (2017) *Mol. Ther.* 25(12):2620-2634).

H-1PV also has demonstrated efficient killing of highly aggressive pancreatic ductal adenocarcinoma (PDAC) cells *in vitro*, including those resistant to

30 gemcitabine, and intratumoral injection of H-1PV resulted in tumor regression and prolonged animal survival in an orthotopic rat model of PDAC (Angelova *et al.*

(2017); Angelova *et al.* (2015)). Similar results, including selective tumor targeting and absence of toxicity, were observed in an immunodeficient nude rat PDAC model (Angelova *et al.* (2015)). The combination of H-1PV and cytostatic (cisplatin, vincristine) or targeted (sunitinib) drugs results in the synergistic induction of apoptosis in human melanoma cells (Moehler *et al.* (2014)). The combination of H-1PV and valproic acid, an HDAC inhibitor, resulted in synergistic cytotoxicity towards cervical and pancreatic cancer cells (Angelova *et al.* (2017)), while the therapeutic efficiency of gemcitabine was improved when combined with H-1PV in a two-step protocol (Angelova *et al.* (2015)). As with other viruses, H-1PV can be engineered to express anti-cancer molecules. For example, studies have shown that a parvovirus-H1-derived vector expressing Apoptin had a greater capacity to induce apoptosis than wild-type H-1PV (Geiss *et al.* (2017)).

i. Coxsackie Virus

Coxsackie virus (CV) belongs to the genus Enterovirus and the family Picornaviridae and has a positive-sense single-stranded RNA genome that does not integrate into the host cell genome. CVs are classified into groups A and B, based on their effects in mice, and can cause mild upper respiratory tract infections in humans (Bradley *et al.* (2014) *Oncolytic Virotherapy* 3:47-55). Commonly investigated coxsackie viruses for oncolytic virotherapy include attenuated coxsackie virus B3 (CV-B3), CV-B4, CV-A9 and CV-A21 (Yla-Pelto *et al.* (2016) *Viruses* 8, 57). CV-A21 infects cells via the ICAM-1 (or CD54) and DAF (or CD55) receptors, which are expressed at much higher levels in tumor cells, including melanoma, breast, colon, endometrial, head and neck, pancreatic and lung cancers, as well as in multiple myeloma and malignant glioma. CV-A21 has shown promising preclinical anticancer activity *in vitro* against malignant myeloma, melanoma, and prostate, lung, head and neck, and breast cancer cells lines, and *in vivo* in mice bearing human melanoma xenografts, and against primary breast cancer tumors as well as their metastases in mice (Yla-Pelto *et al.* (2016); Bradley *et al.* (2014)). A derivative of CV-A21, CV-A21-DAFv, also known as CAVATAK™, was generated from the wild-type Kuykendall strain by serial passage of CV-A21 on DAF-expressing, ICAM-1–negative rhabdomyosarcoma (RD) cells and was found to possess enhanced oncolytic properties in comparison to the parent strain. CAVATAK™ binds only to the DAF

receptor, which can contribute to its enhanced tropism towards cancer cells (Yla-Pelto *et al.* (2016)).

CV-A21 also has been studied in combination with doxorubicin hydrochloride, exhibiting enhanced oncolytic efficiency compared to either treatment alone against human breast, colorectal and pancreatic cancer cell lines, as well as in a xenograft mouse model of human breast cancer (Yla-Pelto *et al.* (2016)). Since a significant portion of the population has already developed neutralizing antibodies against CV, CV-A21 therapy has been combined with immunosuppressants such as cyclophosphamide (Bradley *et al.* (2014)) and is a good candidate for delivery via vehicle cells.

Clinical trials have investigated the use of CAVATAK™ in patients with stage IIIc or IV malignant melanoma (NCT01636882; NCT00438009; NCT01227551), and CAVATAK™ alone or in combination with low dose mitomycin C in patients with non-muscle invasive bladder cancer (NCT02316171). Clinical trials also have studied the effects of intravenous administration of CV-A21 in the treatment of solid tumors including melanoma, breast and prostate cancer (NCT00636558). Ongoing clinical trials include the investigation of CAVATAK™ alone or in combination with pembrolizumab for treatment of patients with non-small cell lung cancer (NCT02824965, NCT02043665) and bladder cancer (NCT02043665); CAVATAK™ in combination with ipilimumab in patients with uveal melanoma and liver metastases (NCT03408587) and in patients with advanced melanoma (NCT02307149); and CAVATAK™ in combination with pembrolizumab in patients with advanced melanoma (NCT02565992).

j. Seneca Valley Virus

Seneca Valley Virus (SVV) is a member of the Senecavirus genus within the family Picornaviridae, that has a positive-sense single-stranded RNA genome and is selective for neuroendocrine cancers, including neuroblastoma, rhabdomyosarcoma, medulloblastoma, Wilms tumor, glioblastoma and small-cell lung cancer (Miles *et al.* (2017) *J. Clin. Invest.* 127(8):2957-2967; Qian *et al.* (2017) *J. Virol.* 91(16):e00823-17; Burke, M. J. (2016) *Oncolytic Virotherapy* 5:81-89). Studies have identified the anthrax toxin receptor 1 (ANTXR1) as the receptor for SVV, which is frequently expressed on the surface of tumor cells in comparison to normal cells, but prior

studies also have indicated that sialic acid can be a component of the SVV receptor in pediatric glioma models (Miles *et al.* (2017)). SVV isolate 001 (SVV-001) is a potent oncolytic virus that can target and penetrate solid tumors following intravenous administration, and is attractive due to its lack of insertional mutagenesis as well as its selective tropism for cancer cells and its non-pathogenicity in humans and animals. Additionally, previous exposure in humans is rare, resulting in low rates of preexisting immunity (Burke, M. J. (2016) *Oncolytic Virotherapy* 5:81-89).

SVV-001 has shown promising *in vitro* activity against small-cell lung cancer, adrenal gland cortical carcinoma, neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma cell lines, and *in vivo* activity in orthotopic xenograft mouse models of pediatric GBM, medulloblastoma, retinoblastoma, rhabdomyosarcoma and neuroblastoma (Burke (2016)). NTX-010, an oncolytic SVV-001 developed by Neotropix®, is for the treatment of pediatric patients with relapsed/refractory solid tumors alone or in combination with cyclophosphamide, but was limited in its therapeutic efficacy due to the development of neutralizing antibodies (Burke *et al.* (2015) *Pediatr. Blood Cancer* 62(5):743-750). Clinical trials include studies using SV-001 in patients with solid tumors with neuroendocrine features (NCT00314925), NTX-010/SVV-001 in combination with cyclophosphamide in patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, adrenocortical carcinoma or carcinoid tumors (NCT01048892), and NTX-010/SVV-001 in patients with small cell lung cancer after chemotherapy (NCT01017601).

H. PHARMACEUTICAL PRODUCTION, COMPOSITIONS, AND FORMULATIONS

Provided herein are methods for manufacturing, pharmaceutical compositions and formulations containing any of the immunostimulatory bacteria provided herein and pharmaceutically acceptable excipients or additives. The pharmaceutical compositions can be used in treatment of diseases, such as hyperproliferative diseases or conditions, such as a tumor or cancer. The immunostimulatory bacteria can be administered in a single agent therapy, or can be administered in a combination therapy with a further agent or treatment. The compositions can be formulated for single dosage administration or for multiple dosage administration. The agents can be

formulated for direct administration. The compositions can be provided as a liquid or dried formulation.

1. Manufacturing

a. Cell Bank Manufacturing

5 As the active ingredient of the immunotherapeutic described herein is composed of engineered self-replicating bacteria, the selected composition will be expanded into a series of cell banks that will be maintained for long-term storage and as the starting material for manufacturing of drug substance. Cell banks are produced under current good manufacturing practices (cGMP) in an appropriate manufacturing facility per the Code of Federal Regulations (CFR) 21 part 211 or other relevant regulatory authority. As the active agent of the immunotherapeutic is a live bacterium, the products described herein are, by definition, non-sterile and cannot be terminally sterilized. Care must be taken to ensure that aseptic procedures are used throughout the manufacturing process to prevent contamination. As such, all raw materials and solutions must be sterilized prior to use in the manufacturing process.

A master cell bank (MCB) is produced by sequential serial single colony isolation of the selected bacterial strain to ensure no contaminants are present in the starting material. A sterile culture vessel containing sterile media (can be complex media *e.g.*, LB or MSBB or defined media *e.g.*, M9 supplemented with appropriate nutrients) is inoculated with a single well-isolated bacterial colony and the bacteria are allowed to replicate *e.g.*, by incubation at 37 °C with shaking. The bacteria are then prepared for cryopreservation by suspension in a solution containing a cryoprotective agent or agents.

Examples of cryoprotective agents include: proteins such as human or bovine serum albumin, gelatin, immunoglobulins; carbohydrates including monosaccharides (galactose, D-mannose, sorbose, *etc.*) and their non-reducing derivatives (*e.g.*, methylglucoside), disaccharides (trehalose, sucrose, *etc.*), cyclodextrins, and polysaccharides (raffinose, maltodextrins, dextrans, *etc.*); amino-acids (glutamate, glycine, alanine, arginine or histidine, tryptophan, tyrosine, leucine, phenylalanine, *etc.*); methylamines such as betaine; polyols such as trihydric or higher sugar alcohols, *e.g.*, glycerin, erythritol, glycerol, arabitol, xylitol, sorbitol, and mannitol; propylene glycol; polyethylene glycol; surfactants *e.g.*, pluronic; or organo-sulfur

compounds such as dimethyl sulfoxide (DMSO), and combinations thereof.

Cryopreservation solutions can include one or more cryoprotective agents in a solution that can also contain salts (*e.g.*, sodium chloride, potassium chloride, magnesium sulfate, and or buffering agents such as sodium phosphate,

5 tris(hydroxymethyl)aminomethane (TRIS), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and other such buffering agents known to those of skill.

Suspension of the bacteria in cryopropreservation solution can be achieved either by addition of a concentrated cryoprotective agent or agents to the culture material to achieve a final concentration that preserves viability of the bacteria during the freezing and thawing process (*e.g.*, 0.5% to 20% final concentration of glycerol), or by harvesting the bacteria (*e.g.*, by centrifugation) and suspending in a cryopreservative solution containing the appropriate final concentration of cryoprotective agent(s). The suspension of bacteria in cryopreservation solution is then filled into appropriate sterile vials (plastic or glass) with a container closure system that is capable of maintaining closure integrity under frozen conditions (*e.g.*, butyl stoppers and crimp seals). The vials of master cell bank are then frozen (either slowly by means of a controlled rate freezer, or quickly by means of placing directly into a freezer). The MCB is then stored frozen at a temperature that preserves long-term viability (*e.g.*, at or below -60 °C). Thawed master cell bank material is thoroughly characterized to ensure identity, purity, and activity per regulation by the appropriate authorities.

Working cell banks (WCBs) are produced much the same way as the master cell bank, but the starting material is derived from the MCB. MCB material can be directly transferred into a fermentation vessel containing sterile media and expanded as above. The bacteria are then suspended in a cryopreservation solution, filled into containers, sealed, and frozen at or below -20 °C. Multiple WCBs can be produced from MCB material, and WCB material can be used to make additional cell banks (*e.g.*, a manufacturer's working cell bank MWCB). WCBs are stored frozen and characterized to ensure identity, purity, and activity. WCB material is typically the starting material used in production of the drug substance of biologics such as engineered bacteria.

b. Drug Substance Manufacturing

Drug substance is manufactured using aseptic processes under cGMP as described above. Working cell bank material is typically used as starting material for manufacturing of drug substance under cGMP, however other cell banks can be used (e.g., MCB or MWCB). Aseptic processing is used for production of all cell therapies including bacterial cell-based therapies. The bacteria from the cell bank are expanded by fermentation, this can be achieved by production of a pre-culture (e.g., in a shake flask) or by direct inoculation of a fermenter. Fermentation is accomplished in a sterile bioreactor or flask that can be single-use disposable or re-usable. Bacteria are harvested by concentration (e.g., by centrifugation, continuous centrifugation, or tangential flow filtration). Concentrated bacteria are purified from media components and bacterial metabolites by exchange of the media with buffer (e.g., by diafiltration). The bulk drug product is formulated and preserved as an intermediate (e.g., by freezing or drying) or is processed directly into a drug product. Drug substance is tested for identity, strength, purity, potency, and quality.

c. Drug Product Manufacturing

Drug product is defined as the final formulation of the active substance contained in its final container. Drug product is manufactured using aseptic processes under cGMP. Drug product is produced from drug substance. Drug substance is thawed or reconstituted if necessary, then formulated at the appropriate target strength. Because the active component of the drug product is live, engineered bacteria, the strength is determined by the number of CFU contained within the suspension. The bulk product is diluted in a final formulation appropriate for storage and use as described below. Containers are filled, and sealed with a container closure system and the drug product is labeled. The drug product is stored at an appropriate temperature to preserve stability and is tested for identity, strength, purity, potency, and quality and released for human use if it meets specified acceptance criteria.

2. Compositions

Pharmaceutically acceptable compositions are prepared in view of approvals for a regulatory agency or other agency prepared in accordance with generally recognized pharmacopeia for use in animals and in humans. The compositions can be prepared as solutions, suspensions, powders, or sustained release formulations.

Typically, the compounds are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see *e.g.*, Ansel *Introduction to Pharmaceutical Dosage Forms*, Fourth Edition, 1985, 126). The formulation should suit the mode of administration.

- 5 Compositions can be formulated for administration by any route known to those of skill in the art including intramuscular, intravenous, intradermal, intralesional, intraperitoneal injection, subcutaneous, intratumoral, epidural, nasal, oral, vaginal, rectal, topical, local, otic, inhalational, buccal (*e.g.*, sublingual), and transdermal administration or any route. Other modes of administration also are
- 10 contemplated. Administration can be local, topical or systemic depending upon the locus of treatment. Local administration to an area in need of treatment can be achieved by, for example, but not limited to, local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant.
- 15 Compositions also can be administered with other biologically active agents, either sequentially, intermittently or in the same composition. Administration also can include controlled release systems including controlled release formulations and device controlled release, such as by means of a pump.

- The most suitable route in any given case depends on a variety of factors, such
- 20 as the nature of the disease, the progress of the disease, the severity of the disease and the particular composition which is used. Pharmaceutical compositions can be formulated in dosage forms appropriate for each route of administration. In particular, the compositions can be formulated into any suitable pharmaceutical preparations for systemic, local intraperitoneal, oral or direct administration. For example, the
- 25 compositions can be formulated for administration subcutaneously, intramuscularly, intratumorally, intravenously or intradermally. Administration methods can be employed to decrease the exposure of the active agent to degradative processes, such as immunological intervention via antigenic and immunogenic responses. Examples of such methods include local administration at the site of treatment or continuous
- 30 infusion.

 The immunostimulatory bacteria can be formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible

tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administrations well as transdermal patch preparation and dry powder inhalers. Typically, the compounds are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see *e.g.*, Ansel *Introduction to Pharmaceutical Dosage Forms*, Fourth Edition, 1985, 126). Generally, the mode of formulation is a function of the route of administration. The compositions can be formulated in dried (lyophilized or other forms of vitrification) or liquid form. Where the compositions are provided in dried form they can be reconstituted just prior to use by addition of an appropriate buffer, for example, a sterile saline solution.

10 3. **Formulations**

a. **Liquids, Injectables, Emulsions**

The formulation generally is made to suit the route of administration. Parenteral administration, generally characterized by injection or infusion, either subcutaneously, intramuscularly, intratumorally, intravenously or intradermally is contemplated herein. Preparations of bacteria for parenteral administration include suspensions ready for injection (direct administration) or frozen suspension that are thawed prior to use, dry soluble products, such as lyophilized powders, ready to be combined with a resuspension solution just prior to use, and emulsions. Dried thermostable formulations such as lyophilized formulations can be used for storage of unit doses for later use.

The pharmaceutical preparation can be in a frozen liquid form, for example a suspension. If provided in frozen liquid form, the drug product can be provided as a concentrated preparation to be thawed and diluted to a therapeutically effective concentration before use.

The pharmaceutical preparations also can be provided in a dosage form that does not require thawing or dilution for use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives, as appropriate, such as suspending agents (*e.g.*, sorbitol, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, or fractionated vegetable oils); and preservatives suitable for use with microbial therapeutics. The pharmaceutical preparations can be presented in dried

form, such as lyophilized or spray-dried, for reconstitution with water or other sterile suitable vehicle before use.

Suitable excipients are, for example, water, saline, dextrose, or glycerol. The solutions can be either aqueous or nonaqueous. If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and other buffered solutions used for intravenous hydration. For intratumoral administration solutions containing thickening agents such as glucose, polyethylene glycol, and polypropylene glycol, oil emulsions and mixtures thereof can be appropriate to maintain localization of the injectant.

Pharmaceutical compositions can include carriers or other excipients. For example, pharmaceutical compositions provided herein can contain any one or more of a diluents(s), adjuvant(s), antiadherent(s), binder(s), coating(s), filler(s), flavor(s), color(s), lubricant(s), glidant(s), preservative(s), detergent(s), or sorbent(s) and a combination thereof or vehicle with which a modified therapeutic bacteria is administered. For example, pharmaceutically acceptable carriers or excipients used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances. Formulations, including liquid preparations, can be prepared by conventional means with pharmaceutically acceptable additives or excipients.

Pharmaceutical compositions can include carriers such as a diluent, adjuvant, excipient, or vehicle with which the compositions are administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions will contain a therapeutically effective amount of the compound or agent, generally in purified form or partially purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Water is a typical carrier. Saline solutions and aqueous dextrose and glycerol solutions also can be employed as liquid carriers, particularly for injectable solutions. Compositions can contain along with an active ingredient: a diluent such as lactose, sucrose, dicalcium phosphate, or

carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acacia, gelatin, glucose, molasses, polyvinylpyrrolidone, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Suitable
5 pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, and ethanol. For example, suitable excipients are, for example, water, saline, dextrose, glycerol or ethanol. A composition, if desired, also can contain other minor amounts of non-toxic auxiliary
10 substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.

Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers,
15 antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances. Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehicles include fixed oils of vegetable origin,
20 cottonseed oil, corn oil, sesame oil and peanut oil. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include, for example,
25 polysorbates, such Polysorbate 80 (TWEEN 80). Sequestering or chelating agents of metal ions, such as EDTA, can be included. Pharmaceutical carriers also include polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment. Non-anti-microbial preservatives can be included.

30 The pharmaceutical compositions also can contain other minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example,

sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins. Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see, *e.g.*, U.S. Pat. No. 3,710,795) also is contemplated herein. The percentage of active compound contained in such parenteral compositions
5 is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.

b. Dried Thermostable Formulations

The bacteria can be dried. Dried thermostable formulations, such as lyophilized or spray dried powders and vitrified glass can be reconstituted for
10 administration as solutions, emulsions and other mixtures. The dried thermostable formulation can be prepared from any of the liquid formulations, such as the suspensions, described above. The pharmaceutical preparations can be presented in lyophilized or vitrified form for reconstitution with water or other suitable vehicle before use.

15 The thermostable formulation is prepared for administration by reconstituting the dried compound with a sterile solution. The solution can contain an excipient which improves the stability or other pharmacological attribute of the active substance or reconstituted solution, prepared from the powder. The thermostable formulation is prepared by dissolving an excipient, such as dextrose, sorbitol, fructose, corn syrup,
20 xylitol, glycerin, glucose, sucrose or other suitable agent, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art. Then, the drug substance is added to the resulting mixture, and stirred until it is mixed. The resulting mixture is apportioned into vials for drying. Each vial will contain a single dosage containing 1×10^5 - 1×10^{11} CFU per vial. After drying, the
25 product vial is sealed with a container closure system that prevents moisture or contaminants from entering the sealed vial. The dried product can be stored under appropriate conditions, such as at -20 °C, 4 °C, or room temperature. Reconstitution of this dried formulation with water or a buffer solution provides a formulation for use in parenteral administration. The precise amount depends upon the indication treated
30 and selected compound. Such amount can be empirically determined.

4. Compositions for Other Routes of Administration

Depending upon the condition treated, other routes of administration in addition to parenteral, such as topical application, transdermal patches, oral and rectal administration are also contemplated herein. The suspensions and powders described above can be administered orally or can be reconstituted for oral administration. Pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets and gel capsules for systemic effect. Rectal suppositories include solid bodies for insertion into the rectum which melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases can be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories can be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration are manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration. Formulations suitable for rectal administration can be provided as unit dose suppositories. These can be prepared by admixing the drug substance with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

For oral administration, pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or wetting agents (*e.g.*, sodium lauryl sulfate). The tablets can be coated by methods well-known in the art.

Formulations suitable for buccal (sublingual) administration include, for example, lozenges containing the active compound in a flavored base, usually sucrose

and acacia or tragacanth; and pastilles containing the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Topical mixtures are prepared as described for the local and systemic administration. The resulting mixtures can be solutions, suspensions, emulsion or the
5 like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

The compositions can be formulated as aerosols for topical application, such
10 as by inhalation (see, *e.g.*, U.S. Patent Nos. 4,044,126; 4,414,209 and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment of lung diseases). These formulations, for administration to the respiratory tract, can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of
15 the formulation will typically have diameters of less than 50 microns, or less than 10 microns.

The compounds can be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or
20 intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients also can be administered.

Formulations suitable for transdermal administration are provided. They can
25 be provided in any suitable format, such as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches contain the active compound in an optionally buffered aqueous solution of, for example, 0.1 to 0.2 M concentration with respect to the active compound. Formulations suitable for transdermal administration also can be delivered by
30 iontophoresis (see, *e.g.*, Tyle, P, (1986) *Pharmaceutical Research* 3(6):318-326) and typically take the form of an optionally buffered aqueous solution of the active compound.

Pharmaceutical compositions also can be administered by controlled release formulations and/or delivery devices (see *e.g.*, U.S. Patent Nos. 3,536,809; 3,598,123; 3,630,200; 3,845,770; 3,916,899; 4,008,719; 4,769,027; 5,059,595; 5,073,543; 5,120,548; 5,591,767; 5,639,476; 5,674,533 and 5,733,566).

5 **5. Dosages and Administration**

The compositions can be formulated as pharmaceutical compositions for single dosage or multiple dosage administration. The immunostimulatory bacteria can be included in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. For example, the
10 concentration of the pharmaceutically active compound is adjusted so that an injection provides an effective amount to produce the desired pharmacological effect. The therapeutically effective concentration can be determined empirically by testing the immunostimulatory bacteria in known *in vitro* and *in vivo* systems such as by using the assays described herein or known in the art. For example, standard clinical
15 techniques can be employed. *In vitro* assays and animal models can be employed to help identify optimal dosage ranges. The precise dose, which can be determined empirically, can depend on the age, weight, body surface area, and condition of the patient or animal, the particular immunostimulatory bacteria administered, the route of administration, the type of disease to be treated and the seriousness of the disease.

20 Hence, it is understood that the precise dosage and duration of treatment is a function of the disease being treated and can be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test data. Concentrations and dosage values also can vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens
25 should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or use of compositions and combinations containing them. The compositions can be administered hourly, daily, weekly,
30 monthly, yearly or once. Generally, dosage regimens are chosen to limit toxicity. It should be noted that the attending physician would know how to and when to terminate, interrupt or adjust therapy to lower dosage due to toxicity, or bone marrow,

liver or kidney or other tissue dysfunctions. Conversely, the attending physician would also know how to and when to adjust treatment to higher levels if the clinical response is not adequate (precluding toxic side effects).

The immunostimulatory bacteria are included in the composition in an amount
5 sufficient to exert a therapeutically useful effect. For example, the amount is one that achieves a therapeutic effect in the treatment of a hyperproliferative disease or condition, such as cancer.

Pharmaceutically and therapeutically active compounds and derivatives thereof are typically formulated and administered in unit dosage forms or multiple
10 dosage forms. Each unit dose contains a predetermined quantity of therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Unit dosage forms, include, but are not limited to, tablets, capsules, pills, powders, granules, parenteral suspensions, and oral solutions or suspensions, and oil water emulsions containing
15 suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof. Unit dose forms can be contained in vials, ampoules and syringes or individually packaged tablets or capsules. Unit dose forms can be administered in fractions or multiples thereof. A multiple dose form is a plurality of identical unit dosage forms packaged in a single container to be administered in segregated unit
20 dose form. Examples of multiple dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit doses that are not segregated in packaging. Generally, dosage forms or compositions containing active ingredient in the range of 0.005% to 100% with the balance made up from non-toxic carrier can be prepared. Pharmaceutical compositions can be
25 formulated in dosage forms appropriate for each route of administration.

The unit-dose parenteral preparations are packaged in an ampoule, a vial or a syringe with a needle. The volume of liquid solution or reconstituted powder preparation, containing the pharmaceutically active compound, is a function of the disease to be treated and the particular article of manufacture chosen for package. All
30 preparations for parenteral administration must be sterile, as is known and practiced in the art.

As indicated, compositions provided herein can be formulated for any route known to those of skill in the art including, but not limited to, subcutaneous, intramuscular, intravenous, intradermal, intralesional, intraperitoneal injection, epidural, vaginal, rectal, local, otic, transdermal administration or any route of
5 administration. Formulations suited for such routes are known to one of skill in the art. Compositions also can be administered with other biologically active agents, either sequentially, intermittently or in the same composition.

Pharmaceutical compositions can be administered by controlled release formulations and/or delivery devices (see, *e.g.*, U.S. Patent Nos. 3,536,809;
10 3,598,123; 3,630,200; 3,845,770; 3,847,770; 3,916,899; 4,008,719; 4,687,660; 4,769,027; 5,059,595; 5,073,543; 5,120,548; 5,354,556; 5,591,767; 5,639,476; 5,674,533 and 5,733,566). Various delivery systems are known and can be used to administer selected compositions, are contemplated for use herein, and such particles can be easily made.

15 **6. Packaging and Articles of Manufacture**

Also provided are articles of manufacture containing packaging materials, any pharmaceutical composition provided herein, and a label that indicates that the compositions are to be used for treatment of diseases or conditions as described herein. For example, the label can indicate that the treatment is for a tumor or cancer.

20 Combinations of immunostimulatory bacteria described herein and another therapeutic agent also can be packaged in an article of manufacture. In one example, the article of manufacture contains a pharmaceutical composition containing the immunostimulatory bacteria composition and no further agent or treatment. In other examples, the article of manufacture another further therapeutic agent, such as a
25 different anti-cancer agent. In this example, the agents can be provided together or separately, for packaging as articles of manufacture.

The articles of manufacture provided herein contain packaging materials. Packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. See, for example, U.S. Patent Nos. 5,323,907, 5,052,558 and
30 5,033,252, each of which is incorporated herein in its entirety. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any

packaging material suitable for a selected formulation and intended mode of administration and treatment. Exemplary of articles of manufacture are containers including single chamber and dual chamber containers. The containers include, but are not limited to, tubes, bottles and syringes. The containers can further include a
5 needle for intravenous administration.

The choice of package depends on the agents, and whether such compositions will be packaged together or separately. In general, the packaging is non-reactive with the compositions contained therein. In other examples, some of the components can be packaged as a mixture. In other examples, all components are packaged separately.
10 Thus, for example, the components can be packaged as separate compositions that, upon mixing just prior to administration, can be directly administered together. Alternatively, the components can be packaged as separate compositions for administration separately.

Selected compositions including articles of manufacture thereof also can be
15 provided as kits. Kits can include a pharmaceutical composition described herein and an item for administration provided as an article of manufacture. The compositions can be contained in the item for administration or can be provided separately to be added later. The kit can, optionally, include instructions for application including dosages, dosing regimens and instructions for modes of administration. Kits also can
20 include a pharmaceutical composition described herein and an item for diagnosis.

I. METHODS OF TREATMENT AND USES

The methods provided herein include methods of administering or using the immunostimulatory bacteria, for treating subjects having a disease or condition whose symptoms can be ameliorated or lessened by administration of such bacteria, such as
25 cancer. In particular examples, the disease or condition is a tumor or a cancer. Additionally, methods of combination therapies with one or more additional agents for treatment, such as an anticancer agent or an anti-hyaluronan agent, also are provided. The bacteria can be administered by any suitable route, including, but not limited to, parenteral, systemic, topical and local, such as intra-tumoral, intravenous,
30 rectal, oral, intramuscular, mucosal and other routes. Formulations suitable for each are provided. The skilled person can establish suitable regimens and doses and select routes.

1. Tumors

The immunostimulatory bacteria, combinations, uses and methods provided herein are applicable to treating all types of tumors, including cancers, particularly solid tumors including lung cancer, bladder, non-small cell lung cancer, gastric
5 cancers, head and neck cancers, ovarian cancer, liver cancer, pancreatic cancer, kidney cancer, breast cancer, colorectal cancer, and prostate cancer. The methods also can be used for hematological cancers.

Tumors and cancers subject to treatment by the uses methods provided herein include, but are not limited to, those that originate in the immune system, skeletal
10 system, muscles and heart, breast, pancreas, gastrointestinal tract, central and peripheral nervous system, renal system, reproductive system, respiratory system, skin, connective tissue systems, including joints, fatty tissues, and circulatory system, including blood vessel walls. Examples of tumors that can be treated with the immunostimulatory bacteria provided herein include carcinomas, gliomas, sarcomas
15 (including liposarcoma), adenocarcinomas, adenosarcomas, and adenomas. Such tumors can occur in virtually all parts of the body, including, for example, breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix or liver.

Tumors of the skeletal system include, for example, sarcomas and blastomas such as osteosarcoma, chondrosarcoma, and chondroblastoma. Muscle and heat
20 tumors include tumors of both skeletal and smooth muscles, *e.g.*, leiomyomas (benign tumors of smooth muscle), leiomyosarcomas, rhabdomyomas (benign tumors of skeletal muscle), rhabdomyosarcomas, cardiac sarcoma. Tumors of the
25 gastrointestinal tract include *e.g.*, tumors of the mouth, esophagus, stomach, small intestine, colon and colorectal tumors, as well as tumors of gastrointestinal secretory organs such as salivary glands, liver, pancreas, and the biliary tract. Tumors of the central nervous system include tumors of the brain, retina, and spinal cord, and can also originate in associated connective tissue, bone, blood vessels or nervous tissue.
30 Treatment of tumors of the peripheral nervous system are also contemplated. Tumors of the peripheral nervous system include malignant peripheral nerve sheath tumors. Tumors of the renal system include those of the kidneys, *e.g.*, renal cell carcinoma, as

well as tumors of the ureters and bladder. Tumors of the reproductive system include tumors of the cervix, uterus, ovary, prostate, testes and related secretory glands.

Tumors of the immune system include both blood based and solid tumors, including lymphomas, *e.g.*, both Hodgkin's and non-Hodgkin's. Tumors of the respiratory
5 system include tumors of the nasal passages, bronchi and lungs. Tumors of the breast include, *e.g.*, both lobular and ductal carcinoma.

Other examples of tumors that can be treated by the immunostimulatory bacteria and methods provided herein include Kaposi's sarcoma, CNS neoplasms, neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases,
10 melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma (such as glioblastoma multiforme) and leiomyosarcoma. Examples of other cancer that can be treated as provided herein include but are not limited to lymphoma, blastoma, neuroendocrine tumors, mesothelioma, schwannoma, meningioma, melanoma, and leukemia or lymphoid malignancies. Examples of such
15 cancers include hematologic malignancies, such as Hodgkin's lymphoma; non-Hodgkin's lymphomas (Burkitt's lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mycosis fungoides, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, hairy cell leukemia and lymphoplasmacytic leukemia), tumors of lymphocyte precursor cells,
20 including B-cell acute lymphoblastic leukemia/lymphoma, and T-cell acute lymphoblastic leukemia/lymphoma, thymoma, tumors of the mature T and NK cells, including peripheral T-cell leukemias, adult T-cell leukemia/T-cell lymphomas and large granular lymphocytic leukemia, Langerhans cell histiocytosis, myeloid neoplasias such as acute myelogenous leukemias, including AML with maturation,
25 AML without differentiation, acute promyelocytic leukemia, acute myelomonocytic leukemia, and acute monocytic leukemias, myelodysplastic syndromes, and chronic myeloproliferative disorders, including chronic myelogenous leukemia; tumors of the central nervous system such as glioma, glioblastoma, neuroblastoma, astrocytoma, medulloblastoma, ependymoma, and retinoblastoma; solid tumors of the head and
30 neck (*e.g.*, nasopharyngeal cancer, salivary gland carcinoma, and esophageal cancer), lung (*e.g.*, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung), digestive system (*e.g.*, gastric or stomach

cancer including gastrointestinal cancer, cancer of the bile duct or biliary tract, colon cancer, rectal cancer, colorectal cancer, and anal carcinoma), reproductive system (*e.g.*, testicular, penile, or prostate cancer, uterine, vaginal, vulval, cervical, ovarian, and endometrial cancer), skin (*e.g.*, melanoma, basal cell carcinoma, squamous cell cancer, actinic keratosis, cutaneous melanoma), liver (*e.g.*, liver cancer, hepatic carcinoma, hepatocellular cancer, and hepatoma), bone (*e.g.*, osteoclastoma, and osteolytic bone cancers) additional tissues and organs (*e.g.*, pancreatic cancer, bladder cancer, kidney or renal cancer, thyroid cancer, breast cancer, cancer of the peritoneum, and Kaposi's sarcoma), tumors of the vascular system (*e.g.*, angiosarcoma and hemangiopericytoma), Wilms' tumor, retinoblastoma, osteosarcoma and Ewing's sarcoma.

2. Administration

In practicing the uses and methods herein, immunostimulatory bacteria provided herein can be administered to a subject, including a subject having a tumor or having neoplastic cells, or a subject to be immunized. One or more steps can be performed prior to, simultaneously with, or after administration of the immunostimulatory bacteria to the subject including, but not limited to, diagnosing the subject with a condition appropriate for administering immunostimulatory bacteria, determining the immunocompetence of the subject, immunizing the subject, treating the subject with a chemotherapeutic agent, treating the subject with radiation, or surgically treating the subject.

For embodiments that include administering immunostimulatory bacteria to a tumor-bearing subject for therapeutic purposes, the subject typically has previously been diagnosed with a neoplastic condition. Diagnostic methods also can include determining the type of neoplastic condition, determining the stage of the neoplastic conditions, determining the size of one or more tumors in the subject, determining the presence or absence of metastatic or neoplastic cells in the lymph nodes of the subject, or determining the presence of metastases of the subject.

Some embodiments of therapeutic methods for administering immunostimulatory bacteria to a subject can include a step of determination of the size of the primary tumor or the stage of the neoplastic disease, and if the size of the primary tumor is equal to or above a threshold volume, or if the stage of the

neoplastic disease is at or above a threshold stage, an immunostimulatory bacterium is administered to the subject. In a similar embodiment, if the size of the primary tumor is below a threshold volume, or if the stage of the neoplastic disease is at or below a threshold stage, the immunostimulatory bacterium is not yet administered to the

5 subject; such methods can include monitoring the subject until the tumor size or neoplastic disease stage reaches a threshold amount, and then administering the immunostimulatory bacterium to the subject. Threshold sizes can vary according to several factors, including rate of growth of the tumor, ability of the immunostimulatory bacterium to infect a tumor, and immunocompetence of the

10 subject. Generally the threshold size will be a size sufficient for an immunostimulatory bacterium to accumulate and replicate in or near the tumor without being completely removed by the host's immune system, and will typically also be a size sufficient to sustain a bacterial infection for a time long enough for the host to mount an immune response against the tumor cells, typically about one week

15 or more, about ten days or more, or about two weeks or more. Exemplary threshold stages are any stage beyond the lowest stage (*e.g.*, Stage I or equivalent), or any stage where the primary tumor is larger than a threshold size, or any stage where metastatic cells are detected.

Any mode of administration of a microorganism to a subject can be used,

20 provided the mode of administration permits the immunostimulatory bacteria to enter a tumor or metastasis. Modes of administration can include, but are not limited to, intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intratumoral, multipuncture, inhalation, intranasal, oral, intracavity (*e.g.*, administering to the bladder via a catheter, administering to the gut by suppository or enema), aural, rectal,

25 and ocular administration.

One skilled in the art can select any mode of administration compatible with the subject and the bacteria, and that also is likely to result in the bacteria reaching tumors and/or metastases. The route of administration can be selected by one skilled in the art according to any of a variety of factors, including the nature of the disease,

30 the kind of tumor, and the particular bacteria contained in the pharmaceutical composition. Administration to the target site can be performed, for example, by

ballistic delivery, as a colloidal dispersion system, or systemic administration can be performed by injection into an artery.

The dosage regimen can be any of a variety of methods and amounts, and can be determined by one skilled in the art according to known clinical factors. A single
5 dose can be therapeutically effective for treating a disease or disorder in which immune stimulation effects treatment. Exemplary of such stimulation is an immune response, that includes, but is not limited to, one or both of a specific immune response and non-specific immune response, both specific and non-specific responses, innate response, primary immune response, adaptive immunity, secondary immune
10 response, memory immune response, immune cell activation, immune cell proliferation, immune cell differentiation, and cytokine expression.

As is known in the medical arts, dosages for a subject can depend on many factors, including the subject's species, size, body surface area, age, sex, immunocompetence, and general health, the particular bacteria to be administered,
15 duration and route of administration, the kind and stage of the disease, for example, tumor size, and other compounds such as drugs being administered concurrently. In addition to the above factors, such levels can be affected by the infectivity of the bacteria and the nature of the bacteria, as can be determined by one skilled in the art. In the present methods, appropriate minimum dosage levels of bacteria can be levels
20 sufficient for the bacteria to survive, grow and replicate in a tumor or metastasis. Exemplary minimum levels for administering a bacterium to a 65 kg human can include at least about 5×10^6 colony forming units (CFU), at least about 1×10^7 CFU, at least about 5×10^7 CFU, at least about 1×10^8 CFU, or at least about 1×10^9 CFU. In the present methods, appropriate maximum dosage levels of bacteria can be levels
25 that are not toxic to the host, levels that do not cause splenomegaly of 3x or more, levels that do not result in colonies or plaques in normal tissues or organs after about 1 day or after about 3 days or after about 7 days. Exemplary maximum levels for administering a bacterium to a 65 kg human can include no more than about 5×10^{11} CFU, no more than about 1×10^{11} CFU, no more than about 5×10^{10} CFU, no more
30 than about 1×10^{10} CFU, or no more than about 1×10^9 CFU.

The methods and uses provided herein can include a single administration of immunostimulatory bacteria to a subject or multiple administrations of

immunostimulatory bacteria to a subject or others of a variety of regimens, including combination therapies with other anti-tumor therapeutics and/or treatments. These include, cellular therapies, such as administration of modified immune cells, CAR-T therapy, CRISPR therapy, immune checkpoint inhibitors, such as antibodies (*e.g.*,
5 anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies), chemotherapy/chemotherapeutic compounds, such as nucleoside analogs, surgery and radiotherapy.

In some embodiments, a single administration is sufficient to establish immunostimulatory bacteria in a tumor, where the bacteria can colonize and can cause or enhance an anti-tumor response in the subject. In other embodiments, the
10 immunostimulatory bacteria provided for use in the methods herein can be administered on different occasions, separated in time typically by at least one day. Separate administrations can increase the likelihood of delivering a bacterium to a tumor or metastasis, where a previous administration may have been ineffective in delivering the bacterium to a tumor or metastasis. In embodiments, separate
15 administrations can increase the locations on a tumor or metastasis where bacterial colonization/proliferation can occur or can otherwise increase the titer of bacteria accumulated in the tumor, which can increase eliciting or enhancing a host's anti-tumor immune response.

When separate administrations are performed, each administration can be a
20 dosage amount that is the same or different relative to other administration dosage amounts. In one embodiment, all administration dosage amounts are the same. In other embodiments, a first dosage amount can be a larger dosage amount than one or more subsequent dosage amounts, for example, at least 10x larger, at least 100x larger, or at least 1000x larger than subsequent dosage amounts. In one example of a
25 method of separate administrations in which the first dosage amount is greater than one or more subsequent dosage amounts, all subsequent dosage amounts can be the same, smaller amount relative to the first administration.

Separate administrations can include any number of two or more administrations, including two, three, four, five or six administrations. One skilled in
30 the art readily can determine the number of administrations to perform, or the desirability of performing one or more additional administrations, according to methods known in the art for monitoring therapeutic methods and other monitoring

methods provided herein. Accordingly, the methods provided herein include methods of providing to the subject one or more administrations of an immunostimulatory bacteria, where the number of administrations can be determined by monitoring the subject, and, based on the results of the monitoring, determining whether or not to provide one or more additional administrations. Deciding whether or not to provide one or more additional administrations can be based on a variety of monitoring results, including, but not limited to, indication of tumor growth or inhibition of tumor growth, appearance of new metastases or inhibition of metastasis, the subject's anti-bacterial antibody titer, the subject's anti-tumor antibody titer, the overall health of the subject and the weight of the subject.

The time period between administrations can be any of a variety of time periods. The time period between administrations can be a function of any of a variety of factors, including monitoring steps, as described in relation to the number of administrations, the time period for a subject to mount an immune response, the time period for a subject to clear bacteria from normal tissue, or the time period for bacterial colonization/proliferation in the tumor or metastasis. In one example, the time period can be a function of the time period for a subject to mount an immune response; for example, the time period can be more than the time period for a subject to mount an immune response, such as more than about one week, more than about ten days, more than about two weeks, or more than about a month; in another example, the time period can be less than the time period for a subject to mount an immune response, such as less than about one week, less than about ten days, less than about two weeks, or less than about a month. In another example, the time period can be a function of the time period for bacterial colonization/proliferation in the tumor or metastasis; for example, the time period can be more than the amount of time for a detectable signal to arise in a tumor or metastasis after administration of a microorganism expressing a detectable marker, such as about 3 days, about 5 days, about a week, about ten days, about two weeks, or about a month.

The methods used herein also can be performed by administering compositions, such as suspensions and other formulations, containing the immunostimulatory bacteria provided herein. Such compositions contain the bacteria

and a pharmaceutically acceptable excipient or vehicle, as provided herein or known to those of skill in the art.

As discussed above, the uses and methods provided herein also can include administering one or more therapeutic compounds, such as anti-tumor compounds or
5 other cancer therapeutics, to a subject in addition to administering immunostimulatory bacteria to the subject. The therapeutic compounds can act independently, or in conjunction with the immunostimulatory bacteria, for tumor therapeutic effects. Therapeutic compounds that can act independently include any of a variety of known chemotherapeutic compounds that can inhibit tumor growth,
10 inhibit metastasis growth and/or formation, decrease the size of a tumor or metastasis, eliminate a tumor or metastasis, without reducing the ability of the immunostimulatory bacteria to accumulate in a tumor, replicate in the tumor, and cause or enhance an anti-tumor immune response in the subject. Examples of such chemotherapeutic agents include, but are not limited to, alkylating agents such as
15 thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; androgens such as calusterone, dromostanolone propionate, epitioestanol, mepitioestane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; antibiotics such as aclacinomycins, actinomycin, anthramycin, azaserine,
20 bleomycins, cactinomycin, calicheamicin, carubicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin,
25 tubercidin, ubenimex, zinostatin, zorubicin; anti estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; aziridines such as benzodepa,
30 carboquone, meturedpa, and uredepa; ethylenimines and methylmelamines including altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate and trimethylol melamine; folic acid replenisher such

as folinic acid; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine,

5 lomustine, nimustine, ranimustine; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; proteins such as arginine deiminase and asparaginase; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; taxanes, such as

10 paclitaxel and docetaxel and albuminated forms thereof (*i.e.*, *nab*-paclitaxel and *nab*-docetaxel), topoisomerase inhibitor RFS 2000; thymidylate synthase inhibitor (such as Tomudex); additional chemotherapeutics including aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestabucil; bisantrene; edatrexate; defosfamide; demecolcine; diaziquone; difluoromethylornithine (DMFO);

15 eflornithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2', 2"-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol;

20 mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; Navelbine; Novantrone; teniposide; daunomycin; aminopterin; Xeloda; ibandronate; CPT-11; retinoic acid; esperamycins; capecitabine; and topoisomerase inhibitors such

25 as irinotecan. Pharmaceutically acceptable salts, acids or derivatives of any of the above can also be used.

Therapeutic compounds that act in conjunction with the immunostimulatory bacteria include, for example, compounds that increase the immune response eliciting properties of the bacteria. For example, a gene expression-altering compound can

30 induce or increase transcription of a gene in a bacterium, such as an exogenous gene, such as a STING protein. Any of a wide variety of compounds that can alter gene expression are known in the art, including IPTG and RU486. Exemplary genes whose

expression can be up-regulated include proteins and RNA molecules, including toxins, enzymes that can convert a prodrug to an anti-tumor drug, cytokines, transcription regulating proteins, shRNA, siRNA, and ribozymes. In other embodiments, therapeutic compounds that can act in conjunction with the immunostimulatory bacteria to increase the colonization/proliferation or immune response eliciting properties of the bacteria are compounds that can interact with a bacteria-expressed gene product, and such interaction can result in an increased killing of tumor cells or an increased anti-tumor immune response in the subject. A therapeutic compound that can interact with a bacteria-expressed gene product can include, for example a prodrug or other compound that has little or no toxicity or other biological activity in its subject-administered form, but after interaction with a bacteria-expressed gene product, the compound can develop a property that results in tumor cell death, including but not limited to, cytotoxicity, ability to induce apoptosis, or ability to trigger an immune response. A variety of prodrug-like substances are known in the art, including ganciclovir, 5-fluorouracil, 6-methylpurine deoxyriboside, cephalosporin-doxorubicin, 4-[(2-chloroethyl)(2-mesuloxyethyl)amino]benzoyl-L-glutamic acid, acetaminophen, indole-3-acetic acid, CB1954, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycampothecin, bis-(2-chloroethyl)amino-4-hydroxyphenylaminomethanone 28, 1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole, epirubicin-glucoronide, 5'-deoxy-5-fluorouridine, cytosine arabinoside, and linamarin.

3. Monitoring

The methods provided herein can further include one or more steps of monitoring the subject, monitoring the tumor, and/or monitoring the immunostimulatory bacteria administered to the subject. Any of a variety of monitoring steps can be included in the methods provided herein, including, but not limited to, monitoring tumor size, monitoring the presence and/or size of metastases, monitoring the subject's lymph nodes, monitoring the subject's weight or other health indicators including blood or urine markers, monitoring anti-bacterial antibody titer,

monitoring bacterial expression of a detectable gene product, and directly monitoring bacterial titer in a tumor, tissue or organ of a subject.

The purpose of the monitoring can be simply for assessing the health state of the subject or the progress of therapeutic treatment of the subject, or can be for
5 determining whether or not further administration of the same or a different immunostimulatory bacterium is warranted, or for determining when or whether or not to administer a compound to the subject where the compound can act to increase the efficacy of the therapeutic method, or the compound can act to decrease the pathogenicity of the bacteria administered to the subject.

10 In some embodiments, the methods provided herein can include monitoring one or more bacterially expressed genes. Bacteria, such as those provided herein or otherwise known in the art, can express one or more detectable gene products, including but not limited to, detectable proteins.

As provided herein, measurement of a detectable gene product expressed in a
15 bacterium can provide an accurate determination of the level of bacteria present in the subject. As further provided herein, measurement of the location of the detectable gene product, for example, by imaging methods including tomographic methods, can determine the localization of the bacteria in the subject. Accordingly, the methods provided herein that include monitoring a detectable bacterial gene product can be
20 used to determine the presence or absence of the bacteria in one or more organs or tissues of a subject, and/or the presence or absence of the bacteria in a tumor or metastases of a subject. Further, the methods provided herein that include monitoring a detectable bacterial gene product can be used to determine the titer of bacteria present in one or more organs, tissues, tumors or metastases. Methods that include
25 monitoring the localization and/or titer of bacteria in a subject can be used for determining the pathogenicity of bacteria since bacterial infection, and particularly the level of infection, of normal tissues and organs can indicate the pathogenicity of the bacteria. The methods that include monitoring the localization and/or titer of immunostimulatory bacteria in a subject can be performed at multiple time points
30 and, accordingly, can determine the rate of bacterial replication in a subject, including the rate of bacterial replication in one or more organs or tissues of a subject; accordingly, methods that include monitoring a bacterial gene product can be used for

determining the replication competence of the bacteria. The methods provided herein also can be used to quantitate the amount of immunostimulatory bacteria present in a variety of organs or tissues, and tumors or metastases, and can thereby indicate the degree of preferential accumulation of the bacteria in a subject; accordingly, the

5 bacterial gene product monitoring can be used in methods of determining the ability of the bacteria to accumulate in tumor or metastases in preference to normal tissues or organs. Since the immunostimulatory bacteria used in the methods provided herein can accumulate in an entire tumor or can accumulate at multiple sites in a tumor, and can also accumulate in metastases, the methods provided herein for monitoring a

10 bacterial gene product can be used to determine the size of a tumor or the number of metastases present in a subject. Monitoring such presence of bacterial gene product in tumor or metastasis over a range of time can be used to assess changes in the tumor or metastases, including growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, and also can be used to determine the rate

15 of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, or the change in the rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases.

Accordingly, monitoring a bacterial gene product can be used for monitoring a neoplastic disease in a subject, or for determining the efficacy of treatment of a

20 neoplastic disease, by determining rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, or the change in the rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases.

Any of a variety of detectable proteins can be detected by monitoring,

25 exemplary of which are any of a variety of fluorescence proteins (*e.g.*, green fluorescence proteins), any of a variety of luciferases, transferring or other iron binding proteins; or receptors, binding proteins, and antibodies, where a compound that specifically binds the receptor, binding protein or antibody can be a detectable agent or can be labeled with a detectable substance (*e.g.*, a radionuclide or imaging

30 agent).

Tumor and/or metastasis size can be monitored by any of a variety of methods known in the art, including external assessment methods or tomographic or magnetic

imaging methods. In addition to the methods known in the art, methods provided herein, for example, monitoring bacterial gene expression, can be used for monitoring tumor and/or metastasis size.

Monitoring size over several time points can provide information regarding
5 the increase or decrease in size of a tumor or metastasis, and can also provide information regarding the presence of additional tumors and/or metastases in the subject. Monitoring tumor size over several time points can provide information regarding the development of a neoplastic disease in a subject, including the efficacy of treatment of a neoplastic disease in a subject.

10 The methods provided herein also can include monitoring the antibody titer in a subject, including antibodies produced in response to administration of immunostimulatory bacteria to a subject. The bacteria administered in the methods provided herein can elicit an immune response to endogenous bacterial antigens. The bacteria administered in the methods provided herein also can elicit an immune
15 response to exogenous genes expressed by the bacteria. The bacteria administered in the methods provided herein also can elicit an immune response to tumor antigens. Monitoring antibody titer against bacterial antigens, bacterially expressed exogenous gene products, or tumor antigens can be used to monitor the toxicity of the bacteria, monitoring the efficacy of treatment methods, or monitoring the level of gene product
20 or antibodies for production and/or harvesting.

Monitoring antibody titer can be used to monitor the toxicity of the bacteria. Antibody titer against a bacteria can vary over the time period after administration of the bacteria to the subject, where at some particular time points, a low anti-(bacterial antigen) antibody titer can indicate a higher toxicity, while at other time points a high
25 anti-(bacterial antigen) antibody titer can indicate a higher toxicity. The bacteria used in the methods provided herein can be immunogenic, and can, therefore, elicit an immune response soon after administering the bacteria to the subject. Generally, immunostimulatory bacteria against which the immune system of a subject can mount a strong immune response can be bacteria that have low toxicity when the subject's
30 immune system can remove the bacteria from all normal organs or tissues. Thus, in some embodiments, a high antibody titer against bacterial antigens soon after administering the bacteria to a subject can indicate low toxicity of the bacteria.

In other embodiments, monitoring antibody titer can be used to monitor the efficacy of treatment methods. In the methods provided herein, antibody titer, such as anti-(tumor antigen) antibody titer, can indicate the efficacy of a therapeutic method such as a therapeutic method to treat neoplastic disease. Therapeutic methods
5 provided herein can include causing or enhancing an immune response against a tumor and/or metastasis. Thus, by monitoring the anti-(tumor antigen) antibody titer, it is possible to monitor the efficacy of a therapeutic method in causing or enhancing an immune response against a tumor and/or metastasis.

In other embodiments, monitoring antibody titer can be used for monitoring
10 the level of gene product or antibodies for production and/or harvesting. As provided herein, methods can be used for producing proteins, RNA molecules such as shRNA, or other compounds, by expressing an exogenous gene in a microorganism that has accumulated in a tumor. Monitoring antibody titer against the protein, RNA molecule or other compound can indicate the level of production of the protein, RNA molecule
15 or other compound by the tumor-accumulated microorganism, and also can directly indicate the level of antibodies specific for such a protein, RNA molecule or other compound.

The methods provided herein also can include methods of monitoring the health of a subject. Some of the methods provided herein are therapeutic methods,
20 including neoplastic disease therapeutic methods. Monitoring the health of a subject can be used to determine the efficacy of the therapeutic method, as is known in the art. The methods provided herein also can include a step of administering to a subject an immunostimulatory bacterium, as provided herein. Monitoring the health of a subject can be used to determine the pathogenicity of an immunostimulatory
25 bacterium administered to a subject. Any of a variety of health diagnostic methods for monitoring disease such as neoplastic disease, infectious disease, or immune-related disease can be monitored, as is known in the art. For example, the weight, blood pressure, pulse, breathing, color, temperature or other observable state of a subject can indicate the health of a subject. In addition, the presence or absence or level of one or
30 more components in a sample from a subject can indicate the health of a subject. Typical samples can include blood and urine samples, where the presence or absence or level of one or more components can be determined by performing, for example, a

blood panel or a urine panel diagnostic test. Exemplary components indicative of a subject's health include, but are not limited to, white blood cell count, hematocrit, and c-reactive protein concentration.

The methods provided herein can include monitoring a therapy, where
5 therapeutic decisions can be based on the results of the monitoring. Therapeutic methods provided herein can include administering to a subject immunostimulatory bacteria, where the bacteria can preferentially accumulate in a tumor and/or metastasis, and where the bacteria can cause or enhance an anti-tumor immune response. Such therapeutic methods can include a variety of steps including multiple
10 administrations of a particular immunostimulatory bacterium, administration of a second immunostimulatory bacterium, or administration of a therapeutic compound. Determination of the amount, timing or type of immunostimulatory bacteria or compound to administer to the subject can be based on one or more results from monitoring the subject. For example, the antibody titer in a subject can be used to
15 determine whether or not it is desirable to administer an immunostimulatory bacterium and, optionally, a compound, the quantity of bacteria and/or compound to administer, and the type of bacteria and/or compound to administer, where, for example, a low antibody titer can indicate the desirability of administering an additional immunostimulatory bacterium, a different immunostimulatory bacterium,
20 and/or a therapeutic compound such as a compound that induces bacterial gene expression or a therapeutic compound that is effective independent of the immunostimulatory bacteria.

In another example, the overall health state of a subject can be used to determine whether or not it is desirable to administer an immunostimulatory
25 bacterium and, optionally, a compound, the quantity of bacterium or compound to administer, and the type of bacterium and/or compound to administer where, for example, determining that the subject is healthy can indicate the desirability of administering additional bacteria, different bacteria, or a therapeutic compound such as a compound that induces bacterial gene expression. In another example, monitoring
30 a detectable bacterially expressed gene product can be used to determine whether it is desirable to administer an immunostimulatory bacterium and, optionally, a compound, the quantity of bacterium and/or compound to administer, and the type of bacterium

and/or compound to administer where, for example, determining that the subject is healthy can indicate the desirability of administering additional bacteria, different bacteria, or a therapeutic compound such as a compound that induces bacterial gene expression. Such monitoring methods can be used to determine whether or not the therapeutic method is effective, whether or not the therapeutic method is pathogenic to the subject, whether or not the bacteria have accumulated in a tumor or metastasis, and whether or not the bacteria have accumulated in normal tissues or organs. Based on such determinations, the desirability and form of further therapeutic methods can be derived.

In another example, monitoring can determine whether or not immunostimulatory bacteria have accumulated in a tumor or metastasis of a subject. Upon such a determination, a decision can be made to further administer additional bacteria, a different immunostimulatory bacterium and, optionally, a compound to the subject.

J. EXAMPLES

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

Summary of exemplary engineered immunostimulatory bacterial strains and nomenclature:

Strain #	Plasmid	Strain Background	RNAi Targets	Alternate name
AST-100	None	YS1646	none	VNP20009
AST-101	None	YS1646-ASD	none	ASD (<i>asd</i> gene knockout)
AST-102	pEQU6	YS1646	none	YS1646 (pEQU6 – plasmid)
AST-103	pEQU6	YS1646	Scrambled (shRNA)	YS1646 (pEQU6-shSCR)
AST-104	pEQU6	YS1646	muTREN1 (shRNA) ARI-108	YS1646 (pEQU6-shTREN1)
AST-105	pEQU6	YS1646	muPD-L1 (shRNA) ARI-115	YS1646 (pEQU6-shPDL1)
AST-106	pEQU6	YS1646	muTREN1 (microRNA) ARI-203	YS1646 (pEQU6-miTREN1)
AST-107	pATI-U6	YS1646-ASD	Scrambled (shRNA)	ASD (pATI-shSCR)
AST-108	pATI-U6	YS1646-ASD	muTREN1 (shRNA) ARI-108	ASD (pATI-shTREN1)

Strain #	Plasmid	Strain Background	RNAi Targets	Alternate name
AST-109	pATIKAN-U6	YS1646-ASD	Scrambled (shRNA)	ASD (pATIKAN-shSCR)
AST-110	pATIKAN-U6	YS1646-ASD	muTREX1 (shRNA) ARI-108	ASD (pATIKAN-shTREX1)
AST-111	None	YS1646-ASD-fljb-fluC	None	ASD/FLG (<i>asd</i> and flagellin knockout)
AST-112	pATI-U6	YS1646-ASD-fljb-fluC	muTREX1 (shRNA) ARI-108	ASD/FLG (pATI-shTREX1)
AST-113	pATI-U6	YS1646-ASD-fljb-fluC	muTREX1 (shRNA) ARI-108	ASD/FLG (pATI-U6 Kan shTREX1)
AST-114	None	YS1646-ASD-LLO	None	ASD/LLO (<i>asd</i> knockout / cytoLLO knock-in)
AST-115	pATI-U6	YS1646-ASD-LLO	muTREX1 (shRNA) ARI-108	ASD/LLO (pATIKAN-shTREX1)
AST-116	pATIKANpBRori-U6	YS1646-ASD	Scrambled	ASD (pATIKANLow-shSCR)
AST-117	pATIKANpBRori-U6	YS1646-ASD	muTREX1 (shRNA) ARI-108	ASD (pATIKANLow-shTREX1)
AST-118	pATIKANpBRori-U6	YS1646-ASD-fljb-fluC	muTREX1 (shRNA) ARI-108	ASD/FLG (pATIKANLow-shTREX1)
AST-119	pATIKANpBRori-U6	YS1646-ASD-pMTL-LLO	muTREX1 (shRNA) ARI-108	ASD/LLO (pATIKANLow-shTREX1)
AST-120	pEQU6	YS1646-ASD-pMTL-LLO	muTREX1 (microRNA) ARI-203	ASD/LLO(pEQU6-miTREX1) Suicidal
AST-121	pEQU6	YS1646	muVISTA ARI-157	YS1646 (pEQU6-shVISTA)
AST-122	pEQU6	YS1646	muTGF-beta ARI-149	YS1646 (pEQU6-TGF-beta)
AST-123	pEQU6	YS1645	muBeta-Catenin ARI-166	YS1646 (pEQU6-Beta-Catenin)

Example 1

Auxotrophic Strains of *S. typhimurium*

The *Salmonella* Strain YS1646 is Auxotrophic for Adenosine

- 5 Strains provided herein are engineered to be auxotrophic for adenosine. As a result, they are attenuated *in vivo* because they are unable to replicate in the low adenosine concentrations of normal tissue, and colonization occurs primarily in the solid tumor microenvironment (TME), where adenosine levels are high. The *Salmonella* strain YS1646 is a derivative of the wild-type strain ATCC #14028, and

was engineered to be auxotrophic for purines due to disruption of the *purI* gene (synonymous with *purM*) (Low *et al.* (2004) *Methods Mol. Med* 90:47-60).

Subsequent analysis of the entire genome of YS1646 demonstrated that the *purI* gene was not in fact deleted, but was instead disrupted by a chromosomal inversion

5 (Broadway *et al.* (2014) *J. Biotechnol.* 20:177-178), and that the entire gene is still contained within two parts of the YS1646 chromosome that is flanked by insertion sequences, one of which has an active transposase. The presence of the complete genetic sequence of the *purI* gene, disrupted by means of a chromosomal reengagement, leaves open the possibility of reversion to a wild-type gene. While it
10 has previously been demonstrated that the purine auxotrophy of YS1646 was stable after >140 serial passages *in vitro*, it was not clear what the reversion rate is (Clairmont *et al.* (2000) *J. Infect. Dis.* 181:1996-2002).

It is shown herein that, when provided with adenosine, YS1646 is able to replicate in minimal medium, whereas the wild-type parental strain, ATCC #14028
15 can grow in minimal media that is not supplemented with adenosine. YS1646 was grown overnight in lysogeny broth (LB) medium, washed with M9 minimal medium, and diluted into M9 minimal medium containing no adenosine, or increasing concentrations of adenosine. Growth was measured using a SpectraMax® M3 Spectrophotometer (Molecular Devices) at 37 °C, reading the OD₆₀₀ every 15
20 minutes.

The results showed that, unlike a wild-type strain (ATCC #14028), which was able to grow in all concentrations of adenosine, the YS1646 strain only was able to replicate when adenosine was provided at concentrations ranging from 11 to 300 micromolar, but was completely unable to replicate in M9 alone or M9 supplemented
25 with 130 nanomolar adenosine. These data demonstrate that *purI* mutants are able to replicate at concentrations of adenosine that are found in the tumor microenvironment, but not at concentrations found in normal tissues. Engineered adenosine auxotrophic strains exemplified herein include strains in which all or portions of the *purI* open reading frame are deleted from the chromosome to prevent
30 reversion to wild-type. Such gene deletions can be achieved by any method known to one of skill in the art, including the lambda red system, as described below.

The *Salmonella* Strain YS1646 is Auxotrophic for ATP

In addition to the purine and adenosine auxotrophy, it was determined whether the *purI* deleted strain also can scavenge ATP. ATP accumulates to high levels in the tumor microenvironment, due to leakage from dying tumor cells. It is shown herein that, when provided with ATP, strain YS1646 is able to replicate in minimal media, but is unable to grow when not supplemented with ATP. To demonstrate this, strain YS1646 was grown overnight in LB medium, washed with M9 minimal medium, and diluted into M9 minimal medium containing no ATP, or increasing concentrations of ATP (Fisher). Growth was measured using a SpectraMax® M3 Spectrophotometer (Molecular Devices) at 37 °C, reading the OD₆₀₀ every 15 minutes. The results demonstrated that strain YS1646 is able to replicate when ATP is provided at concentrations of 0.012 millimolar, or in M9 alone.

Example 2

Defects in Intracellular Replication are Attributed to the *msbB* Mutation

The YS1646 strain contains mutations in *purI*, which limits replication to sites containing high concentrations of purines, adenosine, or ATP, and in *msbB*, which alters the lipopolysaccharide (LPS) surface coat in order to reduce TLR4-mediated pro-inflammatory signaling. It also has been established that, unlike wild-type *Salmonella*, strain YS1646 is unable to replicate in macrophages. Experiments were performed to determine which of these genetic mutations is responsible for conferring that phenotype within the wild-type strain, ATCC 14028.

In this assay, mouse RAW macrophage cells (InvivoGen, San Diego, Ca.) were infected with wild-type *Salmonella* strains containing deletions in *purI*, *msbB*, or both, at a multiplicity of infection (MOI) of approximately 5 bacteria per cell for 30 minutes, then the cells were washed with PBS, and medium containing gentamicin was added to kill extracellular bacteria. Intracellular bacteria are not killed by gentamicin, as it cannot cross the cell membrane. At various time points after infection, cell monolayers were lysed by osmotic shock with water, and the cell lysates were diluted and plated on LB agar to enumerate surviving colony forming units (CFUs).

As shown in the table below, wild-type *Salmonella* strains containing only the *purI* mutation still were able to replicate. This explains why there is only a modest improvement in tolerability observed with the *purI* deletion alone, while achieving a

high degree of specificity to the tumor microenvironment. Strains containing only the *msbB*⁻ mutation, as well as strains containing the *purI*⁻ and *msbB*⁻ mutations, were unable to replicate and were rapidly cleared from cells within 48 hours.

Hours	CFUs/Well					
	ATCC 14028 Δ <i>purI</i>		ATCC 14028 Δ <i>purI</i> / Δ <i>msbB</i>		ATCC 14028 Δ <i>msbB</i>	
1	104000	108000	68000	68000	88000	40000
2.5	5600	6000	760	960	3200	3200
5	5600	4000	1120	880	800	680
27	11200	5600	4	4	20	4

Example 3

5 **Salmonella *asd* Gene Knockout Strain Engineering and Characterization**

Strain YS1646 Δ *asd* was prepared. It is an attenuated *Salmonella typhimurium* strain derived from strain YS1646 (which can be purchased from ATCC, Catalog # 202165) that has been engineered to have a deletion in the *asd* gene. In this example, the *Salmonella typhimurium* strain YS1646 Δ *asd* was engineered using modifications of the method of Datsenko and Wanner (*Proc. Natl. Acad. Sci. USA* 97:6640–6645 (2000)), as described below.

Introduction of the Lambda Red Helper Plasmid into Strain YS1646

The YS1646 strain was prepared to be electrocompetent as described previously (Sambrook J. (1998) *Molecular Cloning, A Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory*), by growing a culture in LB and concentrating 100-fold, and then washing three times with ice-cold 10% glycerol. The electrocompetent strain was electroporated with the Lambda red helper plasmid pKD46 (SEQ ID NO:218) using a 0.2 cm gap cuvette at the following settings: 2.5 kV, 186 ohms, 50 μ F. Transformants carrying pKD46 were grown in 5 mL SOC medium with ampicillin and 1 mM L-arabinose at 30 °C, and selected on LB agar plates containing ampicillin. A YS1646 clone containing the lambda red helper plasmid pKD46 then was made electrocompetent, as described above for strain YS1646.

Construction of *asd* Gene Knockout Cassette

The *asd* gene from the genome of strain YS1646 (Broadway *et al.* (2014) *J. Biotechnology* 192:177-178) was used for designing the *asd* gene knockout cassette.

A plasmid containing 204 and 203 bp of homology to the left hand and right hand regions, respectively, of the *asd* gene, was transformed into DH5-alpha competent cells (Thermo Fisher Scientific). A kanamycin gene cassette flanked by lox P sites was cloned into this plasmid. The *asd* gene knockout cassette then was PCR amplified using primers asd-1 and asd-2 (Table 1) and gel purified.

Deletion of *asd* gene

The YS1646 strain carrying plasmid pKD46 was electroporated with the gel-purified linear *asd* gene knock-out cassette. Electroporated cells were recovered in SOC medium and plated onto LB Agar plates supplemented with Kanamycin (20 µg/mL) and diaminopimelic acid (DAP, 50 µg/mL). During this step, lambda red recombinase induces homologous recombination of the chromosomal *asd* gene with the *kam* cassette (due to the presence of homologous flanking sequences upstream and downstream of the chromosomal *asd* gene), and knockout of the chromosomal copy of the *asd* gene occurs. The presence of the disrupted *asd* gene in the selected kanamycin resistant clones was confirmed by PCR amplification, with primers from the YS1646 genome flanking the sites of disruption (primer asd-3) and from the multi-cloning site (primer scFv-3) (Table 1). Colonies were also replica plated onto LB plates with and without supplemental DAP to demonstrate DAP auxotrophy. All clones with the *asd* gene deletion were unable to grow in the absence of supplemental DAP, demonstrating DAP auxotrophy.

Table 1. Primer Information

Primer name	Primer sequence	SEQ. ID NO.
asd-1	ccttctaacgcaaattccctg	219
asd-2	ccaatgctctgcttaactcctg	220
asd-3	gcctcgccatgtttcagtagc	221
asd-4	ggtctggtgcatccgagtagc	222
scFv-3	cataatctgggtccttggtctgc	223
APR-001	AAAAAAGCTTGCAGCTCTGGCCCGTG	226
APR-002	AAAAAAGCTTTTAGAAAACTCATCGAGCATCAAATGA	227
APR-003	ACACTAGAAGgACAGTATTTGGTATCTG	228
APR-004	AGCCGTAGTTAGGCCACC	229
flic-1	CGTTATCGGCAATCTGGAGGC	232
flic-2	CCAGCCCTTACAACAGTGGTC	233
flic-3	GTCTGTCAACAACCTGGTCTAACGG	234
flic-4	AGACGGTCCTCATCCAGATAAGG	235

Primer name	Primer sequence	SEQ. ID NO.
fljb-1	TTCCAGACGACAAGAGTATCGC	236
fljb-2	CCTTTAGGTTTATCCGAAGCCAGAATC	237
fljb-3	CACCAGGTTTTTCACGCTGC	238
fljb-4	ACACGCATTTACGCCTGTCTG	239
pagp-1	gcgtgacgggtctgagtgc	321
pagp-2	cgctttgctgccatctccg	322
pagp-3	acaataacgacgactccgataagg	323
pagp-4	ctgctgaatgtgctgattaacctg	324
ansb-1	acctagaagatagccgcaaagc	372
ansb-2	cagagacatgacacccacgattatc	373
ansb-3	gcaaaccgctatccagaacga	374
ansb-4	agtttaagtatgccgtggtactgc	375
csgd-1	cacttgctttaagattgtaatggctag	317
csgd-2	ggtgtattcgcttccattgtc	318
csgd-3	tgtgctgtccaggtaatgcc	319
csgd-4	gacgacggtttctcgaagtctc	320

Kanamycin Gene Cassette Removal

The *kan* selectable marker was removed by using the Cre/loxP site-specific recombination system. The YS1646 Δ *asd* gene Kan^R mutant was transformed with pJW168, a temperature sensitive plasmid expressing the cre recombinase (SEQ ID NO:224). Amp^R colonies were selected at 30 °C; pJW168 was subsequently eliminated by growth at 42 °C. A selected clone was tested for loss of *kan* by replica plating on LB agar plates with and without kanamycin, and confirmed by PCR verification using primers from the YS1646 genome flanking the sites of disruption (primers asd-3 and asd-4, for primer sequence, see Table 1).

10 Confirmation of Functional *asd* Deletion Mutant Strain YS1646 Δ *asd* (also designated AST-101)

The Δ *asd* mutant was unable to grow on LB agar plates at 37 °C, but was able to grow on LB plates containing 50 µg/mL diaminopimelic acid (DAP). The Δ *asd* mutant growth rate was evaluated in LB liquid media; it was unable to grow in liquid
15 LB but was able to grow in LB supplemented with 50 µg/mL DAP, as determined by measuring absorbance at 600 nM.

Sequence Confirmation of the *asd* Locus Sequence in Strain YS1646 Δ *asd* After *asd* Gene Deletion

The *asd* gene deletion strain was verified by DNA sequencing using primers *asd*-3 and *asd*-4. Sequencing of the region flanking the *asd* locus was performed and the sequence confirmed that the *asd* gene was deleted from the YS1646 chromosome.

Complementation of *asd* Deletion by *asd* Expression From Plasmids

A plasmid (pATIU6) was chemically synthesized and assembled (SEQ ID NO:225). The plasmid contained the following features: a high copy (pUC19) origin of replication, a U6 promoter for driving expression of a short hairpin, an ampicillin resistance gene flanked by HindIII restriction sites for subsequent removal, and the *asd* gene containing 85 base pairs of sequence upstream of the start codon (SEQ ID NO:246). Into this vector, shRNAs targeting murine TREX1 were introduced by restriction digestion with SpeI and XhoI and ligation and cloning into *E. coli* DH5-alpha cells. The resulting plasmid was designated pATI-shTREX1.

Electroporation of Plasmids into Immunostimulatory Bacterial Strains

Selected plasmids, containing expression cassettes encoding immunostimulatory proteins and a functional *asd* gene, were electroporated into *S. typhimurium* strains lacking the *asd* gene with a BTX600 electroporator using a 0.2 cm gap cuvette (BTX, San Diego, Calif.) at the following settings: 2.5 kV, 186 ohms, 50 μ F. Electroporated cells were added to 1 mL SOC supplemented with 50 μ M diaminopimelic acid (DAP), incubated for 1 hour at 37 °C, and then spread onto agar plates that do not contain DAP, to select for strains that received plasmids with a functional *asd* gene. After single colony isolation, cell banks were produced by inoculating a flask of sterile lysogeny broth (LB) with a single well isolated colony of *S. typhimurium*, and incubating at 37 °C with agitation at 250 RPM. After the culture was grown to stationary phase, the bacteria were washed in PBS containing 10% glycerol, and stored in aliquots frozen at less than -60 °C.

The plasmid pATI-shTREX1 was amplified in *E. coli* and purified for transformation into the YS1646 Δ *asd* strain by electroporation and clonal selection on LB amp plates, to produce the strain YS1646 Δ *asd*-shTREX1. The YS1646 Δ *asd* mutants complemented with pATIU6-derived plasmids were able to grow on LB agar and liquid media in the absence of DAP.

In a subsequent iteration, the ampicillin resistance gene (AmpR) from pATI-shTREX1 was replaced with a kanamycin resistance gene. This was accomplished by digestion of the pATI-shTREX1 plasmid with HindIII, followed by gel purification to remove the AmpR gene. The kanamycin resistance (KanR) gene was amplified by
5 PCR using primers APR-001 and APR-002 (SEQ ID NO:226 and SEQ ID NO:227, respectively), followed by digestion with HindIII and ligation into the gel purified, digested pATIU6 plasmid.

In subsequent iterations, a single point mutation was introduced into the pATIKan plasmid at the pUC19 origin of replication using the Q5® Site-Directed
10 Mutagenesis Kit (New England Biolabs) and the primers APR-003 (SEQ ID NO:228) and APR-004 (SEQ ID NO:229), to change the nucleotide T at position 148 to a C. This mutation makes the origin of replication homologous to the pBR322 origin of replication, which is a low copy origin of replication, in order to reduce the plasmid copy number.

15 **Plasmid Maintenance Demonstrated *in vivo* Using *asd* Complementation System**

In this example, CT26 tumor-bearing mice were treated with strain YS1646 containing a plasmid that expresses an shRNA targeting TREX1 (YS1646-shTREX1), or an *asd* deleted strain of YS1646 containing a plasmid with a functional *asd* gene and an shRNA targeting TREX1 (YS1646 Δ *asd*-shTREX1).

20 CT26 (Colon Tumor #26) is a tumor model that originated from exposing BALB/c mice to N-nitro-N-methylurethane (NMU), resulting in a highly metastatic carcinoma that recapitulates the aggressive, undifferentiated and checkpoint-refractory human colorectal carcinoma (Castle *et al.* (2014) *BMC Genomics* 15(1):1-11). When implanted subcutaneously in the flank, as opposed to orthotopically in the
25 colon, the tumor immunophenotype is much more immunosuppressive and checkpoint refractory. While largely lacking in T-cell infiltration, the tumor is rich in myeloid cells, such as macrophages and myeloid-derived suppressor cells (MDSCs) (Zhao *et al.* (2017) *Oncotarget* 8(33):54775-54787). As this model more closely resembles human microsatellite stable (MSS) colorectal cancer, it is an ideal model to evaluate
30 the therapeutic approach provided herein.

For this experiment, 6-8 week-old female BALB/c mice (3 mice per group) were inoculated SC in the right flank with CT26 (purchased from ATCC) tumor cells

(2×10^5 cells in 100 μ L PBS). Mice bearing 8 day-old established flank tumors were IV injected with three doses of 5×10^6 CFUs of the YS1646 Δ *asd*-shTREX1 strain or the parental strain YS1646 on days 8, 15 and 23. The plasmid encodes shTREX1 as an exemplary therapeutic product; any other desired therapeutic product or products
5 can be substituted.

Body weights and tumors were measured twice weekly. Tumor measurements were performed using electronic calipers (Fowler, Newton, MA). Tumor volume was calculated using the modified ellipsoid formula, $1/2(\text{length} \times \text{width}^2)$. Mice were euthanized when tumor size reached $>20\%$ of body weight or became necrotic, as per
10 IACUC regulations.

At 12 days after the final *Salmonella* injection, tumors were homogenized, and homogenates were serially diluted and plated on LB agar plates, to enumerate the total number of colony forming units (CFUs) present, or on LB plates containing kanamycin, to enumerate the number of kanamycin resistant colonies.

15 The results demonstrated that *S. typhimurium* YS1646-shTREX1 did not have selective pressure to maintain the shRNA plasmid, and demonstrated significant plasmid loss, as the percent kanamycin resistant (KanR) colonies was less than 10%. The strain that used the *asd* gene complementation system for plasmid maintenance, YS1646 Δ *asd*-shTREX1, had nearly identical numbers of kanamycin resistant and
20 kanamycin sensitive CFUs. These data demonstrate that the *asd* gene complementation system is sufficient to maintain the plasmid in the context of the tumor microenvironment in mice.

Enhanced Anti-Tumor Efficacy Using *asd* Complementation System

The *asd* complementation system is designed to prevent plasmid loss and
25 potentiate the anti-tumor efficacy of the therapeutic product delivery by *S. typhimurium* strains *in vivo*. To test this, YS1646 Δ *asd* strains containing the shTREX1 plasmid (YS1646 Δ *asd*-shTREX1) or scrambled control (YS1646 Δ *asd*-shSCR) that contain a functional *asd* gene cassette were compared for anti-tumor efficacy in a murine colon carcinoma model, to strain YS1646 containing pEQU6-
30 shTREX1 (YS1646-shTREX1), a plasmid that lacks an *asd* gene cassette, and therefore, does not have a mechanism for plasmid maintenance. shTREX1 is an exemplary therapeutic product.

For this experiment, 6-8 week-old female BALB/c mice (8 mice per group) were inoculated SC in the right flank with CT26 (2×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected twice, on day 8 and day 18, with 5×10^6 CFUs of YS1646 Δ asd-shTREX1 or YS1646-shTREX1, and compared to PBS control.

The YS1646-shTREX1 strain demonstrated enhanced tumor control compared to PBS (70% tumor growth inhibition (TGI), day 28) despite its demonstrated plasmid loss over time. The Δ asd strain containing the plasmid with the *asd* gene complementation system and shTREX1 (YS1646 Δ asd-shTREX1) demonstrated superior tumor growth inhibition compared to PBS (82% TGI, $p = 0.002$, day 25). These data demonstrate that improved potency is achieved by preventing plasmid loss, using the *asd* complementation system, and delivery of shTREX1, as compared to YS1646 containing plasmids without the *asd* gene complementation system. Thus, strains with *asd* complementation systems are superior anti-cancer therapeutics.

Example 4

Modified *S. typhimurium* Strains with Plasmids Containing CpG Elements Demonstrate Enhanced Anti-Tumor Activity Compared to the YS1646 Parental Strain

Toll-like receptors (TLRs) are key receptors for sensing pathogen-associated molecular patterns (PAMPs) and activating innate immunity against pathogens (Akira *et al.* (2001) *Nat. Immunol.* 2(8):675-680). Of these, TLR9 is responsible for recognizing hypomethylated CpG motifs in pathogenic DNA which do not occur naturally in mammalian DNA (McKelvey *et al.* (2011) *J. Autoimmunity* 36:76). Recognition of CpG motifs upon phagocytosis of pathogens into endosomes in immune cell subsets induces IFR7-dependent type I interferon signaling and activates innate and adaptive immunity. It is shown herein, that the *S. typhimurium* strain YS1646 carrying modified *Salmonella typhimurium* plasmids containing CpG motifs (YS1646 pEQU6 Scramble) similarly activate TLR9 and induce type I IFN-mediated innate and adaptive immunity, as compared to the YS1646 strain without a plasmid.

The CpG motifs in the engineered plasmids used here are shown in **Table 2**. The pEQU6 shSCR (non-cognate shRNA) plasmid in strain AST-103 possesses 362 CpG motifs, indicating that *Salmonella*-based plasmid delivery can be immuno-

stimulatory and have an anti-tumor effect, when compared to the same *Salmonella* lacking transformation with this plasmid. To assess the ability of CpG-containing plasmids within YS1646 to induce tumor growth inhibition in a murine colon carcinoma model, 6-8 week-old female BALB/c mice (9 mice per group) were

5 inoculated SC in the right flank with CT26 (2×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected weekly with three doses of 5×10^6 CFUs of YS1646 (AST-100) or YS1646 containing an shRNA scrambled plasmid with CpG motifs (AST-103), and compared to PBS control.

Table 2. CpG motifs in the Engineered Plasmids

Sequence Name	Number of CpG Motifs	SEQ ID NO.
pBR322 Origin	80	243
pEQU6 (shSCR)	362	244
Asd Gene ORF	234	242
pATI-2.0	538	245

10 The YS1646 (AST-100) strain demonstrated modest tumor control (32% TGI, $p = \text{ns}$, day 28) compared to PBS. The AST-103 strain, that varies from YS1646 only by the addition of the CpG-containing plasmid encoding a non-cognate scrambled shRNA, demonstrated highly significant tumor growth inhibition compared to YS1646 alone, untransformed and therefore lacking a plasmid ($p = 0.004$, day 32).

15 The *asd* gene possesses 234 CpG motifs (see, **Table 2**), indicating that a plasmid containing it can have immunostimulatory properties. AST-109 (YS1646-ASD with scrambled shRNA) had 51% tumor growth inhibition vs. PBS alone, indicative of a strong immuno-stimulatory effect.

20 These data demonstrate the potent immunostimulatory properties of plasmid DNA containing TLR9-activating CpG motifs within a tumor-targeting attenuated strain of *S. typhimurium*.

Example 5

Vector Synthesis

Complementation of *asd* deletion by *asd* expression from plasmids

25 A plasmid (pATIU6) was chemically synthesized and assembled (SEQ ID NO:225). The plasmid contains the following features: a high copy (pUC19) origin or replication, a U6 promoter for driving expression of a short hairpin, an ampicillin resistance gene flanked by HindIII restriction sites for subsequent removal, and the

asd gene containing 85 base pairs of sequence upstream of the start codon (SEQ ID NO:246). Into this vector, shRNAs targeting murine TREX1 or a scrambled, non-cognate shRNA sequence were introduced by restriction digestion with SpeI and XhoI and ligation and cloning into *E. coli* DH5-alpha. The resulting plasmids, designated

5 pATI-shTREX1 and pATI-shSCR, respectively, were amplified in *E. coli* and purified for transformation into the *asd* knockout strain AST-101 by electroporation and clonal selection on LB amp plates to produce strains AST-108, and AST-107, respectively. Alternatively, other nucleic acid molecules encoding other therapeutic products, including the gain-of-function variants of cytosolic DNA/RNA sensors described

10 herein, are introduced into this vector. *asd* mutants complemented with pATIU6-derived plasmids were able to grow on LB agar and liquid media in the absence of DAP.

In a subsequent iteration, the ampicillin resistance gene (AmpR) from pATI-shTREX1 was replaced with a kanamycin resistance gene. This was accomplished by

15 digestion of pATI-shTREX1 plasmid with HindIII followed by gel purification to remove the AmpR gene. PCR amplification of the kanamycin resistance (KanR) gene using primers APR-001 and APR-002 (SEQ ID NO:226 and SEQ ID NO:227), digestion with HindIII and ligation into the gel purified, digested pATIU6 plasmid.

In subsequent iterations, a single point mutation was introduced into the

20 pATIKan plasmid at the pUC19 origin of replication using the Q5® Site-Directed Mutagenesis Kit (New England Biolabs) and the primers APR-003 (SEQ ID NO:228) and APR-004 (SEQ ID NO:229) to change the nucleotide T at position 148 to a C. This mutation makes the origin of replication homologous to the pBR322 origin of replication in order to reduce the plasmid copy number.

Primer ID	Description	Sequence	SEQ ID NO
APR-001	Kan primerF	AAAAAAGCTTGCAGCTCTGGCCCGTG	226
APR-002	Kan PrimerR	AAAAAAGCTTTTAGAAAACTCATCGAGCATCAA ATGA	227
APR-003	pATI ori T148CF	ACACTAGAAGgACAGTATTTGGTATCTG	228
APR-004	pATI ori T148CR	AGCCGTAGTTAGGCCACC	229

pATI2.0

A plasmid was designed and synthesized that contains the following features: a pBR322 origin of replication, an SV40 DNA nuclear targeting sequence (DTS), an *rrnB* terminator, a U6 promoter for driving expression of shRNAs followed by flanking restriction sites for cloning the promoter and shRNAs or microRNAs, the *asd* gene, an *rrnG* terminator, and a kanamycin resistance gene flanked by HindIII sites for curing and a multicloning site (SEQ ID NO:247). In addition, a plasmid was designed and synthesized for expression of two separate shRNAs or microRNAs. This plasmid contains the following features: a pBR322 origin of replication, an SV40 DNA nuclear targeting sequence (DTS), an *rrnB* terminator, a U6 promoter for driving expression of shRNAs followed by flanking restriction sites for cloning the promoter and shRNAs or microRNAs, an H1 promoter for driving the expression of a 2nd shRNA or microRNA, a 450 bp randomly generated stuffer sequence placed between the H1 and U6 promoters, the *asd* gene, an *rrnG* terminator, and a kanamycin resistance gene flanked by HindIII sites for curing and a multicloning site (SEQ ID NO:245).

Example 6***S. typhimurium* Flagellin Knockout by Deletion of the *fliC* and *fliB* Genes
Strain Engineering and Characterization**

In the example herein, the live attenuated *S. typhimurium* YS1646 strain containing the *asd* gene deletion was further engineered to delete the *fliC* and *fliB* genes, in order to remove both flagellin subunits. This eliminates pro-inflammatory TLR5 activation, in order to reduce pro-inflammatory signaling and improve anti-tumor adaptive immunity.

25 Deletion of *fliC* Gene

In this example, the *fliC* gene was deleted from the chromosome of the YS1646Δ*asd* strain using modifications of the method of Datsenko and Wanner (*Proc. Natl. Acad. Sci. USA* 97:6640–6645 (2000)), as described in detail above. Briefly, synthetic *fliC* gene homology arm sequences, that contained 224 and 245 bases of homologous sequence flanking the *fliC* gene, were cloned into a plasmid called pSL0147 (SEQ ID NO:230). A kanamycin gene cassette flanked by cre/loxP sites then was cloned into pSL0147, and the *fliC* gene knockout cassette was then

PCR amplified with primer flic-1 (SEQ ID NO:232) and flic-2 (SEQ ID NO:233), gel purified and then introduced into the YS1646 Δ asd strain carrying the temperature sensitive lambda red recombination plasmid pKD46 by electroporation.

Electroporated cells were recovered in SOC+DAP medium and plated onto LB Agar plates supplemented with Kanamycin (20 μ g/mL) and diaminopimelic acid (DAP, 50 μ g/mL). Colonies were selected and screened for insertion of the knockout fragment by PCR using primers flic-3 (SEQ ID NO:234) and flic-4 (SEQ ID NO:235). pKD46 then was cured by culturing the selected kanamycin resistant strain at 42 °C and screening for loss of ampicillin resistance. The Kanamycin resistance marker then was cured by electroporation of a temperature sensitive plasmid expressing the Cre recombinase (pJW168) and Amp^R colonies were selected at 30 °C; pJW168 was subsequently eliminated by growing cultures at 42 °C. Selected *fliC* knockout clones were then tested for loss of the kanamycin marker by PCR, using primers flanking the sites of disruption (flic-3 and flic-4), and evaluation of the electrophoretic mobility on agarose gels.

Deletion of *fljB* Gene

fljB was then deleted in the YS1646 Δ asd/ Δ *fliC* strain using modifications of the methods described above. Synthetic *fljB* gene homology arm sequences that contained 249 and 213 bases of the left hand and right hand sequence, respectively, flanking the *fliC* gene, were synthesized and cloned into a plasmid called pSL0148 (SEQ ID NO:231). A kanamycin gene cassette flanked by cre/loxP sites then was cloned into pSL0148 and the *fljB* gene knockout cassette was PCR amplified with primers fljb-1 (SEQ ID NO:236) and fljb-2 (SEQ ID NO:237) (see, Table 1), gel purified and introduced into strain YS1646 Δ asd carrying the temperature sensitive lambda red recombination plasmid pKD46 by electroporation. The kanamycin resistance gene then was cured by cre-mediated recombination as described above, and the temperature-sensitive plasmids were cured by growth at non-permissive temperature. The *fliC* and *fljB* gene knockout sequences were amplified by PCR using primers flic-3 and flic-4, or fljb-3 (SEQ ID NO:238) and fljb-4 (SEQ ID NO:239), respectively, and verified by DNA sequencing. This mutant derivative of YS1646 was designated YS1646 Δ asd/ Δ *fliC*/ Δ *fljB*, or YS1646 Δ asd/ Δ FLG for short.

***In vitro* Characterization of Engineered *S. typhimurium* Flagellin Knockout Strain**

The YS1646 derived *asd^r* mutant strain harboring the deletions of both *fliC* and *fliB*, herein referred to as YS1646 Δ *asd*/ Δ FLG, was evaluated for swimming motility by spotting 10 microliters of overnight cultures onto swimming plates (LB containing 0.3% agar and 50 mg/mL DAP). While motility was observed for the YS1646 Δ *asd* strain, no motility was evident with the YS1646 Δ *asd*/ Δ FLG strain. The YS1646 Δ *asd*/ Δ FLG strain then was electroporated with a plasmid containing an *asd* gene, and its growth rate in the absence of DAP was assessed. The YS1646 Δ *asd*/ Δ FLG strain with an *asd* complemented plasmid was able to replicate in LB in the absence of supplemental DAP, and grew at a rate comparable to the YS1646 Δ *asd* strain containing an *asd* complemented plasmid. These data demonstrate that the elimination of flagellin does not decrease the fitness of *S. typhimurium* *in vitro*.

Elimination of Flagella Decreases Pyroptosis in Murine Macrophages

5x10⁵ mouse RAW macrophage cells (InvivoGen, San Diego, Ca.) were infected with the YS1646 Δ *asd*/ Δ FLG strain or the parental YS1646 Δ *asd* strain, both harboring an *asd* complemented plasmid, at an MOI of approximately 100 in a gentamicin protection assay. After 24 hours of infection, culture supernatants were collected and assessed for lactate dehydrogenase release as a marker of cell death, using a PierceTM LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific, Waltham, Ma.). The YS1646 Δ *asd* strain induced 75% maximal LDH release, while the YS1646 Δ *asd*/ Δ FLG strain induced 54% maximal LDH release, demonstrating that deletion of the flagellin genes reduces the *S. typhimurium*-induced pyroptosis of infected macrophages.

Flagella-Deleted Mutants Lead to Less Pyroptosis in Infected Human Monocytes

To demonstrate that the YS1646 Δ *asd*/ Δ FLG strains are reduced in their ability to cause cell death in macrophages, THP-1 human macrophage cells (ATCC Catalog # 202165) were infected with the *S. typhimurium* strains YS1646 and YS1646 Δ *asd*/ Δ FLG, with the Δ *asd* strains containing plasmids encoding a functional *asd* gene to ensure plasmid maintenance. 5x10⁴ cells were placed in a 96-well dish with DMEM and 10% FBS. Cells were infected with washed log-phase cultures of *S.*

typhimurium for 1 hour at an MOI of 100 CFUs per cell, then the cells were washed with PBS, and the media was replaced with media containing 50 µg/mL gentamicin to kill extracellular bacteria, and 50 ng/mL of IFN γ to convert the monocytes into a macrophage phenotype. After 24 hours, the THP-1 cells were stained with CellTiter-Glo[®] reagent (Promega), and the percentage of viable cells was determined using a luminescent cell viability assay using a SpectraMax plate reader to quantify the luminescence. The cells infected with the YS1646 strain had only 38% viability, while the cells infected with the YS1646 Δ *asd*/ Δ FLG strain had 51% viability, indicating that the deletion of the flagellin genes induced less cell death of human macrophages, despite a very high and supraphysiological MOI.

Flagella is not Required for Tumor Colonization After Systemic Administration

To assess the impact of the flagellin knockout strains, administered in a murine model of colon carcinoma, 6-8 week-old female BALB/c mice (5 mice per group) were inoculated SC in the right flank with CT26 cells (2×10^5 cells in 100 µL PBS). Mice bearing 10-day established flank tumors were IV injected with a single dose of 3×10^5 CFUs of the YS1646 Δ *asd*/ Δ FLG-shTREX1 strain or the parental YS1646 Δ *asd*-shTREX1 strain. At day 35 post tumor implantation, mice were euthanized, and tumors were homogenized and plated on LB plates to enumerate the number of colony forming units (CFUs) per gram of tumor tissue. The YS1646 Δ *asd*-shTREX1 strain colonized tumors at a mean of 5.9×10^7 CFUs per gram of tumor tissue, while the flagella-deleted YS1646 Δ *asd*/ Δ FLG-shTREX1 strain colonized the tumors with almost a 2-fold increased mean of 1.1×10^8 CFUs/g of tumor tissue. The splenic colonization of the YS1646 Δ *asd*-shTREX1 strain was calculated as a mean of 1.5×10^3 CFU/g of spleen tissue, whereas splenic colonization of the flagella-deleted YS1646 Δ *asd*/ Δ FLG-shTREX1 strain was slightly lower, at a mean of 1.2×10^3 CFU/g of spleen tissue.

These data demonstrate that the absence of flagella not only does not negatively impact tumor colonization after IV administration, but it enhances tumor colonization compared to the flagella-intact strain. Importantly, deletion of the flagella slightly reduces splenic colonization, giving a tumor to spleen ratio of 100,000-fold. These data demonstrate that, contrary to the expectation from the art,

not only are the flagella not required for tumor colonization, but their elimination enhances tumor colonization while reducing splenic colonization.

The Flagella-Deleted Strain Demonstrates Enhanced Anti-Tumor Activity in Mice

5 To assess the impact of the flagellin knockout strains, administered in a murine model of colon carcinoma, 6-8 week-old female BALB/c mice (5 mice per group) were inoculated SC in the right flank with CT26 cells (2×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected with a single dose of 3×10^5 CFUs of the YS1646 Δ asd/ Δ FLG-shTREX1 strain or the YS1646 Δ asd-shTREX1
10 strain, and compared to PBS control. Mice were monitored by caliper measurements for tumor growth.

 The results demonstrated that the YS1646 Δ asd/ Δ FLG-shTREX1 strain, incapable of making flagella, showed enhanced tumor control compared to the parental YS1646 Δ asd-shTREX1 strain (27% TGI, day 24), and significant tumor
15 control compared to the PBS control (73% TGI, $p = 0.04$, day 24). These data demonstrate that, not only is the flagella not required for tumor colonization, but its loss can enhance anti-tumor efficacy.

Flagella-Deleted Strains Demonstrate Enhanced Adaptive Immunity in a Murine Tumor Model

20 The impact of deletion of the flagella on the immune response, and whether STING activation from tumor myeloid cell-delivery of shRNA to the STING checkpoint gene TREX1 would promote an adaptive type I IFN immune signature, was assessed. The CT26 murine model of colon carcinoma was used, where 6-8 week-old female BALB/c mice (5 mice per group) were inoculated SC in the right
25 flank with CT26 cells (2×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected 11 days post tumor implantation with 5×10^6 CFUs of either the YS1646 Δ asd/ Δ FLG-shTREX1 strain, the parental YS1646 Δ asd-shTREX1, or the scrambled plasmid control strain YS1646 Δ asd-shSCR, and compared to PBS control.

 Mice were bled 7 days post dosing on Sodium Heparin coated tubes (Beckton
30 Dickinson). Non-coagulated blood was then diluted in the same volume of PBS and peripheral blood mononuclear cells (PBMCs) were separated from the interphase layer of whole blood using Lympholyte®-M cell separation reagent (Cedarlane).

Isolated PBMCs were washed with PBS + 2% FBS by centrifugation at 1300 RPM for 3 minutes at room temperature, and resuspended in flow buffer. One million PBMCs were seeded per well of a V-bottom 96-well plate. Cells were centrifuged at 1300 RPM for 3 minutes at room temperature (RT) and resuspended in 100 μ L of flow

5 buffer containing fluorochrome-conjugated AH1 peptide:MHC class I tetramers (MBL International), and the cell surface flow cytometry antibodies CD4 FITC clone RM4-5; CD8a BV421 clone 53-6.7; F4/80 APC clone BM8; CD11b PE-Cy7 clone M1/70; CD45 BV570 clone 30-F11; CD3 PE clone 145-2C11; Ly6C BV785 clone HK1.4; I-A/I-E APC-Cy7 clone M5/114.15.2; Ly6G BV605 clone 1A8; and CD24

10 PercP-Cy5.5 clone M1/69 (all from BioLegend), for 45 minutes at room temperature and in the dark. After 45 min, cells were washed twice with PBS + 2% FBS by centrifugation at 1200 RPM for 3 min. Cells were then resuspended in PBS + 2% FBS containing DAPI (dead/live staining) and data were immediately acquired using the NovoCyte flow cytometer (ACEA Biosciences, Inc.) and analyzed using FlowJo

15 software (Tree Star, Inc.).

The following cell types were enumerated as a percentage of total live cells: CD11b⁺ Gr1⁺ neutrophils (possibly MDSCs, although further phenotyping in an *ex vivo* functional assay would be required), CD11b⁺ F4/80⁺ macrophages, CD8⁺ T-cells, and CD8⁺ T-cells that recognize the CT26 tumor rejection antigen gp70 (AH1), the

20 product of the envelope gene of murine leukemia virus (MuLV)-related cell surface antigen (Castle *et al.* (2014) *BMC Genomics* 15(1):1-11).

The results, summarized in the table below, show that the YS1646 Δ asd-shSCR strain, containing a plasmid encoding a non-specific scrambled shRNA, elicits the typical anti-bacterial immune profile of significantly increased neutrophils, as

25 compared to PBS ($p = 0.02$), to the flagella-intact YS1646 Δ asd-shTREX1 strain ($p = 0.02$), and to the flagella-deleted strain YS1646 Δ asd/ Δ FLG-shTREX1 ($p = 0.01$), which had the lowest levels of circulating neutrophils. Similarly, bacterially-induced macrophages also were significantly elevated in response to the YS1646 Δ asd-shSCR strain, as compared to PBS ($p = 0.01$), to the YS1646 Δ asd-shTREX1 strain ($p =$

30 0.01), and to YS1646 Δ asd/ Δ FLG-shTREX1 strain ($p = 0.01$). Thus, both strains carrying type I IFN-inducing payloads were capable of overwriting the normal anti-bacterial immune response, which clears bacterial infections through neutrophils and

macrophages, and does not induce adaptive T-cell-mediated immunity. However, while the overall circulating levels of CD8⁺ T-cells were similar across all groups, the flagella-deleted YS1646 Δ asd/ Δ FLG-shTREX1 strain demonstrated significantly increased percentages of AH1-tetramer⁺ CD8⁺ T-cells, as compared to PBS ($p =$
5 0.04).

These data demonstrate the feasibility of engineering a bacteria to deliver viral-like type I IFN-inducing plasmids to tumor-resident myeloid cells. This results in a dramatic reprogramming of the immune response towards a more viral, and less bacterial, immune profile. Deletion of the flagella further enhanced the shift away
10 from bacterially-recruited neutrophils and macrophages, and towards significantly increased tumor antigen-specific CD8⁺ T-cells. Thus, eliminating bacterial TLR5-mediated inflammation can enhance adaptive immunity.

Immune Cells	% Live Cells Mean $\pm$ SD			
	PBS	YS1646 Δ asd-shSCR	YS1646 Δ asd-shTREX1	YS1646 Δ asd/ Δ FLG-shTREX1
Neutrophils	6.27 $\pm$ 2.62	19.21 $\pm$ 9.46	5.87 $\pm$ 3.94	4.01 $\pm$ 1.65
Macrophages	10.08 $\pm$ 2.11	23.14 $\pm$ 9.04	9.12 $\pm$ 3.84	7.39 $\pm$ 2.11
CD8 ⁺ T-cells	6.64 $\pm$ 0.56	7.17 $\pm$ 0.60	7.14 $\pm$ 2.30	6.44 $\pm$ 1.43
AH1 ⁺ CD8 ⁺ T-cells	0.83 $\pm$ 0.12	1.06 $\pm$ 1.11	2.27 $\pm$ 1.44	4.12 $\pm$ 3.08

Flagella-Deleted Strains are Restricted to the Phagocytic Myeloid Immune Cell Compartment *in vivo*

According to the literature, Δ fliB/ Δ fliC strains demonstrate suppression of many downstream genes associated with SPI-1-mediated entry into non-phagocytic cells. In order to determine whether the YS1646 Δ asd/ Δ FLG strain also is deficient for non-phagocytic cell uptake, a YS1646 Δ asd/ Δ FLG strain, constitutively expressing mCherry under the bacterial *rpsM* promoter, was IV administered to MC38
15 subcutaneous flank tumor-bearing mice.

The MC38 (murine colon adenocarcinoma #38) model was derived similarly as the CT26 model using mutagenesis, but with dimethylhydralazine and in a C57BL/6 mouse strain (Corbett *et al.* (1975) *Cancer Res.* 35(9):2434-9). Similarly to CT26, subcutaneous implantation results in a more T-cell excluded and
20 immunosuppressive tumor microenvironment than when implanted orthotopically in the colon (Zhao *et al.* (2017) *Oncotarget* 8(33):54775-54787). MC38 has a higher

mutational burden than CT26, and a similar viral-derived gp70 antigen (p15E) can be detected by CD8⁺ T-cells, although it is not considered a rejection antigen. While variants of MC38 have been found to be partially responsive to checkpoint therapy, most variants of the cell line are considered checkpoint refractory and T-cell excluded
5 (Mariathasan *et al.* (2018) *Nature* 555:544-548), including the MC38 cells used herein.

6-8 week-old female C57BL/6 mice (5 mice per group) were inoculated SC in the right flank with MC38 cells (5x10⁵ cells in 100 µL PBS). Mice bearing large established flank tumors were IV injected on day 34 with 1x10⁶ CFUs of the
10 YS1646Δ*asd*/ΔFLG-mCherry strain. Tumors were resected 7 days post IV dosing and cut into 2-3 mm pieces into gentleMACS™ C tubes (Miltenyi Biotec) filled with 2.5 mL enzyme mix (RPMI-1640 10% FBS with 1 mg/mL Collagenase IV and 20 µg/mL DNase I). The tumor pieces were dissociated using OctoMACS™ (Miltenyi Biotec) specific dissociation program (mouse implanted tumors), and the whole cell
15 preparation was incubated with agitation for 45 minutes at 37 °C. After the 45 minute incubation, a second round of dissociation was performed using the OctoMACS™ (mouse implanted tumor program) and the resulting single cell suspensions were filtered through a 70 µm nylon mesh into a 50 mL tube. The nylon mesh was washed once with 5 mL of RPMI-1640 10% FBS, and the cells were filtered a second time
20 using a new 70 µm nylon mesh into a new 50 mL tube. The nylon mesh was washed with 5 mL of RPMI-1640 10% FBS and the filtered cells were then centrifuged at 1000 RPM for 7 minutes. The resulting dissociated cells were resuspended in PBS and kept on ice before the staining process.

For the flow-cytometry staining, 100 µL of the single cell suspensions were
25 seeded in wells of a V-bottom 96-well plate. PBS containing a dead/live stain (Zombie Aqua™, BioLegend) and Fc Blocking reagents (BD Biosciences) were added at 100 µL per well and incubated on ice for 30 minutes in the dark. After 30 minutes, cells were washed twice with PBS + 2% FBS by centrifugation at 1300 RPM for 3 minutes. Cells were then resuspended in PBS + 2% FBS containing
30 fluorochrome-conjugated antibodies (CD4 FITC clone RM4-5; CD8a BV421 clone 53-6.7; F4/80 APC clone BM8; CD11b PE-Cy7 clone M1/70; CD45 BV570 clone 30-

F11; CD3 PE clone 145-2C11; Ly6C BV785 clone HK1.4; I-A/I-E APC-Cy7 clone M5/114.15.2; Ly6G BV605 clone 1A8; and CD24 PercP-Cy5.5 clone M1/69, all from BioLegend), and incubated on ice for 30 minutes in the dark. After 30 minutes, cells were washed twice with PBS + 2% FBS by centrifugation at 1300 RPM for 3 minutes and resuspended in flow cytometry fixation buffer (ThermoFisher Scientific). Flow cytometry data were acquired using the NovoCyte Flow Cytometer (ACEA Biosciences, Inc.) and analyzed using the FlowJo software (Tree Star, Inc.).

The results demonstrate that 7.27% of tumor infiltrating monocytes had taken up the flagella-deleted mCherry strain in the tumor microenvironment. Similarly, 8.96% of the tumor-associated macrophage (TAM) population, and 3.33% of the tumor-infiltrating dendritic cells (DCs) had taken up the flagella-deleted mCherry strain. In contrast, within the CD45⁺ population, corresponding to stromal and tumor cells, only 0.076% showed positivity for mCherry expression (compared to 0.067% background staining). These data demonstrate that the flagella and its downstream signaling impact on SPI-1 are necessary to enable epithelial cell infectivity, and that the lack thereof restricts uptake of the bacteria to only the phagocytic immune cell compartment of the tumor microenvironment (*i.e.*, tumor-resident immune/myeloid cells).

Deletion of the flagella confers multiple benefits to the immunostimulatory *S. typhimurium* strain, including eliminating TLR5-induced inflammatory cytokines that suppress adaptive immunity, reducing macrophage pyroptosis, as well as maintaining (or enhancing) tumor-specific enrichment upon systemic administration, where uptake is confined to tumor-resident phagocytic cells.

Example 7

***S. typhimurium* Engineered to Express cytoLLO for Enhanced Plasmid Delivery**

In this example, the *asd* deleted strain of YS1646 described in Example 3 (AST-101) was further modified to express the listeriolysin O (LLO) protein lacking the signal sequence that accumulates in the cytoplasm of the *Salmonella* strain (referred to herein as cytoLLO). LLO is a cholesterol-dependent pore-forming cytolysin that is secreted from *Listeria monocytogenes* and mediates phagosomal escape of bacteria. A gene encoding LLO, with codons 2-24 deleted, was synthesized with codons optimized for expression in *Salmonella*. The sequence of the open

reading frame (ORF) of cytoLLO is shown in SEQ ID NO:240. The cytoLLO gene was placed under control of a promoter that induces transcription in *S. typhimurium* (SEQ ID NO:241, reproduced below). The cytoLLO expression cassette was inserted in single copy into the knockout-out *asd* locus of the *asd* deleted strain AST-101, using modifications of the method of Datsenko and Wanner (*Proc Natl Acad Sci USA* (2000) 97:6640–6645), as described above.

Sequence of promoter driving expression of cytoLLO

LLO promoter	attatgtcttgacatgtagtgagtgggctgtataatgcagcaag	SEQ ID NO: 241
--------------	--	----------------

The *asd* deleted strain with the cytoLLO expression cassette inserted at the *asd* locus (referred to herein as ASD/LLO or AST-114) was further modified by electroporation with a pATI plasmid encoding an *asd* gene that allows the strain to grow in the absence of exogenous DAP and selects for plasmid maintenance, and also contains a U6 promoter driving expression of shTREX1 as described above (referred to herein as ASD/LLO (pATI-shTREX1) or AST-115). The ASD/LLO (pATI-shTREX1) strain, AST-115, grew at a comparable rate to the *asd* deleted strain containing the same plasmid (pATI-shTREX1), AST-110, demonstrating that the LLO knock-in does not impact bacterial fitness *in vitro*.

***S. typhimurium* engineered to produce cytoLLO demonstrates potent anti-tumor activity**

To determine whether the *cytoLLO* gene knock-in provided anti-tumor efficacy, the ASD/LLO (pATI-shTREX1) strain AST-115 was evaluated in a murine model of colon carcinoma. For this study, 6-8 week-old female BALB/c mice (8 mice per group) were inoculated SC in the right flank with CT26 (2x10⁵ cells in 100 μL PBS). Mice bearing established flank tumors were IV injected with a single dose of 5 x10⁶ CFUs of AST-115, and compared to PBS control.

Addition of the *cytoLLO* gene into the strain ASD/LLO (pATI-shTREX1) demonstrated highly significant tumor control compared to PBS control (76% TGI, *p* = 0.002, day 28), and comparable efficacy after a single dose to previous studies where the TREX1 shRNA plasmid containing strains were given at multiple doses. These data demonstrate the *cytoLLO*-mediated advantage of delivering more plasmid

into the cytosol, resulting in greater gene knockdown, thereby improving the therapeutic efficacy of RNAi against targets such as TREX1.

Example 8

Adenosine Auxotrophic Strains of *S. typhimurium*

5 Strains provided herein are engineered to be auxotrophic for adenosine. As a result, they are attenuated *in vivo* because they are unable to replicate in the low adenosine concentrations of normal tissue, therefore, colonization occurs primarily in the solid tumor microenvironment where adenosine levels are high. The *Salmonella* strain YS1646 (AST-100) is a derivative of the wild type strain ATCC 14028, and
10 was engineered to be auxotrophic for purine due to disruption of the *purI* gene (Low *et al.*, (2004) *Methods Mol. Med* 90:47-60). Subsequent analysis of the entire genome of YS1646 demonstrated that the *purI* gene (synonymous with *purM*) was not in fact deleted, but was instead disrupted by a chromosomal inversion (Broadway *et al.* (2014) *J.Biotechnol.* 20:177-178), and that the entire gene is still contained within two
15 parts of the YS1646 chromosome that is flanked by insertion sequences (one of which has an active transposase). The presence of the complete genetic sequence of the *purI* gene disrupted by means of a chromosomal reengagement leaves open the possibility of reversion to a wild type gene. While it has previously been demonstrated that purine auxotrophy of YS1646 was stable after serial passage *in vitro*, it was not clear
20 what the reversion rate is (Clairmont *et al.* (2000) *J. Infect. Dis.* 181:1996-2002).

 It is shown herein that, when provided with adenosine, YS1646 is able to replicate in minimal medium; whereas the wild-type parental strain ATCC 14028 can grow in minimal media that is not supplemented with adenosine. YS1646 was grown overnight in LB medium washed with M9 minimal medium and diluted into M9
25 minimal media containing no adenosine, or increasing concentrations of adenosine. Growth was measured using a SpectraMax® M3 spectrophotometer (Molecular Devices) at 37 °C, reading the OD₆₀₀ every 15 minutes.

 YS1646 was able to replicate when adenosine was provided at concentrations ranging from 11 to 300 micromolar, but was completely unable to replicate in M9
30 alone or M9 supplemented with 130 nanomolar adenosine. These data demonstrate that *purI* mutants are able to replicate in concentrations of adenosine that are found in the tumor microenvironment, but not at concentrations found in normal tissues.

Engineered adenosine auxotrophic strains exemplified herein include strains wherein all, or portions of the *purI* open reading frame are deleted from the chromosome to prevent reversion to wild-type. Such gene deletions can be achieved utilizing the lambda red system as described above.

5 *Salmonella* strains containing a *purI* disruption, further engineered to contain an *asd* gene deletion (ASD) as described above, or to contain an *asd* gene deletion and further engineered to have deletions of *fliC* and *fliB* (ASD/FLG) (as described in Example 6), or *asd* mutants further engineered to express cytoLLO (ASD/LLO) (as described in Example 7), and complemented with a low copy number plasmid
10 (pATIlow) expressing *asd* (Strains AST-117, AST-118, and AST-119, respectively), were also evaluated for growth in M9 minimal media. The data show that each strain was able to replicate when adenosine was provided at concentrations ranging from 11 to 300 micromolar, but was completely unable to replicate in M9 alone or M9 supplemented with 130 nanomolar adenosine.

15 **Example 9**

Characterization and use of the *asd* Gene Complementation System *in vitro* **Growth of Strains with *asd* Gene Complementation**

To assess fitness of the bacterial strains containing plasmids, growth curves were performed in LB liquid media using a Spectramax plate reader at 37 °C, reading
20 the OD₆₀₀ every 15 minutes. YS1646 containing a low copy plasmid pEQU6-shTREX1 (AST-104) grew comparably to YS1646 that did not contain a plasmid (AST-100). An *asd* mutant strain harboring a high copy shTREX1 plasmid with an *asd* gene that can complement the *asd* auxotrophy (AST-110) was able to replicate in LB in the absence of DAP, but grew slower than YS1646. An *asd* deleted strain
25 containing an shTREX-1 expression plasmid with low copy number origin of replication and an *asd* gene that can complement the *asd* auxotrophy (pATIlow-shTREX1), strain AST-117, grew at a faster rate than AST-110. These data demonstrate that low copy number plasmids that complement the *asd* gene auxotrophy are superior to high copy number plasmids, as they allow for more rapid
30 replication rates of *S. typhimurium in vitro*.

Intracellular growth of *asd* complemented strains

To measure fitness of the *asd* mutants complemented with *asd* on high and low copy number plasmids, the ability of bacterial strains to replicate intracellularly in mouse tumor cell lines was assessed using a gentamycin protection assay. In this assay, mouse melanoma B16.F10 cells or mouse colon cancer CT26 cells were
5 infected with *asd* mutant *Salmonella* strains containing plasmids that contain a complementary *asd* gene and have either a high copy origin of replication, AST-110 (ASD pATI-shTREX1), or a low copy origin of replication, AST-117 (ASD pATI low copy-shTREX1). Cells were infected at a multiplicity of approximately 5 bacteria per cell for 30 minutes, then cells were washed with PBS, and medium containing
10 gentamycin was added to kill extracellular bacteria. Intracellular bacteria are not killed by gentamycin, as it cannot cross the cell membrane. At various time points after infection, cell monolayers were lysed by osmotic shock with water and the cell lysates were diluted and plated on LB agar to enumerate surviving colony forming units (CFU).

15 The *asd* mutant strain complemented with a high copy plasmid, AST-110, had an initial decline in CFUs, but was able to grow in B16.F10 cells but not in CT26 cells, demonstrating that the *asd* gene complementation system is sufficient to support growth inside mammalian tumor cells. The *asd* mutant strain containing the low copy plasmid, AST-117, was able to invade and replicate in both cell types, demonstrating
20 that *asd* gene complementation on a low copy plasmid allows for robust *asd* mutant growth inside mammalian cells. The strain with low copy plasmids replicated to higher numbers in both tumor cell types compared to the strain with high copy plasmids. This demonstrates that *Salmonella* strains with low copy plasmids have enhanced fitness over strains with high copy plasmids.

25 **Plasmid maintenance in tumors using *asd* complementation system**

In this example, CT26 tumor-bearing mice were treated with YS1646 containing a plasmid that expresses an shRNA targeting TREX1 (pEQU6-TREX1), strain AST-104, or an *asd* deleted strain of YS1646 containing a plasmid with a functional *asd* gene and an shRNA targeting TREX1 (pATI-shTREX1), strain AST-
30 110. At 12 days after the final *Salmonella* injection, tumors were homogenized, and homogenates were serially diluted and plated on LB agar plates to enumerate the total

number of CFUs present, or on LB plates containing kanamycin to enumerate the number of kanamycin resistant colonies.

S. typhimurium that did not have selective pressure to maintain the shRNA plasmid, AST-104, demonstrated plasmid loss, as the percent kanamycin resistant (KanR) colonies was less than 10%. The strain that used the *asd* gene
5 complementation system for plasmid maintenance, AST-110, had nearly identical numbers of kanamycin resistant and kanamycin sensitive CFUs. These data demonstrate that the *asd* gene complementation system is sufficient to maintain the plasmid in the context of the tumor microenvironment in mice.

10 **Enhanced anti-tumor efficacy using *asd* complementation system**

The *asd* complementation system is designed to prevent plasmid loss and potentiate the anti-tumor efficacy of the inhibitory RNA delivery by *S. typhimurium* strains *in vivo*. To test this, *asd* deleted strains containing shTREN1 plasmid (AST-110) or scrambled control (AST-109) that contain a functional *asd* gene cassette were
15 compared to strain YS1646 containing pEQU6-shTREN1 (AST-104, a plasmid that lacks an *asd* gene cassette and therefore does not have a mechanism for plasmid maintenance), for anti-tumor efficacy in a murine colon carcinoma model. For this experiment, 6-8 week-old female BALB/c mice (8 mice per group) were inoculated SC in the right flank with CT26 (2×10^5 cells in 100 μ L PBS). Mice bearing
20 established flank tumors were IV injected twice, on day 8 and day 18, with 5×10^6 CFUs of AST-109 (ASD transformed with pATI-shScramble), AST-110 (ASD transformed with pATI-shTREN1), or AST-104 (YS1646 transformed with pEQU6-shTREN1) and compared to PBS control.

The YS1646 strain AST-104 demonstrated tumor control compared to PBS
25 (70% TGI, day 28) despite its demonstrated plasmid loss over time. The *asd⁺* strain containing the scramble control in a pATI plasmid with the *asd* gene complementation system (AST-109) demonstrated tumor control compared to PBS (51% TGI, day 25), indicating that maintained delivery of CpG plasmids stimulates an anti-tumor response. The *asd⁺* strain containing a plasmid with the *asd* gene
30 complementation system and shTREN1 (AST-110) demonstrated the highest tumor growth inhibition compared to PBS (82% TGI, $p = 0.002$, day 25). These data demonstrate that improved potency is achieved by preventing plasmid loss using the

asd complementation system and delivery of shTREX1, as compared to YS1646 containing plasmids without gene complementation systems or shTREX1 (the therapeutic product).

***S. typhimurium* strains with low copy plasmids demonstrate superior anti-tumor efficacy and tumor colonization compared to strains with high copy plasmids**

In order to compare the anti-tumor efficacy of the low copy shTREX1 plasmid with the *asd* complementation system, relative to the high copy shTREX1 plasmid, in a murine model of colon carcinoma, 6-8 week-old female BALB/c mice (10 mice per group) were inoculated SC in the right flank with CT26 (2×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected with two weekly doses of 5×10^6 CFUs of AST-117 (ASD (pATI Low-shTREX1)) or AST-110 (ASD (pATI-shTREX1)) and were compared to PBS injections as a negative control. The strain with the low copy plasmid, AST-117, demonstrated superior anti-tumor efficacy compared to the strain with the high copy plasmid AST-110 (High, 59 % TGI; Low 79% TGI, $p = 0.042$, day 25).

At the end of this tumor growth inhibition study, 4 mice from each group were euthanized, and tumors and spleens were homogenized as described above to evaluate tumor colonization and tumor to spleen colonization ratios. The strain containing the low copy plasmid, AST-117, colonized tumors at a level greater than 100 times higher than the strain with the high copy plasmid, AST-110. When the ratio of colonies recovered from tumor and spleen were calculated, AST-117 had a greater than 10-fold higher tumor to spleen colonization ratio compared to AST-110, demonstrating that strains with the low copy plasmids have greater specificity for tumor colonization than strains with the high copy plasmids.

These data demonstrate a previously unknown attribute that *S. typhimurium* engineered to deliver plasmids have improved tumor colonizing capabilities and anti-tumor activity.

Example 10

Exemplary strains engineered for increased tolerability

***adrA* or *csgD* deletion**

In this example, a live attenuated strain of *Salmonella typhimurium* that contains a *purI* deletion, an *msbB* deletion, an *asd* gene deletion and is engineered to

deliver plasmids encoding interfering RNA, is further modified to delete *adrA*, a gene required for *Salmonella typhimurium* biofilm formation. *Salmonella* that cannot form biofilms are taken up more rapidly by host phagocytic cells and are cleared more rapidly. This increase in intracellular localization enhances the effectiveness of
5 plasmid delivery and gene knockdown by RNA interference. The increased clearance rate from tumors/tissues increases the tolerability of the therapy, and the lack of biofilm formation prevents colonization of prosthetics and gall bladders in patients.

In another example, a live attenuated strain of *Salmonella typhimurium* that contains a *purI* deletion, an *msbB* deletion, an *asd* gene deletion and is engineered to
10 deliver plasmids encoding a therapeutic product also is modified to delete *csgD* (engineering of strains with *csgD* deletion is described below). This gene is responsible for the activation of *adrA*, and also induces expression of the curli fimbriae, a TLR2 agonist. Loss of *csgD* also prevents biofilm formation, with the added benefit of inhibiting TLR2 activation, thereby further reducing the bacterial
15 virulence and enhancing delivery of encoded therapeutic products.

***pagP* deletion**

In this example, a live attenuated strain of *S. typhimurium* that contains a *purI* deletion, an *msbB* deletion, and an *asd* gene deletion, and that is engineered to deliver plasmids encoding interfering RNA, is further modified to delete *pagP*. The *pagP*
20 gene is induced during the infectious life cycle of *S. typhimurium* and encodes an enzyme that palmitylates lipid A. In wild type *S. typhimurium*, expression of *pagP* results in a lipid A that is hepta-acylated. In an *msbB* mutant in which the terminal acyl chain of the lipid A cannot be added, the expression of *pagP* results in a hexa-acylated LPS. Hexa-acylated LPS has been shown to be the most pro-inflammatory.
25 In this example, a strain deleted of *pagP* and *msbB* can produce only penta-acylated LPS, allowing for lower pro-inflammatory cytokines, enhanced tolerability, and increased adaptive immunity when the bacteria are engineered to deliver interfering RNAs or other therapeutic products.

Example 11

30 ***pagP* Deletion Mutants have Penta-acylated LPS and Induce Reduced Inflammatory Cytokines**

***Salmonella pagP* Gene Knockout Strain Engineering and Characterization**

The *pagP* gene was deleted from the YS1646 Δ *asd*/ Δ FLG strain using modifications of the methods described in the preceding examples. The *pagP* gene is induced during the infectious life cycle of *S. typhimurium* and encodes an enzyme (lipid A palmitoyltransferase) that modifies lipid A with palmitate. In wild-type *S. typhimurium*, expression of *pagP* results in a lipid A that is hepta-acylated. In an *msbB* mutant, in which the terminal acyl chain of lipid A cannot be added, the expression of *pagP* results in a hexa-acylated LPS. Hexa-acylated LPS has been shown to be highly pro-inflammatory and have a high affinity for TLR4 (hepta-acylated LPS, found in wild-type, has the highest affinity for TLR4). In this example, a strain deleted of *pagP* and *msbB* can produce only penta-acylated LPS, allowing for lower pro-inflammatory cytokines due to low affinity for TLR4, enhanced tolerability, and increased adaptive immunity when the bacteria are engineered to deliver plasmids encoding immunomodulatory proteins.

Δ *pagP* Strain Construction

Synthetic *pagP* gene homology arm sequences that contain 203 and 279 bases of the left hand and right hand sequence, respectively, flanking the *pagP* gene, were synthesized and cloned into a plasmid called pSL0191 (SEQ ID NO:315). A kanamycin gene cassette flanked by cre/loxP sites then was cloned into pSL0191 and the *pagP* gene knockout cassette was PCR amplified with primers pagp-1 (SEQ ID NO:321) and pagp-2 (SEQ ID NO:322) (see, Table 1), gel purified and introduced into strain YS1646 Δ *asd* carrying the temperature sensitive lambda red recombination plasmid pKD46 by electroporation. The kanamycin resistance gene then was cured by cre-mediated recombination as described above, and the temperature-sensitive plasmids were cured by growth at non-permissive temperature. The *pagP* gene knockout sequences were amplified by PCR using primers pagp-3 (SEQ ID NO:323) and pagp-4 (SEQ ID NO:324), and verified by DNA sequencing. The resulting mutant derivative of YS1646 was designated YS1646 Δ *asd*/ Δ FLG/ Δ *pagP*.

***pagP* Deletion Mutants have Penta-Acylated LPS and Induce Reduced Inflammatory Cytokines**

The *pagP* gene also was deleted from the YS1646 Δ *asd* strain using the lambda-derived Red recombination system as described in Datsenko and Wanner (*Proc. Natl. Acad. Sci. USA* 97:6640–6645 (2000)) and above, to generate the strain

YS1646 Δ *asd*/ Δ *pagP*. This strain then was electroporated with a plasmid containing a functional *asd* gene, to complement the deleted *asd* gene and to ensure plasmid maintenance *in vivo*. The lipid A then was extracted from this strain and evaluated by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI MS) and compared to lipid A from the wild-type *S. typhimurium* strain ATCC 14028, the YS1646 strain (which is deleted for *msbB* and *purI*), and the YS1646 Δ *asd* strain. Wild-type *Salmonella* had a minor lipid A peak with a mass of 2034, and a major peak with a mass of 1796, corresponding to the hepta-acylated and hexa-acylated species, respectively, due to the presence of a functional *msbB* gene. The *msbB* deleted strains YS1646 and YS1646 Δ *asd* had major peaks at 1828 and 1585, corresponding to a mixture of hexa-acylated and penta-acylated LPS. The *msbB* and *pagP* deleted strain, YS1646 Δ *asd*/ Δ *pagP*, had only a single peak with a mass of 1585, corresponding to penta-acylated LPS. These data demonstrate that deletion of *pagP* prevents palmitoylation of the LPS, thereby restricting it to a single penta-acylated species.

To show that the penta-acylated LPS from the Δ *pagP* mutant strains reduced TLR4 signaling, 4 μ g of purified LPS from the wild-type strain, the YS1646 strain or the YS1646 Δ *asd*/ Δ *pagP* strain were added to THP-1 human monocytic cells, and the supernatants were evaluated 24 hours later for the presence of inflammatory cytokines using a Cytometric Bead Array (CBA) kit (BD Biosciences). The results show that LPS from the YS1646 Δ *asd*/ Δ *pagP* strain induced 25% the amount of TNF α compared to wild-type LPS, and induced 7-fold less IL-6 than wild-type LPS. The LPS from the YS1646 Δ *asd*/ Δ *pagP* strain induced 22-fold less IL-6 than strain YS1646, demonstrating that the penta-acylated LPS species from a Δ *pagP* mutant is significantly less inflammatory in human cells, and indicating that the Δ *pagP* mutant would be better tolerated in humans.

Deletion of *pagP* Induces Significantly Less IL-6 in Primary Human M2 Macrophages

To demonstrate that the YS1646 Δ *asd*/ Δ FLG/ Δ *pagP* strain also elicits less inflammatory and dose-limiting IL-6 from primary human M2 macrophages, the strain was evaluated and compared with the YS1646 Δ *asd*/ Δ FLG and the parental YS1646 strains. The M2 macrophages derived from human donors are representative

of the immunosuppressive phenotypes that are highly enriched in T-cell excluded solid tumors. Frozen human PBMCs, isolated from healthy human donors, were thawed in complete medium (RPMI-1640 + 1X non-essential amino acids + 5% human AB serum) and washed by centrifugation for 10 minutes at 800 RPM at room temperature. PBMCs were resuspended in PBS + 2% FBS, and monocytes were negatively isolated using a CD16 depletion kit (StemCell Technologies). Isolated untouched monocytes were then washed by centrifugation in PBS + 2% FBS and resuspended in complete medium containing 100 ng/mL human macrophage colony-stimulating factor (M-CSF) and 10 ng/mL human IL-4. Isolated monocytes (3e5 per well) were then seeded in a 24-well plate with a final volume of 750 μ L. Two days after seeding, the cell culture media was entirely aspirated and replaced with fresh complete medium containing 100 ng/mL human M-CSF and 10 ng/mL human IL-4. Two days later (on day 4), 500 μ L of complete medium containing the cytokines was added per well for 48 hours. On day 6, the cell culture media was entirely aspirated and replaced with fresh complete medium without cytokines alone, or with media containing the log-phase cultures of the *S. typhimurium* strains at an MOI of 20. Cells were infected for 1 hour, then washed with PBS, and the media was replaced with fresh media containing 50 μ g/mL gentamicin to kill extracellular bacteria. The wells were then washed and replaced with fresh media and allowed to incubate at 37 °C and 5% CO₂. After 48 hours, supernatants were harvested and assayed for cytokines using a human IL-6 cytometric bead array (CBA) according to manufacturer's instructions (BD Biosciences).

The results demonstrate that secreted IL-6 levels from human primary M2 macrophages, infected with parental strain YS1646, yielded an average of 14839 $\pm$ 926 pg/mL, while the IL-6 levels from the YS1646 Δ asd/ Δ FLG strain were significantly lower, at 2075 $\pm$ 723 pg/mL ($p = 0.004$). This further affirms the impact that the deletion of flagella, and elimination of TLR5 signaling, has on the induction of IL-6. The strain YS1646 Δ asd/ Δ FLG/ Δ pagP elicited the lowest IL-6 levels, at 332 $\pm$ 100 pg /mL, demonstrating the reduced ability of this modified LPS coating to stimulate TLR4, and the resulting dramatically reduced inflammatory IL-6 production.

The Combined Flagella and *pagP* Deletions Significantly Enhance Tolerability in Mice

To show that the modified strains described above are more attenuated than parental strain YS1646, a median lethal dose (LD₅₀) study was conducted. 6-8 week-old BALB/c mice (5 mice per group) were injected intravenously with a dose range of 3e5 to 3e7 CFUs of strain YS1646, or the derivative strains YS1646Δ*asd*/ΔFLG, YS1646Δ*asd*/Δ*pagP*, and YS1646Δ*asd*/ΔFLG/Δ*pagP*. Unlike strain YS1646, the derivative strains also carried a plasmid encoding murine IL-2, an FDA-approved cytokine that has demonstrated significant toxicity when systemically administered.

The LD₅₀ for strain YS1646 was found to be 4.4×10^6 CFUs (average of two studies), in line with previously published LD₅₀ reports of YS1646, and a >1000-fold improvement compared to wild-type *S. typhimurium* (Clairmont *et al.* (2000) *J. Infect. Dis.* 181:1996-2002). The LD₅₀ for the YS1646Δ*asd*/ΔFLG strain was determined to be 2.07×10^7 CFUs, demonstrating a greater than 4.5-fold reduction in virulence compared to strain YS1646. The LD₅₀ for the YS1646Δ*asd*/Δ*pagP* strain was determined to be 1.39×10^6 CFUs, demonstrating a 3.2-fold reduction in virulence, which is expected, given that the strain still has a highly inflammatory flagella. The LD₅₀ for the YS1646Δ*asd*/ΔFLG/Δ*pagP* strain could not be established, as no mice died at the highest dose given, but was $>6.2 \times 10^7$ CFUs. The YS1646Δ*asd*/ΔFLG/Δ*pagP* strain therefore demonstrates a >14-fold reduction in virulence compared to parental strain YS1646. These data demonstrate that the genetic modifications described above reduce the virulence of the clinical *S. typhimurium* strain YS1646, and therefore, lead to increased tolerability in humans.

In the Phase I clinical trial of VNP20009 (Toso *et al.* (2002) *J. Clin. Oncol.* 20(1):142-152), the presence of the bacteria in patients' tumors only partially was observed at the two highest doses tested, 3×10^8 CFU/m² (33% presence), and 1×10^9 CFU/m² (50% presence), indicating that the tolerable dose of VNP20009 was too low to achieve tumor colonization. By improving the tolerability of the strains through the modifications described above, >14-fold higher doses can be administered, if necessary, improving the percentage of patients whose tumors will be colonized, and increasing the level of therapeutic colonization per tumor, thereby solving the observed problems with VNP20009.

The Combined Flagella and *PagP* Deletions Significantly Limit the Generation of Anti-*S. typhimurium* Antibodies in Mice

The surviving mice from the 3×10^6 CFU dosing group (N=5, except for N=4 in the YS1646 dosing group) were kept for 40 days post IV dosing, at which time they were bled for serum and assessed for antibody titers to *S. typhimurium* by a modified flow-based antibody titering system. Overnight cultures of the strain YS1646 Δ asd/ Δ FLG-mCherry were washed and fixed with flow cytometry fixation buffer. Sera from previously-treated mice and from naïve control mice were seeded in a 96-well plate, and serial dilutions were performed in PBS. Next, 25 μ L of the YS1646 Δ asd/ Δ FLG-mCherry cultures, containing 1×10^6 CFUs, were added to the sera and incubated for 25 min at RT. The bacteria were then washed twice with PBS by spinning them at 4000 RPM for 5 min. After the last wash, the bacteria were resuspended in PBS containing a secondary Goat anti-Mouse Fc AF488 Ab (1/400 dilution from stock) and incubated for 25 minutes at RT and protected from light. The bacteria were then washed three times with PBS by spinning them at 4000 RPM for 5 min. After the last wash, the bacteria were resuspended in PBS and data were acquired using the NovoCyte flow cytometer (ACEA Biosciences, Inc.) and analyzed using the MFI FlowJo software (Tree Star, Inc.).

To evaluate the results by flow cytometry, the highest dilution with signal in all groups was chosen (the 1250X serum dilution), and the corresponding mean fluorescence intensity (MFI) values were plotted. The limit of detection (LOD) was chosen at an MFI of 1000, as that is the MFI obtained without staining, as well as with background staining with Goat anti-Mouse Fc AF488 Ab only. Therefore, an MFI greater than 1000 was considered a positive signal, and everything equal to or under this value was considered a negative result, despite having an MFI value.

The results of this assay reveal a high MFI titer of anti-*S. typhimurium* serum antibodies from mice treated with 3×10^6 CFUs of the YS1646 strain (29196.3 ± 20730), in line with previously published data that YS1646 is able to generate serum antibodies (that are non-neutralizing). Fewer antibodies were detected in the mice treated with the YS1646 Δ asd/ Δ FLG strain (11257 ± 9290), which can be due to the lack of adjuvant activity from the flagella. In the mice treated with the YS1646 Δ asd/ Δ pagP strain, significantly fewer antibodies were generated ($4494 \pm$

3861), as compared to strain YS1646 ($p = 0.033$), which can be due to the altered LPS surface coating. The most significant reduction in serum antibodies was demonstrated in the YS1646 Δ asd/ Δ FLG/ Δ pagP treatment group (1930 ± 2445), where several of the mice had MFI titers under 1000, and were thus considered negative for serum antibodies ($p = 0.021$, vs. strain YS1646). Thus, the combined deletions of the flagella and the pagP gene enable both improved safety, as well as significantly reduced immunogenicity, which will enable repeat dosing of high CFUs in humans.

pagP and Flagella Deleted Strains, and Their Combination, Demonstrate Significantly Higher Viability in Human Serum Compared to YS1646

Strain YS1646 (VNP20009) exhibits limited tumor colonization in humans after systemic administration. It is shown herein that strain YS1646 is inactivated by complement factors in human blood. To demonstrate this, strains YS1646 and *E. coli* D10B were compared to exemplary immunostimulatory bacteria provided herein, that contain additional mutations that alter the surface of the bacteria. These exemplary modified strains were YS1646 Δ asd/ Δ pagP, YS1646 Δ asd/ Δ FLG, and YS1646 Δ asd/ Δ FLG/ Δ pagP. These three strains, in addition to YS1646 and *E. coli* D10B cultures, were incubated with serum or heat-inactivated (HI) serum from either pooled mouse blood, or pooled healthy human donors ($n=3$), for 3 hours at 37 °C. After incubation with serum, bacteria were serially diluted and plated on LB agar plates, and the colony forming units (CFUs) were determined.

In mouse serum, all strains remained 100% viable and were completely resistant to complement inactivation. In human serum, all strains were 100% viable in the heat-inactivated serum. The *E. coli* D10B strain was completely eliminated after 3 hours in whole human serum. In whole human serum, the YS1646 strain exhibited only 6.37% of live colonies, demonstrating that tumor colonization of the YS1646 clinical strain was limited due to complement inactivation in human blood. For the YS1646 Δ asd/ Δ FLG strain, 31.47% of live colonies remained, and for the YS1646 Δ asd/ Δ pagP strain, 72.9% of live colonies remained, after incubation with human serum for 3 hours. The combined YS1646 Δ asd/ Δ FLG/ Δ pagP strain was completely resistant to complement in human serum.

These data explain why strain YS1646 (VNP20009) has very low tumor colonization when systemically administered. It is shown herein that strain YS1646 is

highly sensitive to complement inactivation in human serum, but not mouse serum. These data explain why limited tumor colonization was observed in humans, while mouse tumors were colonized at a high level. The *fliB/fliC* or *pagP* deletions, or the combination of these mutations, partially or completely rescues this phenotype. Thus, the enhanced stability observed in human serum with the YS1646 Δ *asd*/ Δ *pagP*, YS1646 Δ *asd*/ Δ FLG, and YS1646 Δ *asd*/ Δ FLG/ Δ *pagP* strains provides for increased human tumor colonization.

These data, and others provided herein, show that deletion of the flagella and/or *pagP* increases tumor colonization, improves tolerability, and increases the anti-tumor activity of the immunostimulatory bacteria. For example, it is shown herein that LPS from immunostimulatory bacteria that are *pagP*⁻ induced 22-fold less IL-6 than LPS from YS1646, and therefore are less inflammatory in human cells. Additionally, each and all of FLG, *hilA* and *pagP* deletion mutants are more attenuated than YS1646 (see Example 12, below). Immunostimulatory bacteria, such as *Salmonella* strains, including wild-type strains, that are one or both of flagellin⁻ and *pagP*⁻ exhibit properties that increase tumor/tumor microenvironment colonization and increase anti-tumor activity. Such strains can be used to deliver a therapeutic payload, such as an immunotherapeutic product and/or other anti-tumor product, and also can include modifications that improve therapeutic properties, such as deletion of *hilA*, and/or *msbB*, adenosine auxotrophy, and other properties as describe elsewhere herein. The resulting strains are more effectively targeted to the tumor/tumor microenvironment, by virtue of the modifications that alter infectivity, toxicity to certain cells, and nutritional requirements, such as auxotrophy for purines, that are provided in the tumor environment.

Example 12

***FLG and PagP* deletion mutants are more attenuated than YS1646 in mice**

To determine whether the modified strains described above are more attenuated than YS1646, a median lethal dose (LD₅₀) study was conducted. C57BL/6 mice were injected intravenously with increasing concentrations of YS1646, FLG/ASD (pATI-TREX1), HilA/ASD (pATI-TREX1), or PagP/ASD (pATI-TREX1). The LD₅₀ for YS1646 was found to be 1.6 x 10⁶ cfu, which is consistent with published reports of this strain. The LD₅₀ for the HilA/ASD (pATI-TREX1)

strain was determined to be 5.3×10^6 cfu, demonstrating a 3-fold reduction in virulence. The LD₅₀ for the PagP/ASD (pATI-TREX1) strain was determined to be 6.9×10^6 cfu, demonstrating a 4-fold reduction in virulence. The LD₅₀ for the FLG/ASD (pATI-TREX1) strain was determined to be $>7 \times 10^6$ cfu, demonstrating a
5 >4.4 -fold reduction in virulence compared to YS1646. These data indicate that the genetic modifications described above reduce the virulence of the *S. typhimurium* therapy and will lead to increased tolerability in humans. In the Phase I clinical trial of VNP20009 (Toso *et al.* (2002) *J. Clin. Oncol.* 20(1):142-152), the presence of the bacteria in patients' tumors was only partially observed at the two highest doses
10 tested, 3×10^8 CFU/m² (33% presence), and 1×10^9 CFU/m² (50% presence), indicating that the tolerable dose of VNP20009 was too low to achieve colonization. By improving the tolerability of the strains through the modifications described above, higher doses can be administered than VNP20009. This improves the percentage of patients that will have their tumors colonized, and the level of therapeutic
15 colonization per tumor.

Example 13

***S. typhimurium* Immune Modulator Strains Demonstrate Expression of Heterologous Proteins in Human Monocytes**

As described above, the *hilA* gene and flagellin genes *fliB* and *fliC* were
20 deleted from the YS1646 strain of *S. typhimurium* with the *asd* gene deleted, generating strains HilA/ASD and FLG/ASD strains, respectively. In addition, the FLG/ASD strain was further modified to express the listeriolysin O (LLO) protein lacking the signal sequence that accumulates in the cytoplasm of the *Salmonella* strain (FLG/ASD/cLLO). These strains were electroporated with a plasmid containing an
25 expression cassette for the EF-1 α promoter and the murine cytokine IL-2. In addition, the FLG/ASD strain was electroporated with an expression plasmid for IL-15 δ as a control for a non-cognate cytokine. Additional constructs were created using the CMV promoter.

To determine whether these strains containing expression plasmids could
30 infect human monocytes and induce their production of murine IL-2, THP-1 human monocytic cells were plated at 50,000 cells/well in RPMI (Corning) + 10% Nu Serum (Gibco) one day prior to infection. The cells were infected at an MOI of 50 for one

hour in RPMI, then washed 3 times with PBS, and resuspended in RPMI + 100 µg/ml Gentamycin (Sigma). Supernatants were collected 48 hrs later from a 96 well plate and assessed for the concentration of murine IL-2 by ELISA (R&D Systems). The concentration of IL-2 detected in the FLG/ASD-IL15δ control wells was found to be very low as expected, and likely reflective of some cross-reactivity to endogenous human IL-2 (6.52 pg/mL). In contrast, the FLG/ASD-IL-2 strain induced an average of 35.1 pg/ml, and even higher in the FLG/ASD/cLLO strain, 59.8 pg/mL. The highest levels were detected in the HilA/ASD-IL-2 strain, 103.4 pg/mL. These data demonstrate the feasibility of expressing and secreting functional heterologous proteins, such as IL-2, from the *S. typhimurium* immune modulator platform strains.

Example 14

Cell Infection with $\Delta hilA$ Mutant Leads to Less Human Epithelial Cell Infection

To demonstrate that *hilA* deleted *S. typhimurium* strains are reduced in their ability to infect epithelial cells, HeLa cervical carcinoma cells were infected with the following *S. typhimurium* strains: YS1646, and YS1646 Δasd and YS1646 $\Delta asd/\Delta hilA$, containing plasmids encoding a functional *asd* gene for plasmid maintenance. 1×10^6 HeLa cells were placed in a 24-well dish with DMEM and 10% FBS. Cells were infected with log-phase cultures of *S. typhimurium* for 1 hour, then the cells were washed with PBS and the media was replaced with media containing 50 µg/mL gentamicin to kill extracellular bacteria. After 4 hours, the HeLa cell monolayers were washed with PBS and lysed with 1% Triton X 100 lysis buffer to release intracellular bacteria. The lysates were serially diluted and plated on LB agar plates to quantify the number of intracellular bacteria. The strain with the *hilA* deletion had a 90% reduction in recovered CFUs compared to the strains with a functional *hilA* gene, demonstrating that deletion of *hilA* significantly decreases *S. typhimurium* infection of epithelial-derived cells.

Example 15

Cell Infection with $\Delta hilA$ or $\Delta fljB/\Delta fliC$ Mutants Leads to Less Pyroptosis in Human Macrophages

To demonstrate that $\Delta hilA$ or $\Delta fljB/\Delta fliC$ *S. typhimurium* strains are reduced in their ability cause cell death in macrophages, THP-1 human macrophage cells were infected with the following *S. typhimurium* strains: YS1646, and YS1646 Δasd ,

YS1646 Δ *asd*/ Δ *fljB*/ Δ *fliC*, and YS1646 Δ *asd*/ Δ *hilA*, containing plasmids encoding a functional *asd* gene to ensure plasmid maintenance. 5×10^4 cells were placed in a 96-well dish with DMEM and 10% FBS. Cells were infected with washed log-phase cultures of *S. typhimurium* for 1 hour at a MOI of 100 CFU per cell, then the cells were washed with PBS, and the media was replaced with media containing 50 μ g/mL gentamicin to kill extracellular bacteria, and 50 ng/mL of interferon gamma. After 24 hours the THP-1 cells were stained with CellTiter-Glo[®] reagent (Promega), and the percentage of viable cells was determined using a luminescent cell viability assay using a Spectramax plate reader to quantify the luminescence. The cells infected with the *hilA* deletion strain had approximately 72% viable cells, whereas the YS1646 infected cells had only 38% viability, demonstrating that deletion of *hilA* prevents cell death of human macrophages. Cells infected with the plasmid-containing strains YS1646 Δ *asd*, YS1646 Δ *asd*/ Δ *fljB*/ Δ *fliC* had 40% and 51% viability, respectively, indicating that the deletion of the flagellin genes also prevented cell death of human macrophages.

Example 16

Infection of Human Macrophages with an Immunostimulatory *S. typhimurium* Strain Containing a Plasmid Encoding IL-2 Expression Cassette Leads to Secretion of IL-2

Human THP-1 macrophages were infected with the following *S. typhimurium* strains: YS1646 Δ *asd*/ Δ *fljB*/ Δ *fliC*, YS1646 Δ *asd*-cytoLLO, and YS1646 Δ *asd*/ Δ *hilA*, containing plasmids encoding an expression cassette for the mouse IL-2 under a eukaryotic promoter, and a functional *asd* gene to ensure plasmid maintenance. 5×10^4 cells were placed in a 96-well dish with DMEM and 10% FBS. Cells were infected with washed log-phase cultures of *S. typhimurium* for 1 hour at a MOI of 50 CFU per cell, then the cells were washed with PBS and the media was replaced with media containing 50 μ g/mL gentamicin to kill extracellular bacteria. After 48 hours, the cellular supernatants were removed and tested for mouse IL-2 using an R&D Systems[™] Mouse IL-2 Quantikine ELISA Kit. The remaining cells were stained with CellTiter-Glo[®] reagent (Promega), and the percentage of viable cells was determined using a luminescent cell viability assay using a Spectramax plate reader to quantify the luminescence. The YS1646 Δ *asd*/ Δ *fljB*/ Δ *fliC*, YS1646 Δ *asd*-cytoLLO, and YS1646 Δ *asd*/ Δ *hilA* strains, containing plasmids encoding an

expression cassette for the mouse IL-2, expressed 35 pg/mL, 60 pg/mL, and 103 pg/mL of IL-2, respectively.

Example 17

S. typhimurium* Strains Expressing Murine IL-2 Demonstrate Potent Tumor Growth Inhibition *In Vivo

5

The immunostimulatory *S. typhimurium* strains containing deletions in *hilA* or the flagellin genes *fljB* and *fliC* in the YS1646 strain of *S. typhimurium* were combined with the *asd* gene deletion to form the strains $\Delta asd/\Delta hilA$ and $\Delta asd/\Delta fljB/\Delta fliC$, respectively. These strains were electroporated with a plasmid containing an expression cassette for the EF1 α promoter and the murine cytokine IL-2.

10

To show that the *S. typhimurium* strains containing the IL-2 expression plasmids induce anti-tumor efficacy, the $\Delta asd/\Delta hilA$ strains containing the muIL-2 plasmid or the $\Delta asd/\Delta fljB/\Delta fliC$ strains containing the muIL-2 plasmid were compared to vehicle control. 6-8 week-old female C57BL/6 mice (5 mice per group) were inoculated SC in the right flank with MC38 cells (5×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected on day 8 with 5×10^5 CFUs of $\Delta asd/\Delta hilA$ (pATI-muIL-2), $\Delta asd/\Delta fljB/\Delta fliC$ (pATI-muIL-2), or PBS vehicle control. Body weights and tumors were measured twice weekly. Tumor measurements were performed using electronic calipers (Fowler, Newton, MA). Tumor volume was calculated using the modified ellipsoid formula, $1/2(\text{length} \times \text{width}^2)$. Mice were euthanized when tumor size reached >20% of body weight or became necrotic, as per IACUC regulations.

15

20

The experiment demonstrated that the $\Delta asd/\Delta hilA$ (pATI-muIL-2) strain elicited significant tumor control compared to PBS ($P = 0.003$, D21). These data were comparable to that observed with the $\Delta asd/\Delta fljB/\Delta fliC$ (pATI-muIL-2) strain, which also demonstrated significant tumor growth inhibition compared to PBS ($P = 0.005$, D21). Thus, both strains demonstrate the ability of expressed IL-2 to potently inhibit tumor growth inhibition in a model of colorectal carcinoma.

25

30

Example 18

***Salmonella csgD* Gene Knockout Strain Engineering and Characterization $\Delta ansB$ Strain Construction**

The *ansB* gene, which encodes L-asparaginase II, was deleted from the YS1646 Δ *asd*/ Δ FLG/ Δ *pagP* strain using modifications of the methods described in the preceding examples. Synthetic *ansB* gene homology arm sequences that contained 236 and 251 bases of the left hand and right hand sequence, respectively, flanking the *ansB* gene, were synthesized and cloned into a plasmid called pSL0230 (SEQ ID NO:377). A kanamycin gene cassette flanked by cre/loxP sites then was cloned into pSL0230 and the *ansB* gene knockout cassette was PCR amplified with primers ansb-1 (SEQ ID NO:372) and ansb-2 (SEQ ID NO:373), gel purified and introduced into strain YS1646 Δ *asd* carrying the temperature sensitive lambda red recombination plasmid pKD46 by electroporation. The kanamycin resistance gene then was cured by cre-mediated recombination as described above, and the temperature-sensitive plasmids were cured by growth at non-permissive temperature. The *ansB* gene knockout sequences were amplified by PCR using primers ansb-3 (SEQ ID NO:374) and ansb-4 (SEQ ID NO:375) (see, Table 1), and verified by DNA sequencing. The resulting mutant derivative of YS1646 was designated YS1646 Δ *asd*/ Δ FLG/ Δ *pagP*/ Δ *ansB*.

Strain YS1646 Δ *asd*/ Δ FLG/ Δ *pagP*/ Δ *ansB* was further modified to delete *csgD*, a master gene that controls *S. typhimurium* curli fimbriae formation, cellulose production, and c-di-GMP production. The *csgD* deletion eliminates the possibility of cellulose-mediated biofilm formation, reduces pro-inflammatory signaling, and enhances uptake by host phagocytic cells. This increase in intracellular localization would thereby enhance the effectiveness of plasmid delivery and immunomodulatory protein production.

Δ *csgD* Strain Construction

The *csgD* gene was deleted from the YS1646 Δ *asd*/ Δ FLG/ Δ *pagP*/ Δ *ansB* strain, using modifications of the methods described in the preceding examples. Synthetic *ansB* gene homology arm sequences that contained 207 and 209 bases of the left hand and right hand sequence, respectively, flanking the *csgD* gene, were synthesized and cloned into a plasmid called pSL0196 (SEQ ID NO:316). A kanamycin gene cassette flanked by cre/loxP sites then was cloned into pSL0196 and the *csgD* gene knockout cassette was PCR amplified with primers csgd-1 (SEQ ID NO:317) and csgd-2 (SEQ ID NO:318), gel purified and introduced into strain

- YS1646 Δ asd carrying the temperature sensitive lambda red recombination plasmid pKD46 by electroporation. The kanamycin resistance gene then was cured by cre-mediated recombination as described above, and the temperature-sensitive plasmids were cured by growth at non-permissive temperature. The *csgD* gene knockout
- 5 sequences were amplified by PCR using primers cgsd-3 (SEQ ID NO:319) and cgsd-4 (SEQ ID NO:320), and verified by DNA sequencing. The resulting mutant derivative of parental strain YS1646 was designated YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB/ Δ csgD.

Primer Sequence Information

Primer name	Primer sequence	SEQ. ID NO.
csgd-1	cacttgctttaagatttgtaatggctag	317
csgd-2	gggtgtattcgctttccattgtc	318
csgd-3	tgtgctgtccagggttaatgcc	319
csgd-4	gacgacgggtttctcgaagtctc	320

csgD Deleted Strains Cannot Form RDAR Colonies on Congo Red Plates

- 10 The ability to form Rough Dry And Red (RDAR) colonies after growth on Congo Red plates is a well-validated assay for bacterial biofilm formation. The Rough and Dry texture occurs through cellulose production, and the red is due to the accumulation of pigment by the curli fimbriae surface structures. For this assay, the YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB strain was compared to the
- 15 YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB/ Δ csgD strain for the ability to form the RDAR phenotype after incubation on Congo Red agar plates. Congo Red agar plates were prepared with soytone (10 g/L) and yeast extract (5 g/L) (modified LB without NaCl) and complemented with Congo red (40 mg/L) and Coomassie brilliant blue G-250 (20 mg/L). Five microliters of a stationary phase bacterial culture was spotted onto Congo
- 20 Red plates and incubated at 37 °C for 16 hours, then transferred to 30 °C and incubated for an additional 120 hours. Visual analysis of colony morphology and color was performed and recorded daily to confirm presence or absence of the RDAR colony morphotype.

- Comparing the colony morphotypes between the two strains, the
- 25 YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB/ Δ csgD strain had a smooth phenotype, and the colonies lacked pigment. In comparison, the YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB strain, still containing the *csgD* gene, exhibited the classic rough and dry appearance, and clear evidence of pigment uptake. Thus, the functional assay confirms that the

ΔcsgD strain is unable to form biofilms, as it lacks curli fimbriae and cellulose production.

***csgD*-Deleted Strains Demonstrate Superior Anti-Tumor Efficacy in a Highly Refractory Mouse Model of Triple Negative Breast Cancer**

5 The impact of the *csgD* deletion in models where the immunostimulatory bacterial therapy colonizes tumors, but has shown limited efficacy, was assessed. This can indicate the presence of bacterially-produced cellulose that can limit uptake into tumor-resident myeloid cells, thereby limiting therapeutic benefit (Crull *et al.* (2011) *Cellular Microbiology* 13(8):1223–1233). The difficult-to-treat EMT6 model was
10 utilized, which is a representative model of human triple negative breast cancer (Yu *et al.* (2018) *PLoS ONE* 13(11):1-27). When EMT6 tumor cells are administered orthotopically into the mammary fat pad, as opposed to subcutaneously in the flank, the model is T-cell excluded, highly metastatic, and highly refractory to immunotherapy, including to all approved checkpoint antibodies (Mariathasan *et al.*
15 (2018) *Nature* 554: 544–548).

For this experiment, 6-8 week-old female BALB/c mice (5 mice per group) were inoculated in the left mammary fat pad with EMT6 tumors cells (2×10^5 cells in 100 μ L PBS). Mice bearing 13 day-old established mammary tumors ($\sim 55 \text{ mm}^3$) were IV injected with a single dose of 1×10^7 CFUs of the *csgD*-deleted strain
20 YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB/ Δ csgD, or the parental YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB strain, and compared to PBS control. The bacterial strains contained a plasmid expressing a constitutively active murine STING (EF1a muSTING R283G, see Examples below for details).

The tumors in the PBS-treated mice grew evenly, reaching a max tumor
25 volume at day 35 ($1199.0 \pm 298.1 \text{ mm}^3$). Mice treated with the *csgD*-intact strain, YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB, did not demonstrate evidence of anti-tumor efficacy in this model, also reaching max tumor volume at day 35 (1689.1 ± 537.0). *Ex vivo* LB plating of these tumors revealed all tumors to be colonized. However, the *csgD*-deleted strain, YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB/ Δ csgD, resulted in 3 out of 5
30 mice being completely cured of both their primary and any metastatic disease (day 60+). Overall TGI was 45.7%, with one of the other two tumors partially responding before eventually growing out. The two bacterial strains contained the same plasmid

payload, yet only one demonstrated significant efficacy. Thus, in one of the most intractable and highly metastatic syngeneic tumor models, orthotopic EMT6, a strain with a *csgD* deletion was able to induce systemic anti-tumor efficacy and result in 60% complete responses.

5 ***csgD*-Deleted Strains Demonstrate Enhanced Intracellular Uptake *in vivo***

In order to determine whether the *csgD*-deleted strain demonstrated improved efficacy because of greater bacterial uptake into tumor-resident myeloid cells, an *ex vivo* gentamicin protection assay was performed (see, Crull *et al.* (2011) *Cellular Microbiology* 13(8):1223–1233). For this experiment, 6-8 week-old female C57BL/6
10 mice (4 mice per group) were inoculated SC in the right flank with MC38 cells (5×10^5 cells in 100 μ L PBS). Mice bearing large established flank tumors were IV injected on day 17 with 1×10^7 CFUs of the *csgD*-deleted
YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB/ Δ csgD strain (N=12), or the parental YS1646 strain (N=4). Tumors were resected 7 days post IV dosing, weighed and minced in
15 RPMI supplemented with 1 mg/mL collagenase IV and 20 mg/mL DNase I, and incubated with shaking at 37 °C for 30 minutes to generate a single cell suspension. After 30 minutes, the suspension was passed through a 70 μ m filter and the recovered volume was divided into two separate, identical samples. Gentamicin (Thermo Fisher Scientific) was added at 200 mg/mL to one of each of the paired samples to kill
20 extracellular bacteria, and the samples were incubated with shaking at 37 °C for 90 minutes. Cell suspension samples were then washed and lysed with 0.05% Triton X and plated for CFUs.

The results demonstrate that, compared to the CFUs from YS1646-treated tumors without gentamicin treatment (11925 ± 19859 CFUs), gentamicin treatment
25 resulted in very few CFUs detected from the tumors (51 ± 45 CFUs). This indicates that the bacteria reside largely extracellularly in these tumors, and are thus sensitive to gentamicin elimination. In the *csgD*-deleted
YS1646 Δ asd/ Δ FLG/ Δ pagP/ Δ ansB/ Δ csgD treatment group, the non-gentamicin treated tumors yielded high CFUs, as expected from well-colonized tumors, and
30 treatment with gentamicin yielded less CFUs (1276 ± 2410 CFUs), and much more in the parental YS1646 strain-treated tumors. This is due to more of the *csgD*-deleted bacteria residing intracellularly, and thus being protected from gentamicin. These data

demonstrate that the *csgD* deletion improves intracellular uptake of the bacteria, which can enhance plasmid delivery of immunomodulatory proteins *in vivo*.

Example 19

Plasmid Construction

5 A plasmid, designated pATI-1.75, was designed and synthesized; it contains the following features: a pBR322 origin of replication, the *asd* gene, a kanamycin resistance gene flanked by HindIII sites for curing, and a multicloning site for expression cassette insertion. The vector was designated pATI-1.75. The expression cassette is composed of multiple elements, including eukaryotic promoters, open
10 reading frames, posttranscriptional regulatory elements and polyadenylation signals, that are assembled in various configurations

Exemplary promoters include the human cytomegalovirus (CMV) immediate early core promoter encoded directly downstream of the CMV immediate early enhancer sequence and core promoter for human elongation factor-1 alpha (EF-
15 1 α). Open reading frames (ORFs) can include one or more sequences that each are translated into a protein, and can be separated into distinct polypeptides by insertion of a 2A sequence, whereby eukaryotic ribosomes fail to insert a peptide bond between Gly and Pro residues within the 2A sequence. Examples of 2A sequences are the T2A peptide from the *Thosea asigna* virus (TaV) capsid protein, and the P2A peptide from
20 porcine teschovirus (PTV). Upstream furin cleavage sites (RRKR) and other enhancer elements, are placed upstream to facilitate cleavage of expressed proteins.

Examples of post-transcriptional regulatory elements (PREs) include the Woodchuck Hepatitis virus PRE (WPRES) and the Hepatitis B virus PRE (HPRE), which increase accumulation of cytoplasmic mRNA of a gene by promoting mRNA
25 nuclear export to the cytoplasm, enhancing 3' end processing and stability. Examples of polyadenylation signal sequences include the SV40 polyadenylation signal and the bovine growth hormone polyadenylation signal, both of which are 3' regulatory elements that serve to promote transcriptional termination and contain the sequence motif recognized by the RNA cleavage complex.

Example 20**Identification of Gain-of-Function Mutations in Genes That Promote Interferonopathies**

Cases of subjects presenting with severe auto-inflammatory conditions and vasculopathies of unknown etiology occur, and, often derive from mutations. The cause for these conditions can be identified. Steps to identify a mutational basis for such a pathology are as follows. In step one, intact genomic DNA is obtained from patients experiencing symptoms, and from healthy individuals. Whole exome sequencing is performed, then introns and exons are analyzed. Analysis of genes and identification of mutations in products in the pathways associated with the expression of type I interferon (IFN) is performed. The Table below (and in the detailed description) lists mutations in genes known to lead to constitutive functional activation of the encoded proteins, and subsequent persistent expression of type I IFN. After identification of mutations, cDNA encoding the full-length gene, with and without the identified mutation(s), are transfected into a reporter cell line that measures expression of type I IFN. For example, a reporter cell line can be generated where the expression of luciferase is placed under control of the promoter for IFN- β . A gain-of-function mutant that is constitutively active will promote the expression of IFN- β , whereas the unstimulated wild-type (WT) protein will not. In the case of known STING SAVI (STING-associated vasculopathy with onset in infancy) mutants, the WT-STING stimulation of IFN- β requires the addition of increasing exogenous levels of cGAMP to directly activate WT-STING. Constitutively active mutations stimulate the expression of IFN- β in a cGAMP-independent manner. Exemplary gain-of-function mutations in each of STING, RIG-I, MDA5, IRF3 and IRF7 are set forth below. Other such genes, in which gain-of-function mutations can be identified in subjects or produced by *in vitro* mutation and screening, include, but are not limited to STING, RIG-I, MDA-5, IRF-3, IRF-5, IRF-7, TRIM56, RIP1, Sec5, TRAF3, TRAF2, TRAF6, STAT1, LGP2, DDX3, DHX9, DDX1, DDX9, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200.

Gain-of-function mutations resulting in the persistent expression of Type I IFN

STING	RIG-I	MDA5	IRF3	IRF7
V147L	E373A	T331I	S396D	S477D/S479D
N154S	C268F	T331R	S396D/S398D	S475D/S476D/S477D/S479D/S483D/S487D

STING	RIG-I	MDA5	IRF3	IRF7
V155M		A489T	S396D/S398D/ S402D/T404D/ S405D	Δ 247-467
G166E		R822Q		S475D/S477D/S479D
C206Y		G821S		
G207E		A452T		
R281Q		A946T		
R284G		R337G		
R284S		D393V		
R284M		G495R		
R284K		R720Q		
R284T		R779H		
S102P, F279L		R779C		
R197A, D205A		L372F		
S272A, Q273A				
R310A, E316A				
E316A				
E316N				
E316Q				
S272A				
R375A				
R293A, T294A, E296A,				
D231A				
R232A				
K236A				
Q273A				
S358A, E360A, S366A				
D231A, R232A, K236A, R238A				
R238A				
V147M				
S324A, S326A				
R375A				

Amino acid residues R197, D205, R310, R293, T294, E296, S272, Q273, R310, E316, D231, R232, K236, S358, E360, S366, and R238, with reference to the sequence of human STING, as set forth in SEQ ID NOs:305-309, correspond to amino acid residues R196, D204, R309, R292, T293, E295, S271, Q272, R309, E315, D230, R231, K235, S357, E359, S365 and
5 R237, respectively, with reference to the sequence of murine STING, as set forth in SEQ ID NO:351.

Also included are conservative substitutions of each of the replacements (see, Table in the definitions section listing exemplary conservative mutations for each amino acid, *i.e.*, Ser for Ala, where the wild-type is not Ser).

10 After identification of mutations, cDNA encoding the full-length gene, with and without the identified mutation(s), are transfected into a reporter cell line that measures expression of type I IFN. For example, a reporter cell line can be generated where the expression of luciferase is placed under control of the promoter for IFN- β . A gain-of-function (GOF) mutant that is constitutively active will promote the
15 expression of IFN- β , whereas the unstimulated wild-type (WT) protein will not. In the case of known STING SAVI (STING-associated vasculopathy with onset in infancy) mutants, the WT-STING stimulation of IFN- β requires the addition of increasing exogenous levels of cGAMP to directly activate WT-STING. Constitutively active mutations stimulate the expression of IFN- β in a cGAMP-independent manner.
20 Exemplary gain-of-function mutations in each of STING, RIG-I, MDA5, IRF3 and IRF7 are set forth below in Example 15 and discussed elsewhere herein. Other such genes, in which gain-of-function mutations can be identified in subjects or produced by *in vitro* mutation and screening, include, but are not limited to STING, RIG-I, MDA-5, IRF-3, IRF-5, IRF-7, TRIM56, RIP1, Sec5, TRAF3, TRAF2, TRAF6,
25 STAT1, LGP2, DDX3, DHX9, DDX1, DDX9, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200. The gain-of-function mutation increase expression of type I IFNs or render expression constitutive.

Expression of Functional Constitutive Type I IFN Mutants in Human Cells

The specific human STING (allele R232) and IRF3 gain-of-function (GOF)
30 mutants were cloned into the pATI-1.75 vector, and the sequences were confirmed by PCR. To determine whether the STING and IRF3 GOF expression plasmids could induce functional type I IFN in human cells, the plasmids were assessed using

HEK293T STING Null Reporter cells (InvivoGen), which do not contain endogenous STING. These cells express secreted embryonic alkaline phosphatase (SEAP), placed under the control of the endogenous IFN-stimulated response element (ISRE) promoter, where the coding sequence of ISRE has been replaced by the SEAP ORF using knock-in technology. Type I interferon activity can be assessed by monitoring Type I IFN-stimulated SEAP production in the cell supernatants.

To test the relative production of type I IFN by the GOF mutants, 1×10^5 293T-Dual™ Null cells were plated one day prior on plates coated with poly-L-lysine, to achieve 80% confluency in a 24-well plate. On the day of transfection, 200 ng of plasmids encoding a panel of STING and IRF3 GOF mutants, including a STING wild-type (WT) and IRF3 WT control, and a negative control (NC) mutation that has been reported in the literature to be non-functional in human cells (V155R), were diluted in serum-free media and added to FuGENE® transfection reagent (Promega) at the proper reagent:DNA ratios. Cell culture supernatants from each sample were collected after overnight incubation, and 10 μ L of the cell culture supernatants was added to 50 μ L QUANTI-Blue™ reagent (InvivoGen) (which is used for measuring SEAP). Type I interferon activation was determined by measuring ISRE-induced SEAP activity on a SpectraMax® M3 Spectrophotometer (Molecular Devices) at an absorbance of 650 nm.

As shown in the table below, all GOF mutants were able to induce type I IFN activity in a STING ligand-independent manner in human cells, compared to the wild-type and negative controls, which did not induce type I IFN activity. The highest levels of type I IFN induction were observed with the human STING R284G and IRF3 S396D phosphomimetic variants. These data support the ability of the plasmids encoding GOF mutants to produce functional, constitutive STING and constitutive phosphomimetic IRF3 that can induce type I IFN in a cGAMP-independent manner.

GOF Mutant	Mean Absorbance (650 nm)	Standard Deviation
Plasmid control	0.049	0.002
huSTING WT	0.144	0.004
huSTING V147L	1.399	0.015
huSTING N154S	1.382	0.008
huSTING V155M	1.360	0.048
huSTING C206Y	1.566	0.121
huSTING R281Q	1.546	0.132

GOF Mutant	Mean Absorbance (650 nm)	Standard Deviation
huSTING R284G	1.831	0.039
huSTING V155R (NC)	0.181	0.014
huIRF3 WT	0.781	0.073
huIRF3 S396D	1.922	0.131

Infection of Flagella-Deleted Strains Containing Plasmids Encoding Constitutive Type I IFN Mutants Converts Human M2 Macrophages to Type I IFN-Producing M1 Macrophages

It was determined if primary human M2 macrophages, infected with flagella-
 5 deleted strains containing plasmids encoding constitutive type I IFN GOF variants, could be converted to producers of type I IFN and downstream chemokines, such as CXCL10 (also known as IP-10).

Frozen human PBMCs, isolated from healthy human donors, were thawed in complete medium (RPMI-1640 + 1X non-essential amino acids + 5% Human AB
 10 serum) and washed by centrifugation for 10 minutes at 800 RPM at room temperature. PBMCs were resuspended in PBS + 2% FBS, and monocytes were negatively isolated using a CD16 depletion kit (StemCell Technologies). Isolated untouched monocytes were then washed by centrifugation in PBS + 2% FBS and resuspended in complete medium containing 100 ng/mL human M-CSF and 10 ng/mL human IL-4. Isolated
 15 monocytes (3e5 per well) were then seeded in a 24-well plate with a final volume of 750 microliters. Two days after the seeding, the cell culture media was entirely aspirated and replaced with fresh complete medium containing 100 ng/mL human M-CSF and 10 ng/mL human IL-4. Two days later (on day 4), 500 μ L of complete medium containing the cytokines was added per well and incubated for 48 hours. On
 20 day 6, the cell culture media was entirely aspirated and replaced with fresh complete medium without cytokines. Duplicate wells were infected at an MOI of 450, for one hour in RPMI, with the following strains: YS1646 Δ asd/ Δ FLG containing a plasmid encoding wild-type (WT) human (hu) STING; YS1646 Δ asd/ Δ FLG containing a plasmid encoding the huSTING R284G variant; YS1646 Δ asd/ Δ FLG containing a
 25 plasmid encoding WT huIRF3; YS1646 Δ asd/ Δ FLG containing a plasmid encoding the huIRF3 S396D variant; or a strain containing a plasmid control. The cells were then washed 3 times with PBS, and resuspended in RPMI + 100 μ g/mL gentamicin

(Sigma). As a control, the STING agonist 3'5' RpRp c-di-AMP (InvivoGen), an analog of the clinical compound ADU-S100, was added to the cells at 10 µg/mL.

After 24 hours, the cells were lysed with 350 µL Buffer RLT with β-ME (Qiagen) and RNA extraction was performed using the Qiagen RNeasy Mini Kit with the following modification. A genomic DNA elimination step, using an RNase-Free DNase kit (Qiagen), was included to remove genomic DNA from the total RNA. Total RNA concentration was measured using a NanoDrop™ One^C UV-Vis Spectrophotometer (Thermo Scientific). The purity of each sample also was assessed from the A₂₆₀/A₂₃₀ absorption ratio. RNA was stored at -80 °C without freeze-thawing until reverse-transcription was performed. Synthesis of cDNA was performed from 0.4-1 µg of template RNA using a C1000 Touch Thermal Cycler (Bio-Rad) and SuperScript™ VILO™ Master Mix (Invitrogen) in a 30 µL reaction, according to the manufacturer's instructions.

qPCR was performed with a CFX96 Real-Time System (Bio-Rad). SYBR® primers for huCXCL10 (qHsaCED0046619), huIRF3 (qHsaCID0013122), huSTING (qHsaCID0010565), and huIFNB1 (qHsaCED0046851) were purchased from Bio-Rad. The qPCR reaction (20 µL) was conducted per protocol, using the iTaq Universal SYBR® Green Supermix (Bio-Rad). The standard thermocycling program on the BioRad CFX96 Real-Time System consisted of a 95 °C denaturation for 30 sec, followed by 40 cycles of 95 °C for 5 sec and 60 °C for 30 sec. Reactions with template free control were included for each set of primers on each plate. All samples were run in duplicate, and the mean C_q values were calculated. Quantification of the target mRNA was normalized using Gapdh reference mRNA (Bio-Rad, qMmuCED0027497). ΔC_q was calculated as the difference between the target and reference gene. ΔΔC_q was obtained by normalizing the ΔC_q values of the treatments to the ΔC_q values of the non-treatment control. Fold increase was calculated as 2^{-ΔΔC_q}. The values are shown in the table below, as the average of the duplicate wells.

As shown in the table below, compared to the infection of the plasmid control, strains of YS1646Δ*asd*/ΔFLG containing plasmids encoding huSTING WT and huSTING R284G induced high levels of STING expression, which were significantly higher compared to the small molecule STING agonist. Similarly, the strains containing plasmids encoding huIRF3 WT and huIRF3-S396D induced high levels of

- IRF3 expression, which were significantly higher than the plasmid control or the small molecule STING agonist. The bacterial strain containing a plasmid encoding the huSTING R284G variant induced much higher expression of IFN β and CXCL10 as compared to the strain containing a plasmid encoding huSTING WT. This
- 5 demonstrates the ability of the strain, containing a plasmid encoding a constitutive STING GOF variant, to convert a human primary, immunosuppressive M2 macrophage into an M1 type I IFN producing cell. While the strains containing plasmids encoding huIRF3 WT and huIRF3-S396D both induced more IFN β , they induced less CXCL10 than the huSTING-R284G variant.

GOF Mutant	Fold Expression Over Untransfected Control			
	STING	IRF3	IFN β	CXCL10
Plasmid Control	22.3	0	ND	ND
huSTING WT	24017.1	ND	3.4	3934.5
huSTING R284G	36542.7	ND	20	23484.5
huIRF3 WT	22.7	478.9	17.5	10766.2
huIRF3-S396D	30.8	346.4	26.3	15696.1
3'5' RpRp c-di-AMP	244.8	1.11	1.77	594.1

10 ND = No Data

These data demonstrate the expression of constitutive GOF type I IFN variants in human primary M2 macrophages, and converting these cells to M1-like type I IFN producing cells.

Example 21

15 **Protein Engineering Screening to Identify Improved Gain-of-Function Mutations in STING, RIG-I, MDA5, IRF3, IRF7, and other Interferon Pathway Genes**

- Gain-of-function (GOF) amino acid mutants that are constitutively active and promote interferonopathies are identified from humans as outlined in Example 20.
- 20 Many GOF mutations occur due to single base pair nucleotide changes that alter the amino acid codon at that particular position in the gene. For example, in STING, the V147L mutation occurs due to a mutation at c.439G $\rightarrow$ C; N154S occurs due to a mutation at c.461A $\rightarrow$ G; and V155M occurs due to a mutation at c.463G $\rightarrow$ A. The purpose of the screening is to identify constitutively active mutants that lead to high
- 25 levels of type I interferon expression. Designed mutations, at sites known to promote interferonopathies when mutated, allow for a greater number of amino acid substitutions to be tested. In this example, site-directed mutagenesis with designed

amino acids is performed in the positions of known mutations (outlined in the table above (Example 20)), to identify mutations with enhanced activity, that lead to high level type I interferon expression.

PCR primers are generated with designed substitutions flanked on the 5' and 3' ends with homologous cDNA sequences from the gene. The QuikChange Site-Directed Mutagenesis Kit (Agilent), or other comparable commercially available kit, is used to generate a PCR product incorporating the designed mutation. PCR amplified plasmids are treated with DpnI, then electroporated in competent *E. coli* cells. Individual clones are isolated, plasmid mini-preps are performed, and the sequence identity of the desired mutation is confirmed. Larger scale plasmid preps are then performed (using a Qiagen Kit) and the DNA is transfected into HEK293T STING Reporter cells (InvivoGen), which do not contain endogenous STING. These cells express Lucia™ luciferase, a secreted luciferase, placed under the control of the endogenous IFN- β promoter; the coding sequence of IFN- β has been replaced by the Lucia™ luciferase ORF using knock-in technology. Constitutively activated mutants then are identified and ranked by measurement of IFN- β promoter induced expression of luciferase activity.

Example 22

Transformation of Plasmids Encoding Constitutively Active Immunostimulatory Proteins into Immunostimulatory Bacterial Strains

Selected plasmids, containing expression cassettes encoding immunostimulatory proteins and a functional *asd* gene, are electroporated into *S. typhimurium* strains lacking the *asd* gene with a BTX600 electroporator using a 0.2 cm gap cuvette (BTX, San Diego, Calif.) at the following settings: 2.5 kV, 186 ohms, 50 uF. Electroporated cells are added to 1-ml SOC supplemented with 50 μ M diaminopimelic acid (DAP), incubated for 1 hour at 37 °C, and then spread onto agar plates that do not contain DAP, to select for strains that received plasmids with a functional *asd* gene. After single colony isolation, cell banks are produced by inoculating a flask of sterile lysogeny broth (LB) with a single well isolated colony of *S. typhimurium*, and incubating at 37 °C with agitation at 250 RPM. After the culture has grown to stationary phase, the bacteria are washed in PBS containing 10% glycerol, and stored in aliquots frozen at less than -60 °C.

Example 23

Plasmids Demonstrate Expression of Functional STING Gain-of-Function Mutants in Human Cells

The immunostimulatory bacterial strains are electroporated with a plasmid
5 containing the complemented *asd* gene, and the expression cassette with a eukaryotic promoter controlling expression of the STING gain-of-function (GOF) mutants.

To determine whether the STING GOF expression plasmids can be transfected into human cells and express functional STING protein, HEK293T STING Reporter cells (Invivogen), which do not contain endogenous STING, are used. These cells
10 express Lucia™ luciferase, a secreted luciferase, placed under the control of the endogenous IFN-β promoter; the coding sequence of IFN-β has been replaced by the Lucia™ luciferase ORF using knock-in technology. Cyclic dinucleotide (CDN) stimulation can be assessed in 293T-Dual™ STING (ISG/KI-IFNβ) cells (Invivogen), by monitoring IFN-stimulated response element (ISRE)-induced secreted embryonic
15 alkaline phosphatase (SEAP) production and/or IFN-β-dependent expression of Lucia™ luciferase. The two reporter proteins, SEAP and Lucia™ luciferase, are measured in the cell culture supernatant by using QUANTI-Blue™ and QUANTI-Luc™, respectively.

For this, 5×10^5 HEK293T-Dual cells containing huSTING (human WT
20 STING), huSTING-null (human Null STING), or WT mSTING (mouse STING) are plated one day prior on plates coated with poly-L-lysine, to achieve 80% confluency. On the day of transfection, plasmids encoding a panel of STING variants (outlined in Example 20 or the written description, or designed as in Example 21) are diluted in serum-free media and added to FuGENE® transfection reagent at the proper
25 reagent:DNA ratios (Promega), and cells are incubated in the presence or absence of cGAMP, to directly activate STING signaling. Cell culture supernatants from each sample are collected after overnight incubation, and 10 μL of the cell culture supernatants are added to 50 μL QUANTI-Luc™ reagent (Invivogen). Type I interferon activation is determined by measuring secreted luciferase levels on a
30 SpectraMax® M3 spectrophotometer (Molecular Devices). These data support the ability of the transfected plasmids to produce functional, constitutive STING that can induce type I IFN in a cGAMP-independent manner.

Example 24**mSTING Gain-Of-Function (GOF) Encoding Strains Demonstrate Significant Anti-Tumor Activity in Mice**

The mSTING GOF strains that encode a constitutive mutant of a cytosolic DNA/RNA sensor, leading to constitutive type I IFN expression, enhance the anti-tumor efficacy of the plasmid-containing target strains *in vivo*. To demonstrate this, the *S. typhimurium* strain containing the expression plasmids for the mSTING GOF mutants tested in Example 23 are compared to the *S. typhimurium* plasmid vector control strain and vehicle control, for tumor efficacy in a murine colon carcinoma model. 6-8 week-old female C57BL/6 mice (9 mice per group) are inoculated SC in the right flank with MC38 cells (5×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors are IV injected on day 8 with 5×10^5 CFUs of *S. typhimurium* transformed with mSTING GOF-encoding variants, *S. typhimurium* plasmid control, or PBS vehicle control. Body weights and tumors are measured twice weekly. Tumor measurements are performed using electronic calipers (Fowler, Newton, MA). Tumor volume is calculated using the modified ellipsoid formula, $1/2(\text{length} \times \text{width}^2)$. Mice are euthanized when tumor size reached >20% of body weight or became necrotic, as per IACUC regulations.

The experiment demonstrates that the immunostimulatory bacteria, such as *Salmonella*, such as *S. typhimurium*, that encode mSTING gain-of-function products induce potent tumor control compared to the controls that do not express the mSTING gain-of-function, and compared to PBS.

Example 25**Systemically Administered Bacteria Encoding a Constitutively Active STING Variant Inhibits Growth of MC38 Colon Tumors *in vivo***

To demonstrate that immunostimulatory bacterial strains containing expression plasmids encoding constitutively active STING induce anti-tumor efficacy, strain YS1646- Δ asd/ Δ FLG (knockout of both flagellin genes *fljB* and *fliC*) was electroporated with a plasmid containing an expression cassette for human STING with allele R232 and GOF mutation V155M (STING R232-V155M) behind the human elongation factor-1 alpha (EF-1 alpha) promoter, and was compared to YS1646 alone and a PBS vehicle control. The gene encoding STING R232-V155M was generated using DNA synthesis. 6-8 week-old female C57BL/6 mice (5 mice per

group) were inoculated SC in the right flank with MC38 (5×10^5 cells in 100 μ L PBS). Mice (n=5) bearing established flank tumors were IV injected on day 8 as follows: (1) PBS; (2) 5×10^5 CFUs of YS1646; and (3) 5×10^5 CFUs of YS1646- Δ asd/ Δ FLG STING R232-V155M. Tumor measurements were performed using calipers and tumor volume was calculated using the modified ellipsoid formula, $1/2(\text{length} \times \text{width}^2)$.

The results, depicted in the table below, showed that the YS1646- Δ asd/ Δ FLG human STING R232-V155M strain elicited significant tumor control (60% TGI) compared to PBS ($p < 0.05$), and had an immediate complete response of 20%. Thus, an immunostimulatory bacterial strain that delivers a constitutively active STING variant can potentially inhibit tumor growth inhibition, and demonstrate a 20% cure rate in a model of colorectal carcinoma.

	Mean Tumor Volume (mm ³)	Tumor Growth Inhibition %	p-value vs. Control	% Cures
PBS	188.9	0%		0%
YS1646	122.2	35%	N.S.	0%
YS1646- Δ asd/ Δ FLG huSTING R232-V155M	75.5	60%	<0.05	20%

N.S. = not significant

Example 26

Immunostimulatory Bacteria Encoding Constitutively Active STING Variants Stimulate Enhanced Expression from the Interferon Regulatory Factor (IRF) Promoter

Interferon regulatory factors (IRFs), such as IRF-3 and IRF-7, are proteins that regulate the transcription of IFNs. To demonstrate the effects of immunostimulatory bacteria encoding constitutively active STING on the activation of IRFs, a dual IRF-Lucia and MIP-2-SEAP (secreted embryonic alkaline phosphatase) murine reporter cell line (RAW-Dual™; InvivoGen), generated from RAW 264.7 murine macrophages, was used. These macrophages express several pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), cGAS and STING. The reporter cells stably express two reporter genes encoding SEAP (secreted embryonic alkaline phosphatase) and Lucia luciferase. The Lucia luciferase reporter gene is under control of an ISG54 (interferon stimulated gene 54) minimal promoter, in conjunction with five IFN-stimulated response elements (ISREs). When IRFs, such as

IRF-3 and IRF-7 are activated, they bind to ISREs to induce type I IFN responses. Thus, the expression of the Lucia luciferase reports activation of IRFs.

RAW-Dual™ (IRF-Lucia/KI-[MIP-2]SEAP) reporter cells (InvivoGen, Cat. Code: rawd-ismip) were seeded into a 96-well tissue culture plate at 2×10^5 cells per well in media (DMEM containing glucose, L-glutamine and 10% FBS) without antibiotic and incubated at 37 °C in 5% CO₂ overnight. 3 mL of modified LB cultures (tryptone substituted with soytone) containing 50 µg/mL Kanamycin were inoculated with bacterial strains directly from glycerol stocks and incubated overnight with shaking at 37 °C. Strains YS1646- $\Delta asd/\Delta FLG$ and YS1646- $\Delta asd/\Delta hila$ were transformed with plasmids encoding human STING with the R232 allele (huSTING), or STING variants with the GOF mutation V147L (huSTING V147L) or V155M (huSTING V155M), behind the human elongation factor-1 alpha (EF-1 alpha) promoter. The expression cassettes were generated by DNA synthesis.

The following day, overnight cultures were analyzed by OD600nm, and culture volumes were adjusted to a concentration of 4×10^8 CFU/mL by diluting into eukaryotic cell media (DMEM containing glucose, L-glutamine and 10% FBS without antibiotic). Infections with the bacterial strains were performed at an MOI of 200, by addition of 100 µL diluted culture per well and centrifugation for 5 minutes at 1000 rcf, followed by 1 hour incubation at 37 °C. Infections were then washed twice with 100 µL/well sterile PBS, and fresh medium containing 50 µg/mL gentamycin was added, to kill extracellular bacteria. The cyclic dinucleotide, 2'3'-c-di-AM(PS)2 (Rp,Rp) (InvivoGen, Cat. Code: tlrl-nacda2r-01, tlrl-nacda2r) was added to uninfected wells as a positive control for interferon regulatory factor (IRF) induction (CDN positive control). 1 µg cyclic dinucleotide was added per well by addition of 10 µL of 100 µg/mL stock. Infections continued for 48 hours at 37 °C. Uninfected reporter cells were used as a negative control, as were reporter cells that were infected with strain YS1646- $\Delta asd/\Delta FLG$ encoding mu-IL-2.

IRF pathway induction was analyzed at 48 hours post infection. 20 µL supernatant was harvested per well and mixed with 50 µL freshly prepared QUANTI-Luc™ detection medium (a Lucia luciferase detection reagent; InvivoGen, Cat. Code: rep-qlc1, rep-qlc2) in a black, flat clear-bottom 96-well plate, and luminescence was

-277-

detected on a SpectraMax M5 Microplate Reader (Molecular Devices). The results are shown in the table below. Uninfected cells, and cells infected with YS1646- $\Delta asd/\Delta FLG$ encoding mu-IL-2 (negative controls) showed the lowest amount of IRF illuminance. Uninfected cells with added CDN (CDN positive control) showed the highest amount of IRF illuminance. In the YS1646- $\Delta asd/\Delta FLG$ strain, huSTING with the V147L mutation had a 258% increase in IRF illuminance compared to huSTING, and huSTING with the V155M mutation had a 282% increase compared to huSTING. In the YS1646- $\Delta asd/\Delta hila$ strain, huSTING with the V147L mutation had a 1086% increase in IRF illuminance compared to huSTING, and huSTING with the V155M mutation had a 201% increase compared to huSTING. Thus, constitutively active STING variants can be delivered to macrophages via infection with immunostimulatory bacteria to activate downstream IRF pathway signaling.

Raw-Dual™ Cell IRF Illuminance at 48 hours post infection

			YS1646 Strain+plasmid combination						
			$\Delta asd/\Delta FLG$				$\Delta asd/\Delta hila$		
			mu-IL-2	Hu-STING	Hu-STING V147L	Hu-STING V155M	HuSTING	HuSTING V147L	HuSTING V155M
Measurement	Uninfected Cells (no CDN)	CDN Positive Control							
1	53	1407	84	146	414	473	81	1204	190
2	31	1401	84	146	364	355	93	1164	187
3	37	1537	90	121	289	339	134	977	243
Average	40.3	1448.3	86.0	137.7	355.7	389.0	102.7	1115.0	206.7
Standard Dev.	11.4	76.8	3.5	14.4	62.9	73.2	27.8	121.2	31.5

15

Example 27**Immunostimulatory Bacteria Containing Plasmids Encoding Constitutive Type I IFN Variants Demonstrate Potent Anti-tumor Immunity in a Murine Model of Colorectal Cancer****Human GOF STING Mutants Show Anti-Tumor Activity in Mouse Models**

20

To demonstrate that immunostimulatory bacterial strains containing expression plasmids encoding constitutively active STING variants induce anti-tumor efficacy, strain YS1646 $\Delta asd/\Delta FLG$ (knockout of both flagellin genes *fljB* and *fliC*) was electroporated with a plasmid containing an expression cassette for human

STING with the allele R232 and the GOF mutation V155M (huSTING V155M), behind the human elongation factor-1 alpha (EF-1 α) promoter, and was compared to strain YS1646 alone and a PBS vehicle control. The gene encoding huSTING V155M was generated using DNA synthesis and cloned into the pATI-1.75 vector. In order to

5 evaluate whether a constitutive human STING variant could demonstrate anti-tumor activity in mice, 6-8 week-old female C57BL/6 mice (5 mice per group) were inoculated SC in the right flank with MC38 colorectal adenocarcinoma cells (5×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected on day 8 with 5×10^5 CFUs of strain YS1646 Δ asd/ Δ FLG huSTING V155M, with strain

10 YS1646, or with PBS control.

The results showed that the YS1646 parental strain was only mildly effective as an anti-tumor therapy and was not curative (35% TGI, $p = \text{NS}$, day 28), in line with previously published data. The more attenuated strain, containing a plasmid encoding constitutively active human STING, YS1646 Δ asd/ Δ FLG huSTING V155M, however,

15 elicited significant tumor control (60% TGI, $p < 0.05$, day 28) compared to PBS, and had a cure rate of 20%. Thus, an immunostimulatory bacterial strain that delivers a constitutively active STING variant potently inhibits tumor growth inhibition, and demonstrates curative effects in a model of colorectal adenocarcinoma.

20 **Murine Phosphomimetic IRF3 Shows Curative Effects *in vivo***

The murine version of the phosphomimetic human IRF3 variant was designed, designated muIRF3-S388D, and evaluated in a murine model of colorectal adenocarcinoma. Strain YS1646 Δ asd/ Δ FLG was electroporated with a plasmid containing an expression cassette for murine IRF3 with the GOF mutation S388D

25 (muIRF3-S388D), behind the human elongation factor-1 alpha (EF-1 α) promoter, and was compared to PBS vehicle control. The gene encoding muIRF3-S388D was generated using DNA synthesis and cloned into the pATI-1.75 vector. 6-8 week-old female C57BL/6 mice (5 mice per group) were inoculated SC in the right flank with MC38 colorectal adenocarcinoma cells (5×10^5 cells in 100 μ L PBS). Mice bearing

30 established flank tumors were IV injected on day 10 with 5×10^5 CFUs of strain YS1646 Δ asd/ Δ FLG-EF-1 α -muIRF3-S388D, and compared to PBS vehicle control.

The therapy was very well tolerated, with an initial weight loss nadir of only 0.3%. Compared to PBS, the bacterial strain containing the plasmid encoding the muIRF3-S388D GOF mutant was highly effective and curative (81.8% TGI, 60% cure rate, day 42). These data demonstrate the potency and safety of delivering

5 constitutive type I IFN inducing variants in a tumor-specific manner.

Murine STING GOF Variants Show Potent and Curative Anti-Tumor Activity

A panel of murine orthologs of the human STING variants, discovered in human patients, was designed. These orthologs differ by one codon from the human variants, and were cloned into the pATI-1.75 vector under the control of an EF-1 α

10 promoter, to yield the following set of mutants: muSTING N153S, V154M, R280Q, V146L, R283G, and C205Y, among others. The STING variants were evaluated in the MC38 model of murine adenocarcinoma for anti-tumor efficacy. For the studies, 6-8 week-old female C57BL/6 mice (5 mice per group) were inoculated SC in the right flank with MC38 colorectal adenocarcinoma cells (5×10^5 cells in 100 μ L PBS).

15 Mice bearing established flank tumors were IV injected on day 10 with 5×10^5 CFUs of strain YS1646 Δ asd/ Δ FLG, containing a plasmid with EF-1 α driving the expression of muSTING N153S, V154M, R280Q, V146L, or R283G, or a scrambled shRNA plasmid control, and compared to PBS vehicle control.

In this experiment, the YS1646 Δ asd/ Δ FLG EF-1 α plasmid control (shSCR)

20 demonstrated anti-tumor efficacy as compared to PBS control (73% TGI, day 26), which was much more potent than the YS1646 parental strain has shown historically. This can be due to inherently immunostimulatory elements on the plasmid, such as CpGs and RNAi stimulatory elements. This therapy was the least well tolerated of the group, demonstrating a weight loss nadir of 9.9% that only resolved at the very end of

25 the study. In contrast, the constitutive murine STING mutants resulted in a lower weight loss that was transient and that resolved within days. The relative anti-tumor efficacy of these variants revealed interesting differences in activity, with only two variants demonstrating curative effects and enhanced efficacy over the plasmid control, N153S and R283G.

GOF Mutant	TGI vs. PBS, Day 26	Complete Response	Weight Loss Nadir and Day
Plasmid Control	73.0%	0/5	9.9%, day 19
muSTING N153S	81.7%	1/5	6.2%, day 12

muSTING V154M	69.4%	0/5	4.3%, day 12
muSTING R280Q	68.7%	0/5	5.4%, day 12
muSTING V146L	63.4%	0/5	2.8%, day 12
muSTING R283G	81.2%	1/5	6.9%, day 12

In a follow-up study, the murine STING C205Y variant was tested along with the R283G and N153S variants to compare their anti-tumor efficacy. 6-8 week-old female C57BL/6 mice (5 mice per group) were inoculated SC in the right flank with MC38 colorectal adenocarcinoma cells (5×10^5 cells in 100 μ L PBS). Mice bearing established flank tumors were IV injected on day 9 with 5×10^5 CFUs of strain YS1646 Δ asd/ Δ FLG containing a plasmid with EF-1 α driving expression of muSTING N153S, R283G, or C205Y, and compared to PBS vehicle control. As before, the STING variants were well tolerated, and only a transient dip in weight loss was observed that resolved quickly. This is likely due to on-target therapy, as it is also observed with the small molecule STING agonists. The efficacy of the two constitutively active murine STING variants, N153S and R283G, was nearly identical to the previous study, although the weight loss was much less, for reasons unclear. The C205Y variant also was highly effective, although not curative.

GOF Mutant	TGI vs. PBS, Day 29	Complete response (CR)	Weight Loss Nadir and Day
muSTING C205Y	79.4%	0/5	2.6%, day 13
muSTING N153S	79.3%	1/5	2.2%, day 13
muSTING R283G	85.1%	1/5	1.8%, day 13

The STING-cured mice from these studies were re-challenged at day 40 post-initial tumor implantation on the opposite flank, SC with MC38 colorectal adenocarcinoma cells (5×10^5 cells in 100 μ L PBS). Compared to naïve mice (N=5), in which all tumors grew out, all of the STING-cured mice rejected the tumors, demonstrating the engagement of adaptive immunity.

These data validate the safety and potency of the murine versions of the human constitutive STING variants in a murine model of colorectal carcinoma, and reveal a small subset that have enhanced potency compared to the other STING

variants. These highly active variants also elicit protective immunity, demonstrating the potency of tumor-specific production of type I interferon.

Murine STING GOF Variants Demonstrate Significant Tumor Remodeling Following IV Dosing

5 It was next determined whether the bacterial strains containing plasmids encoding constitutive STING variants demonstrate differences in their ability to remodel the tumor microenvironment (TME) following IV dosing. To test this, 6-8 week-old female C57BL/6 mice (5 mice per group) were inoculated SC in the right flank with MC38 colorectal adenocarcinoma cells (5×10^5 cells in 100 μ L PBS). Mice
10 bearing established flank tumors were IV injected on day 8 with 5×10^5 CFUs of strain YS1646 Δ asd/ Δ FLG containing a plasmid with EF-1 α driving the expression of muSTING N153S, V154M, R280Q, V146L, R283G, or plasmid control, and compared to PBS vehicle control.

 At day 28 post tumor implantation, tumors were excised for analysis. Tumors
15 were cut into 2-3 mm pieces into gentleMACS™ C tubes (Miltenyi Biotec) filled with 2.5 mL enzyme mix (RPMI-1640 + 10% FBS with 1 mg/mL Collagenase IV and 20 μ g/mL DNase I). The tumor pieces were dissociated using OctoMACS™ (Miltenyi Biotec) specific dissociation program (mouse implanted tumors) and the whole cell preparation was incubated with agitation for 45 minutes at 37 °C. After 45 minutes of
20 incubation, a second round of dissociation was performed using the OctoMACS™ (mouse implanted tumor program), and the resulting single cell suspensions were filtered through a 70 μ M nylon mesh into a 50 mL tube. The nylon mesh was washed once with 5 mL of RPMI-1640 10% FBS and the cells were filtered a second time using a new 70 μ M nylon mesh into a new 50 mL tube. The nylon mesh was washed
25 with 5 mL of RPMI-1640 with 10% FBS and the filtered cells were then centrifuged at 1000 RPM for 7 minutes. The resulting dissociated cells were resuspended in PBS and kept on ice before the staining process.

 The percentage of live tumor-infiltrating leukocytes (TILs), including CD4⁺ Tregs, CD4⁺ Th1 cells, CD8⁺ T cells, neutrophils, monocytes, dendritic cells (DCs),
30 M1 macrophages and M2 macrophages, following the administration of strain YS1646 Δ asd/ Δ FLG, containing plasmids encoding the various GOF muSTING mutants, was determined by flow cytometry. For the flow-cytometry staining, 100 μ L

of the single cell suspensions were seeded in wells of a V-bottom 96-well plate. PBS containing a dead/live stain (Zombie Aqua™, BioLegend) and Fc Blocking reagents (BD Biosciences) were added at 100 µL per well and incubated on ice for 30 minutes in the dark. After 30 minutes, cells were washed twice with PBS + 2% FBS by

5 centrifugation at 1300 RPM for 3 minutes. Cells were then resuspended in PBS + 2% FBS, containing fluorochrome-conjugated antibodies (CD4 FITC clone RM4-5; CD8a BV421 clone 53-6.7; F4/80 APC clone BM8; CD11b PE-Cy7 clone M1/70; CD45 BV570 clone 30-F11; CD3 PE clone 145-2C11; Ly6C BV785 clone HK1.4; I-A/I-E APC-Cy7 clone M5/114.15.2; Ly6G BV605 clone 1A8; and CD24 PercP-Cy5.5 clone

10 M1/69; all from BioLegend) and incubated on ice for 30 minutes in the dark. After 30 minutes, cells were washed twice with PBS + 2% FBS by centrifugation at 1300 RPM for 3 minutes and resuspended in flow cytometry fixation buffer (Thermo Fisher Scientific). Flow cytometry data were acquired using the ACEA NovoCyte flow cytometer (ACEA Biosciences, Inc.) and analyzed using the FlowJo software (Tree

15 Star, Inc.).

As shown in the tables below, the strain YS1646 Δ asd/ Δ FLG with the EF-1 α plasmid control demonstrated predominantly high neutrophil infiltration, despite some CD8⁺ T-cell recruitment, likely due to immunostimulatory elements on the plasmid. In contrast, the different muSTING variants had unique tumor-infiltrating immune

20 cell signatures, with some, such as muSTING V146L and muSTING R283G resulting in fewer immunosuppressive neutrophils than the PBS control. The most favorable immune profiles were observed in the tumors from mice that were administered muSTING mutants R283G and N153S, with high numbers of CD4⁺ Th1 cells and CD8⁺ T cells, and low numbers of neutrophils, which indicates highly favorable

25 conditions for generating an adaptive immune response. These trends were also recapitulated in the total cell counts, show below. Thus, delivery of constitutively active STING variants to the tumor-resident myeloid cells leads to a complete remodeling of the immunosuppressive tumor microenvironment, towards an adaptive anti-tumor phenotype, and away from a bacterial phenotype, which is characterized

30 by the promotion of innate immunity and the suppression of adaptive immunity.

% of Live Tumor-Infiltrating Leukocytes (TILs)

% among TILs	GOF muSTING Mutants Encoded on Plasmids in IV Administered Strain YS1646Δ <i>asd</i> /ΔFLG						
	PBS	Plasmid Control	muSTING N153S	muSTING V154M	muSTING R280Q	muSTING V146L	muSTING R283G
CD4 ⁺ Tregs	2.9 ± 1.7	1.8 ± 0.5	3.3 ± 2.6	1.5 ± 0.5	2 ± 0.9	1.8 ± 0.5	1.5 ± 0.4
CD4 ⁺ Th1 cells	6.6 ± 3.2	13 ± 4.3	20.7 ± 10.4	13.2 ± 6.1	22.6 ± 7.4	19.5 ± 4.9	25.6 ± 7.8
CD8 ⁺ T cells	16.2 ± 10.2	24.5 ± 11.6	25.8 ± 9.2	16.5 ± 4.4	20.2 ± 7.2	20.8 ± 3.6	27.8 ± 8.7
Neutrophils	11.3 ± 14.2	30.6 ± 17.4	13.5 ± 12.4	21.4 ± 12.5	15.9 ± 11.6	9.1 ± 6.5	6.6 ± 5.9
Monocytes	16.6 ± 3.5	12.7 ± 2.7	13.7 ± 3.9	16.4 ± 5.4	15.8 ± 6.5	15.6 ± 2.2	13.5 ± 1.3
DCs	1.4 ± 0.4	0.5 ± 0.3	0.9 ± 0.7	0.4 ± 0.2	0.5 ± 0.3	0.5 ± 0.2	0.5 ± 0.3
M1 Macrophages	10.2 ± 6.2	3.1 ± 2.1	4.6 ± 2.1	9.4 ± 5	5.6 ± 4.2	8.6 ± 3.7	5.4 ± 2
M2 Macrophages	14.9 ± 10.6	4.6 ± 2.6	7.3 ± 3.1	11.6 ± 5.2	8.6 ± 6.3	12.8 ± 5	9.2 ± 4

Total Cell Counts

	PBS	Plasmid Control	muSTING N153S	muSTING V154M	muSTING R280Q	muSTING V146L	muSTING R283G
CD4 ⁺ Tregs	437 ± 230	148 ± 102	530 ± 117	310 ± 114	520 ± 169	297 ± 207	438 ± 176
CD4 ⁺ Th1 cells	1108 ± 599	1059 ± 711	3765 ± 917	3349 ± 2869	5864 ± 1618	2961 ± 1800	7463 ± 3240
CD8 ⁺ T cells	2948 ± 3119	1571 ± 601	6152 ± 3820	3898 ± 2823	5446 ± 2454	3266 ± 1277	7566 ± 1782
Neutrophils	1531 ± 1604	2604 ± 1975	3699 ± 4400	4815 ± 3423	4301 ± 3502	1240 ± 1160	1698 ± 1485
Monocytes	2871 ± 1472	912 ± 369	3182 ± 1708	3350 ± 1183	4132 ± 1595	2524 ± 1420	3811 ± 996
DCs	233 ± 97	28 ± 18	161 ± 45	82 ± 31	130 ± 90	78 ± 48	135 ± 90
M1 Macrophages	2163 ± 2025	227 ± 213	881 ± 316	1797 ± 750	1421 ± 910	1325 ± 856	1524 ± 658
M2 Macrophages	3046 ± 2996	334 ± 275	1391 ± 373	2183 ± 608	2189 ± 1402	2043 ± 1237	2612 ± 1330

Example 28

5 **Immunostimulatory Bacteria Modified to Express Vertebrate STING Variants that Induce Stronger Type I IFN Signaling and/or Weaker NF-κB Signaling than Human STING**

STING signaling activates two signaling pathways. The first is the TANK binding kinase (TBK1)/IRF3 axis, resulting in the induction of type I IFNs, and the activation of dendritic cells (DCs) and cross-presentation of tumor antigens to activate CD8⁺ T cell-mediated anti-tumor immunity. The second is the nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) signaling axis, resulting in a pro-inflammatory response, but not in the activation of the DCs and CD8⁺ T cells that are

10

required for anti-tumor immunity. Bacterially-based cancer immunotherapies are limited in their ability to induce type I IFN to recruit and activate the CD8⁺ T cells necessary to promote tumor antigen cross-presentation and durable anti-tumor immunity. Hence, provided are immunostimulatory bacteria herein that induce and/or
5 increase type I IFN signaling, and that have decreased NF-κB signaling, thereby increasing the induction of CD8⁺ T cell mediated anti-tumor immunity, and enhancing the therapeutic efficacy of the bacteria. The immunostimulatory bacteria described above encode modified STING proteins that are gain-of-function mutants of STING that can increase induction of type I IFN compared to wild type STING, or render the
10 expression of type I IFN constitutive. In this example (and also described in the detailed description), the STING protein is modified to reduce or eliminate NF-κB signaling activity, and retain the ability to induce type I IFN, and/or is modified for increased or constitutive type I IFN expression. This results in immunostimulatory bacteria that induce anti-tumor immunity, and do not induce (or induce less) NF-κB
15 signaling that normally results from infection by bacterial pathogens.

STING proteins from different species exhibit different levels of type I IFN and NF-κB signaling activities. For example, STING signaling in human and mouse cells results in a strong type I IFN response, and a weak pro-inflammatory NF-κB response. STING signaling in ray-finned fish, such as salmon and zebrafish, in
20 comparison, elicits robust activation of a primarily NF-κB-driven response, that is more than 100-fold higher compared with the IRF3-driven (*i.e.*, type I IFN inducing) response. In other species, such as Tasmanian devil, STING signaling results in a type I IFN response, but essentially no NF-κB response. The immunostimulatory bacteria provided herein encode STING from non-human species, such as Tasmanian devil
25 STING, in order exploit the ability of STING to induce a type I IFN response, but without the concomitant induction of an NF-κB response. As described herein, these non-human STING proteins also are modified by mutation to increase the type I IFN response, or to render it constitutive. The identified mutations that have this effect in human STING are introduced into the non-human STING proteins. The
30 corresponding residues are identified by alignment.

Also provided are chimeras in which the C-terminal tail (CTT) of STING is replaced in one species, such as human, with the CTT from a second (*e.g.*, non-

human) species that exhibits little or no NF- κ B signaling activity. The CTT is an unstructured stretch of approximately 40 amino acids that contains sequence motifs required for STING phosphorylation and recruitment of IRF3. It can shape downstream immunity by altering the balance between type I IFN and NF- κ B signaling. This is controlled through independent modules in the CTT, including IRF3, TBK1 and TRAF6 binding modules. For example, human STING residue S366 (see, *e.g.*, SEQ ID NOs:305-309) is a primary TBK1 phosphorylation site that is part of an LxIS motif in the CTT, which is required for IRF3 binding, while a second PxPLR motif, including residue L374, is required for TBK1 binding. The LxIS and PxPLR motifs are highly conserved in all vertebrate STING alleles. Replacing the CTT of human STING with that of, for example, Tasmanian devil STING, produces a STING that induces a type I IFN response, but not an NF- κ B response.

In this Example, the immunostimulatory bacteria are engineered to express a STING variant with increased type I IFN signaling, and/or reduced NF- κ B signaling, compared to wild type (WT) human STING (SEQ ID NOs:305-309). The STING variants can be from a non-human vertebrate, such as a mammalian, bird, reptilian, amphibian or fish species. Species from which the non-human STING proteins are derived include, but are not limited to, Tasmanian devil (*Sarcophilus harrisii*; SEQ ID NO:331), marmoset (*Callithrix jacchus*; SEQ ID NO:341), cattle (*Bos taurus*; SEQ ID NO:342), cat (*Felis catus*; SEQ ID NO:338), ostrich (*Struthio camelus australis*; SEQ ID NO:343), crested ibis (*Nipponia nippon*; SEQ ID NO:344), coelacanth (*Latimeria chalumnae*; SEQ ID NOs:345 and 346), boar (*Sus scrofa*; SEQ ID NO:347), bat (*Rousettus aegyptiacus*; SEQ ID NO:348), manatee (*Trichechus manatus latirostris*; SEQ ID NO:349), ghost shark (*Callorhynchus milii*; SEQ ID NO:350), and mouse (*Mus musculus*; SEQ ID NO:351). These vertebrate STING proteins readily activate immune signaling in human cells, indicating that the molecular mechanism of STING signaling is shared among vertebrates (see, *e.g.*, de Oliveira Mann *et al.* (2019) *Cell Reports* 27:1165-1175). STING proteins from these species induce less NF- κ B signal activation and/or more type I IFN signal activation, than human STING (see, *e.g.*, de Oliveira Mann *et al.* (2019) *Cell Reports* 27:1165-1175, Fig. 1A). Wild-type or modified STING proteins from different non-human species can be expressed by the

immunostimulatory bacteria herein, as can chimeras of human and non-human STING proteins.

The various non-human STING proteins are modified, such that the non-human STING has lower NF- κ B activation, and, optionally, higher type I interferon activation, than human STING. These non-human STING proteins are modified to include a mutation or mutations so that they have increased type I IFN activity, or act constitutively, in the absence of cytosolic nucleic acid ligands (*e.g.*, CDNs). The mutations typically are amino acid mutations, such as gain-of-function mutations, that are associated with interferonopathies in humans. The corresponding mutations are introduced into the non-human species STING proteins, where corresponding amino acid residues are identified by alignment. For example, mutations include, but are not limited to, S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A, E296A, R197A/D205A, S272A/Q273A, R310A/E316A, E316A, E316N, E316Q, S272A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A, S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, R375A, and S324A/S326A, with reference to the sequence of human STING, as set forth in SEQ ID NOs:305-309. Corresponding mutations in STING from other species are listed in the tables below. The resulting variants of the non-human STING proteins include one or more of these mutations, and optionally, a CTT replacement, and optionally a TRAF6 deletion.

The STING variants include one or more replacements of the amino acid serine (S) or threonine (T) at a phosphorylation site, with aspartic acid (D), which is phosphomimetic, resulting in increased or constitutive activity. Other mutations, include deletion or replacement of a phosphorylation site or sites, such as 324-326 SLS $\rightarrow$ ALA in STING, and other replacements to eliminate a phosphorylation site to reduce NF- κ B signaling in STING. Additionally, chimeras of human STING with STING from other species are provided, in which the C-terminal tail (CTT) of human STING is replaced with the CTT of STING from another species that has lower NF- κ B signaling activity, and/or higher type I IFN signaling activity. The variant STING proteins can include a deletion in the TRAF6 binding site of the CTT, to reduce NF- κ B signaling.

Human STING (SEQ ID NOs: 305-309)	Tasmanian devil STING (SEQ ID NO:331)	Marmoset STING (SEQ ID NO:341)	Cattle STING (SEQ ID NO:342)	Cat STING (SEQ ID NO:338)	Ostrich STING (SEQ ID NO:343)	Crested ibis STING (SEQ ID NO:344)	Coelacanth STING (SEQ ID NO:345)
S102P	S102P	S102P	S102P	S102P	C107P	V106P	A102P
V147L	V147L	V145L	I147L	V146L	M152L	M151L	I147L
V147M	V147M	V145M	I147M	V146M	-	-	I147M
N154S	N154S	N152S	N154S	N153S	N159S	N158S	G154S
V155M	V155M	V153M	V155M	V154M	V160M	V159M	V155M
G166E	G166E	G164E	G166E	G165E	G171E	G170E	G166E
C206Y	C206Y	C204Y	C206Y	C205Y	C211Y	C210Y	C206Y
G207E	S207E	G205E	G207E	G206E	N212E	D211Y	S207E
S102P/F 279L	S102P/F27 9L	S102P/F27 7L	S102P/F279 L	S102P/F2 78L	C107P/F2 83L	V106P/F283 L	A102P/F279 L
F279L	F279L	F277L	F279L	F278L	F283L	F283L	F279L
R281Q	R281Q	R279Q	R281Q	R280Q	R285Q	R285Q	K281Q
R284G	R284G	R282G	R284G	R283G	R288G	R288G	R284G
R284S	R284S	R282S	R284S	R283S	R288S	R288S	R284S
R284M	R284M	R282M	R284M	R283M	R288M	R288M	R284M
R284K	R284K	R282K	R284K	R283K	R288K	R288K	R284K
R284T	R284T	R282T	R284T	R283T	R288T	R288T	R284T
R197A	R197A	R195A	R197A	R196A	K202A	K201A	R197A
D205A	D205A	D203A	D205A	D204A	S210A	S209A	S205A
R310A	R310A	R308A	R310A	R309A	R314A	R314A	R310A
R293A	R293A	R291A	R293A	R292A	R297A	R297A	R293A
T294A	T294A	T291A	T294A	I293A	T298A	T298A	T294A
E296A	E296A	E294A	E296A	E295A	E300A	E300A	K296A
R197A/ D205A	R197A/D2 05A	R195A/D2 03A	R197A/D20 5A	R196A/ D204A	K202A/S2 10A	K201A/S209 A	R197A/S205 A
S272A/Q 273A	S272A/Q27 3A	S270A/Q27 1A	S272A/Q273 A	S271A/Q27 2A	S276A/Q2 77A	S276A/Q277 A	S272A/K273 A
R310A/E 316A	R310A/E31 6A	R308A/E31 4A	R310A/E316 A	R309A/E31 5A	R314A/E3 20A	R314A/E320 A	R310A/E318 A
E316A	E316A	E314A	E316A	E315A	E320A	E320A	E318A
E316N	E316N	E314N	E316N	E315N	E320N	E320N	E318N
E316Q	E316Q	E314Q	E316Q	E315Q	E320Q	E320Q	E318Q
S272A	S272A	S270A	S272A	S271A	S276A	S276A	S272A/K273 A
R375A	R377A	R373A	R374A	R373A	R371A	R379A	K376A
R293A/T 294A/E2 96A	R293A/T29 4A/E296A	R291A/T29 2A/E294A	R293A/T294 A/E296A	R292A/ I293A/ E295A	R297A/ T298A/ E300A	R297A/T298 A/E300A	R293A/T294 A/K296A
D231A	D231A	D229A	D231A	D230A	T236A	T235A	N231A
R232A	R232A	R230A	R232A	R231A	R237A	R236A	R232A
K236A	K236A	K234A	K236A	K235A	K241A	K240A	K236A
Q273A	Q273A	Q271A	Q273A	Q272A	Q277A	Q277A	K273A
S358A/E 360A/S3 66A	S360A/E36 2A/S368A	S356A/E35 8A/S364A	S357A/ E359A/ S365A	D230A/ E358A/ S364A	S354A/ D356A/ S362A	S362A/E364 A/S370A	S359A/E361 A/S367A
D231A/ R232A/ K236A/ R238A	D231A/R2 32A/K236 A/R238A	D229A/R2 30A/K234 A/R236A	D231A/R23 2A/K236A/ R238A	D230A/ R231A/ K235A/ R237A	T236A/R2 37A/K241 A/R243A	T235A/R236 A/K240A/R 242A	N231A/R23 2A/K236A/ R238A
S358A	S360A	S356A	S357A	S356A	S354A	S362A	S359A
E360A	E362A	E358A	E359A	E358A	D356A	E364A	E361A
S366A	S368A	S364A	S365A	S364A	S362A	S370A	S367A
R238A	R238A	R236A	R238A	R237A	R243A	R242A	R238A
S324A/S 326A	S326A/S32 8A	L322A/S32 4A	S324A/S326 A	S323A/S32 5A	F328A/S3 30A	S328A/S330 A	S327A

Human STING (SEQ ID NOs: 305-309)	Boar STING (SEQ ID NO:347)	Bat STING (SEQ ID NO:348)	Manatee STING (SEQ ID NO:349)	Ghost Shark STING (SEQ ID NO:350)	Mouse STING (SEQ ID NO:351)
S102P	S102P	S103P	S105P	S98P	S102P
V147L	I147L	V148L	I150L	I148L	V1476
V147M	I147M	V148M	I150M	I148M	V146M
N154S	N154S	N155S	N157S	N155S	N153S
V155M	V155M	V156M	V158M	V156S	V154M
G166E	G166E	G167E	G169E	G167E	G165E
C206Y	C206Y	C207Y	C209Y	C206Y	C205Y
G207E	G207E	G208E	G210E	K207E	G206Y
S102P/F279L	S102P/F279L	S103P/F280L	S105P/F282L	S98P/F280L	S102P/F278L
F279L	F279L	F280L	F282L	F280L	F278L
R281Q	R281Q	-	R284Q	K282Q	R280Q
R284G	R284G	R285G	R287G	R285G	R283G
R284S	R284S	R285S	R287S	R285S	R283S
R284M	R284M	R285M	R287M	R285M	R283M
R284K	R284K	R285K	R287K	R285K	R283K
R284T	R284T	R285T	R284T	R285T	R283T
R197A	R197A	R198A	R200A	K197A	R196A
D205A	D205A	D206A	D208A	S205A	D204A
R310A	R310A	R311A	R313A	R311A	R309A
R293A	R293A	R294A	R296A	R294A	R292A
T294A	T294A	T295A	T297A	T295A	T293A
E296A	E296A	-	E299A	K297A	E295A
R197A/D205A	R197A/D205A	R198A/D206A	R200/D208A	K197A/S205A	R196A/D204A
S272A/Q273A	S272A/Q273A	S273A/Q274A	S275A/Q276A	T273A/N274A	S271A/Q272A
R310A/E316A	R310A/E316A	R311A/E317A	R313A/E319A	R311A/D317A	R309A/E315A
E316A	E316A	E317A	E319A	D317A	E315A
E316N	E316N	E317N	E319N	D317N	E315N
E316Q	E316Q	E317Q	E319Q	D317Q	E315Q
S272A	S272A	S273A	S275A	T273A	S271A
R375A	S374A	R376A	R383A	R374A	R374A
R293A/T294A/ E296A	R293A/T294A/E 296A	R294A/T295A	R296A/T297A/ E299A	R294A/T295A/ K297A	R292A/T293A/ E295A
D231A	D231A	D232A	D234A	D231A	D230A
R232A	R232A	R233A	C235A	R232A	R231A
K236A	K236A	K237A	K239A	K236A	K235A
Q273A	Q273A	Q274A	Q276A	N274A	Q272A
S358A/E360A/ S366A	S357A/E359A/S3 65A	H359A/E361A/ S367A	S366A/E368A/ S374A	S359A/ E361A/ S367A	S357A/E359A/S 365A
D231A/R232A /K236A/R238 A	D231A/R232A/K 236A/R238A	D232A/R233A/ K237A/R239A	D234A/C235A /K239A/R241 A	D231A/R232A /K236A/R238 A	D230A/R231A/ K235A/R237A
S358A	S357A	H359A	S366A	S359A	S357A
E360A	E359A	E361A	E368A	E361A	E359A
S366A	S365A	S367A	S374A	S367A	S365A
R238A	R238A	R239A	R241A	R238A	R237A
S324A/S326A	S324A/S326A	S325A/S327A	S327A/S329A	G325A/S330A	S323A/S325A

For example, modified STING variants include Tasmanian devil STING with the mutations C206Y (SEQ ID NO:332) or R284G (SEQ ID NO:333); a variant in which the CTT of human STING is replaced with the CTT of Tasmanian devil STING (SEQ ID NO:334); human STING with the mutation C206Y (SEQ ID NO:335) or R284G (SEQ ID NO:336) and where the CTT is replaced with the CTT

of Tasmanian devil STING; wild type human STING with a deletion in the TRAF6 binding domain (corresponding to residues 377-379, DFS)) (SEQ ID NO:337); cat STING with the mutations C205Y (SEQ ID NO:339) or R283G (SEQ ID NO:340); and other such modified STING variants.

5 To determine the corresponding amino acid residues for the STING mutations, the wild type STING sequences from various non-human species each were aligned with the wild type human STING sequence (of the allelic variants of SEQ ID NO:305 (R232 allele) or SEQ ID NO:306 (H232 allele)). The alignments were performed using the Kalign sequence alignment tool, available from ebi.ac.uk/Tools/msa/kalign/,
10 or the EMBOSS needle sequence alignment tool, available from ebi.ac.uk/Tools/psa/emboss_needle/. Exemplary sequence alignments, for human STING with STING proteins from Tasmanian devil, marmoset, cattle, cat, ostrich, crested ibis, coelacanth, zebrafish, boar, bat, manatee, ghost shark and mouse species, are depicted in Figures 1-13.

15 **STING GOF Hybrid Variants Demonstrate Significantly Enhanced Type I Interferon to NF- κ B ratios in Dendritic Cells**

 In order to determine the optimal STING GOF mutant that would elicit the highest levels of the CD8⁺ T-cell chemokine CXCL10 in mice, a panel of mutants were tested in murine primary bone marrow-derived dendritic cells (BMDC). These
20 included the Tasmanian devil STING with the constitutive human GOF mutations in C206Y (SEQ ID NO:332) or R284G (SEQ ID NO:333); the murine STING GOF mutants C205Y (SEQ ID NO:339) or R283G (SEQ ID NO:340); as well as variants in which the CTT of human STING was replaced with the CTT of Tasmanian devil STING (SEQ ID NO:334) and containing either wild-type human STING, or the
25 human STING mutations C206Y (SEQ ID NO:335) or R284G (SEQ ID NO:336). Also included were cat STING with the mutations C205Y (SEQ ID NO:339) or R283G (SEQ ID NO:340).

 To test these, murine bone marrow was isolated and flushed into 1.5 mL Eppendorf tubes and spun at 1200 RPM for 5 minutes to collect the bone marrow
30 cells. Cells were washed once in RPMI-1640 + 10% FBS, then seeded in 6 well TC-treated plates in RPMI-1640 + 10% FBS with 20 ng/ml GM-CSF. Every 2 days, 50% of the medium is replaced with fresh complete media. After six days, non-adherent

cells are pipetted off the wells and re-seeded at 1×10^5 cells per well in RPMI-1640 + 10% FBS in a 96 well plate for transfection. Cells were transfected using Viromer® RED, according to the manufacturer's instructions. Briefly, 200 ng of plasmid DNA from a panel of STING GOF mutants, as well as untransfected control, were diluted in

5 the provided buffer, and mixed with 0.08 μ L of Viromer® RED and incubated at room temperature for 15 minutes to allow the Viromer® complexes to form. The DNA/Viromer® RED complexes were then slowly added to each well of the 96-well plate (in duplicates) and the plate was incubated at 37 °C in a CO₂ incubator. Supernatants were harvested at 48 hours and assayed for murine CXCL10 (IP-10)

10 using flow cytometry-based cytokine bead array (CBA), according to manufacturer's protocol.

As shown in the table below, the construct that induced the highest expression of murine CXCL10 contained the CTT of human STING replaced with the CTT of Tasmanian devil STING, and containing the human STING GOF mutation R284G

15 (huSTING R284G tazCTT). The next highest was the Tasmanian STING containing the human STING GOF mutation R284G (tazSTING R284G). Interestingly, the human STING GOF mutations were more potent than the murine STING GOF mutations (muSTING C205Y and muSTING R283G), which were even less potent than the cat STING containing the murine GOF mutations, in primary murine

20 dendritic cells.

Construct	CXCL10 pg/mL
Untransfected	11.48 ± 3.889
huSTING C206Y	861.0 ± 58.48
huSTING R284G	769.7 ± 95.16
mSTING C205Y	194 ± 27.15
mSTING R283G	230.1 ± 1.018
huSTING C206Y taz CTT	366.6 ± 42.61
huSTING R284G taz CTT	1326 ± 137.9
tazSTING C206Y	808.8 ± 95.78
tazSTING R284G	831.3 ± 30.15
catSTING C205Y	480.7 ± 24.94
catSTING R283G	376.2 ± 6.682

These data demonstrate the feasibility of utilizing STING obtained from other species such as Tasmanian devil, and combining those with constitutive GOF human STING mutations to elicit potent T-cell recruiting chemokines.

STING GOF Hybrid Variants Demonstrate Significantly Enhanced Type I Interferon to NF- κ B ratios in Human Monocytes

In order to demonstrate that the ratio of STING-induced type I interferon to NF- κ B signaling can be altered using STING GOF hybrid variants from other species, a panel was tested in a human monocyte cell line. The panel included wild-type human STING, or constitutive human GOF mutations C206Y or R284G; Tasmanian devil STING with wild-type or constitutive GOF mutations C206Y or R284G; the variants in which the CTT of human STING was replaced with the CTT of Tasmanian devil STING, and containing either wild-type human STING or the human STING mutations C206Y or R284G; and murine STING with the mutations C205Y or R283G. Also included were a wild-type human STING with a deletion in the TRAF6 binding domain (corresponding to residues 377-379, DFS), and zebrafish wild-type STING.

For this experiment, the THP1-DualTM KO STING cells were utilized, which have been altered to lack endogenous STING, and to also express LuciaTM luciferase, a secreted luciferase, placed under the control of the endogenous IFN- β promoter. Constitutively active STING GOF mutants then are identified and ranked by measurement of IFN- β promoter induced expression of luciferase activity. These cells also express secreted embryonic alkaline phosphatase (SEAP) placed under the control of the endogenous NF- κ B promoter, where the coding sequence of NF- κ B has been replaced by the SEAP ORF using knock-in technology. NF- κ B activity induced by STING GOF mutants can be assessed by monitoring SEAP production in the cell supernatants.

For this experiment, THP1-DualTM KO STING cells were transfected using Viromer[®] RED, according to the manufacturer's instructions. Briefly, 200 ng of plasmid DNA from a panel of STING GOF mutants, as well as untransfected control, were diluted in the provided buffer, and mixed with 0.08 μ L of Viromer[®] RED and incubated at room temperature for 15 minutes to allow the Viromer[®] complexes to form. The DNA/Viromer[®] RED complexes were then slowly added to each well of

the 96-well plate (in duplicates) and the plate was incubated at 37 °C in a CO₂ incubator. In addition, the wild-type STING variants were treated with or without the STING agonist 3'5' RpRp c-di-AMP (CDN, InvivoGen), an analog of the clinical compound ADU-S100, added to the cells after 24 hours of incubation at 10 µg/mL.

- 5 Supernatants were harvested at 48 hours and assayed for NF-κB-SEAP and IFN-Lucia reporter signals according to the manufacturer's protocol. Briefly, 10 µL of the cell culture supernatants was added to 50 µL QUANTI-Blue™ reagent (InvivoGen) (which is used for measuring SEAP). NF-κB activation was determined by measuring NF-κB-induced SEAP activity on a SpectraMax® M3 Spectrophotometer (Molecular
- 10 Devices) at an absorbance (Abs) of 650 nm. For measuring type I interferon activity from IFN-Lucia, 10 µL of the cell culture supernatants was added to 50 µL QUANTI-Luc™, containing the coelenterazine substrate for the luciferase reaction, which produces a light signal that is quantified using a SpectraMax® M3 luminometer and expressed as relative light units (RLUs).

- 15 As shown in the table below, the highest type I IFN responses were observed from the variant in which the CTT of human STING was replaced with the CTT of Tasmanian devil STING, and that contained the human STING GOF mutation R284G (huSTING R284G tazCTT), as well as from the wild-type zebrafish STING with the CDN STING agonist (zfSTING WT + CDN). However, unlike the wild-type zebrafish
- 20 STING, which had very high NF-κB signaling, the huSTING R284G tazCTT variant had high type I IFN signaling with much lower NF-κB signaling activity. The best ratio of higher type I IFN to lower NF-κB signaling was found with the Tasmanian devil STING variant containing the human STING GOF mutation R284G (tazSTING R284G).

STING Variant	ISRE-Lucia (RLU)	± SD	NF-κB-SEAP (Abs)	± SD
Untransfected	47.96	33.91	0.065	0.007
huSTING WT + CDN	170.8	38.15	0.100	0.014
huSTING WT delTRAF6 + CDN	164.8	8.48	0.120	0.014
huSTING WT tazCTT + CDN	31.47	10.59	0.060	0.000
tazSTING WT + CDN	143.9	4.24	0.090	0.014
zfSTING WT + CDN	310.2	23.31	0.690	0.028

-293-

CMV catSTING WT WPRE + CDN	202.3	6.36	0.125	0.007
huSTING C206Y	175.3	36.03	0.105	0.007
huSTING R284G	143.9	29.67	0.100	0.000
huSTING C206Y tazCTT	137.9	21.19	0.095	0.007
huSTING R284G tazCTT	301.2	61.46	0.250	0.127
tazSTING C206Y	199.3	2.12	0.120	0.000
tazSTING R284G	217.3	19.08	0.105	0.007
muSTING C205Y	43.46	2.12	0.070	0.000
muSTING R283G	32.97	4.24	0.070	0.000
catSTING C205Y	202.3	23.31	0.135	0.007
catSTING R283G	157.4	10.60	0.120	0.000

These data further demonstrate the feasibility of using non-human STING proteins, such as the STING protein from Tasmanian devil, and combining those with human constitutive gain-of-function STING mutations, in order to enhance the beneficial type I interferon activity, while minimizing the immunosuppressive NF- κ B activity, in human monocytes.

Since modifications will be apparent to those of skill in the art, it is intended that this invention be limited only by the scope of the appended claims.

WHAT IS CLAIMED:

1. A modified Stimulator of Interferon Genes (STING) protein from a non-human species, where the non-human STING is one that has lower NF- κ B signaling activity compared to the NF- κ B signaling activity of human STING, and,
5 optionally, higher type I interferon (IFN) pathway signaling activity compared to human STING, wherein:
the non-human STING protein is modified to include a mutation or mutations so that it has increased activity or acts constitutively in the absence of cytosolic nucleic acids;
10 the mutations are insertions, deletions, and/or replacements of amino acids;
and
the STING protein optionally has a deletion of the TRAF6 binding site.
2. A modified Stimulator of Interferon Genes (STING) protein from a non-human species, or a chimeric human STING protein, or variants of the chimeric
15 STING protein, wherein the modified STING protein and variant of the chimeric STING protein comprise one or more mutation(s) associated with gain-of-function (GOF) that result(s) in the constitutive activation of the encoded STING protein and/or enhanced sensitivity, or increased affinity or binding to endogenous ligands, wherein:
20 the STING protein is modified by one or more of an insertion, deletion, and replacement of an amino acid or amino acids;
the chimeric human STING protein comprises a portion of a human STING protein and a portion of the non-human STING protein;
the non-human or chimeric STING protein has IFN-beta signaling activity,
25 and attenuated nuclear factor kappa-light-chain-enhancer of activated B cell (NF- κ B) signaling activity, compared to the NF- κ B signaling activity of human STING; and
the mutation or mutations resulting in a variant or modified protein result in increased STING activity or constitutive activity in inducing IFN-beta production.
3. The modified STING protein of claim 1 or claim 2, wherein the
30 unmodified human STING protein comprises the sequence of amino acids set forth in any of SEQ ID NOs:305-309, or is a human allelic variant thereof with at least 98%

sequence identity to the sequence of amino acids set forth in any of SEQ ID NOs:305-309.

4. The modified STING protein of any of claims 1-3, wherein:
the STING protein is a chimera comprising replacement of a C-terminal tail
5 (CTT) region in a STING protein from a first species with the CTT of a STING
protein from a second species;
the STING protein of the second species has lower NF- κ B signaling activity
than the NF- κ B signaling activity of human STING; and
the TRAF6 binding site in the CTT optionally is deleted.
- 10 5. The modified STING protein of any of claims 1-4, wherein the
mutation or mutations is/are any that correspond to those associated with the human
auto-inflammatory disease STING-associated vasculopathy with onset in infancy
(SAVI).
6. A modified Stimulator of Interferon Genes (STING) protein that is a
15 chimera, comprising replacement of the CTT (C-terminal tail) region in a STING
from a first species with the CTT of STING from a second species, wherein:
the STING protein of the second species has lower NF- κ B signaling activity
than the NF- κ B signaling activity of human STING; and
the TRAF6 binding site in the CTT is deleted.
- 20 7. The modified STING protein of any of claims 2-6, wherein:
the chimera comprises a portion of a human STING protein and a portion of a
non-human STING protein; and
the human STING protein comprises the sequence of amino acids set forth in
any of SEQ ID NOs:305-309, or is a human allelic variant thereof with at least 98%
25 sequence identity to the sequence of amino acids set forth in any of SEQ ID NOs:305-
309.
8. The modified STING protein of any of claims 2 and 4-7 that is a
chimera comprising portions of STING proteins from two species, whereby the
resulting STING protein has IFN-beta signaling activity, wherein the first species is
30 human, and the second species is selected from among Tasmanian devil, marmoset,
cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, mouse and ghost shark.

9. The modified STING protein of any of claims 1-8, wherein the type I IFN signaling activity of non-human STING is at least or at least about 30% that of a wild type human STING protein.

10. The modified STING protein of any of claims 1-9, wherein the NF- κ B signaling activity of the non-human STING is less than 30%, less than 20%, less than 15%, less than 10%, or less than 5% that of wild type human STING NF- κ B signaling activity.

11. The modified STING protein of any of claims 1-10, wherein the non-human species or second species is selected from among Tasmanian devil, marmoset, cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, mouse and ghost shark.

12. The modified STING protein of any of claims 1-11, wherein the modification of STING is a mutation or mutations that correspond, by reference to and alignment with human STING, to a mutation that occurs in an interferonopathy, wherein the sequence of human STING with which alignment is effected is set forth in any of SEQ ID NOs:305-309.

13. The modified STING protein of any of claims 1-12 that comprises replacement of the C-terminal tail (CTT) with the CTT from a second STING protein that has reduced NF- κ B signaling activity compared to the NF- κ B signaling activity of human STING.

14. The modified STING protein of any of claims 1-13, wherein the TRAF6 binding site in the CTT is deleted.

15. The modified STING protein of claim 13 or claim 14, wherein the second CTT is from a Tasmanian devil, marmoset, cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, mouse or ghost shark STING protein.

16. The modified STING protein of claim 13 or claim 14, wherein the second CTT is from a Tasmanian devil, marmoset, cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, mouse or ghost shark STING protein, and it replaces the human STING CTT.

17. The modified STING protein of any of claims 13-16, wherein the replacing CTT is selected from among the following species and has a sequence:

Tasmanian devil	RQEEFAIGPKRAMTVTTSSTLSQEPQLLISGMEQPLSLRTDGF	SEQ ID NO:353,
Marmoset	EEEEVTVGSLKTSEVPSTSTMSQEPPELLISGMEKPLPLRSDLF	SEQ ID NO:354,

-297-

Cow	EREVTMGSTETSVMPGSSVLSQEPPELLISGLEKPLPLRSDVF	SEQ ID NO:355,
Cat	EREVTVGSGVGTSMVRNPSVLSQEPNLLISGMEQPLPLRTDVF	SEQ ID NO:356,
Ostrich	RQEEYTVCDGTLCSTDLSLQISESDLQPPLRSDCL	SEQ ID NO:357,
Boar	EREVTMGSAETSVVPTSSLSQEPPELLISGMEQPLPLRSDIF	SEQ ID NO:358,
Bat	EKEEVTVGTVGTVEAPGSSTLHQEPPELLISGMDQPLPLRTDIF	SEQ ID NO:359,
Manatee	EREEVTVGSGVTSVVPSPSPSTSSLSQEPKLLISGMEQPLPLR TDVF	SEQ ID NO:360,
Crested ibis	CHEEYTVYEGNQPHNPSTTLHSTELNLQISESDLQPPLRSDCF	SEQ ID NO:361,
Coelacanth	QKEEYFMSEQTQPNSSTSLSTEPQLMISDTDAPHTLKRQVC	SEQ ID NO:362,
(variant 1)		
Coelacanth	QKEEYFMSEQTQPNSSTSLSTEPQLMISDTDAPHTLKSFG	SEQ ID NO:363,
(variant 2)		
Ghost shark	LTEYPVAEPSNANETDCMSSEPHLMISDDPKPLRSYCP	SEQ ID NO:365, and
Mouse	EKEEVTMNAPMTSVAPPSVLSQEPRLISGMDQPLPLRTDLI	SEQ ID NO:366,

or allelic variants of each of these sequences having at least 98% sequence identity thereto.

18. The modified STING protein of any of claims 4-17, wherein the human STING CTT comprises the sequence
- 5 EKEEVTVGLKTSAPVSTSTMSQEPPELLISGMEKPLPLRTDFS (SEQ ID NO:352), or is an allelic variant having at least 98% sequence identity thereto.
19. The modified STING protein of any of claims 4-18, wherein the modified STING protein is a chimera in which the human STING CTT is replaced with a CTT from the Tasmanian devil STING.
- 10 20. The modified STING protein of claim 19, wherein the C-terminal tail (CTT) from the Tasmanian devil STING comprises the sequence: RQEEFAIGPKRAMTVTTSSTLSQEPQLISGMEQPLSLRTDGF (SEQ ID NO:353), or is an allelic variant having at least 98% sequence identity thereto.
- 15 21. The modified STING protein of any of claims 1-20, comprising deletion of the TRAF6 binding site.
22. The modified STING protein of claim 21, wherein the STING is a human STING, and the TRAF6 binding site comprises the amino acid residues DFS at the C-terminus.
23. The modified STING protein of any of claims 1-22, comprising a
- 20 modification that increases type I interferon signaling activity or renders the activity constitutive in the absence of cytosolic nucleic acids.
24. The modified STING protein of claim 23, wherein the modification corresponds, by reference to and alignment with human STING, to a mutation that

occurs in an interferonopathy, wherein the human STING has the sequence set forth in any of SEQ ID NOs:305-309.

25. The modified STING protein of any of claims 1-24, wherein the modification that confers increased activity or constitutive activity is one or more amino acid replacements that correspond(s) to one or more of S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A, E296A, R197A/D205A, S272A/Q273A, R310A/E316A, E316A, E316N, E316Q, S272A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A, S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, R375A, and S324A/S326A, with reference to the sequence of human STING, as set forth in any one of SEQ ID NOs:305-309.

26. The modified STING protein of any of claims 1-25, wherein the non-human STING protein is a Tasmanian Devil STING protein of SEQ ID NO:331, or an allelic variant thereof having at least 98% sequence identity to the STING protein of SEQ ID NO:331.

27. The modified STING protein of any of claims 1-26, comprising a replacement corresponding to C206Y or R284G, with reference to the sequence of human STING as set forth in any of SEQ ID NOs:305-309.

28. The modified STING protein of claim 27, comprising the sequence of amino acids set forth in SEQ ID NO: 332 or 333.

29. The modified STING protein of any of claims 1-25, wherein the sequences of the non-human species STING proteins are those set forth in SEQ ID NOs: 331, 338 and 341-350, or the non-human STING proteins are allelic variants of any of the STING proteins set forth in SEQ ID NOs: 331, 338 and 341-350 having at least 98% sequence identity therewith.

30. An immunostimulatory bacterium, comprising a plasmid encoding the modified STING protein of any of claims 1-29, or encoding a STING protein from a non-human species, wherein the STING protein has type I IFN signaling activity, and attenuated NF- κ B signaling activity compared to the NF- κ B signaling activity of human STING.

31. The immunostimulatory bacterium of claim 30, wherein the non-human species is selected from among Tasmanian devil, marmoset, cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, mouse and ghost shark.

32. An immunostimulatory bacterium, comprising a plasmid encoding a gain-of-function variant of an immunostimulatory protein that, in unmodified form, is part of a cytosolic DNA/RNA sensor pathway that leads to expression of type I interferon (IFN).

33. The immunostimulatory bacterium of claim 32, wherein:
the gain-of function (GOF) variant is a constitutively active variant of an immunostimulatory protein that, in humans, promotes or causes interferonopathies;
and

the genome of the immunostimulatory bacterium is modified so that the bacterium preferentially infects tumor-resident immune cells, and/or the genome of the immunostimulatory bacterium is modified so that it induces less cell death in tumor-resident immune cells (decreases pyroptosis), whereby the immunostimulatory bacterium accumulates in tumors or in the tumor microenvironment or in tumor-resident immune cells to thereby deliver the constitutively active immunostimulatory protein to the host cell to stimulate or induce expression of type I IFN.

34. The immunostimulatory bacterium of claim 32 or claim 33, wherein the GOF variant protein comprises a mutation that eliminates a phosphorylation site in the immunostimulatory protein, to thereby reduce nuclear factor kappa-light-chain-enhancer of activated B cell (NF- κ B) signaling.

35. The immunostimulatory bacterium of any of claims 32-34, wherein the immunostimulatory protein that induces type I IFN is STING, RIG-I, IRF-3, IRF-7 or MDA5.

36. An immunostimulatory bacterium, comprising a plasmid encoding an immunostimulatory protein that induces expression of type I IFN, or a variant thereof that has increased activity or constitutive activity, wherein the immunostimulatory protein is STING, RIG-I, IRF-3, IRF-7 or MDA5.

37. The immunostimulatory bacterium of any of claims 32-36, wherein the immunostimulatory protein is a variant of STING, RIG-I, IRF-3, IRF-7 or MDA5 that comprises a gain-of-function mutation resulting in increased expression of type I IFN.

38. The immunostimulatory bacterium of any of claims 32-37, wherein the immunostimulatory protein is a variant of STING, RIG-I, IRF-3, IRF-7 or MDA5, in which one or more serine (S) or threonine (T) residue(s) that is/are phosphorylated as a consequence of viral infection, is/are replaced with an aspartic acid (D) residue,
5 whereby the resulting variant protein is a phosphomimetic that constitutively induces type I IFN.

39. The immunostimulatory bacterium of claim 38, wherein:
the variant protein is IRF-3 and comprises one or more replacement(s) at residues at positions corresponding to positions 385, 386, 396, 398, 402, 404 and 405,
10 with reference to SEQ ID NO:312; and

the residues are replaced with aspartic acid residues.

40. The immunostimulatory bacterium of claim 39, wherein the variant IRF-3 protein has the replacement S396D, with reference to SEQ ID NO:312.

41. The immunostimulatory bacterium of claim 39, wherein the variant
15 IRF-3 protein comprises the replacements S396D/S398D/S402D/T404D/S405D, with reference to SEQ ID NO:312, or conservative replacements thereof.

42. The immunostimulatory bacterium of claim 39, wherein the the variant IRF-3 protein comprises the replacements S396D/S398D/S402D/T404D/S405D, with reference to SEQ ID NO:312.

20 43. The immunostimulatory bacterium of any of claims 32-42, wherein the immunostimulatory protein is a variant that, when expressed in a subject, leads to constitutive expression of type I IFN.

44. The immunostimulatory bacterium of any of claims 30-43, wherein the modified immunostimulatory protein or modified STING protein has at least 95%
25 sequence identity with the corresponding unmodified protein, or has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid modifications selected from among insertions, deletions, and replacements.

45. The immunostimulatory bacterium of any of claims 32-44, wherein the immunostimulatory protein is a variant that, when expressed in a subject, leads to
30 constitutive expression of type I IFN.

46. The immunostimulatory bacterium of any of claims 32-44, wherein the immunostimulatory protein, in its unmodified form, senses or interacts directly or

indirectly with cytosolic nucleic acids, nucleotides, dinucleotides, or cyclic dinucleotides to induce expression of type I IFN, and the variant protein induces expression of type I IFN in the absence of the sensing or interacting with the cytosolic nucleic acids, nucleotides, dinucleotides, or cyclic dinucleotides.

5 47. The immunostimulatory bacterium of claim 46, wherein the immunostimulatory protein is a gain-of-function (GOF) variant that does not require cytosolic nucleic acids, nucleotides, dinucleotides, or cyclic dinucleotides to result in expression of type I IFN.

 48. The immunostimulatory bacterium of any of claims 32-47, wherein the
10 immunostimulatory protein, in unmodified form, activates or induces expression of type I IFN.

 49. The immunostimulatory bacterium of any of claims 32-48, wherein the unmodified form of the immunostimulatory protein is involved in innate cytosolic DNA/RNA recognition that activates type I IFN.

15 50. The immunostimulatory bacterium of claim 49, wherein the type I IFN is an interferon- α or interferon- β .

 51. The immunostimulatory bacterium of any of claims 32-50, wherein the immunostimulatory protein is selected from among STING, RIG-I, MDA-5, IRF-3, IRF-7, TRIM56, RIP1, Sec5, TRAF3, TRAF2, TRAF6, STAT1, LGP2, DDX3,
20 DHX9, DDX1, DDX9, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200.

 52. The immunostimulatory bacterium of any of claims 32-50, wherein the immunostimulatory protein is selected from among TRIM56, RIP1, Sec5, TRAF3, TRAF2, TRAF6, STAT1, LGP2, DDX3, DHX9, DDX1, DDX9, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200.

25 53. The immunostimulatory bacterium of any of claims 32-52, wherein the immunostimulatory protein that is part of a cytosolic DNA/RNA sensor pathway is a variant that comprises a gain-of-function mutation, or a mutation whereby expression of type I interferon, or other immune mediator/modulator, is constitutive.

 54. The immunostimulatory bacterium of claim 53, wherein:
30 the immunostimulatory protein that senses cytosolic DNA/RNA is a variant STING, MDA5, RIG-I, IRF-7 or IRF-3 protein;

unmodified STING has the sequence set forth in any of SEQ ID NOs:305-309, unmodified MDA5 has the sequence set forth in SEQ ID NO:310, unmodified RIG-I has the sequence set forth in SEQ ID NO:311, unmodified IRF-7 has the sequence set forth in SEQ ID NO:313, and unmodified IRF-3 has the sequence set forth in SEQ ID NO:312; and

the modified immunostimulatory protein has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid modifications selected from among replacements, deletions, and insertions.

55. The immunostimulatory bacterium of any of claims 32-54, wherein the immunostimulatory protein is selected from among STING, MDA5, IRF-3, IRF-7, and RIG-I, and comprises a gain-of-function mutation(s) that renders the STING, MDA5, IRF-3, IRF-7, or RIG-I constitutively active, whereby expression of type I IFN is constitutive.

56. The immunostimulatory bacterium of claim 54 or claim 55, wherein the modifications, which are amino acid replacements, are selected as follows:

- a) in STING, with reference to SEQ ID NOs:305-309, one or more selected from among: S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A, E296A, R197A/D205A, S272A/Q273A, R310A/E316A, E316A, E316N, E316Q, S272A, R375A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A, S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, and S324A/S326A;
- b) in MDA5, with reference to SEQ ID NO:310, one or more of: T331I, T331R, A489T, R822Q, G821S, A946T, R337G, D393V, G495R, R720Q, R779H, R779C, L372F, and A452T;
- c) in RIG-I, with reference to SEQ ID NO:311, one or both of E373A and C268F;
- d) in IRF-3, with reference to SEQ ID NO:312, S396D;
- e) in IRF-7, with reference to SEQ ID NO:313, one or more of: S477D/S479D, S475D/S477D/S479D, and S475D/S476D/S477D/S479D/S483D/S487D; and

f) conservative amino acids replacements that increase activity or render type I interferon expression constitutive.

57. The immunostimulatory bacterium of any of claims 54-56, wherein the immunostimulatory protein is a variant STING that contains one or more amino acid replacement(s) selected, with reference to SEQ ID NOs:305-309, from among:
5 S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A, E296A, R197A/D205A, S272A/Q273A, R310A/E316A, E316A, E316N, E316Q, S272A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A,
10 S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, R375A, and S324A/S326A.

58. An immunostimulatory bacterium, comprising nucleic acids encoding a modified STING protein, which is an immunostimulatory protein that, in unmodified form, senses cytosolic RNA/DNA, wherein the STING protein is encoded
15 on a plasmid and the encoding nucleic acid is operatively linked to regulatory sequences recognized by a eukaryotic host.

59. The immunostimulatory bacterium of claim 58, wherein the modified STING protein does not require cyclic dinucleotides (CDNs) for activity.

60. The immunostimulatory bacterium of claim 58 or claim 59, comprising
20 a sequence of nucleotides encoding a modified STING protein, wherein:

the modification(s) in STING render its activity constitutive so that it does not require cGAMP for activity;

the modified STING protein is encoded by a modified *TMEM173* gene;

the modification(s) comprise insertions, deletions or replacements of amino
25 acid(s); and

the modified STING protein has enhanced immunostimulatory activity compared to the unmodified STING protein.

61. The immunostimulatory bacterium of claim 59 or claim 60, wherein the amino replacement(s) in STING, with reference to SEQ ID NOs:305-309, is one
30 or more selected from among: S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A, E296A, R197A/D205A,

S272A/Q273A, R310A/E316A, E316A, E316N, E316Q, S272A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A, S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, R375A, and S324A/S326A, and conservative amino acid replacements thereof.

5 62. The immunostimulatory bacterium of any of claims 30-61, comprising a mutation in the genome of the bacterium that reduces toxicity or infectivity of non-immune cells in a host.

 63. The immunostimulatory bacterium of any of claims 30-62, wherein the genome of the immunostimulatory bacterium is modified whereby the bacterium is
10 flagellin⁻ (*fliC*⁻/*fljB*⁻) and/or *pagP*⁻.

 64. The immunostimulatory bacterium of any of claims 30-63 wherein the genome of the immunostimulatory bacterium is modified whereby the bacterium is flagellin⁻ (*fliC*⁻/*fljB*⁻).

 65. The immunostimulatory bacterium of any of claims 30-64, wherein the
15 genome of the immunostimulatory bacterium is modified whereby the bacterium is *pagP*⁻/*msbB*⁻.

 66. The immunostimulatory bacterium of any of claims 30-63, wherein the bacterium is flagellin⁻ (*fliC*⁻/*fljB*⁻) and *pagP*⁻.

 67. The immunostimulatory bacterium of any of claims 30-66, wherein the
20 immunostimulatory bacterium is aspartate-semialdehyde dehydrogenase⁻ (*asd*⁻).

 68. The immunostimulatory bacterium of any of claims 30-66 that is aspartate-semialdehyde dehydrogenase⁻ (*asd*⁻), wherein the bacterium is *asd*⁻ by virtue of disruption or deletion of all or a portion of the endogenous gene encoding aspartate-semialdehyde dehydrogenase (*asd*), whereby endogenous *asd* is not
25 expressed.

 69. The immunostimulatory bacterium of any of claims 30-68 that encodes aspartate-semialdehyde dehydrogenase (*asd*) on the plasmid under control of a bacterial promoter.

 70. The immunostimulatory bacterium of any of claims 30-69 that is *msbB*⁻.

30 71. The immunostimulatory bacterium of any of claims 30-70 that is *purM*⁻ (*purM*⁻).

72. The immunostimulatory bacterium of any of claims 30-71 that is *asd⁻*, *purI⁻*, *msbB⁻*, flagellin⁻ (*fliC⁻/fliB⁻*), and *pagP⁻*.

73. The immunostimulatory bacterium of any of claims 30-72, wherein one or more genes or operons involved in SPI-1-dependent invasion are deleted or
5 inactivated, whereby the immunostimulatory bacterium does not invade or infect epithelial cells.

74. The immunostimulatory bacterium of claim 73, wherein one or more of *avrA*, *hilA*, *hilD*, *invA*, *invB*, *invC*, *invE*, *invF*, *invG*, *invH*, *invI*, *invJ*, *iapP*, *iagB*, *spaO*, *spaQ*, *spaR*, *spaS*, *orgA*, *orgB*, *orgC*, *prgH*, *prgI*, *prgJ*, *prgK*, *sicA*, *sicP*, *sipA*,
10 *sipB*, *sipC*, *sipD*, *sirC*, *sopB*, *sopD*, *sopE*, *sopE2*, *sprB*, and *sptP* is deleted or inactivated.

75. The immunostimulatory bacterium of any of claims 30-72, wherein one or more genes involved in SPI-1-independent invasion are deleted or inactivated,, wherein:
15 the immunostimulatory bacterium does not invade or infect epithelial cells;
and

the one or more genes is/are selected from among *pagN*, *hlyE*, *pefI*, *srgD*, *srgA*, *srgB*, and *srgC*.

76. The immunostimulatory bacterium of any of claims 30-75, comprising:
20 a modification of the bacterial genome, whereby the bacterium induces less cell death in tumor-resident immune cells; and/or
a modification of the bacterial genome, whereby the bacterium preferentially infects tumor-resident immune cells compared to other cell types.

77. The immunostimulatory bacterium of any of claims 30-76, wherein the
25 bacterium encodes *asd* on a plasmid, and its expression is under the control of a promoter expressed in a tumor microenvironment (TME) of a eukaryotic subject.

78. The immunostimulatory bacterium of any of claims 30-77 that is auxotrophic for adenosine and adenine.

79. The immunostimulatory bacterium of any of claims 30-77 that is
30 auxotrophic for adenosine.

80. The immunostimulatory bacterium of any of claims 30-79 that is auxotrophic for adenosine and lacks flagella, wherein the wild-type bacterium has flagella.

81. The immunostimulatory bacterium of any of claims 30-80, comprising
5 a mutation in the genome of the bacterium that reduces toxicity or infectivity of non-immune cells in a host.

82. The immunostimulatory bacterium of any of claims 30-81, wherein the bacterium is *pagP*⁻.

83. The immunostimulatory bacterium of any of claims 30-82, wherein the
10 immunostimulatory bacterium is flagellin⁻ (*fliC*⁻/*fljB*⁻) and/or *pagP*⁻, and one or more of *purI*⁻ (*purM*⁻), *msbB*⁻, *purD*⁻, *adrA*⁻, *csgD*⁻, *qseC*⁻, and *hilA*⁻, *lppA*⁻, or *lppB*⁻.

84. The immunostimulatory bacterium of any of claims 30-83, wherein the immunostimulatory bacterium is *hilA*⁻, *pagP*⁻, and flagellin⁻ (*fliC*⁻/*fljB*⁻).

85. The immunostimulatory bacterium of any of claims 30-84 that
15 comprises a nucleic acid encoding a CpG motif, wherein the nucleic acid encoding the CpG motif is included in or is part of a bacterial gene that is encoded on the plasmid.

86. The immunostimulatory bacterium of claim 85, wherein the gene that comprises CpGs is *asd*, wherein the *asd* is encoded on the plasmid.

87. The immunostimulatory bacterium of any of claims 30-86 that is
20 flagellin deficient, wherein the wild-type bacterium comprises flagella.

88. The immunostimulatory bacterium of any of claims 30-87, wherein the plasmid comprises a nucleic acid encoding cytoLLO, which is listeriolysin O (LLO) protein lacking the signal sequence.

89. The immunostimulatory bacterium of any of claims 30-88 that
25 comprises a DNA nuclear targeting sequence (DTS) encoded on the plasmid.

90. The immunostimulatory bacterium of claim 89, wherein the DTS is an SV40 DTS.

91. The immunostimulatory bacterium of any of claims 30-90 that has a deletion or modification in the gene encoding endonuclease I (*endA*), whereby *endA*
30 activity is inhibited or eliminated.

92. The immunostimulatory bacterium of any of claims 30-91, wherein the plasmid comprises one or more of a CpG motif, an *asd* gene selectable marker for plasmid maintenance and a DNA nuclear targeting sequence.

93. The immunostimulatory bacterium of any of claims 30-92, wherein the
5 immunostimulatory bacterium comprises a *purI* deletion, an *msbB* deletion, an *asd* deletion, and an *adrA* deletion.

94. The immunostimulatory bacterium of any of claims 30-93, wherein the immunostimulatory bacterium comprises:

one or more of a mutation in a gene that alters the biosynthesis of
10 lipopolysaccharide, selected from among one or more of *rfaL*, *rfaG*, *rfaH*, *rfaD*, *rfaP*, *rFb*, *rfa*, *msbB*, *htrB*, *firA*, *pagL*, *pagP*, *lpxR*, *arnT*, *eptA*, and *lpxT*; and/or

one or more of a mutation that introduces a suicide gene and is selected from among one or more of *sacB*, *nuk*, *hok*, *gef*, *kil* and *phlA*; and/or

one or more of a mutation that introduces a bacterial lysis gene and is selected
15 from among one or both of *hly* and *cly*; and/or

a mutation in one or more virulence factor(s) selected from among *isyA*, *pag*, *prg*, *iscA*, *virG*, *plc* and *act*; and/or

one or more of a mutation in a gene that modifies the stress response, selected from among *recA*, *htrA*, *htpR*, *hsp* and *groEL*; and/or

20 a mutation in *min* that disrupts the cell cycle; and/or

one or more of a mutation in a gene that disrupts or inactivates regulatory functions, selected from among *cya*, *crp*, *phoP/phoQ* and *ompR*.

95. The immunostimulatory bacterium of any of claims 30-94 that is
25 *msbB*/*asd*/*purI*.

96. The immunostimulatory bacterium of any of claims 30-95 in which
prgH and/or *prgK* are inactivated or deleted.

97. The immunostimulatory bacterium of any of claims 30-96, wherein the nucleic acid encoding the immunostimulatory protein or STING protein on the plasmid is operatively linked to nucleic acid encoding a secretory signal, whereby,
30 upon expression in a host, the product is secreted.

98. The immunostimulatory bacterium of any of claims 30-97, wherein the plasmid encoding the immunostimulatory protein is present in low copy number or medium copy number.

99. The immunostimulatory bacterium of any of claims 30-98, wherein the
5 plasmid comprises a medium-to-low copy number origin of replication.

100. The immunostimulatory bacterium of any of claims 30-98, wherein the plasmid comprises a low copy number origin of replication.

101. The immunostimulatory bacterium of any of claims 30-100, wherein the plasmid is present in low copy number.

102. The immunostimulatory bacterium of any of claims 98-101, wherein
10 medium copy number is less than 150 or less than about 150 and more than 20 or about 20 or is between 20 or 25 and 150.

103. The immunostimulatory bacterium of claim 101, wherein low copy
15 number is less than 25 or less than 20 or less than about 25 or less than about 20 copies.

104. The immunostimulatory bacterium of any of claims 30-103, wherein the origin of replication in the plasmid is selected from among the origins derived from pBR322, p15A, pSC101, pMB1, colE1, colE2, pPS10, R6K, R1, RK2, and pUC.

105. The immunostimulatory bacterium of any of claims 30-104, wherein
20 the nucleic acid encoding the immunostimulatory protein or STING protein, whose unmodified form senses cytosolic RNA/DNA, is on a plasmid and is operatively linked to regulatory sequences recognized by a eukaryotic host.

106. The immunostimulatory bacterium of any of claims 30-105, wherein
25 the plasmid encodes the immunostimulatory protein or STING under control of a eukaryotic promoter.

107. The immunostimulatory bacterium of claim 105 or claim 106, wherein the regulatory sequences comprise an RNA polymerase II promoter or an RNA polymerase III promoter.

108. The immunostimulatory bacterium of claim 105 or claim 106, wherein
30 the regulatory sequences comprise a terminator and/or promoters selected from among SV40, hGH, BGH, chicken beta-globulin, and rbGlob (rabbit globulin) genes.

109. The immunostimulatory bacterium of claim 107, wherein the promoter is an RNA polymerase II promoter.

110. The immunostimulatory bacterium of claim 107, wherein the promoter is an RNA polymerase II promoter that is a viral promoter or a mammalian RNA
5 polymerase II promoter.

111. The immunostimulatory bacterium of claim 110, wherein the promoter is a viral promoter selected from among a cytomegalovirus (CMV) promoter, an SV40 promoter, an Epstein Barr virus (EBV) promoter, a herpes virus promoter, a respiratory syncytial virus (RSV) promoter, and an adenovirus promoter.

10 112. The immunostimulatory bacterium of any of claims 105-110, wherein the promoter that controls expression of one or more of the encoded heterologous proteins on the plasmid is an elongation factor-1 (EF-1) alpha promoter, or a UBC promoter, or a PGK promoter, an MND promoter, or a CAGG promoter.

113. The immunostimulatory bacterium of any of claims 105-110, wherein
15 the promoter is an EF-1 alpha promoter, a CMV promoter, an SV40 promoter, a PGK promoter, an MND promoter, an EIF4A1 promoter, a CAG promoter, or a CD68 promoter.

114. The immunostimulatory bacterium of claim 113, wherein the promoter is an EF-1 alpha promoter.

20 115. The immunostimulatory bacterium of any of claims 105-113, wherein the promoter is a viral promoter that is a late promoter.

116. The immunostimulatory bacterium of any of claims 30-115, wherein the bacterium is a Gram-negative bacterium.

117. The immunostimulatory bacterium of any of claims 30-116, wherein
25 the bacterium is *Rickettsia rickettsiae*, *Rickettsia prowazekii*, *Rickettsia tsutsugamuchi*, *Rickettsia mooseri*, *Rickettsia sibirica*, *Bordetella bronchiseptica*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Aeromonas eucrenophila*, *Aeromonas salmonicida*, *Francisella tularensis*, *Corynebacterium pseudotuberculosis*, *Citrobacter freundii*, *Chlamydia pneumoniae*, *Haemophilus sordani*, *Brucella abortus*, *Mycobacterium intracellulare*, *Legionella pneumophila*, *Rhodococcus equi*,
30 *Pseudomonas aeruginosa*, *Helicobacter mustelae*, *Vibrio cholerae*, *Bacillus subtilis*, *Erysipelothrix rhusiopathiae*, *Yersinia enterocolitica*, *Rochalimaea quintana*, or

Agrobacterium tumerfacium, or an attenuated strain thereof or a modified strain thereof of any of the preceding list of bacterial strains.

118. The immunostimulatory bacterium of any of claims 30-116, wherein the bacterium is a strain of *Salmonella*, *Shigella*, *E. coli*, *Bifidobacteriae*, *Rickettsia*,
5 *Vibrio*, *Listeria*, *Klebsiella*, *Bordetella*, *Neisseria*, *Aeromonas*, *Francisella*, *Cholera*, *Corynebacterium*, *Citrobacter*, *Chlamydia*, *Haemophilus*, *Brucella*, *Mycobacterium*, *Mycoplasma*, *Legionella*, *Rhodococcus*, *Pseudomonas*, *Helicobacter*, *Bacillus*, or *Erysipelothrix*, or an attenuated strain thereof or a modified strain thereof of any of the preceding list of bacterial strains.

10 119. The immunostimulatory bacterium of any of claims 30-119 that is an attenuated bacterium.

120. The immunostimulatory bacterium of any of claims 30-120 that is a strain of *Salmonella*.

121. The immunostimulatory bacterium of claim 120 that is a *Salmonella*
15 *typhimurium* strain.

122. The immunostimulatory bacterium of claim 120 or claim 121, wherein the unmodified *Salmonella* is a wild-type strain.

123. The immunostimulatory bacterium of claim 120 or claim 121, wherein the unmodified *Salmonella* strain is attenuated.

20 124. The immunostimulatory bacterium of any of claims 30-123, wherein the immunostimulatory bacterium is derived from an attenuated *Salmonella typhimurium* strain selected from among strains designated as AST-100, VNP20009, YS1646 (ATCC #202165), RE88, SL7207, χ 8429, χ 8431, and χ 8468, or is derived from a wild-type bacterium that has all of the identifying characteristics of the strain
25 deposited as ATCC Accession No. 14028, or is strain ATCC 14028.

125. The immunostimulatory bacterium of any of claims 30-124 that comprises, encoded on the plasmid, a combination of:

- a) nucleic acid encoding one or more of a gain-of-function mutant of STING, RIG-I, MDA5, IRF3, and IRF7; and
- 30 b) nucleic acid encoding one or more of IL-2, IL-7, IL-12p70 (IL-12p40 + IL-12p35), IL-15, IL-15/IL-15R alpha chain complex, IL-2 that has attenuated binding to IL-2Ra, IL-2 modified so that it does not bind to IL-2Ra, IL-18, IL-36 gamma,

CXCL9, CXCL10, CXCL11, CCL3, CCL4, CCL5, proteins that are involved in or that effect or potentiate recruitment/persistence of T cells, CD40, CD40 Ligand (CD40L), OX40, OX40 Ligand (OX40L), 4-1BB, 4-1BB Ligand (4-1BBL), members of the B7-CD28 family, a TGF-beta polypeptide antagonist, and members of the
5 tumor necrosis factor receptor (TNFR) superfamily.

126. The immunostimulatory bacterium of claim 125 that comprises nucleic acid encoding two of the proteins in a) and two of the proteins in b).

127. The immunostimulatory bacterium of claim 125 or claim 126, wherein different promoters and terminators control expression of each protein.

10 128. The immunostimulatory bacterium of any of claims 125-127, wherein the genes are expressed from a single promoter and comprise a single terminator, and the sequence encoding each protein comprises an Internal Ribosome Entry Site (IRES), whereby the encoded nucleic acid is polycistronic.

129. The immunostimulatory bacterium of any of claims 125-128, wherein
15 the promoters are selected from among EF-1 alpha, CMV, or GAPDH promoters, and the terminators are selected from among SV40, hGH, BGH, and rbGlob.

130. The immunostimulatory bacterium of any of claims 30-129, wherein the plasmid that encodes the protein comprises a construct that includes an enhancer, a promoter, the open reading frame encoding the protein, and a polyA tail.

20 131. The immunostimulatory bacterium of any of claims 30-130, wherein the plasmid encoding the protein comprises a construct that includes an enhancer, a promoter, an IRES, the open reading frame encoding the protein, and a polyA tail.

132. The immunostimulatory bacterium of any of claims 30-131, wherein the plasmid encoding the protein comprises a construct that includes an enhancer, a
25 promoter, an IRES, a localization sequence, the open reading frame encoding the protein, and a polyA tail.

133. The immunostimulatory bacterium of any of claims 30-132, wherein the construct on the plasmid encoding the protein comprises a Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE) or a Hepatitis B virus
30 Posttranscriptional Regulatory Element (HPRE).

134. The immunostimulatory bacterium of any of claims 30-133 that has a deletion in the SPI-2 complex.

135. The immunostimulatory bacterium of any of claims 30-134, wherein the bacterium is treated with polymyxin to reduce pyrogenicity.

136. A delivery vehicle, comprising nucleic acids encoding the modified STING protein of any of claims 1-29.

5 137. A delivery vehicle, comprising nucleic acids encoding a STING protein from a non-human species, wherein the STING protein has type I IFN signaling activity, and attenuated NF- κ B signaling activity compared to the NF- κ B signaling activity of human STING.

10 138. The delivery vehicle of claim 136 or claim 137, wherein the human STING protein comprises the sequence set forth in any of SEQ ID NOs:305-309, or is a human allelic variant thereof with at least 98% sequence identity to the sequence of amino acids set forth in any of SEQ ID NOs:305-309.

15 139. The delivery vehicle of any of claims 136-138, wherein the type I IFN signaling activity is at least or at least about 30% of the type I IFN signaling activity of wild type human STING.

140. The delivery vehicle of any of claims 136-139, wherein the NF- κ B signaling activity is less than 30%, less than 20%, less than 15%, less than 10%, or less than 5% of the NF- κ B signaling activity of human STING.

20 141. The delivery vehicle of any of claims 136-140, wherein the non-human species is Tasmanian devil, marmoset, cattle, cat, ostrich, boar, bat, manatee, crested ibis, coelacanth, mouse, zebrafish, or ghost shark.

25 142. A delivery vehicle, comprising nucleic acids encoding an immunostimulatory protein that, when expressed in a subject, leads to constitutive expression of type I IFN, wherein the delivery vehicle is selected from among a nanoparticle, a liposome, an exosome, a bacterium, a virus, a cell, and a microvesicle.

143. The delivery vehicle of claim 142, wherein the immunostimulatory protein is in a signaling pathway that senses or interacts directly or indirectly with cytosolic nucleic acids, nucleotides, dinucleotides, cyclic nucleotides, or cyclic dinucleotides.

30 144. The delivery vehicle of claim 143, wherein the immunostimulatory protein that is in a pathway that senses or interacts directly or indirectly with cytosolic

nucleic acids, nucleotides, dinucleotides, cyclic nucleotides, or cyclic dinucleotides, activates type I IFN.

145. The delivery vehicle of any of claims 142-144, wherein the immunostimulatory protein is involved in innate DNA/RNA recognition that activates type I interferon, and is selected from among STING, RIG-I, MDA-5, IRF-3, IRF-7, TRIM56, RIP1, Sec5, TRAF3, TRAF2, TRAF6, STAT1, LGP2, DDX3, DHX9, DDX1, DDX9, DDX21, DHX15, DHX33, DHX36, DDX60, and SNRNP200.

146. The delivery vehicle of any of claims 142-145, wherein the immunostimulatory protein is selected from among STING, MDA5, IRF-3, IRF-7 and RIG-1.

147. The delivery vehicle of claim 146, wherein:

The unmodified STING protein has the sequence set forth in any of SEQ ID NOs:305-309;

the unmodified MDA5 protein has the sequence set forth in SEQ ID NO:310;

the unmodified RIG-I protein has the sequence set forth in SEQ ID NO:311;

the unmodified IRF-3 protein has the sequence set forth in SEQ ID NO:312;

and

the unmodified IRF-7 protein has the sequence set forth in SEQ ID NO:313.

148. The delivery vehicle of any of claims 142-147, wherein the immunostimulatory protein contains an amino acid replacement(s) that render(s) its activity constitutive.

149. The delivery vehicle of any of claims 142-148, wherein the immunostimulatory protein, when it occurs in a subject, results in an interferonopathy.

150. The delivery vehicle of any of claims 142-149, wherein the immunostimulatory protein is selected from among a variant STING, variant MDA5, variant IRF-3, variant IRF-7, and variant RIG-I that comprises a gain-of-function mutation or mutations.

151. The delivery vehicle of claim 150, wherein the gain-of-function mutation(s) results in constitutive expression of type I interferon.

152. The delivery vehicle of claim 150 or claim 151, wherein the mutations are as follows:

- a) in STING, with reference to SEQ ID NOs:305-309, one or more selected from among: S102P, V147L, V147M, N154S, V155M, G166E, C206Y, G207E, S102P/F279L, F279L, R281Q, R284G, R284S, R284M, R284K, R284T, R197A, D205A, R310A, R293A, T294A, E296A, R197A/D205A, S272A/Q273A,
- 5 R310A/E316A, E316A, E316N, E316Q, S272A, R293A/T294A/E296A, D231A, R232A, K236A, Q273A, S358A/E360A/S366A, D231A/R232A/K236A/R238A, S358A, E360A, S366A, R238A, R375A, and S324A/S326A;
- b) in MDA5, with reference to SEQ ID NO:310, one or more of: T331I, T331R, A489T, R822Q, G821S, A946T, R337G, D393V, G495R, R720Q, R779H,
- 10 R779C, L372F, and A452T;
- c) in RIG-I, with reference to SEQ ID NO:311, one or both of E373A and C268F;
- d) in IRF-3, with reference to SEQ ID NO:312, S396D; and
- e) in IRF-7, with reference to SEQ ID NO:313, one or more of:
- 15 S477D/S479D, S475D/S477D/S479D, and S475D/S476D/S477D/S479D/S483D/S487D.

153. The delivery vehicle of claim 152, wherein unmodified STING has the sequence set forth in any of SEQ ID NOs:305-309, unmodified MDA5 has the sequence set forth in SEQ ID NO:310, unmodified RIG-I has the sequence set forth in

20 SEQ ID NO:311, unmodified IRF-3 has the sequence set forth in SEQ ID NO:312, and unmodified IRF-7 has the sequence set forth in SEQ ID NO:313, and each modified protein has at least 95% sequence identity to the unmodified protein.

154. The delivery vehicle of any of claims 136-153 that is a cell, an exosome, an oncolytic virus or viral vector, a liposome or other lipid-based vehicle, or

25 an immunostimulatory bacterium.

155. The delivery vehicle of claim 154, wherein the delivery vehicle is a cell that is a stem cell or an immune cell.

156. The delivery vehicle of any of claims 136-154 that is an exosome.

157. The delivery vehicle of any of claims 136-154 that is an oncolytic

30 virus.

158. The delivery vehicle of any of claims 136-154 that is an oncolytic virus selected from among an oncolytic adenovirus, adeno-associated virus, retrovirus,

herpes simplex virus, rhabdovirus, papillomavirus, vesicular stomatitis virus, measles virus, Newcastle disease virus, picornavirus, Sindbis virus, poxvirus, parvovirus, reovirus, coxsackievirus, influenza virus, mumps virus, poliovirus, Seneca Valley Virus, Sendai Virus, Dengue Virus, poliovirus, semliki forest virus, alphavirus, and
5 flavivirus.

159. The delivery vehicle of claim 158, wherein the oncolytic virus is a vaccinia virus, a herpes virus, a measles virus, or a reovirus.

160. The delivery vehicle of any of claims 136-159, wherein the nucleic acid encoding the immunostimulatory protein is expressed under control of a
10 eukaryotic regulatory sequence.

161. The delivery vehicle of any of claims 136-160, wherein the nucleic acid encoding the immunostimulatory protein is expressed under control of a eukaryotic promoter.

162. The delivery vehicle of any of claims 136-161, wherein the
15 immunostimulatory protein is a constitutively active STING protein.

163. The delivery vehicle of any of claims 136-162 that further comprises nucleic acids encoding an immunostimulatory protein, that, when expressed in a mammalian subject, confers or contributes to anti-tumor immunity in the tumor microenvironment.

20 164. The delivery vehicle of claim 163, wherein the immunostimulatory protein is a cytokine, a chemokine, a co-stimulatory protein or receptor, or a co-stimulatory receptor with the cytoplasmic domain deleted.

165. The delivery vehicle of any of claims 136-164 that is a cell.

166. The delivery vehicle of claim 165, wherein the cell is a stem cell.

25 167. The delivery vehicle of claim 166, wherein the stem cell is a mesenchymal stem cell (MSC).

168. The delivery vehicle of claim 167, wherein the MSC is genetically modified to express a combination of immunomodulatory cytokines.

30 169. The delivery vehicle of claim 168, wherein the cytokines are Interleukin 12 (IL-12) and Interleukin 21 (IL-21).

170. The delivery vehicle, STING protein, immunostimulatory protein, or immunostimulatory bacterium of any of claims 1-169, wherein the type I interferon is interferon- α or interferon- β .

5 171. An isolated cell, comprising the delivery vehicle of any of claims 136-164.

172. The cell of claim 171 that is an immune cell, a stem cell, a tumor cell, or a primary cell line.

173. The cell of claim 172 that is a hematopoietic cell.

174. The cell of claim 172 that is a T-cell.

10 175. The cell of any of claims 171-174 that is produced *ex vivo* by infecting the cell with the delivery vehicle.

176. An isolated cell, comprising an immunostimulatory bacterium, wherein:

15 the immunostimulatory bacterium is modified so that it preferentially infects tumor-resident immune cells, and/or the genome of the immunostimulatory bacterium is modified so that it induces less cell death in tumor-resident immune cells; and

the cell is an immune cell, a stem cell, a cell from a primary cell line, or a tumor cell.

20 177. The cell of claim 176, wherein the immunostimulatory bacterium is a *Salmonella* species that is flagellin⁻ (*fliC*⁻/*fliB*⁻).

178. An isolated cell or cultured cells, comprising the immunostimulatory bacterium of any of claims 30-135.

179. The cell of any of claims 176-178 that is a T-cell, or a hematopoietic cell.

25 180. The cell of any of claims 177-179 that is produced *ex vivo* by infecting the cell with the immunostimulatory bacterium.

181. A method of treatment of cancer, comprising administering the cell of any of claims 176-180 to a subject with a cancer that comprises a solid tumor or is a hematological malignancy.

30 182. The method of claim 181, wherein the cancer comprises a solid tumor.

183. The method of claim 181 or claim 182, wherein the cancer is metastatic.

184. The method of any of claims 181-183, wherein the cancer is selected from among cancer of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, colorectum, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, liver, gastric cancer, lymphoma, and leukemia.
185. Use of the cell of any of claims 176-180 for the treatment of cancer.
186. The use of claim 185, wherein the cancer comprises a solid tumor or a hematological malignancy.
187. The use of claim 185 or claim 186, wherein the cancer is metastatic.
188. The use of any of claims 185-187, wherein the cancer is selected from among cancer of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, colorectum, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, liver, gastric cancer, lymphoma, and leukemia.
189. A pharmaceutical composition, comprising the modified STING protein of any of claims 1-29, the immunostimulatory bacterium of any of claims 30-135, the delivery vehicle of any of claims 136-170, or the cell of any of claims 171-180, in a pharmaceutically acceptable vehicle.
190. An isolated cell, comprising the modified STING protein of any of claims 1-29, the immunostimulatory bacterium of any of claims 30-135, or the delivery vehicle of any of claims 136-170, wherein the cell is not a zygote of a fertilized human egg.
191. The cell of claim 190 that is an immune cell, a stem cell, a tumor cell, or a primary cell line.
192. The cell of claim 191 that is a hematopoietic cell, wherein the hematopoietic cell is a chimeric antigen myeloid cell that is a macrophage.
193. The cell of claim 191 that is a T-cell.
194. The cell of any of claims 190-193 that is produced *ex vivo* by infecting the cell with the modified STING protein, immunostimulatory bacterium or delivery vehicle.
195. A method of treatment of cancer, comprising administering the modified STING protein of any of claims 1-29, or the immunostimulatory bacterium

of any of claims 30-135, or the delivery vehicle of any of claims 136-170, or the cell of any of claims 171-180 and 190-194, or the pharmaceutical composition of claim 189, or the cell of any of claims 190-194, to a subject with a cancer that comprises a solid tumor or is a hematological malignancy.

5 196. The method of claim 195, wherein the cancer comprises a solid tumor.

 197. The method of claim 195 or claim 196, wherein the cancer is metastatic.

 198. The method of any of claims 195-197, wherein the cancer is selected from among lymphoma, leukemia, gastric cancer, and cancer of the breast, heart,
10 lung, small intestine, colon, spleen, kidney, bladder, head and neck, colorectum, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, and liver.

 199. Use of the modified STING protein of any of claims 1-29, or the immunostimulatory bacterium of any of claims 30-135, or the delivery vehicle of any
15 of claims 136-170, or the cell of any of claims 171-180 and 190-194, or the pharmaceutical composition of claim 189, or the cell of any of claims 190-194 for the treatment of cancer.

 200. The use of claim 199, wherein the cancer comprises a solid tumor or a hematological malignancy.

20 201. The use of claim 199 or claim 200, wherein the cancer is metastatic.

 202. The use of any of claims 199-201, wherein the cancer is selected from among lymphoma, leukemia, gastric cancer, and cancer of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, colorectum, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles,
25 cervix, and liver.

 203. The modified STING protein, delivery vehicle, immunostimulatory bacterium, pharmaceutical composition, cell, method or use of any of claims 1-202, wherein the non-human STING protein has the sequence of amino acids set forth in any of SEQ ID NOs: 331, 338 or 341-351, or is an allelic variant of the STING
30 protein of each species, having at least 98% sequence identity to the sequence of amino acids set forth in any of SEQ ID NOs: 331, 338 or 341-351.

204. The modified STING protein, delivery vehicle, immunostimulatory bacterium, pharmaceutical composition, cell, method or use of any of claims 1-202, wherein the non-human STING protein or chimera has the sequence of amino acids set forth in any of SEQ ID NOs: 332-337, 339, or 340.

5 205. A pharmaceutical composition, comprising the immunostimulatory bacterium of any of claims 30-135 in a pharmaceutically acceptable vehicle.

206. The pharmaceutical composition of claim 189 or claim 205 that is formulated for administration without dilution.

10 207. The pharmaceutical composition of any of claims 189, 205 and 206 that is formulated as a single dose.

208. The pharmaceutical composition of any of claims 189 and 205-207 that is formulated for parenteral administration.

15 209. A method of treatment of cancer that comprises a solid tumor or a hematological malignancy in a subject, comprising administering the pharmaceutical composition of any of claims 189 and 205-208.

210. Use of the pharmaceutical composition of any of claims 189 and 205-208 for treatment of a cancer that comprises a solid tumor or a hematological malignancy in a subject.

20 211. The immunostimulatory bacterium of any of claims 30-135 for use for treatment of a cancer that comprises a solid tumor or a hematological malignancy in a subject.

212. The method or use or immunostimulatory bacterium of any of claims 195-202 and 209-211, wherein the subject is a human.

25 213. The method or use or immunostimulatory bacterium of any of claims 195-202 and 209-212, wherein the treatment comprises combination therapy in which a second anti-cancer agent or treatment is administered.

214. The method or use or immunostimulatory bacterium of claim 213, wherein the second anti-cancer agent or treatment is administered before, concomitantly with, after, or intermittently with, the immunostimulatory bacterium.

30 215. The method or use or immunostimulatory bacterium of claim 214, wherein the second anti-cancer agent or treatment is an immunotherapy.

216. The method or use or immunostimulatory bacterium of any of claims 195-202 and 209-215, wherein administration of the protein, cell, delivery vehicle, pharmaceutical composition, or immunostimulatory bacterium is parenteral.

217. The method or use or immunostimulatory bacterium of any of claims
5 195-202 and 209-216, wherein administration is oral or rectal or by aerosol into the lung or intratumoral.

218. The method or use or immunostimulatory bacterium of any of claims 195-202 and 209-216, wherein administration is intravenously, intramuscularly, or subcutaneously.

10 219. The method or use or immunostimulatory bacterium of any of claims 195-202 and 209-218, wherein the cancer is selected from among leukemia, lymphoma, gastric cancer, and cancer of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, colorectum, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, and liver.

15 220. The method or use or immunostimulatory bacterium of claim 215, wherein the immunotherapy comprises administration of an anti-PD-1, or anti-PD-L1, or anti-CTLA-4 antibody.

221. A method of increasing the ability of a therapeutic bacterium to colonize a tumor, comprising modifying the genome, whereby the bacterium is
20 flagellin⁻ (*fliC*⁻/*fljB*⁻) and/or *pagP*⁻.

222. The method of claim 220, wherein the therapeutic bacterium is an immunostimulatory bacterium.

223. The method of claim 221 or claim 222, wherein the bacterium is a *Salmonella* species.

25 224. A method of producing an immunostimulatory bacterium or oncolytic virus for treating cancer, comprising:

identifying a mutated gain-of-function, constitutively active immunostimulatory protein that promotes interferonopathies in human patients; and

introducing nucleic acid encoding the identified protein into a tumor-targeting
30 bacterium or virus, whereby the resulting bacterium or virus, when introduced into a subject, promotes immunostimulation of the tumor microenvironment.